

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 October 2002 (24.10.2002)


PCT

(10) International Publication Number  
**WO 02/083851 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number: PCT/US02/11406
- (22) International Filing Date: 10 April 2002 (10.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/832,355 10 April 2001 (10.04.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/832,355 (CIP)  
Filed on 10 April 2001 (10.04.2001)
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **KOVESDI, Imre** [US/US]; 7713 Warbler Lane, Rockville, MD 20855 (US).  
**KESSLER, Paul, D.** [US/US]; 1716 Algonquin Road, Frederick, MD 21701 (US).
- (74) Agents: **SMITH, Len, S.** et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
- (71) Applicant (for all designated States except US): **GEN-VEC, INC.** [US/US]; 65 West Watkins Mill Road, Gaithersburg, MD 20878 (US).

[Continued on next page]

(54) Title: VEGF FUSION PROTEINS



(57) Abstract: The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides, encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

WO 02/083851 A2



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## VEGF FUSION PROTEINS

## FIELD OF THE INVENTION

[0001] This invention pertains to fusion proteins, polynucleotides encoding such fusion proteins, and methods of producing and administering such fusion proteins and polynucleotides.

## BACKGROUND OF THE INVENTION

[0002] Several therapeutic proteins are known to be involved in angiogenesis, bone growth, and wound healing. An exemplary group of such proteins are the vascular endothelial growth factors (VEGFs).

[0003] Through recombinant DNA technology, scientists have been able to generate fusion proteins that contain the combined amino acid sequence of two or more proteins. Fusion proteins including a VEGF portion are known in the art. For example, U.S. Patent 5,194,597 discloses fusion proteins, which include a platelet-derived growth factor (PDGF) portion and a vascular endothelial growth factor (VEGF) portion; International Patent Application WO 00/06195 discloses fusion proteins comprising specific VEGFs fused to a collagen-binding peptides, International Patent Application WO 00/37642 discloses fusion proteins including an angiopoietin portion fused to a VEGF portion; and U.S. Patent 5,972,338 discloses fusion proteins including NL1, an angiopoietin homolog, and a VEGF. However, the VEGF fusion proteins of the '597 patent are believed to lack the ability to work on different aspects of a biological system (e.g., by targeting different receptors or promoting different aspects of a therapeutic biologic cascade), and those of the '642 application and '338 patent may have limited therapeutic potential due to poor *in vivo* half-life, limited *in vivo* mobility, undesired receptor interaction, interference with desired receptor binding, or combinations of such drawbacks, while the fusion proteins of the '195 application are limited in their range of therapeutic potential.

[0004] Accordingly, there remains a need for therapeutic fusion proteins which exhibit improved therapeutic potential over those presently known in the art. This invention provides such fusion proteins, polynucleotides that encode such fusion proteins, and methods of producing and administering such fusion proteins and polynucleotides. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

## BRIEF SUMMARY OF THE INVENTION

[0005] The invention provides a fusion protein comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with

the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. The invention also provides polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0006] Figure 1 is a comparison of light emission measurements in reporter cells expressing a luciferase fusion protein in response to flk-1 VEGF receptor binding, variously treated with select VEGF fusion proteins of the invention and various controls.

[0007] Figure 2 is a graph of erythema measurements observed over a seven day period in a murine intradermal ear model after *in vivo* administration of recombinant adenoviral vectors encoding select VEGF fusion proteins of the invention or treatment by select positive and negative control treatments.

[0008] Figure 3 is a graphical summary of mean extravasated Evans Blue concentrations obtained by administering adenoviral vectors encoding select VEGF fusion proteins of the invention or by applying select controls in a murine intradermal ear model.

[0009] Figure 4 is a graph of the mean serotonin stimulated/basal Evans Blue concentration ratios obtained by administering adenoviral vectors encoding select VEGF fusion proteins of the invention as compared to select control treatments in an intradermal murine ear model.

[0010] Figure 5 is a graph of mean blood vessel densities measured after administration of adenoviral vectors encoding exemplary VEGF fusion proteins of the invention and application of select control treatments in murine tissue *in vivo*.

### DETAILED DESCRIPTION OF THE INVENTION

[0011] The invention provides a fusion protein including a first VEGF peptide portion (referred to herein as the "first" or "VEGF" peptide portion) and a second non-VEGF peptide portion (referred to herein as the "second" or "non-VEGF" peptide portion) covalently associated with the first peptide portion. The first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. The peptide portions can be any sequence of covalently-associated amino acid residues. Typically, the peptide portions will include an amino acid sequence of a naturally occurring protein or related amino acid sequence. A peptide portion can include an entire protein, e.g., a naturally occurring protein. The peptide portion can be any suitable size and consist of any suitable number of amino acid residues (e.g., 10, 20, 50, 75, 100, 400, 500, or more amino acid residues). Preferably, the peptide portion includes about 10-700 amino acid



residues, more preferably about 20-600 amino acid residues, even more preferably about 50-500 amino acid residues (e.g., about 100-450 amino acid residues).

**[0012]** The first or VEGF peptide portion typically and preferably comprises a non-heparin-binding VEGF. As such, the term "VEGF peptide portion" or "first peptide portion" is directed to such peptides (although fusion proteins comprising heparin-binding VEGF peptide portions also are contemplated and separately discussed herein). The VEGF peptide portion can comprise any suitable non-heparin-binding VEGF. Preferably, the VEGF peptide portion includes a VEGF-A (VEGF-I). A particularly preferred non-heparin-binding VEGF-A isoform is human VEGF<sub>121</sub> (SEQ ID NO: 1) and homologs thereof (e.g., bovine or murine VEGF<sub>120</sub>), which are described in, e.g., U.S. Patents 5,219,739 and 5,194,596. Fragments of such VEGFs also can be used (e.g., a fragment comprising at least 65%, preferably at least about 75%, 80%, 85%, 87%, and more preferably at least about 90% (e.g., about 95%) of VEGF<sub>121</sub>). Typically and preferably, the non-heparin-binding VEGF portion will be a portion of a naturally occurring VEGF, e.g., human VEGF<sub>121</sub> (described generally in, e.g., Gitay-Goren et al., *J. Biol. Chem.*, 271, 5519-23 (1996), and U.S. Patent 5,219,739), VEGF-C, or VEGF-E (described generally in, e.g., Ogawa et al., *J. Biol. Chem.*, 273(47), 31273-82 (1998), and Meyer et al., *EMBO J.*, 18(2), 363-74 (1999)).

**[0013]** The VEGF peptide portion is not limited to naturally occurring non-heparin-binding VEGFs, but also can be a non-heparin-binding fragment of a naturally occurring heparin-binding VEGF (e.g., VEGF<sub>110</sub>) (as described in, e.g., Keck et al., *Arch. Biochem. Biophys.*, 344(1), 103-113 (1997)). Thus, for example, the VEGF peptide portion can include a non-heparin-binding fragment of a mammalian VEGF-B (VEGF-II) (e.g., VEGF-B<sub>167</sub> and VEGF-B<sub>186</sub>) (described in, e.g., Grimmond et al., *Genome Res.*, 6, 122-29 (1996), Olofsson et al., *Proc. Natl. Acad. Sci. USA*, 93, 2567-81 (1996), and U.S. Patent 5,840,693, or a fragment of a modified VEGF-B (e.g., as described in International Patent Application WO 98/49300)), VEGF-C (described in, e.g., Joukov et al., *EMBO J.*, 15, 290-98 (1996), and Lee et al., *Proc. Natl. Acad. Sci. USA*, 93, 1988-92 (1996)), VEGF-C (as described in e.g., Juokov et al., *EMBO J.*, 16, 3898-11 (1997) and Lee et al., *Proc. Natl. Acad. Sci. USA*, 93, 1988-1992 (1996)), VEGF-D (described in, e.g., Achen et al. *Proc. Natl. Acad. Sci. USA*, 95, 548-53 (1998) and International Patent Application WO 99/33485), Placenta Growth Factor (PlGF) (e.g., PlGF-129 or PlGF-150) (described in, e.g., Maglione et al., *Proc. Natl. Acad. Sci. USA*, 88, 9267-71 (1991)), mammalian VEGF-E (not to be confused with non-heparin-binding Orf virus VEGF-E, discussed further herein) (as described in, e.g., International Patent Application WO 99/47677), the "VEGF-3s" described in International Patent Application WO 00/09148, the VEGF-2s described in International Patent Application WO 95/24473, the VEGF-2 of U.S. Patent 5,932,540, placenta growth factor

(PlGF) (as described in, e.g., Achen et al., *Int. J. Exp. Path.*, 79, 255-65 (1998) and references cited therein), GD-VEGF, or spinal cord derived growth factor (SCDGF) (as described in, e.g., Hanada et al., *FEBS Lett.*, 475(2), 97-102 (2000)). A preferred fragment comprises the VEGF-A receptor binding domain (about residues 8-109 of VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub>, and VEGF<sub>206</sub>) (SEQ ID NO: 2). Where the VEGF peptide portion comprises a non-heparin-binding fragment of a heparin-binding VEGF, or a truncated non-heparin-binding VEGF, it can be preferred that the VEGF peptide portion comprises the VEGF<sub>110</sub> sequence plus at least 5, more preferably at least 10 (but optionally more, e.g., 15, 20, or 25) amino acid sequences, which desirably correspond to or homologous with the 21 additional residues in VEGF<sub>121</sub>.

[0014] Alternatively, the VEGF peptide portion can include a non-heparin-binding fragment of a non-mammalian VEGF, such as ORFV2-VEGF or OV-VEGF7 (as described in, e.g., Lytle et al., *J. Virol.*, 68, 84-92 (1991) and Ogawa et al., *J. Biol. Chem.*, 273, 31273-82 (1998)). Where a non-heparin-binding fragment of an otherwise heparin-binding VEGF is used as the VEGF peptide portion, the VEGF peptide portion is preferably a fragment of a mammalian VEGF-A, such as VEGF<sub>138</sub>, VEGF<sub>145</sub>, VEGF<sub>148</sub>, VEGF<sub>162</sub>, VEGF<sub>165</sub>, VEGF<sub>182</sub>, VEGF<sub>189</sub>, VEGF<sub>206</sub>, PlGF-2, and variants thereof (as described in, e.g., Poltorak et al., *J. Biol. Chem.*, 272, 7151-58 (1997), U.S. Patents 6,057,428 and 6,013,780, and International Patent Applications WO 98/10071 and WO 99/40197). For example, the VEGF peptide portion can be a VEGF<sub>189</sub> or VEGF<sub>165</sub> fragment lacking about 25, preferably about 35, and more preferably about 40, of the amino acid residues located between positions 116 and 159 in these peptides (SEQ ID NO: 3). Other suitable fragments include modified wild-type VEGFs, such as the truncated VEGFs described in International Patent Application WO 98/49300.

[0015] Alternatively still, the VEGF peptide portion can include an amino acid sequence of a VEGF variant or homolog, which (1) exhibits high levels of amino acid sequence identity (either globally or locally) to a naturally occurring VEGF, (2) exhibits high levels of amino acid sequence homology to a naturally occurring VEGF, (3) exhibits a substantially similar hydrophilicity to a naturally occurring VEGF, (4) is encoded by a polynucleotide which hybridizes to a polynucleotide which encodes naturally occurring VEGF or a degenerate sequence thereof and which, when expressed, produces a non-heparin binding protein, or (5) meets any combination of (1)-(4). Preferably, the VEGF homolog exhibits high levels of sequence identity to a naturally occurring VEGF. VEGF homologs that do not exhibit high levels of identity to a naturally occurring VEGF preferably exhibit high levels of amino acid conservation and similar hydrophobicity to a naturally occurring VEGF. Such VEGF homolog peptide portions can be obtained in any suitable manner, including by synthetically preparing such homologs (e.g., through

recombinant DNA technologies such as those further described herein) and identifying genes encoding naturally occurring VEGF homologs or orthologs, using techniques described herein and/or otherwise known in the art.

**[0016]** Preferably, the VEGF homolog peptide portion exhibits a significant level of identity to a naturally occurring VEGF, preferably a naturally non-heparin binding VEGF, and most preferably VEGF<sub>121</sub>. The VEGF homolog peptide portion desirably exhibits at least about 50%, preferably at least about 75% (e.g., at least about 80%), more preferably at least about 85%, and even more preferably at least about 90% (e.g., at least about 95%) amino acid global sequence identity (i.e., overall or total) to a naturally occurring VEGF (e.g., VEGF-E (as described in, e.g., Meyer et al., *EMBO J.*, 18(2), 363-74 (1999)), PlGF-1, or VEGF<sub>121</sub>).

**[0017]** "Identity" with respect to amino acid or polynucleotide sequences refers to the percentage of residues or bases that are identical in the two sequences when the sequences are optimally aligned. If, in the optimal alignment, a position in a first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the sequences exhibit identity with respect to that position. The level of identity between two sequences (or "percent sequence identity") is measured as a ratio of the number of identical positions shared by the sequences with respect to the size of the sequences (i.e., percent sequence identity = (number of identical positions/total number of positions) x 100).

**[0018]** The "optimal alignment" is the alignment which provides the highest identity between the aligned sequences. In obtaining the optimal alignment, gaps can be introduced, and some amount of non-identical sequences and/or ambiguous sequences can be ignored. Preferably, if a gap needs to be inserted into a first sequence to achieve the optimal alignment, the percent identity is calculated using only the residues that are paired with a corresponding amino acid residue (i.e., the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence). However, it is often preferable that the introduction of gaps and/or the ignoring of non-homologous/ambiguous sequences is associated with a "gap penalty."

**[0019]** A number of mathematical algorithms for rapidly obtaining the optimal alignment and calculating identity between two or more sequences are known and incorporated into a number of available software programs. Examples of such programs include the MATCH-BOX, MULTAIN, GCG, FASTA, and ROBUST programs for amino acid sequence analysis, and the SIM, GAP, NAP, LAP2, GAP2, and PIPMAKER programs for nucleotide sequences. Preferred software analysis programs for both amino acid and polynucleotide sequence analysis include the ALIGN, CLUSTAL-W (e.g., version 1.6 and

later versions thereof), and BLAST programs (e.g., BLAST 2.1, BL2SEQ, and later versions thereof).

[0020] For amino acid sequence analysis, a weight matrix, such as the BLOSUM matrixes (e.g., the BLOSUM45, BLOSUM50, BLOSUM62, and BLOSUM80 matrixes), Gonnet matrixes (e.g., the Gonnet40, Gonnet80, Gonnet120, Gonnet160, Gonnet250, and Gonnet350 matrixes), or PAM matrixes (e.g., the PAM30, PAM70, PAM120, PAM160, PAM250, and PAM350 matrixes), are used in determining identity. BLOSUM matrixes are preferred. The BLOSUM50 and BLOSUM62 matrixes are typically most preferred. In the absence of availability to use such weight matrixes (e.g., in nucleic acid sequence analysis and with some amino acid analysis programs), a scoring pattern for residue/nucleotide matches and mismatches can be used (e.g., a +5 for a match -4 for a mismatch pattern).

[0021] The ALIGN program produces an optimal global alignment of the two chosen protein or nucleic acid sequences using a modification of the dynamic programming algorithm described by Myers and Miller, *CABIOS*, 4, 11-17 (1988). Preferably, if available, the ALIGN program is used with weighted end-gaps. If gap opening and gap extension penalties are available, they are preferably set between about -5 to -15 and 0 to -3, respectively, more preferably about -12 and -0.5 to -2, respectively, for amino acid sequence alignments, and -10 to -20 and -3 to -5, respectively, more preferably about -16 and -4, respectively, for nucleic acid sequence alignments. The ALIGN program and principles underlying it are further described in, e.g., Pearson et al., *Proc. Natl. Acad. Sci. USA*, 85, 2444-48 (1988), and Pearson et al., *Methods Enzymol.*, 183, 63-98 (1990).

[0022] The BLAST programs provide analysis of at least two amino acid or nucleotide sequences, either by aligning a selected sequence against multiple sequences in a database (e.g., GenSeq), or, with BL2SEQ, between two selected sequences. BLAST programs are preferably modified by low complexity filtering programs such as the DUST or SEG programs, which are preferably integrated into the BLAST program operations (see, e.g., Wootton et al., *Compu. Chem.*, 17, 149-63 (1993), Altschul et al., *Nat. Genet.*, 6, 119-29 (1994), Hancock et al., *Comput. Appl. Biosci.* 10, 67-70 (1994), and Wootton et al., *Meth. in Enzym.*, 266, 554-71 (1996)). If a lambda ratio is used, preferred settings for the ratio are between 0.75 and 0.95, more preferably between 0.8 and 0.9. If gap existence costs (or gap scores) are used, the gap existence cost is preferably set between about -5 and -15, more preferably about -10, and the per residue gap cost is preferably set between about 0 to -5, more preferably between 0 and -3 (e.g., -0.5). Similar gap parameters can be used with other programs as appropriate. The BLAST programs and principles underlying them are further described in, e.g., Altschul, et al., *J. Mol. Biol.*, 215, 403-10 (1990), Karlin and Altschul, *Proc. Natl. Acad. Sci. USA*, 87, 2264-68 (1990) (as modified by Karlin and

Altschul, *Proc. Natl. Acad. Sci. USA*, 90, 5873-77 (1993)), and Altschul et al., *Nucl. Acids Res.*, 25, 3389-3402 (1997).

**[0023]** For multiple sequence analysis, the CULSTAL-W program can be used. The CLUSTAL-W program desirably is run using "dynamic" (versus "fast") settings. Preferably, nucleotide sequences are compared using the BESTFIT matrix, whereas amino acid sequences are evaluated using a variable set of BLOSUM matrixes depending on the level of identity between the sequences (e.g., as used by the CLUSTAL-W version 1.6 program available through the San Diego Supercomputer Center (SDSC)). Preferably, the CLUSTAL-W settings are set to the SDSC CLUSTAL-W default settings (e.g., with respect to special hydrophilic gap penalties in amino acid sequence analysis). The CLUSTAL-W program and underlying principles of operation are further described in, e.g., Higgins et al., *CABIOS*, 8(2), 189-91 (1992), Thompson et al., *Nucleic Acids Res.*, 22, 4673-80 (1994), and Jeanmougin et al., *Trends Biochem. Sci.*, 23, 403-07 (1998).

**[0024]** Several commercially available software suites incorporate the ALIGN, BLAST, and CLUSTAL-W programs and similar functions, and may include significant improvements in settings and analysis. Examples of such programs include the GCG suite of programs and those available through DNASTAR, Inc. (Madison, Wisconsin). Particular preferred programs include the Lasergene and Protean programs sold by DNASTAR.

**[0025]** Because various algorithms, matrixes, and programs are commonly used to analyze sequences, "identity" is commonly understood in the art to represent a variable measurement. Accordingly, the identity between two sequences is preferably not limited to any exact measurement by a single technique, but, rather, is understood to represent an approximate range "about" a particular identity (e.g., +/- 10%, more preferably +/- 8%, and even more preferably +/- 5% of the particular identity). Alternatively, an exact identity can be measured by using only one of the aforementioned programs, preferably one of the BLAST programs, as described herein.

**[0026]** The VEGF homolog peptide portion also can include or consist of a peptide which exhibits significant levels of local sequence identity to a naturally occurring, preferably naturally non-heparin-binding, VEGF, despite lacking an overall sequence identity at the above-described levels. For example, VEGF homolog peptide portions which exhibit at least about 70% identity, preferably at least about 80% (e.g., about 85%), and more preferably at least about 90% (e.g., about 95%) identity, across a local alignment of at least about 65, preferably at least about 75, and more preferably at least about 90 amino acid residues, to a naturally occurring VEGF (e.g., VEGF<sub>121</sub>) can be suitable.

**[0027]** Local sequence alignment can be determined using local sequence alignment software, e.g., the BLAST programs described above, the LFASTA program, or, more preferably, the LALIGN program. Preferably, the LALIGN program using a BLOSUM50

matrix analysis is used for amino acid sequence analysis, and a +5 match/-4 mismatch analysis is used for polynucleotide sequence analysis. Gap extension and opening penalties are preferably the same as those described above with respect to analysis with the ALIGN program. For LALIGN (or other program) analysis using k-tup value settings (also referred to as "k-tuple" or ktup values), a k-tup value of 0-3 for proteins, and 0-10 (e.g., about 6) for nucleotide sequences, is preferred.

**[0028]** The VEGF homolog peptide portion can alternatively include a peptide portion that exhibits high levels of homology to a naturally occurring, preferably naturally non-heparin binding, VEGF, despite lacking the above-described levels of global or local identity. For example, a VEGF homolog peptide portion which exhibits at least about 80%, preferably at least about 90%, and more preferably at least about 95% to a naturally occurring VEGF homology amino acid sequence, can be suitable, even though the homolog exhibits relatively low levels of identity (e.g., less than about 40% identity) to its wild-type VEGF homolog. "Homology" is a function of the number of corresponding conserved and identical amino acid residues in the optimal homology alignment. The "optimal homology alignment" is the alignment which provides the highest level of homology between two amino acid sequences, using the principles described above with respect to the "optimal alignment." Conservative amino acid residue substitutions involve exchanging a member within one class of amino acid residues for a residue that belongs to the same class. VEGF homolog peptide portions containing conservative substitutions are expected to substantially retain the biological properties and functions associated with their wild-type counterpart. The classes of amino acids and the members of those classes are presented in Table 1.

*Table 1 – Amino Acid Residue Classes*

Amino Acid Class	Amino Acid Residues
Acidic Residues	ASP and GLU
Basic Residues	LYS, ARG, and HIS
Hydrophilic Uncharged Residues	SER, THR, ASN, and GLN
Aliphatic Uncharged Residues	GLY, ALA, VAL, LEU, and ILE
Non-polar Uncharged Residues	CYS, MET, and PRO
Aromatic Residues	PHE, TYR, and TRP

**[0029]** Preferably, the highly hydrophilic VEGF homolog peptide portion or highly conserved VEGF homolog peptide portion exhibits high weight homology to a naturally occurring VEGF, most preferably VEGF<sub>121</sub>. "High weight homology" means that at least about 40%, preferably at least about 60%, and more preferably at least about 70% of the non-identical amino acid residues are members of the same weight-based "weak

conservation group" or "strong conservation group" as the corresponding amino acid residue in the wild-type VEGF. Strong group conservation is preferred. Weight-based conservation is determined on the basis of whether the non-identical corresponding amino acid is associated with a positive score on one of the weight-based matrices described herein (e.g., the BLOSUM50 matrix), typically and preferably the PAM250 matrix. Weight-based strong conservation groups include STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, and FYW. Weight-based weak conservation groups include CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, and HFY. The CLUSTAL W sequence analysis program provides analysis of weight based strong conservation and weak conservation groups in its output, and offers the preferred technique for determining weight-based conservation, preferably using the CLUSTAL W default settings used by the San Diego Supercomputer (SDSC).

**[0030]** Alternatively, the VEGF peptide portion can include a peptide exhibiting high levels of hydrophobicity/hydrophilicity conservation ("hydrophilicity") to a naturally occurring, preferably naturally non-heparin binding, VEGF, optimally VEGF<sub>121</sub>. Hydrophilicity can be determined using the Key & Doolittle index, the scores for each naturally occurring amino acid in the index being as follows: I (+4.5), V (+4.2), L (+3.8), F (+2.8), C (+2.5), M (+1.9); A (+1.8), G (-0.4), T (-0.7), S (-0.8), W (-0.9), Y (-1.3), P (-1.6), H (-3.2); E (-3.5), Q (-3.5), D (-3.5), N (-3.5), K (-3.9), and R (-4.5) (see, e.g., U.S. Patent 4,554,101 for further discussion). The VEGF portion can include a peptide where at least 45%, preferably at least 60%, and more preferably at least 75% (e.g., at least 85%, 90%, or 95%) of the amino acid residues which differ from the naturally occurring VEGF exhibit less than a +/-2 change in hydrophilicity, more preferably less than a +/-1 change in hydrophilicity, and even more preferably less than a +/-0.5 change in hydrophilicity. Thus, the VEGF peptide portion preferably exhibits a total change in hydrophilicity of less than about 150, more preferably less than about 100, and even more preferably less than about 50 (e.g., less than about 30, 20, or 10). Examples of typical amino acid substitutions which retain similar or identical hydrophilicity include arginine-lysine substitutions, glutamate-aspartate substitutions, serine-threonine substitutions, glutamine-asparagine substitutions, and valine-leucine-isoleucine substitutions.

**[0031]** In yet another alternative, the non-heparin binding VEGF homolog peptide can include a peptide encoded by a polynucleotide that hybridizes to (1) the complement of a polynucleotide that, when expressed, results in a naturally occurring non-heparin-binding VEGF (e.g., a polynucleotide encoding human VEGF<sub>121</sub> (SEQ ID NO: 4)) or (2) a polynucleotide which would hybridize to the complement of such a sequence but for the degeneracy of the genetic code, under at least moderate, preferably high, stringency conditions. Exemplary moderate stringency conditions include overnight incubation at

37°C in a solution comprising 20% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1x SSC at about 37-50°C, or substantially similar conditions, e.g., the moderately stringent conditions described in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Press 1989). High stringency conditions are conditions that use, for example (1) low ionic strength and high temperature for washing, such as 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate (SDS) at 50°C, (2) employ a denaturing agent during hybridization, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin (BSA)/0.1% Ficoll/0.1% polyvinylpyrrolidone (PVP)/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C, or (3) employ 50% formamide, 5x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at (i) 42°C in 0.2x SSC, (ii) at 55°C in 50% formamide and (iii) at 55°C in 0.1x SSC (preferably in combination with EDTA). Additional details and explanation of stringency of hybridization reactions are provided in, e.g., Ausubel et al., *Current Protocols in Molecular Biology* (Wiley Interscience Publishers 1995).

**[0032]** The VEGF homolog peptide portion desirably retains identity to naturally occurring VEGFs at highly conserved residues. Conserved residues can be identified by using CLUSTAL-W or a similar program to identify positions where sequences are identical across many, most, or all of the members of a group of related proteins in the original alignment. Thus, for example, the VEGF peptide portion preferably retains the eight cysteine residues that are positionally conserved within the VEGF-A and PDGF protein families; preferably the VEGF peptide portion retains the cysteine knot structure formed by the non-dimer associated cysteines in this conserved domain, and more particularly the VEGF portion preferably comprises an amino acid sequence having the sequence pattern Pro Xaa Cys Val Xaa Xaa Xaa Arg Cys Xaa Gly Cys Cys Asn (SEQ ID NO: 5), where Xaa represents any amino acid residue, preferably a residue selected from one of the twenty naturally occurring amino acids. Desirably, the VEGF portion also or alternatively retains conserved residues in the kinase-insert domain-containing (KDR) receptor-binding domain of KDR-binding VEGFs, such as Arg<sub>82</sub>, Lys<sub>84</sub>, His<sub>86</sub>, and/or, even more preferably, Asp<sub>63</sub>, Glu<sub>64</sub>, and Glu<sub>67</sub>, and the hydrophobic residues within about 55 amino acid residues or less (e.g., 50 residues or less, 40 residues or less, or 30 residues or less) of Asp<sub>63</sub> (such sequences are in reference to the positions in the N-terminus of all VEGF-A isoforms, e.g., VEGF<sub>121</sub>). Advantageously, the VEGF peptide portion retains the conserved residues/sequences necessary to induce autophosphorylation at human KDR



receptor positions 1054 and 1059 (or their analogs in other species), which maximizes KDR kinase activity. Also desirably, the VEGF portion retains the VEGF glycosylation site at or near Asn<sub>75</sub> in wild type VEGF-As, or a functionally similar counterpart thereof.

**[0033]** The VEGF homolog peptide portion is desirably recognized by anti-VEGF antibodies, preferably human anti-VEGF antibodies, and desirably at least one monoclonal anti-VEGF antibody. Any suitable anti-VEGF antibody can be used. Examples of suitable antibodies are described in, e.g., Kim et al., *Nature*, 362, 841-44 (1993), Borgstrom et al., *Cancer Res.*, 56(17), 4032-39 (1996), Presta et al., *Cancer Res.*, 57(20), 4593-99 (1997), Wang et al., *J. Cancer Res., Clin. Oncol.*, 124(11), 615-20 (1998), Asano et al. *Jpn. J. Cancer Res.*, 90(1), 93-100 (1999), Mordenti et al., *Toxicol. Pathol.*, 27(1):, 14-21 (1999), and Schlaeppli et al., *J. Cancer Res., Clin. Oncol.*, 125(6), 336-42 (1999), as well as U.S. Patent 5,219,739.

**[0034]** The VEGF homolog peptide portion preferably comprises a region of structural similarity to a non-heparin binding VEGF, preferably VEGF<sub>121</sub>, or a non-heparin-binding VEGF fragment (e.g., VEGF<sub>110</sub>). VEGF peptide portions comprising a portion exhibiting structural similarity to VEGF<sub>121</sub> (i.e., including the C-terminal domain thereof), or consisting essentially of such a structure, are particularly preferred. Structural similarity can be determined by any suitable technique, preferably using a suitable software program for making such assessments. Examples of such programs include the MAPS program and the TOP program (described in Lu, *Protein Data Bank Quarterly Newsletter*, #78, 10-11 (1996), and Lu, *J. Appl. Cryst.*, 33, 176-183 (2000)). Using these programs the VEGF homolog peptide portion will desirably exhibit a low structural diversity, topological diversity (e.g., a topical diversity of less than about 20, preferably less than about 15, and more preferably less than about 10), or both. Alternatively, the homolog can be compared to the desired VEGF using the PROCHECK program (described in, e.g., Laskowski, *J. Appl. Cryst.*, 26, 283-291 (1993)), the MODELLER program, or commercially available programs incorporating such features. Alternatively, a sequence comparison using a program such as the PredictProtein server (available at <http://dodo.cpmc.columbia.edu/predictprotein/>) should reveal similar structure for the VEGF homolog peptide portion and a wild-type non-heparin-binding VEGF, preferably VEGF<sub>121</sub>.

**[0035]** The administration of the VEGF homolog peptide portion, or expression of the peptide portion from a polynucleotide, preferably induces the synthesis of plasminogen activator, plasminogen activator inhibitor type-1, interstitial collagenase, or a combination thereof.

**[0036]** Polynucleotides encoding VEGF homologs including sequences encoding VEGF homolog peptide portions can be identified in living systems through screening polynucleotide libraries (e.g., a genomic library, cDNA library, or sublibrary thereof). Such

screening can be performed by any suitable technique, including, e.g., screening the libraries with polynucleotide probes under conditions wherein hybridization to VEGF homolog-encoding polynucleotides is likely to occur (e.g., under at least moderately stringent conditions). Such screening can be performed in a human DNA or cDNA library (e.g., to determine novel VEGF splice variants or homologs), or in a polynucleotide library obtained from other species, preferably other mammalian species (e.g., *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hvlobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryns*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Orystolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*). Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to perform chromosomal screening for VEGF homolog-encoding genes. Pools of protein candidates can be similarly screened for VEGF homologs using standard biochemical and proteomics-related techniques (e.g., the yeast two hybrid system as described in, e.g., Mendelsohn and Brat, *Curr. Opin. Biotech.*, 5, 482-86 (1994), and/or affinity chromatography (e.g., using the KDR receptor or portion thereof)). The VEGF peptide portion and second peptide portion can be derived from the same or different species (e.g., the fusion protein can include a bovine or murine VEGF peptide portion and a human derived second peptide portion).

[0037] Polynucleotides comprising sequences encoding novel VEGF homolog peptide portions (also referred to as VEGF variant-encoding polynucleotides) also can be synthesized through inducing mutations in known VEGF-encoding polynucleotides (e.g., a VEGF-E gene sequence or VEGF<sub>121</sub> gene sequence). For example, VEGF variant-encoding polynucleotides can be obtained through application of site-directed mutagenesis (as described in, e.g., Edelman et al., *DNA*, 2, 183 (1983), Zoller et al., *Nucl. Acids Res.*, 10, 6487-5400 (1982), and Veira et al., *Meth. Enzymol.*, 153, 3 (1987)), alanine scanning, or random mutagenesis, such as iterated random point mutagenesis induced by error-prone PCR, chemical mutagen exposure, or polynucleotide expression in mutator cells (see, e.g., Bornscheuer et al., *Biotechnol. Bioeng.*, 58, 554-59 (1998), Cadwell and Joyce, *PCR Methods Appl.*, 3(6), S136-40 (1994), Kunkel et al., *Methods Enzymol.*, 204, 125-39 (1991), Low et al., *J. Mol. Biol.*, 260, 359-68 (1996), Taguchi et al., *Appl. Environ. Microbiol.*, 64(2), 492-95 (1998), and Zhao et al., *Nat. Biotech.*, 16, 258-61 (1998)). Suitable primers for PCR-based site-directed mutagenesis or related techniques can be prepared by the methods described in, e.g., Crea et al., *Proc. Natl. Acad. Sci. USA*, 75, 5765 (1978). The application of site-directed mutagenesis to produce novel VEGF variants is described by, e.g., Shortle et al., *Ann. Rev. Genet.*, 15, 288-94 (1981), Keyt et al., *J. Biol. Chem.*, 271, 5638-46 (1996), and Ki et al., *J. Biol. Chem.*, 275(38), 29823-28 (2000).

[0038] Other polynucleotide mutagenesis methods useful for producing novel VEGF variant-encoding polynucleotides include PCR mutagenesis techniques (as described in, e.g., Kirsch et al., *Nucl. Acids Res.*, 26(7), 1848-50 (1998), Seraphin et al., *Nucl. Acids Res.*, 24(16), 3276-7 (1996), Caldwell et al., *PCR Methods Appl.*, 2(1), 28-33 (1992), Rice et al., *Proc. Natl. Acad. Sci. USA*, 89(12), 5467-71 (1992) and U.S. Patent 5,512,463), cassette mutagenesis techniques based on the methods described in Wells et al., *Gene*, 34, 315 (1985), phagemid display techniques (as described in, e.g., Soumillion et al., *Appl. Biochem. Biotechnol.*, 47, 175-89 (1994), O'Neil et al., *Curr. Opin. Struct. Biol.*, 5(4), 443-49 (1995), Dunn, *Curr. Opin. Biotechnol.*, 7(5), 547-53 (1996), and Koivunen et al., *J. Nucl. Med.*, 40(5), 883-88 (1999)), and recursive ensemble mutagenesis (REM) (as described in, e.g., Arkin and Yourvan, *Proc. Natl. Acad. Sci. USA*, 89, 7811-15 (1992), and Delgrave et al., *Protein Eng.*, 6(3), 327-331 (1993)). Alternatively, VEGF variant-encoding polynucleotides can be pre-designed and synthetically produced using techniques such as those described in, e.g., Itakura et al., *Annu. Rev. Biochem.*, 53, 323 (1984), Itakura et al., *Science*, 198, 1056 (1984), and Ike et al., *Nucl. Acid Res.*, 11, 477 (1983). For example, sequence analysis of a number of VEGF polypeptides (e.g., a group of non-heparin-binding VEGF peptides and/or peptide portions) can be subjected to sequence analysis (e.g., using CLUSTAL-W) to identify an amino acid consensus sequence that can be used to design novel DNAs based on the genetic code (e.g., by subjecting the consensus sequence to reverse translation analysis). Further details regarding the above-described techniques are described in Sambrook et al., and Ausubel et al., *supra*.

[0039] Alternatively, VEGF variants can be generated through directed evolution techniques (e.g., polynucleotide shuffling). Examples of such techniques are described in, e.g., Stemmer, *Nature*, 370, 389-91 (1994), Cherry et al., *Nat. Biotechnol.* 17, 379-84 (1999), and Schmidt-Dannert et al., *Nat Biotechnol.*, 18(7), 750-53 (2000). Preferably, VEGF variant-encoding polynucleotide shuffling is performed in combination with staggered extension (StEP), random primer shuffling, backcrossing of improved variants, or any combination thereof, e.g., as described in Zhao et al., *supra*, Cherry et al., *supra*, Arnold et al., *Biophys. J.*, 73, 1147-59 (1997), Zhao and Arnold, *Nucl. Acids Res.*, 25(6), 1307-08 (1997), and Shao et al., *Nucl. Acids Res.*, 26, 681-83 (1998). Alternatively, the incremental truncation for the creation of hybrid enzymes (ITCHY) method (see, e.g., Ostermeier et al., *Nat. Biotechnol.*, 17(12), 1205-09 (1999)) can be applied to combinations of VEGF encoding genes or gene fragments (e.g., to two polynucleotide encoding different non-heparin binding VEGFs (e.g., a human VEGF<sub>121</sub> and zebrafish VEGF<sub>121</sub>), to two polynucleotides encoding substantially similar (or identical) VEGFs, or to combinations of a non-heparin-binding VEGF and other related protein (e.g., a heparin-binding VEGF)) to

produce novel VEGF variant-encoding polynucleotides. Another set of techniques for introducing diversity into a library of homologs are provided in U.S. Patent 6,159,687.

**[0040]** The biological activity of the products of molecular evolution are expected to vary, and, accordingly, some screening for biological activity of the directed evolution product can be required to ensure the peptide portion encoded by the VEGF variant-encoding polynucleotide is suitable for incorporation in the fusion protein and/or fusion protein-encoding polynucleotides of the present invention. Any suitable assay for measuring the desired biological activity of a molecule can be used. The type of assay selected for measuring the biological activity of the VEGF variant will depend on the desired property to be associated with the VEGF variant (e.g., promotion of angiogenesis, bone growth, or wound healing).

**[0041]** Examples of techniques for measuring angiogenesis, and thus for determining the angiogenic potential of angiogenic proteins (e.g., an angiogenic VEGF peptide portion or angiogenic fusion protein), include administering the angiogenic protein or DNA encoding the angiogenic protein (preferably in a suitable vector) in the rabbit or rat hind limb models (using a protocol as described in, e.g., Poliakova et al., *J. Thorac. Cardiovasc. Surg.*, 118(2), 339-47 (1999), Rosengart et al., *J. Vasc. Surg.*, 26(2), 302-12 (1997), Walder et al., *J. Cardiovasc. Pharmacol.*, 27, 91-98 (1996), and/or Takeshita et al., *J. Clin. Invest.*, 93(2), 662-70 (1994), U.S. Patent 6,121,246, or discussed herein in Example 1) and/or the mouse ear model (using a protocol similar to that described in, e.g., Kjosleth et al., *Microsurgery*, 15(6), 390-98 (1994), or as discussed herein in Example 1). Similar techniques are discussed in, e.g., Takeshita et al., *J. Clin. Invest.*, 93(20), 662-70 (1994). Other assays for assessing the angiogenic potential of an angiogenic factor include performing exercise tolerance tests (as described in, e.g., Fujita et al., *Circulation*, 77(5), 1022-29 (1988), Kornowski et al., *Am. J. Cardiol*, 81(7A), 44E-48E (1998), and Rosengart et al., *Circulation*, 100(5), 468-74 (1999)), magnetic resonance imaging (MRI) testing for local perfusion, rest and stress (adenosine) <sup>99m</sup>Tc-sestamibi SPECT tests, rest and stress (dobutamine) echocardiograms, gradient echo tests, intravascular ultrasound (IVUS) (as described in, e.g., Oshima et al., *Vasc. Med.*, 3(4), 281-90 (1998)), angiography tests, or any combinations thereof, after administration of the putative angiogenic factor to a tissue (preferably a potentially ischemic or ischemic tissue in a mammalian host). Other quantitative angiogenesis activity assays include the corneal pocket assay, the matrigel angiogenesis/endothelial cell assay, endothelial cell chemotaxis assays, umbilical artery outgrowth assay, choriollantoic membrane development assay, and related assays described in, e.g., Dellian et al., *Am. J. Path.*, 149, 59-72 (1996), Folkman, *Cell*, 79, 315-28 (1994), O'Reilly et al., *Cell*, 88, 277-84 (1997), and Ribatti et al., *J. Vasc. Res.*, 34, 455-63 (1997). A more recent assay specifically designed for analytically comparing the angiogenic

potential of different factors is described in Wang et al., *Int. J. Mol. Med.*, 6(6), 645-53 (2000). The angiogenesis-inducing capability of a factor also can be determined by comparative measurement of the number of blood vessels, blood vessel density, total blood vessel volume, blood flow measurements, blood pressure ratios, or the like, in a particular tissue to which an angiogenic factor has been administered (as described in, e.g., Sands et al., *Cancer Lett.*, 27(1), 15-21 (1985), Pu, et al., *Circulation*, 88, 208-15 (1993), Bauters et al., *Am. J. Physiol.*, 267, H1263-71 (1994), Takeshita et al., *supra*, Bauters et al., *Circulation*, 91, 2802-09 (1995), Bauters et al., *J. Vasc. Surg.*, 21, 314-25 (1995), and Witzenbichler et al., *Am. J. Pathol.*, 153(2), 381-94 (1998)). Other useful techniques for measuring angiogenesis include those described in U.S. Patents 5,976,782, 5,972,639, and 5,919,759, as well as the *in vitro* angiogenesis assays described in Tolsma et al., *J. Cell Biol.*, 122, 497 (1993), and Vogel et al., *J. Cell. Biochem.*, 53, 74 (1993).

[0042] Bone growth (and thus promotion thereof) can be assessed by assays such as those described in, e.g., Hosh-Choudhery et al., *Endocrinology*, 137, 331-39 (1996), Urist et al., *Proc. Soc. Exp. Biol. Med.*, 176, 472-75 (1984), Deftos et al., *Clin. Chem.*, 38, 2318-21 (1992), Hassager et al., *Metabolism*, 40, 205-08 (1991), Kanzaki et al., *J. Clin. Endocrinol. Metab.*, 75, 1104-1109 (1992), and U.S. Patents 4,857,456, 5,656,598, 6,071,708, 6,080,779, and 6,150,328. Assays for wound healing activity include those described in Winter, *Epidermal Wound Healing*, 71-112 (Maibach, HI and Rovee, DT, eds.), as modified by Eaglstein et al., *J. Invest. Dermatol.*, 71, 382-84 (1978).

[0043] Other biological activities also or alternatively can be considered in assessing the therapeutic potential of a peptide portion or fusion protein. For example, tissue generation/repair activity, which can be associated with VEGF homologs and fusion proteins, can be assayed using the techniques described in International Patent Applications WO 95/16035, WO 95/05846, and WO 91/07491. Chemotactic activity, which also can be associated with VEGF peptide portions and fusion proteins can be assayed by testing their ability to induce the migration of cells across a membrane or to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include those described in, e.g., Current Protocols in Immunology, Chapter 6.12 (Colligan et al. eds.), Taub et al., *J. Clin. Invest.*, 95, 1370-76 (1995), Lind et al. *APMIS*, 103, 140-46 (1995), Muller et al., *Eur. J. Immunol.*, 25, 1744-48 (1994), Gruber et al., *J. Immunol.*, 152, 5860-67 (1994), and Johnston et al., *J. Immunol.*, 153, 1762-68 (1994). Receptor-ligand binding can be determined by the assays described in, e.g., Takai et al., *Proc. Natl. Acad. Sci. USA*, 84, 6864-68 (1987), Bierer et al., *J. Exp. Med.*, 168, 1145-56 (1988), Rosenstein et al., *J. Exp. Med.*, 169, 149-60 (1989), Stoltenborg et al., *J. Immunol. Methods*, 175, 59-68 (1994), Stitt et al., *Cell*, 80, 661-70 (1995), and Chapter 7.28 of Current Protocols in

Immunology (Coligan and Kruisbeek eds). Additional assays related to the aforementioned biological activities are described in U.S. Patent 6,099,823.

**[0044]** The VEGF peptide portion can be any suitable size which enables the VEGF portion to exhibit an angiogenic, bone growth promoting, or wound healing promoting activity, or combinations thereof, as desired. Preferably, the biological activity of the VEGF portion is substantially similar to that of a naturally occurring non-heparin-binding VEGF, preferably VEGF<sub>121</sub> (e.g., about 70% or more, preferably about 80% or more, more preferably about 90% or more, and advantageously at least as much as, and optimally more than, the angiogenesis inducing capacity as VEGF<sub>121</sub>) in a mammalian host. Such biological activity can be measured by any of the methods described herein or their equivalents in the art. Typically and preferably, the VEGF peptide portion will include a VEGF amino acid sequence of less than about 160 amino acid residues, or, more preferably, less than about 150 amino acid residues (e.g., less than about 130 amino acid residues, less than about 120 amino acid residues, less than about 100 amino acid residues, or less than about 90 amino acid residues). Advantageously, the VEGF peptide portion will include a VEGF amino acid sequence of at least 115 amino acid residues, preferably at least about 120 amino acid residues. By non-heparin-binding it is meant that less than about 5% of the VEGF peptide portion of the fusion protein should be bound to heparin-containing sites at a given moment after administration to or expression in a mammalian host (compared to, e.g., about 50-70% binding for VEGF<sub>165</sub>, and about 90-100% for VEGF<sub>189</sub>). More preferably, the VEGF peptide portion exhibits no apparent affinity for heparin, as exhibited by VEGF-C, non-heparin-binding PlGFs, VEGF-E, and, more preferably, VEGF<sub>121</sub>.

**[0045]** Preferably, the VEGF peptide portion exhibits higher affinity for the kinase-insert domain-containing (KDR) receptor (also known as VEGFR-2) than the *fms*-like tyrosine kinase type 1 (*flt-1*) receptor (also known as VEGF-R1) or, e.g., the murine *flk-1* homolog receptor thereof and/or VEGFR-3 (or *Flk* receptor). Such VEGF peptide portions are likely to be associated with higher levels of endothelial cell proliferation due to interaction with the KDR receptor without the growth suppressive effects brought about by too much competing *flt-1* interaction (see, e.g., Ahmed et al., *Lab. Invest.*, 77(6), 779-91 (1997), for discussion). Endothelial cell proliferation can be measured by any suitable technique, such as the technique described in Olofsson et al., *Proc. Natl. Acad. Sci. USA*, 93, 2576-81 (1991). Desirably, the angiogenic fusion proteins of the invention generally exhibit higher levels of endothelial cell proliferation upon *in vivo* expression or administration. Preferably, the VEGF peptide portion exhibits at least about 4x, preferably at least about 5x, and more preferably at least about 6x the affinity for the KDR receptor than the *flt-1* receptor. More particularly, it is preferred that the VEGF peptide portion exhibits an apparent affinity for the *flt-1* receptor marked by a dissociation constant ( $K_d$ ) at

least about 150 pM, more preferably at least about 175 pM, and even more preferably at least about 200 pM, and optimally not binding to flt-1, while exhibiting an affinity for the KDR receptor marked by a dissociation constant of about 20-30 pM, more preferably about 25-35 pM, and even more preferably about 30 pM. Desirably, the VEGF peptide portion exhibits even less affinity for the flk receptor than the flt receptor, and optimally does not bind the flk receptor at all. VEGF receptor binding can be determined using any suitable technique, such as the VEGF receptor binding assays described in International Patent Application WO 98/49300.

**[0046]** The VEGF peptide portion also desirably exhibits low affinity for neurophilin-1, neurophilin-2, or both. Preferably, the VEGF peptide portion exhibits an affinity for either or both neurophilins or related proteins (analogs or variants), e.g., marked by a dissociation constant of at least 1,000 pM, more preferably at least 10,000 pM. Ideally, the VEGF peptide portion exhibits an affinity for neurolipin-1 and neurolipin-2 equal to, or less than, the affinity exhibited by VEGF<sub>121</sub> (i.e., no apparent affinity). By exhibiting low affinity, or, more preferably, by not binding neurophilins whatsoever, the VEGF peptide portion can avoid undesired interactions which reduce the amount of binding to therapeutic receptors of interest (e.g., the KDR receptor) and avoids interaction with neurophilin-associated tumor cells.

**[0047]** The VEGF peptide portion preferably exhibits a lower level of association with cells and matrix than that of VEGF<sub>189</sub> and VEGF<sub>206</sub> (e.g., VEGF<sub>206</sub> residues 115-139 - see, e.g., Ferrara et al., *Endocr. Rev.*, 13, 18-32 (1992)). In this respect, the VEGF peptide portion preferably lacks a functional "matrix targeting" sequence, a functionally homologous sequence or domain, or any similar sequence. Similarly, the VEGF peptide portion preferably lacks cell association signals, such as the 24 mer motif, Lys Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr Lys Ser Trp Ser Val (SEQ ID NO: 6), common to VEGF<sub>189</sub> and VEGF<sub>206</sub>.

**[0048]** The VEGF peptide portion preferably comprises a weakly acidic to neural peptide. Thus, the VEGF peptide portion preferably comprises more acidic residues than basic residues. The VEGF peptide portion preferably exhibits less affinity for S-Sepharose than for Q-Sepharose. Desirably, the VEGF peptide portion is associated with a chaperone-associated sequence, which induces interaction with a chaperone with capacity to restore the VEGF peptide portion if damaged by oxidants. Preferably, such chaperon association does not require heparin; for example heparin-dependent Glypican-1 interaction is not desired.

**[0049]** The VEGF peptide portion preferably comprises the C-terminal domain of VEGF<sub>121</sub> or a closely related domain, particularly the C-terminal cysteine or a counterpart thereof. Thus, the VEGF peptide portion preferably comprises an amino acid sequence falling within the pattern X<sub>h</sub>X<sub>b</sub>X<sub>h</sub>X<sub>a</sub>X<sub>b</sub>C, such as Ala Arg Gln Glu Lys Cys (SEQ ID NO:

7), which is a preferred sequence in this pattern, and more preferably comprises a sequence falling within the pattern  $X_hX_bX_hX_aX_bCX_aX_bX_nX_bX_b$ , such as Ala Arg Gln Glu Lys Cys Asp Lys Pro Arg Arg (SEQ ID NO: 8), which is the preferred sequence within this pattern (wherein  $X_h$  represents a hydrophilic uncharged residue,  $X_b$  represents a basic residue,  $X_a$  represents an acidic residue, C represents a cysteine, and  $X_n$  represents a non-polar uncharged residue) positioned near the peptide portion's C-terminus (e.g., about 30, preferably about 20, and more preferably about 15 amino acid residues or less from the C-terminus). The VEGF peptide portion desirably may comprise, or more typically lack, part or all of a sequence corresponding to the VEGF 6b exon, the VEGF6a exon, or both. Thus, for example, the VEGF peptide can be free of the N-terminal half of the VEGF 6b exon-encoded sequence (SEQ ID NO: 9), the C-terminal half of the VEGF 6b exon-encoded sequence (SEQ ID NO: 10), the core exon 6b-encoded sequence (SEQ ID NO: 11), the core exon 6a-encoded sequence (SEQ ID NO: 12), fragment of the exon 6a-encoded sequence, or sequences which exhibit high levels of identity thereto (e.g., about 80% identity or higher). In some circumstances, a VEGF peptide portion which exhibits a higher level of homology, more preferably identity, to other VEGFs than to a VEGF-B or VEGF-C, particularly to a VEGF-B is preferred.

**[0050]** The VEGF peptide portion is covalently associated with at least one additional non-VEGF peptide portion (also referred to as the "second" peptide portion). The non-VEGF peptide portion can be any suitable peptide portion including a non-VEGF factor, preferably which is capable of promoting angiogenesis, bone growth, wound healing, or any combination thereof, separate from such properties attributed to the VEGF peptide portion (i.e., by directly promoting such biological activities rather than merely augmenting such properties otherwise associated with the VEGF peptide portion). By "non-VEGF" portion, it is meant that the second peptide portion exhibits less than about 20%, preferably less than 10%, and more preferably less than 5% amino acid sequence identity to the VEGF peptide portion, and preferably exhibits at least one distinct biological function from that associated with the VEGF peptide portion, preferably a function related to angiogenesis, bone growth, and/or wound healing. In some circumstances, second peptide portions that exhibit higher levels of angiogenesis inducing activity or bone growth promoting activity than wound healing promoting activity are preferred. Also, in some circumstances, second peptide portions which exhibit less wound healing activity than the wound healing factors described herein can be desirable. Assessments of the angiogenic, bone growth promoting, and wound healing promoting activity of the second peptide proteins can be determined using any of the tests for determining such activities described herein or equivalent such tests. Most preferably, the second peptide portion promotes angiogenesis *in vivo* (alone or in combination with promoting bone growth and/or wound healing). Often it is desirable that



the second peptide portion lacks a functional collagen-binding domain, or more preferably any collagen-binding domain, particularly where the VEGF peptide portion is about 110 amino acids or less in length (e.g., a VEGF<sub>110</sub> peptide portion).

**[0051]** The second peptide portion can interact with any suitable receptor on any suitable cell type (e.g., a TIE2 receptor in the case of an Ang-1 or ARF second peptide portion) or no receptor at all (e.g., in the case of a SEAP second peptide portion).

Typically, the second peptide portion comprises at least one receptor binding domain.

Where the second peptide portion interacts with a receptor, the VEGF peptide portion and second peptide portion can have similar or different cellular receptor profiles. Preferably, the VEGF peptide portion and second peptide portion receptor profiles are different (i.e., the VEGF peptide portion binds to at least one peptide portion not bound by the second peptide portion or visa versa). It can be desirable that the VEGF peptide portion and second peptide portion do not commonly interact with the same receptors, thereby increasing the biological activity of the fusion protein. Receptor binding second peptide portions can include any suitable number of receptor binding domains, each domain interacting with any suitable receptor on any suitable cell type. For example, the fusion protein can comprise a second peptide portion that includes, or consists of, one or more endothelial cell-associated receptor binding domains (e.g., a second peptide domain comprising EphrinB2, biologically active fragment thereof, or homolog thereof), and thereby imparts a high level of endothelial cell specificity to the fusion protein (although the VEGF peptide portion alternatively or additionally can interact with other cells and be combined with a second peptide portion specific for such cells, for example, a macrophage specific factor). Other suitable heterologous receptor binding domains useful for incorporation in the first peptide portion, second peptide portion, or both portions are discussed further herein.

**[0052]** An "angiogenic VEGF fusion protein" (or angiogenic fusion protein) is any fusion protein of the invention where the second peptide portion comprises a peptide portion which promotes angiogenesis (an angiogenic peptide portion). Typically and preferably the VEGF peptide portion in such fusion proteins also will be angiogenic. "Angiogenesis," in the context of the invention, encompasses promoting the formation of new blood vessels (also referred to in the art as neovascularization), e.g., by attracting endothelial cells to promote blood vessel sprouting, promoting blood vessel growth from or within existing blood vessels (such as by increasing the size of existing blood vessels or inducing collateral blood vessel growth from existing blood vessels (also known as vasculogenesis)) promoting blood vessel remodeling, promoting blood vessel maturation, and repairing damaged blood vessels (e.g., repairing leaky blood vessels by reducing plasma leakage). Thus, an angiogenic peptide portion can be any sequence of amino acids that induces the initiation of blood vessel growth at a location not otherwise undergoing angiogenesis, enhances or

heightens collateral blood vessel growth to a location already undergoing angiogenesis, or both.

**[0053]** The angiogenic peptide portion can be associated with any suitable activity, or combination of activities, involved in angiogenesis. For example, the angiogenic peptide portion can comprise an endothelial cell mitogen (e.g., an aFGF or HGF), a mediator that influences endothelial cell migration or portion thereof (e.g., Del-1), a factor that induces lumen formation and vessel sprouting (e.g., NL1) (including second generation sprout formation, primary sprout formation, capillary loop formation, or combination thereof) or that is associated with intussusceptive or intercalated growth, an endothelial cell differentiation factor, a factor that participates in primary capillary plexus formation, a factor involved in pruning, fusion, or regression of emerging vessel networks, a mediator that influences vessel maturation or remodeling (e.g., a midkine), a mediator that influences vessel wall dilatation or a portion thereof (e.g. an iNOS), an extracellular matrix degradation factor or portion thereof (e.g., a TNF- $\alpha$ ), or a factor involved in angiogenesis-related protease secretion, a factor that decreases vascular permeability (e.g., an angiopoietin or midkine), a factor which promotes connection to existing blood vessels, a factor which induces blood vessel branching and/or formation of new capillary networks (i.e., induces non-sprouting angiogenesis or intussusception), a factor that promotes vascular smooth muscle elasticity (e.g., an elastin or a fibrillin (such factors also are useful as wound healing promoting factors, discussed further herein)), a factor involved in vessel differentiation (e.g., formation of a blood barrier or fenestrae), a factor that promotes vessel fusion, a fragment of such factors, or a factor which exhibits any combination of such activities. An angiogenic factor also can be a factor that otherwise influences the amount or size of blood vessels formed or the quality of such vessels (e.g., conduction through such vessels). Thus, the fusion protein can include a second peptide portion that directs/induces blood vessel growth in a different manner than the VEGF peptide portion, thereby improving the angiogenic potential of the protein compared to a protein including or limited to the VEGF peptide portion, second peptide portion, or, preferably, both peptide portions.

**[0054]** Preferably, the fusion protein includes an angiogenic VEGF peptide portion and angiogenic peptide portion which separately act on at least one distinct aspect of angiogenesis from each other. For example, the VEGF peptide portion can act as an endothelial mitogen while the second peptide portion can promote vessel wall maturation, vessel wall dilatation, extracellular matrix degradation, matrix deposition, or combination thereof. Second peptide portions that exhibit blood vessel remodeling activity, blood vessel maturation activity, that reduce vascular permeability, or any combination thereof, are particularly preferred (e.g., an angiopoietin second peptide portion). Preferably, the angiogenic second peptide portion contains a peptide which, upon *in vivo* administration,

exhibits a vascular pattern different than the "hot spot" pattern associated with VEGF<sub>121</sub> (such as a MK or HBNF) (as described in, e.g., Chourdhuri et al., *Cancer Res.*, 57, 1814-19 (1997)).

**[0055]** The angiogenic second peptide portion can be obtained from, derived from, based upon, include, or consist of any suitable angiogenic peptide. Examples of angiogenic peptides include fibroblast growth factors (FGFs) (e.g., aFGF (FGF-1) (also known as heparin binding factor 1), bFGF (FGF-2), HST, *int-2*, FGF-4, FGF-5, FGF-6, and KGF (as discussed in, e.g., Basilico and Moscatelli, "The FGF Family of Growth Factors and Oncogenes" in *Advances in Cancer Research*, 59, 115-65 (Woude and Klien eds., Academic Press 1992) and U.S. Patent 5,614,496) and their relatives (e.g., HDGFs, as described in, e.g., Klagsbrun et al., *Proc. Natl. Acad. Sci. USA*, 83, 2448 (1986)), angiogenins (e.g., angiogenin, angiogenin-2, and mAngiogenin-3, as described in, e.g., Strydom et al., *Biochemistry*, 24, 5486 (1985), Folkman et al., *Science*, 235, 442 (1987), Bond et al., *Biochim. Biophys. Acta*, 1162, 177 (1993), Hu et al., *Biochem. Biophys. Res. Commun.*, 197, 682. (1993), Hu et al., *Proc. Natl. Acad. Sci. USA*, 91, 12096 (1994), and Moenner et al., *Eur. J. Biochem.*, 226, 483 (1994)), pleiotrophin (PTN, also known as HBNF, HB-GAM, HBBM, p18, OSF-1, and HARP, among others as described in, e.g., Kretschmer et al., *Growth Factors*, 5, 99 (1991), Kretschmer et al., *Biochem. Biophys. Res. Commun.*, 192(2), 420-29 (1993), U.S. Patent 5,270,449, European Patent 0 441 763, and European Patent Application 0 474 979), midkine (MK as described in, e.g., Böhlen and Kovessdi, *Prog. Growth Factor Res.*, 3, 143-57 (1991), Inui et al., *J. Peptide Sci.*, 2, 28-39 (1996), Iwasaki et al., *EMBO J.*, 16, 6936-46 (1997), and U.S. Patent 5,210,026), transforming growth factors (TGFs - e.g., TGF- $\beta$ ), survivins (as described in, e.g., International Patent Application 01/46455), placental growth factors, ECGF (as described in, e.g., U.S. Patent 4,868,113), Del-1, angiopoietins (e.g., angiopoietin-1 (Ang-1), Ang-2, Ang-3, and Ang-4), angiopoietin homologs (e.g., muscle or liver ALGF (as described in, e.g., International Patent Application WO 99/67382), FRDGs, NL1, NL2, NL3, NL4, NL5, NL6, NL8, zapo1, FARF and HFARP (as described in, e.g., Lee et al., *Mol. Cells*, 11(1), 100-04 (2001), and Kim et al., *Biochem. J.*, 346 (part 3), 603-10 (2000)), Ang-2A, Ang-2B, and Ang-2C (as described in, e.g., Mezquita et al., *Biochem. Biophys. Res. Commun.*, 275(2), 643-51 (2000)), Ang2(443) (as described in, e.g., Kim et al., *J. Biol. Chem.*, 275(24), 18550-56 (2000)), Ang-6 (as described in, e.g., International Patent Application 01/102429), the angiopoietin related factors described in International Patent Applications WO 00/05241, WO 00/52167, WO 00/37642, WO 00/52167, WO 00/59938, WO 98/05779, WO 99/15653, WO 99/32515, WO 99/32639, WO 99/40193, WO 99/45135, WO 99/62956, WO 99/62925, and WO 99/40193, and variants of such angiopoietins or ARFs (as described in, e.g., Kim et al., *J. Biol. Chem.*, 274, 26523-28 (1999), U.S. Patents 5,521,073, 5,643,755, 5,877,289,

5,879,672, 5,972,338, 6,030,831, 6,057,435, and 6,074,873, International Patent Applications WO 96/11269, WO 96/31598, WO 99/15653, WO 99/32515, WO 99/45135, WO 99/67382, and WO 01/05825), and U.S. Provisional Patent Application 60/334,488, erythropoietin, follistatin, granulocyte colony-stimulating factor (G-CSF), GM-CSF, scatter factor/hepatocyte growth factor (HGF) (as described in, e.g., U.S. Patents 6,011,009 and 6,133,231), leptin, insulin like growth factors (IGFs, e.g., IGF-I and IGF-II), endothelial growth factors (EGFs) (e.g., endothelial cell-derived growth factor (ECDGF) and PD-ECGF (as described in, e.g., Matsukawa et al., *Biochim. Biophys. Acta*, 1314(1-2), 71-82 (1996), Moghaddam et al., *Biochemistry*, 31, 12141-46 (1992), Miyazono et al., *Biochemistry*, 28, 1704-10 (1989), and Ishikawa, *Nature*, 338(6216), 557-62 (1989)), HBEGFs (as described in, e.g., U.S. Patent 6,037,329), epidermal growth factors, connective tissue growth factors (CTGFs - as described in, e.g., U.S. Patent 6,149,916 and Moussad et al., *Mol. Genet. Metab.*, 71(1-2), 276-92 (2000), preferably CTGF-2), matrix metalloproteinases (MMPs) (as described in, e.g., Murphy et al., *Matrix Biol.*, 15(8-9), 511-8 (1997), Baramova et al., *Cell Biol. Int.*, 19(3), 239-42 (1995), and Matrisian, *Ann. N.Y. Acad. Sci.*, 732, 42-50 (1994)), tissue inhibitors of metalloproteinase (TIMPs, e.g., vasosten or TIMP-4) (as described in, e.g., Vallamo et al., *Human Pathol.*, 30(7), 795-802 (1999) and Dollery et al., *Circ. Res.*, 84(5), 498-504 (1999)), Delta-3 (as described in, e.g., U.S. Patent 6,121,045), COUP-TFII, eNOS, iNOS, MCP-1, proliferin, progestins (as described in, e.g., U.S. Patent 6,245,757), E-selectin, VCAM1, COX-2, HIV-tat, ephrins (e.g., EphB1, EphB2, or EphB4) (as described in, e.g., Yancopoulos et al., *Cell*, 93, 661-64 (1998) and references cited therein), TWEAK (as described in, e.g., Lynch et al., *J. Biol. Chem.*, 273(13), 8455-49 (1999)), CYR 61 (as described in, e.g., Babic et al., *Proc. Natl. Acad. Sci. USA*, 95, 6355 (1998)), Fibrin fragment E, PR39 (as described in, e.g., Li et al., *Nat. Med.*, 6(1), 49-55 (2000), and modified by *Nat. Med.*, 6(3), 356 (2000)), tissue plasminogen activator (tPA), urokinase-plasminogen activator (uPA), angiogenic C-x-C chemokines (as described in, e.g., Colville-Nash et al., *Mol. Med. Today*, 13-23 (1997)), Thymosin Beta 4 (TB4), which is particularly useful in wound healing contexts and is described in, e.g., *Exper. Eye Res.*, 72(5), 605-608 (2001), other angiogenic factors described in International Patent Application WO 01/05825, and the AHRs (as described in U.S. Patent 6,121,236). Other angiogenic peptides include cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-3 (IL-3), and interleukin-8 (IL-8), and transcription factors such as HIF-1 (or HIF-1 $\alpha$  and/or HIF-2 $\alpha$ ), chimeric HIF factors (e.g., the HIF-1 $\alpha$ /VP16 factor described in Vincent et al., *Circulation*, 18, 2255-61 (2000)), homologs thereof (e.g., EPAS as described in, e.g., Maemura et al., *J. Biol. Chem.*, 274(44), 3165-70 (1999)), fragments thereof, or heterodimers thereof (e.g., a HIF-1 $\alpha$ /HIF-2 $\alpha$  heterodimer). Preferably, the second peptide portion comprises an angiogenic factor that functions in a manner other than as a

transcription factor. Non-peptide angiogenic mediators that can be associated with the fusion protein or co-administered therewith include hormones such as oestrogens and proliferin, alcohols such as glycerol, pyridine derivatives (e.g., nicotinamide), and oligosaccharides such as hyaluronan. The VEGF fusion protein also can comprise a peptide portion corresponding to a platelet-derived growth factor (e.g., platelet-derived endothelial cell growth factor and PDGF-BB (Regranex)), a fragment of such a factor, or a homolog of such a factor or fragment, provided that the PDGF peptide portion is a third peptide portion (i.e., a portion in addition to a non-VEGF second peptide portion) or serves as the VEGF peptide portion.

**[0056]** The second peptide portion alternatively can include a homolog of any of the aforementioned angiogenic factors, as well as their naturally occurring homologs, orthologs, paralogs, mutants, or variants. A "homolog" in this sense, and as used herein, specifically with respect to bone growth promoting factors, wound healing promoting factors, and other factors contained in or co-administered with the fusion protein can be any factor meeting one of the four qualifications for VEGF homolog peptide portions described herein (i.e., substantial global or local sequence identity, sequence homology, hydrophobicity conservation, or being encoded by a polynucleotide which hybridizes with the complement of a sequence encoding the naturally occurring factor, or a degenerate sequence thereof). Desirably, homologs of factors described herein further exhibit high levels of weight conservation and structural similarity to their wild-type counterparts, as described above with respect to preferred VEGF homolog peptide portions. Advantageously, such homologs will retain sufficient similarity to react with at least one antibody that reacts with their wild-type counterpart and exhibit similar biological properties (e.g., similar receptor interactions and/or *in vivo* angiogenic, bone growth promoting, or wound healing activity).

**[0057]** The second peptide portion of an angiogenic VEGF fusion protein also or alternatively can include a peptide portion including a peptide that modulates growth, chemotactic behavior, and/or functional activities of smooth muscle cells (SMCs). The second peptide portion can include any suitable second peptide portion which exhibits such smooth muscle cell-related biological activity. Examples of such smooth muscle cell factors include Activin A, Adrenomedullin, ANF, Angiotensin-2, Betacellulin, CLAF, endothelins, Factor X, Factor Xa, HB-EGF, Heart derived inhibitor of vascular cell proliferation, IFN- $\gamma$ , IL1, Leiomyoma-derived growth factor (LDGF), SMC-CF, macrophage-derived growth factor (MDGF), monocyte-derived growth factor, Oncostatin M, Prolactin, Protein S, SDGF (smooth muscle cell-derived growth factor), SDMF (smooth muscle cell-derived migration factor), tachykinins, and Thrombospondin. Homologs of such peptides can also be suitable.

**[0058]** As another alternative, the second peptide portion also or alternatively can include a peptide that modulates growth, chemotactic behavior, and/or functional activities of vascular endothelial cells. Examples of such vascular endothelial cell factors include, in addition to the several factors already discussed herein, Angiotropin (as described in, e.g., Höckel et al., *J. Cell Physiol.*, 133, 1-13 (1987)), AtT20-ECGF, B61, CAM-RF, ChDI, CLAF, ECI, EDMF, EGF, EMAP, Neurothelin, EMMPRIN, Endostatin, Endothelial cell-viability maintaining factor, HGF, HUAF, IFN- $\gamma$ , K-FGF, LIF, MD-ECI, MECIF, Oncostatin M, PF4, Transferrin, and homologs of such peptides.

**[0059]** Additionally or alternatively, the angiogenic second peptide portion can comprise an anticoagulant or hemostatic process modifier. A hemostatic process modifier can be any suitable protein that effects an aspect of hemostasis (either primary hemostasis, second hemostasis, or both), and desirably is modifies, and most preferably reduces coagulation upon administration or expression. Apart from affecting coagulation, the hemostatic modifier can be any peptide which effects fibrin formation, fibrin deposition, platelet formation, platelet activation, the activity of the fibrinolytic system, tissue factor activation, or any combination thereof, as well as any other suitable hemostatic process. The anticoagulant/hemostatic process modifier second peptide portion can comprise any suitable anticoagulant/hemostatic process modifier, homolog thereof, or fragment thereof. Examples of suitable anticoagulants and hemostatic process modifiers include hirudin, protein C, protein S, tissue factor pathway inhibitors, urokinase, anticoagulant nematode peptide C, bdellins, antistatin, hementin, ornatin, and decorsin (or functionally-related disintegrins). Preferred peptide portions in this respect include an Arg-Gly-Asp adhesion site (RGD site) (as described in, e.g., Krezel et al., *Science*, 264, 1944-1947 (1994), and references cited therein), a Leu-Asp-Val adhesion site (LDV site) (as described in, e.g., Tselepis et al., *J. Biol. Chem.*, 272(34), 21341-48 (1997), Garat et al., *Acta. Anat.*, 154, 34-35 (1995), Wayner et al., *J. Cell Biol.*, 116(2), 489-97 (1992), and Makarem et al., *Biochem. Soc. Trans.*, 19(4), 380(s) (1991)), a binding site comprising an LDV-like domain (as described in, e.g., Clements et al., *J. Cell Sci.*, 107 (part 8), 2127-35 (1994)), and also or alternatively preferably bind at least one integrin, at least one selectin, at least one lectin, at least one cadherin, at least one thrombin, GP IIb-IIIa, Factor Xa, or combination thereof (preferably, at least one integrin). Preferably, the peptide portion comprises a sequence within the pattern Cys Xaa Xaa Xaa Arg Asp Gly Xaa Xaa Xaa Cys (SEQ ID NO: 13), and more preferably comprises a cysteine rich domain containing at least six cysteines forming three intrachain bonds, desirably within the sequence pattern Cys Xaa<sub>6-12</sub> Cys Xaa Cys Xaa<sub>3-6</sub> Cys Xaa<sub>3-6</sub> Cys Xaa<sub>8-14</sub> Cys (SEQ ID NO: 14), where Xaa represents any amino acid (preferably not a cysteine) and subscripted numbers reference possible numbers of such amino acid residues possible between cysteine residues. Desirably, such peptide portions

comprise the LAP structural motif (as described in, e.g., Krezel et al, *supra*), which can be verified by comparison with other LAP structural motifs (e.g., using the techniques described herein with respect to VEGF homolog peptide portions).

**[0060]** The first or second peptide portions can comprise one or more heterologous and/or artificial receptor sites, which preferably change the receptor binding profile of the peptide portion, and more preferably localize the fusion protein (or at least the peptide portion) to a specific cell, group of cells, tissue, or tissues. For example, the fusion protein can include a SEAP second peptide portion which comprises an RGD domain or LDV domain of one of the aforementioned hemostatic modifiers (preferably from decorsin or a homolog thereof), or other integrin binding domain, selectin binding domain, or similar binding domain (e.g., a laminin, fibrinogen, and/or fibronectin binding domain). Co-administration of fusion proteins comprising an angiogenic, bone growth promoting, or wound healing promoting peptide having such a chimeric receptor (preferably an integrin receptor, which desirably comprises an RGD domain, most preferably a decorsin RGD domain or homolog thereof) also is within the scope of the invention, as is the independent administration of such factors, polynucleotides encoding such factors, and vectors comprising such fusion proteins (as described herein with respect to the VEGF fusion proteins of the invention), preferably to promote angiogenesis, wound healing, or bone growth, *in vivo*.

**[0061]** Fusion proteins comprising angiogenic second peptide portions including an angiopoietin, an Angiopoietin-related factor (ARF), or homolog thereof, are particularly preferred. An ARF is a protein which exhibits at least about 20% amino acid sequence identity (e.g., at least about 30%, at least about 40%, or at least about 45%) to an angiopoietin, preferably to Ang-1 (SEQ ID NO: 15) (as described in, e.g., U.S. Patents 5,521,073, 5,643,755, and 5,879,672), which facilitates angiogenesis in a mammalian host (typically and preferably including promoting and/or inducing vascular sprouting, endothelial cell attraction, and induction of vasculature maturation remodeling). In addition to showing such levels of identity to Ang-1 or another angiopoietin, the ARF peptide portion desirably comprises a fibrinogen-like domain which exhibits at least about 30% identity, more preferably at least about 35%, even more preferably at least about 45%, and advantageously at least about 55% (e.g., at least about 60%, or at least about 65%) amino acid sequence identity to the peptide encoded by polynucleotide KIAA0003 (Nomura et al. - GenBank Accession No. NP001137 (see also Accession No. D13628), as further described in *DNA Res.*, 1(1), 27-35 and 47-56 (1994) (supplement) (1994)) (SEQ ID NO: 16), hereinafter alternatively referred to as KIAA0003-associated peptide or (KAP) (SEQ ID NO: 17). Desirably, the fibrinogen-like domain comprises at least four cysteines, more preferably at least six cysteines, which correspond to the six cysteines present in the

fibrinogen like domain of Ang-1. Other suitable fibrinogen-like domains are those meeting the standards set for identifying a fibrinogen-like domain provided in International Patent Application WO 99/45135, which also provides techniques for analyzing sequences to determine if such a domain is present in a particular peptide.

**[0062]** More preferably, the second peptide portion comprises KAP, Ang-1, or an angiogenic fragment of either peptide (preferably a fragment which binds the TIE-2 receptor). Fragments of Ang-1, lacking a significant portion of the N-terminus of Ang-1 are also preferred. Desirably, such truncated Ang-1 peptide portions comprise less than about 50%, more preferably less than about 60%, of the Ang-1 amino acid sequence. Preferably, the Ang-1 truncated peptide portion is truncated in the N-terminal portion of the Ang-1 amino acid sequence. Truncated Ang-1 peptide portions lacking all or part of the predicted Ang-1 alpha helix rich coiled coil domain (SEQ ID NO: 18) (e.g., at least 10%, preferably at least about 50%, and more preferably at least about 90% of either the C-terminus or N-terminus of the domain, or both) are also desirable (other predicted coiled coil domains, including possible Ang-1 coiled coil domains are discussed further herein), as are Ang-1 peptide portions lacking the variable N-terminal domain (SEQ ID NO: 19) (similar modifications can be applied to other angiopoietin peptide portions and angiopoietin related factor peptide portions). Fusion proteins including such truncated Ang-1, or, more preferably, KAP peptide portions, may permit better binding to the KDR and TIE-2 receptors. Fusion proteins that exhibit higher affinity for both the KDR and TIE-2 receptors over full length VEGF-Ang-1 homologs are preferred. Moreover, due to the non-heparin binding nature of the preferred VEGF peptide portion, binding with undesired receptors (e.g., neutrophilin-1) is reduced, thereby increasing TIE-2/KDR interaction.

**[0063]** Desirably, an angiopoietin homolog peptide portion (but not typically non-angiopoietin ARFs) will react with at least angiopoietin antibodies. Examples of such antibodies are provided in U.S. Patent 6,166,185. VEGF/angiopoietin and VEGF/ARF fusion proteins of the invention desirably include a linker sequence positioned between the VEGF and angiopoietin/ARF peptide portions, thereby retaining the biological activity of both peptide portions. Examples of suitable linker sequences are known in the art and discussed further herein.

**[0064]** Where the ARF peptide portion does not comprise an Ang-1 peptide portion, KAP peptide portion, or homolog thereof, the ARF peptide portion desirably comprises the fibrinogen-like domain of a peptide (i.e., a domain which is recognized as comprising a fibrinogen-like domain (preferably a domain similar to KAP) through structural analysis, sequence analysis, or combination thereof, preferably as determined through CCD analysis available through the NCBI's BLAST program). Desirably, such a domain exhibits at least about 60% homology, preferably at least about 70% homology (and more preferably



identity), to KAP. Preferably, the fibrinogen-like domain is a fibrinogen-like domain of an ARF (e.g., NL4 or Zapo1) or artificial homolog thereof (e.g., a mutated NL1 fibrinogen-like domain). Such peptide portions can be naturally occurring ARFs (e.g., an NL1 peptide portion), or a chimeric peptide portion comprising the fibrinogen-like domain of an ARF other than KAP. Any suitable ARF fibrinogen like domain can be incorporated. Examples of suitable fibrinogen like domains include the zapo1 fibrinogen like domain (FLD) (SEQ ID NO: 20), the Ang2 FLD (SEQ ID NO: 21), the NL3 FLD (SEQ ID NO: 22), the NL4 FLD (SEQ ID NO: 23), the NL8 FLD (SEQ ID NO: 24), human FDRG FLD (SEQ ID NO: 25), the muscle ALGF FLD (SEQ ID NO: 26), the FLS139 FLD (SEQ ID NO: 27), the murine FDRG FLD (SEQ ID NO: 28), the Ang3 FLD (SEQ ID NO: 29), and the Ang4 FLD (SEQ ID NO: 30). Preferred non-KAP fibrinogen-like domains include the fibrinogen-like domain of NL1 (SEQ ID NO: 31) and the fibrinogen-like domain of NL5 (SEQ ID NO: 32). The ARF also can comprise the coiled coil domain from the peptide, or a heterologous coiled coil domain, or a truncated coiled coil domain (e.g., the Ang-2(443) or Ang-2 isoform 1 coiled coil domain (as described in, e.g., Kim et al., *J. Biol. Chem.* (2000), *supra* and International Patent Application 98/05779). Alternatively, the ARF portion can comprise an ARF coiled coil domain in combination with a fibrinogen like domain of a non-ARF factor (e.g., a modified fibrinogen C sequence), which interacts with Tie-2, and preferably results in Tie-2 binding, more preferably Tie-2 activation, similar to a wild-type angiopoietin (preferably Ang-1) or ARF (e.g., NL1 or NL5). Synthetic coiled coils, or coiled coils identified in non-ARF peptides (where the ARF peptide portion comprises an ARF fibrinogen like domain) can be incorporated into the ARF peptide portion, preferably which promote multimerization formation (e.g., dimer formation), promote Tie-2 receptor binding, or both. Coiled coil domains can be identified using sequence analysis software, such as the COIL, PAIRCOIL, and PEPCOIL programs, and coiled coil analysis features of the GCG program suite, or through using the PredictProtein server (available at [http://www.embl-heidelberg.de/predictprotein/submit\\_def.html](http://www.embl-heidelberg.de/predictprotein/submit_def.html)). Alternatively or additionally the ARF peptide portion can act as an apoptosis survival factor for vascular endothelial cells. For example, HFARP second peptide portions are expected to exhibit such activity without binding Tie-2. In some aspects, such non-Tie-2 binding ARFs can be preferred (e.g., where higher levels of VEGF receptor interaction are desired).

**[0065]** Ang-1 peptide portions lacking the multimerization domain function associated with Ang-1 are preferred in certain aspects. For example, a fusion protein in which the multimerization domain of Ang-1 is deleted (or rendered dysfunctional, e.g., through point mutation), but the VEGF peptide portion includes the domain associated with VEGF dimerization, is expected to exhibit greater extracellular mobility in a mammalian host than naturally occurring Ang-1 multimers. Such fusion proteins are further expected to exhibit

better *in vivo* half-life than that of wild-type Ang-1 (e.g., at least twice as long, preferably at least three times as long, and more preferably at least five times as long as a native Ang-1).

**[0066]** The ARF peptide portion can include fragments selected from multiple ARFs (i.e., the ARF peptide portion comprises a fusion protein including two or more ARF peptide portions). Such ARF peptide portions can include any suitable combination of ARF peptide fragments. A preferred chimeric ARF peptide portion in this respect comprises a peptide portion comprising the fibrinogen-like domain of a first ARF fused to the coiled coil domain of a second ARF or other coiled-coil domain containing peptide, which is further fused to the VEGF peptide portion. Illustrations of such peptides, wherein the fibrinogen-like domain peptide portion is provided by KAP, are provided in Examples 6, 9, and 10.

**[0067]** Another preferred group of angiogenic fusion proteins includes a second peptide portion that includes a member of the HBNF-MK family of proteins, homolog thereof, or a fragment thereof, which promotes angiogenesis in a mammalian host. The HBNF-MK family of proteins includes any naturally occurring protein that exhibits at least about 30%, preferably at least about 40%, and more preferably at least about 50% (e.g., at least about 65%, at least about 75%, or even at least about 90% identity) amino acid sequence identity to human HBNF (SEQ ID NO: 33) or MK (SEQ ID NO: 34), preferably to both HBNF and MK, and which are angiogenic, bone growth promoting, or wound growth promoting, when administered to or expressed in a mammalian host. Synthetic homologs of HBNF-MK exhibiting such levels of identity also can be suitable.

✓ **[0068]** The HBNF-MK second peptide portion can include any suitable HBNF-MK peptide or peptide fragment. Preferably, the HBNF-MK peptide portion includes a naturally occurring HBNF, MK, HBNF-MK homolog, or HBNF-MK variant (e.g., a splice variant). Human HBNF, human MK, and more preferably an N-terminal truncated form of human HBNF or MK, which preferably includes about 70% or less, more preferably about 65% or less, and even more preferably about 60% or less (e.g., about 45% or less) of the wild-type HBNF or MK amino acid sequence, are particularly preferred. Typically, deletions in the HBNF or MK sequence required to produce the truncated peptide portion will occur in the N-terminal portion of the full length HBNF or MK protein. Desirably, the HBNF peptide portion will include an amino acid sequence corresponding to (i.e., identical to or highly homologous with) at least about residues 67-109 (SEQ ID NO: 35), more preferably residues 65-118 (encoded by exon 3 of the wild-type HBNF gene) (SEQ ID NO: 36), and even more preferably 65-136 of naturally occurring (mature) HBNF (SEQ ID NO: 37). Advantageously, the HBNF peptide portion comprises a sequence which exhibits at least about 70% homology, more preferably at least about 90% homology, and optimally identity, to the sequence Cys Gly Glu Trp Thr Trp Gly Pro Cys Ile Pro Asn Ser Lys Asp Cys Gly Leu Gly Thr Arg Glu Gly Thr Cys Lys Gln Glu Thr Arg Lys Leu Lys Cys Lys Ile Pro Cys

Asn Trp Lys Lys Gln Phe Gly Ala Asp Cys Lys Tyr Lys Phe Glu Ser Trp Gly Glu Cys Asp Ala Asn Thr Gly Leu Lys Thr Arg Ser Gly Thr Leu Lys Lys Ala Leu Tyr Asn Ala Asp Cys (SEQ ID NO: 38). Where the HBNF peptide portion is combined with a heparin-binding VEGF, the HBNF peptide portion may desirably lack the lysine-rich terminal domains of wild-type HBNF (residues 1-21 (SEQ ID NO: 39) and 121-136 (SEQ ID NO: 40) of wild-type HBNF, respectively) or their functional equivalents. Alternatively, in non-heparin-binding VEGF fusion proteins, the inclusion of one or both of these sequences to promote heparin-binding can be desirable.

[0069] Desirably, an MK peptide portion will comprise a sequence which exhibits at least about 65% sequence homology, more preferably at least about 75% sequence homology, and ideally identity to SEQ ID NO: 10. Advantageously, an MK peptide portion retains the four C-terminal cysteines which form two intrachain disulfide bridges identical or similar to those present in wild-type mammalian MKs, or a similar set of cysteine residues forming a similar set of intrachain cysteine-cysteine bridges. Thus, the MK peptide portion preferably contains a sequence comprising about residues 60-121 of mature human MK (SEQ ID NO: 41), more preferably about residues 62-104 of human MK (SEQ ID NO: 42), which contain the wild-type MK heparin-binding and dimerization domain, or a sequence exhibiting at least about 65%, preferably at least about 75%, and more preferably at least about 90% homology thereto. For MK peptide portions which lack sequences corresponding to the N-terminal portion of wild-type MK, it is preferred that the MK peptide portion exhibits similar biological activity, e.g., heparin-binding, plasminogen-activator enhancing activity, and neurite extension activity (as described in, e.g., Inui et al., *J. Peptide Sci.*, 2, 28-39 (1996)) as a wild-type MK. Advantageously, the MK peptide portion will exhibit a secondary structure comprising a structure similar to the secondary structure of wild-type MK residues 62-104, a tertiary structure similar to the tertiary structure of wild-type MK residues 62-104, or both (as described in e.g., Iwasaki et al., *EMBO J.*, 16(23), 6936-46 (1997)). Structural similarity using techniques described above with respect to VEGF homolog peptide portions also can be used to determine structural similarity. It may often be desirable that the MK peptide portion exhibits an affinity for nucleolin similar to wild-type MK, or greater than wild-type MK, which can be determined using the techniques described in, e.g., Take et al., *J. Biochem.*, 116, 1063-68 (1994). The MK peptide portion may desirably lack the MK heparin-binding domain, or have a modified domain which permits dimerization but lower affinity to heparin, where the fusion protein comprises a heparin-binding VEGF peptide portion.

[0070] Members of the HBNF-MK family that are non-naturally occurring HBNF-MK homologs, e.g., HBNF-MK peptides encoded by polynucleotides produced by mutagenesis, fusion, or directed evolution using naturally occurring HBNF-MK genes, also are

contemplated (e.g., HBNF peptide portions lacking the HBNF signal sequence (SEQ ID NO: 43) (such as fusion proteins comprising the VEGF signal sequence or heterologous sequence), MK peptide portions lacking the MK signal sequence (SEQ ID NO: 44), or MK/HBNF peptide portions comprising a HBNF or MK peptide sequence fused to a heterologous signal sequence). Fusion proteins comprising the HBNF, MK, aFGF or other heterologous secreted peptide signal sequence fused to the VEGF peptide portion also are within the scope of the invention.

**[0071]** The HBNF-MK peptide portion typically will bind heparin, particularly in the case of HBNF peptide portions. Thus, while the VEGF portion is typically and preferably non-heparin binding, the second peptide portion can be a heparin binding peptide, although non-heparin binding second peptide portions are typically more preferred.

**[0072]** The HBNF-MK peptide portion, particularly for HBNF or MK homologs or fragment based HBNF-MK peptide portions, preferably retains at least the four cysteine residues forming the two disulfide bonds present in naturally occurring HBNF and MK C-terminal portion (i.e., Cys<sub>67</sub>-Cys<sub>99</sub> and Cys<sub>77</sub>-Cys<sub>109</sub>, as described in, e.g., Kretschmer et al., *supra*, Fabri et al., *Biochem. Int.*, 28(1), 1-9 (1992), and Inui et al., *J. Peptide Res.*, 55, 384-97 (2000)), or four cysteine residues corresponding thereto capable of forming structurally similar disulfide bonds. The HBNF-MK peptide portion preferably lacks the domain containing the six N-terminal cysteines present in wild-type HBNF and MK, or their counterparts. Desirably, the HBNF-MK peptide portion will be capable of binding N-syndecan (syndecan-3), syndecan-1, nucleolin, or combination thereof, and most preferably capable of binding syndecan-1, syndecan-3, or both. HBNF-MK homolog peptide portions preferably retain at least about 60%, more preferably at least about 80%, and even more preferably at least about 90% of the 55% of the about 65 naturally occurring HBNF amino acids that are conserved in naturally occurring MK (as described in, e.g., Kretschmer et al., *supra*). Typically, the HBNF-MK peptide portion will be stable in low pH conditions, in the presence of organic solvents, or both. Also normally, the HBNF-MK peptide portion will exhibit a basic pH. Preferably, the HBNF or MK peptide portion will react with anti-HBNF antibodies, anti-MK antibodies, or both (as described in, e.g., Yeh et al., *J. Neurosci.*, 18(10), 3699-07 (1998), and Obama et al., *Anticancer Res.*, 18, 145-52 (1998)). Also desirably, the HBNF or MK peptide portion will exhibit neurite extension activity, plasminogen activator (PA) activity, or both, as wild-type HBNF or MK (as described in, e.g., Inui et al., *supra*).

**[0073]** Another preferred angiogenic VEGF fusion protein includes a fibroblast growth factor portion, which preferably is an acidic fibroblast growth factor (aFGF) second peptide portion, which desirably comprises the amino acid sequence of mature human aFGF protein (SEQ ID NO: 45), or homolog thereof, which may or may not be associated with the aFGF

propeptide sequence (SEQ ID NO: 46). The aFGF peptide portion can include a naturally occurring aFGF (as described in, e.g., Gautschi-Sova et al., *Biochem. Biophys. Res. Commun.*, 140(3), 874-80 (1986), and Jaye et al., *Science*, 233(4763), 541-545 (1986)), aFGF fragment, or homolog thereof (e.g., a homolog which meets the conditions described herein for VEGF homologs), such as the aFGF muteins and homologs described in U.S. Patent 5,395,756 and International Patent Application WO 92/11360, preferably which promotes angiogenesis and/or bone growth (most preferably angiogenesis) in a mammalian host. The aFGF peptide portion also can comprise a truncated portion of a wild-type aFGF (e.g., an aFGF comprising at least about 60%, more preferably at least about 75%, of the wild-type aFGF amino acid sequence, such as an aFGF which lacks the wild-type N-terminal acetylation domain (e.g., human aFGF Ala<sub>2</sub>) or its counterpart). Desirably, the aFGF peptide portion comprises two cysteines which correspond to the cysteines conserved in human, bovine, rat, hamster, and chicken aFGFs (e.g., human aFGF Cys<sub>30</sub> and Cys<sub>97</sub>) (as described in, e.g., Burgess et al., *Mol. Reprod. Develop.*, 39, 59-61 (1994)).

Advantageously, the aFGF portion retains a sequence corresponding to the coding sequence of exon 2 of the human aFGF gene, or a sequence that is at least about 80%, preferably at least about 90%, homologous therewith. Where the FGF peptide portion comprises a cysteine corresponding to aFGF Cys<sub>131</sub>, the surrounding sequence desirably comprises a sequence corresponding to the aFGF residues 127-135 (SEQ ID NO: 47) or a sequence which exhibits high levels of homology to this sequence (e.g., at least 80% homology, and more preferably at least about 90% homology), which comprises and flanks Cys<sub>131</sub> or its counterpart. aFGF homolog peptide portions desirably exhibit at least about 60% identity to human aFGF. Advantageously, aFGF homolog peptide portions will comprise a sequence falling within the pattern Arg Leu Tyr Cys Xaa<sub>5-7</sub> Leu Xaa Xaa Xaa Pro Asp Gly Arg (SEQ ID NO: 48), wherein Xaa represents any amino acid residue and subscripted numbers represent numbers of amino acid residues at a given position, preferably wherein the cysteine residue of the sequence corresponds structurally (e.g., is associated with forming a similar two dimensional or three dimensional protein structure) and/or functionally to Cys<sub>30</sub> of human aFGF. Desirably, the aFGF peptide portion comprises a sequence corresponding to residues associated with FGF receptor binding (e.g., the human aFGF ASN<sub>129</sub> and residues functionally associated therewith). Advantageously, the aFGF peptide portion retains the heparin-binding domain of aFGF, and closely associated residues (e.g., residues 113-116 (Ile<sub>113</sub> Ser<sub>114</sub> Lys<sub>115</sub> Lys<sub>116</sub> (SEQ ID NO: 49), or residues 24-28 (Lys<sub>24</sub> Lys<sub>25</sub> Pro<sub>26</sub> Lys<sub>27</sub> Leu<sub>28</sub>) (SEQ ID NO: 50), preferably at least residues 113-116, more preferably both sequences (subscripted numbers reference residues positions in human aFGF precursor), or homologs thereof that exhibit similar affinity for heparin).

[0074] The angiogenic fusion protein is preferably more angiogenic than a protein including or consisting essentially of either the VEGF peptide portion, the second peptide portion, or, most preferably, more than both a protein including or consisting essentially of either peptide portion. Thus, *in vivo* administration of the such fusion proteins will typically and preferably result in greater blood flow in the area of administration than the administration of a protein consisting essentially of the second peptide portion in a mammalian host, preferably more than administration of proteins comprising the VEGF portion in a mammalian host, and most preferably more than administration of two proteins respectively corresponding to the two peptide portions. The increased angiogenic potential of the fusion proteins with respect to such non-fusion protein factors can be quantified using any suitable technique described herein or its equivalent in the art.

[0075] The *in vivo* administration of the fusion protein, particularly a fusion protein containing a second peptide portion which reduces plasma leakage (e.g., a MK, Ang-1, or fragment thereof), can result in growth of blood vessels which exhibit less permeability than blood vessels which result from administration of a protein including or limited essentially to the VEGF peptide portion in a mammalian host. For example, fusion proteins where plasma leakage upon *in vivo* expression or administration result in blood vessels which exhibit about 90% or less, more preferably about 75% or less, and even more preferably about 50% or less (e.g., about 25%) of the vascular permeability exhibited by blood vessels generated by administration of a peptide including or limited essentially to the VEGF peptide portion are contemplated. Blood vessel permeability can be determined using techniques known in the art (see, e.g., Thurston et al., *Nat. Med.*, 6(4), 460-63 (2000), Bates et al., *Microcirculation*, 6, 83-96 (1999), Thurston et al., *Science*, 286, 2511-14 (1999), Cox et al., *J. Surg. Res.*, 83(1), 19-26 (1999), Carter et al., *Biophys. J.*, 74(4), 2121-28 (1998), Kendall et al., *Exp. Physiol.*, 80(3), 359-72 (1995), Adamson et al., *Microcirculation*, 1(4), 251-65 (1994), Yuan et al., *Microvasc. Res.*, 45(3), 269-89 (1993), Olson et al., *J. Appl. Physiol.*, 70(3), 1085-96 (1991), Shibata et al., *Jpn. J. Physiol.*, 41(5), 725-34 (1991), and Kern et al., *Am. J. Physiol.*, 245(2), H229-36 (1983)). Alternatively, the fusion protein can comprise a second peptide portion which does not significantly reduce the VEGF peptide portion-induced permeability. The administration of such fusion proteins, polynucleotides encoding them, and vectors containing such polynucleotides can be advantageous in producing porous (typically peripheral) blood vessels, such as fenestrated capillaries, metaarterioles, blood vessels associated therewith, or blood vessels in association with capillary beds active in filtration, reabsorption, or secretion (e.g., the glomerulus), particularly in areas where cardiovascular exchange with tissues is desirable. Administration of such fusion proteins, polynucleotides and vectors also may induce fenestrae opening and exchange. In contrast, in inducing angiogenesis in the brain or other

tissues associated with “tight” vessels, administration or expression of a fusion protein which is associated with low levels of vascular permeability is preferred (e.g., angiopoietin second peptide portion fusion proteins, such as a VEGF<sub>121</sub>/angiopoietin fusion protein, or a VEGF<sub>189</sub>/angiopoietin fusion protein, which can be associated with lower incidence of intracerebral bleeding than VEGF<sub>121</sub> fusion proteins).

**[0076]** Typically and preferably, *in vivo* expression or administration of the fusion protein is associated with growth of blood vessels which exhibit greater maturity (e.g., blood vessels which exhibit greater density and/or structural similarity to mature mammalian blood vessels) than blood vessels that result from the administration of a protein comprising or limited essentially to the VEGF peptide portion in a mammalian host. More particular examples of maturation events include pericyte coating of forming blood vessels and arterialization of newly formed vessels. Blood vessel maturation can be assessed using any suitable standard. For example, maturity can be observationally assessed by assessing vessel shape, density, luminal regularity, and vessel opening size (as described in, e.g., Bloch et al., *FASEB J.*, 14(5), 2373-76 (2000)). Maturity also can be assessed by signal intensity changes in response to hyperoxia (elevated oxygen) and hypercapnia (elevated carbon dioxide), for example by measuring physiological vasodilatory response to carbon dioxide (as described in, e.g., Gilead and Neeman, *Neoplasia*, 1(3), 226-30 (1999)), measuring smooth muscle plasticity, or smooth muscle and non-muscle vascular associated myosin isoform distribution (as described in, e.g., Pauletto et al., *Am. J. Hypertens.*, 7, 661-74 (1994)). Preferably, maturation is determined by assessing recruitment of pericytes to the vasculature, pericyte coating of new vessels, association between the vascular tube and the mural cells, or any combination thereof (as discussed in, e.g., Darland et al., *J. Clin. Invest.*, 103(2), 157-58 (1999), which can be quantified, e.g., by using the microvessel maturation index (MMI) (see, e.g., Goede et al., *Lab. Invest.*, 78(11), 1385-94 (1998)). The *in vivo* administration of the angiogenic fusion protein to a mammalian host typically will result in a higher number or greater concentration of smooth muscle cells, pericytes, mural cells, total endothelial cells, or any combination thereof, than blood vessels resulting from administration of a protein limited essentially to the first peptide portion. The increase in number of such cells can be detected using techniques known in the art.

**[0077]** In a related sense, blood vessels which result from *in vivo* administration or expression of the fusion protein desirably exhibit a greater level of blood vessel remodeling than blood vessels which result from administration of a peptide including or limited essentially to the VEGF peptide portion. “Blood vessel remodeling” includes any type of vascular restructuring not associated with maturation, although the events often typically overlap and/or occur simultaneously in living systems. Typical types of blood vessel remodeling events include increase in vascular mass, vessel wall thickening, vessel

enlargement or dilation, alteration in capillary density, vascular bed modification, change in vessel tone, or combinations thereof. Blood vessel remodeling can be assessed through stress state and pressure testing, MRI (e.g., as described in Nikol et al., *Angiology*, 49(4), 251-58 (1998)), *in vivo* ultrasound imaging or histologic analysis (as described in, e.g., Fung et al., *J. Biomech. Eng.*, 115(4B), 453-59 (1993)), and techniques otherwise used to assess angiogenesis (e.g., gradient echo testing).

**[0078]** In addition to angiogenic fusion proteins, the present invention provides VEGF fusion proteins which alternatively or additionally promote bone growth. "Promoting" includes accelerating the specific biological activity (e.g., bone growth), enhancing the biological activity, or both. In such bone growth promoting fusion proteins, the second peptide portion includes a bone growth promoting factor, bone growth factor homolog, or active fragment thereof. More specifically, the bone growth promoting portion can include any peptide portion that is capable of promoting, or assisting in the promotion of, bone formation, or that increases the rate of primary bone and/or skeletal connective tissue growth or healing, or a combination thereof.

**[0079]** The bone growth promoting portion can include any suitable bone growth promoting factor which can be involved in any aspect of bone growth. Thus, the bone growth promoting portion can include a bone-associated hemorrhaging factor, clot formation factor, granulated tissue ingrowth factor, cartilage formation factor, cartilage turnover factor, callus tissue formation factor, callus tissue remodeling factor (e.g., a cortical and/or trabecular bone development factor), and other osteogenic and/or osteotropic factors. The bone growth promoting portion also can include a mitogen or chemotractant for bone growth associated cells, such as macrophages, fibroblasts, vascular cells, osteoblasts (e.g., HBNFs or TGF- $\beta$ s), chondroblasts, and osteoclasts. Preferably, the bone growth promoting portion includes a peptide which effects phosphate metabolism, modulates osteocyte activity, otherwise promotes general ossification, osteoblast differentiation, osteopontin expression (e.g., an alkaline phosphatase, preferably a bone specific alkaline phosphatase (BAP) or secreted alkaline phosphatase (SEAP)), or regulating bone mineralization (e.g., an alkaline phosphatase), or the combination thereof, thereby promoting bone healing.

**[0080]** Examples of preferred bone growth factors include the bone morphogenic proteins (BMPs - also sometimes referred to osteogenic proteins (OPs) and COPs, e.g., BMP types 1-12, preferably BMP-2 and homologs/variants thereof, which are variously described in, e.g., U.S. Patents 4,795,804, 4,877,864, 4,968,590, 5,011,691, 5,106,748, 5,013,649, 5,108,753, 5,108,922, 5,116,738, 5,166,058, 5,187,076, and 5,141,905, International Patent Applications WO 88/00205, WO 89/09787, and WO 89/09788, and Wozney, *Growth Fact. Res.*, 1, 267-80 (1989)), transforming growth factors (particularly



TGFs 1-4, more particularly TGF- $\alpha$ , TGF- $\beta$ 1, and TGF- $\beta$ 2, as described in, e.g., U.S. Patents 4,742,003, 4,886,747, and 5,168,051), FGFs (e.g., FGF-1 and/or the FGF homologs described in U.S. Patent 6,352,971), PDGF (including, e.g., PDGF-D), IGF-I, IGF-II, aFGF, bFGF calcitonin, thyroxin, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor (GM-CSF), epidermal growth factor (EGF), leukemia inhibitory factor (LIF - also known as HILDA and DIA), platelet derived growth factor (PDGF), parathyroid hormone (PTH) insulin-like growth factors (IGF), connective tissue growth factor (CTGF), a hedgehog protein, such as Indian hedgehog (Ihh), parathyroid hormone-related protein (PTHrP), growth and differentiation factor-5 (GDF-5), LIM microvascular protein (LM), latent TGF-binding (LTBP), latent membrane protein-1 (LMP-1), other bone growth promoting factors discussed in International Patent Application WO 01/05825 and alkaline phosphatases (e.g., placental alkaline phosphatase, intestinal alkaline phosphatase, BAP, or SEAP) (as described elsewhere herein). Particularly preferred bone growth promoting factors include the BMPs (e.g., BMP-2), PTH, CTGF, and alkaline phosphatases, particularly BAP (and secreted fragments thereof) and SEAP, and homologs thereof. SEAP peptide portions are especially preferred. The second peptide portion also can include a homolog or fragment of such factors. Preferably, such homolog or fragment peptide portions retain a high level of structural homology to corresponding wild-type factors (e.g., alkaline phosphatase homologs or fragments preferably retain the characteristic phosphatase 10 strand mixed beta sheet structure). In addition to the foregoing factors, the bone growth promoting second peptide portion also can include a bone growth promoting aFGF peptide portion, HBNF-MK peptide portion, or angiopoietin or ARF peptide portion, as described above.

**[0081]** Alkaline phosphatase peptide portions can comprise any suitable alkaline phosphatase. For example, the alkaline phosphatase peptide portion can be a human alkaline phosphatase, a non-human alkaline phosphatase (as described in, e.g., U.S. Patent 5,980,890), or a biologically active fragment or homolog thereof (e.g., a synthetic alkaline phosphatase). In addition to preferably retaining the 10 strand mixed beta sheet structure associated with mammalian alkaline phosphatases, the alkaline phosphatase peptide portion desirably retains a zinc ion binding domain (typically, the carboxyl end of the central beta sheet) and magnesium ion binding domain of a wild-type alkaline phosphatase or homolog thereof, and preferably exhibits zinc and magnesium ion binding within similar binding coordinates (e.g., differing by less than about 0.5 angstroms, preferably less than about 0.1 angstroms) as a wild-type alkaline phosphatase (as described in, e.g., Coleman, *Annu. Rev. Biophys. Biomol. Struct.*, 21, 441-83 (1992)). The alkaline phosphatase peptide portion desirably forms multimers with alkaline phosphatases or other alkaline phosphatase peptide portion-containing fusion proteins, desirably in which at least one multimer member binds a

zinc ion in addition to the alkaline phosphatase peptide portion. Also advantageously, the alkaline phosphatase portion exhibits biological activity similar to a wild-type alkaline phosphatase (e.g., substrate binding – as described with respect to select alkaline phosphatases in U.S. Patent 5,783,567 and/or hydrolysis of monophosphate esters, particularly under physiological alkaline conditions (i.e., above a pH of about 7.4)). Preferably, the alkaline phosphatase peptide portion reacts with at least one alkaline phosphatase antibody. Examples of techniques for determining if a BAP will react with a BAP antibody are provided in U.S. Patent 6,201,109, which can be modified with respect to other alkaline phosphatase peptide portions (e.g., human SEAP (SEQ ID NO: 51)) as necessary.

**[0082]** Preferably, the alkaline phosphatase peptide portion exhibits at least about 40% homology (preferably at least about 45% homology, and more preferably at least about 45% identity) to a human placental alkaline phosphatase (e.g., human tissue non-specific alkaline phosphatase), and desirably exhibits at least about 70% weight homology, and more preferably at least about 80% weight homology, to a human wild-type alkaline phosphatase. The alkaline phosphatase may or may not include an alkaline phosphatase signal sequence (such as the human SEAP signal sequence (SEQ ID NO: 52)), and may or may not include the alkaline phosphatase propeptide sequence (e.g., the human SEAP propeptide sequence (SEQ ID NO: 53)). Desirably, the alkaline phosphate portion comprises a sequence exhibiting at least about 60%, more preferably at least about 70%, identity to residues 65-172 of human SEAP (SEQ ID NO: 54). Preferably, the alkaline phosphatase will comprise the sequence Ala Gln Val Pro Asp Ser Ala Xaa Thr Ala Thr Ala Tyr Leu Cys Gly Val Lys Ala Asn (SEQ ID NO: 55) (where X represents any amino acid, preferably an aliphatic uncharged residue, and most preferably a glycine or an alanine), where the serine is phosphorylated under similar conditions as serine 114 of wild-type SEAP, corresponds to the enzymatically active site of the alkaline phosphatase peptide portion, or both. For alkaline phosphatase homolog peptide portions, the peptide portion desirably comprises an amino acid sequence falling within the pattern Thr Asn Val Ala Lys Asn Xaa Ile Met Phe Leu Gly Asp Gly Met Gly Val Ser Thr Val Thr Ala Ala Arg Ile Leu Lys Gly Gln Xaa His His Xaa Xaa Gly Xaa Glu Thr Xaa Leu Xaa Met Asp Xaa Phe Pro Xaa Val Ala Leu Ser Lys Thr Tyr Asn Xaa Xaa Ala Gln Val Pro Asp Ser Ala Xaa Thr Ala Thr Ala Tyr Leu Cys Gly Val Lys Ala Asn Xaa Xaa Thr Xaa Gly Xaa Ser Ala Ala (SEQ ID NO: 56), a sequence falling within the pattern Asn Pro Xaa Gly Phe Phe Leu Xaa Val Glu Gly Gly Arg Ile Asp His Gly His His Glu Gly Lys Ala Xaa Gln Ala Leu Xaa Glu Ala Val Xaa Asp Ala Ile (SEQ ID NO: 57), or a sequence falling within the pattern Glu Asp Thr Leu Thr Xaa Val Thr Ala Asp His Ser His Val Phe Xaa Phe Gly Gly Tyr Thr Xaa Arg Gly Asn Ser Ile Phe Gly Leu Ala Pro Met Xaa Xaa Asp Thr Asp Lys Lys Xaa Xaa Thr Ala Ile Leu Tyr Gly Asn Gly Pro

Gly Tyr (SEQ ID NO: 58), and preferably comprises a combination thereof (most desirably all three sequences). Desirably, the alkaline phosphatase peptide portion will be between about 100-700, more preferably between about 200-550, and even more preferably about 500 amino acid residues in length. The alkaline phosphatase may comprise or lack sequences associated with lipid association, glycosylation, or both present in wild-type alkaline phosphatases (e.g., the N<sub>144</sub>-associated glycosylation site and/or D<sub>506</sub> lipid-binding GPI-anchor site). As the alkaline phosphatase is preferably secreted, it will desirably lack a transmembrane domain (e.g., the SEAP precursor transmembrane domain (SEQ ID NO: 59)), or functional equivalent and typically sequence homolog thereof. Alternatively, the alkaline phosphatase can be rendered in secreted form through small residue changes, including even single residue substitutions, as is known in the art (as discussed in, e.g., Lowe, *supra*).

**[0083]** Other non-peptide factors which can be associated with the VEGF peptide portion or other portion of the fusion protein involved in bone growth promotion include glucocorticoids and estrogen. Such factors can be co-administered with the bone growth promoting fusion protein, as can any one of the aforementioned factors with the fusion protein, polynucleotide, or vector (e.g., co-administration of a BMP and/or a TGF- $\beta$  can be co-administered with a VEGF/SEAP fusion protein). Co-administration of receptors for such factors (e.g., N-syndecan in association with a bone growth promoting fusion protein containing a HBNF second peptide portion) also is within the scope of the invention.

**[0084]** The invention further provides wound healing fusion proteins. In such aspects, the second peptide portion alternatively or additionally includes a wound healing promoting protein, homolog thereof, or protein/homolog fragment. A wound can include any lesion or injury to any portion of the body of a subject including acute conditions such as thermal burns, chemical burns, radiation burns, burns caused by excess exposure to ultraviolet radiation such as sunburn, damage to bodily tissues such as the perineum as a result of labor and childbirth, injuries sustained during medical procedures such as episiotomies, trauma-induced injuries including cuts and injuries sustained in automobile and other mechanical accidents, injuries caused by bullets, knives, or other weapons, and post-surgical injuries, as well as chronic conditions such as pressure sores, bedsores, conditions related to diabetes and poor circulation, and all types of acne. Commonly encountered wounds in humans include excisional wounds (e.g., tears, cuts, punctures, or lacerations in the epithelial layer, dermal layer, and/or subcutaneous layer of the skin), such as those caused by surgical procedures or from accidental penetration of the skin, lesions due to dermatological diseases, burn wounds (such as abrasion burns, surgical burns, and burns from exposure to heat), and dermal skin ulcers (such as decubitus ulcers, diabetic ulcers, venous stasis ulcers, and arterial ulcers). The promotion of wound healing induced by the *in vivo* presence of the

wound healing promoting fusion protein preferably includes the stimulation of new tissue growth, regeneration of connective tissue, or, more preferably, both.

[0085] The wound healing promoting portion can include any suitable wound healing promoting factor involved in any aspect of wound healing. For example, the wound healing peptide portion can include a hemostasis (clot formation) factor (e.g., fibrin, fibronectin, or endothelial cell mitogen), wound healing associated inflammation factor (or vascular congestion/tissue edema factor, e.g., an interleukin), contraction factor (e.g., collagen or collagen deposition associated factor), epithelialization factor, connective tissue disposition factor, granulated tissue formation factor, wound remodeling factor (e.g., a collagen cross linking promoting factor or collagen degradation factor), a collagen synthesis stimulating factor (e.g., angiotensin II), a connective tissue proliferation factor, a factor which promotes mitotic activity in the epidermal basal layer, or a factor which exhibits more than one of the aforementioned aspects. Alternatively or additionally, the wound healing promoting portion can include a factor which induces the growth, or is involved in chemotaxis of, cells involved in wound healing such as neutrophils, macrophages, keratinocytes, lymphocytes fibroblasts, SMCs, and other epithelial and/or endothelial cells (e.g., by attracting such cells to the wound bed).

[0086] Examples of suitable wound healing promoting factors that can be included in the second peptide portion include extracellular matrix proteins such as collagen, laminin (which also may act as an angiogenic factor), and fibronectin, cell adhesion molecules such as the integrins (e.g.,  $\alpha v\beta 3$  and  $\alpha v\beta 5$ ), selectin, Ig family members such as N-CAM and L1, and cadherins, cytokine signaling receptors such as the TGF- $\beta$  type I and type II receptors or the FGF receptor, non-signaling co-receptors such as betaglycan and syndecan, signal transducing kinases, platelet function-associated factors such as von Willebrand factor (vWF), serotonin, platelet activating factor (PAF), and Thromboxane  $A_2$ , coagulation factors such as kininogen, kallikrein, thromboplastin (Factor III), prothrombin and thrombin (Factor II), fibrinogen and fibrin (Factor I), and fibrin-stabilizing factor, and cytoskeletal proteins such as talin and vinculin. Additional examples of specific wound healing promoting factors include the bFGFs (e.g., FGF-1 and FGF-2 as described in, e.g., Slavin et al., *Cell Biol. Int.*, 19, 431-444 (1995)), EGFs, PDGFs, PGF, IGF, calreticulin, CTGF, collagen, keratinocyte growth factor (KGF), tissue transglutaminase (TG), clotting factors (e.g., fibrinogen, prothrombin, and thrombin), M-CSF, growth hormones or somatotrophins (e.g., hGH) Factor VIII, Factor IX (e.g., Factor IXa - see, e.g., U.S. Patent 6,315,995), EPO, tPA, transforming growth factors (particularly TGF- $\beta$ ), activins, inhibins, PTH, and alkaline phosphatases (e.g., placental alkaline phosphatase, intestinal alkaline phosphatase, bone alkaline phosphatase (BAP (also sometimes referred to as B-ALP, which also may be present in liver and kidney tissues)) and/or non-tissue specific alkaline phosphatase, germ

cell alkaline phosphatase, or placenta alkaline phosphatase-derived secreted alkaline phosphatase (SEAP) (as described in, e.g., Coleman, *Annu. Rev. Biophys. Biomol. Struct.*, 21, 441-83 (1992), Lowe, *J. Cell Biol.*, 116 (3), 799-807 (1992), Fishman, *Clin. Biochem.*, 23(2), 99-104 (1990), Kishi et al., *Nucleic Acids Res.*, 17(5), 2129, Harris, *Clin. Chem. Acta*, 186, 133-150 (1989), Berger et al., *Gene*, 66, 1-10 (1988), Millan, *Anticancer Res.*, 8, 995-1004 (1988), Weiss et al., *J. Biol. Chem.*, 263(24), 12002-12010 (1988), Coleman et al., *Adv. Enzymol.*, 55, 381 (1983), and U.S. Patents 4,659,666 and 5,434,067), and the recombinant and modified alkaline phosphatases, such as those described in U.S. Patents 5,081,227, 5,773,226, and 5,821,095), homologs thereof, and fragments thereof (e.g., a secreted alkaline phosphatase derived from a BAP or non-tissue specific alkaline phosphatase). Additionally, wound healing promoting aFGF peptide portions, HBNF-MK peptide portions, and angiopoietin/ARF peptide portions also can form, or be included in, the second peptide portion. Particularly preferred wound healing factors include the PDGFs, aFGF, HBNFs, MKs, TGF- $\beta$ , and CTGFs, of which HBNFs, MKs, TGF- $\beta$ , and CTGFs are most preferred. The wound healing promoting portion can, and typically will, lack a functional collagen binding domain (e.g., a collagen binding domain rendered dysfunctional by truncation or mutation), or any collagen binding domain, especially where the non-heparin-binding VEGF peptide portion comprises a peptide portion of 110 amino acids or less (e.g., a VEGF<sub>110</sub> peptide portion). For example, HBNF, MK, SEAP, and aFGF peptide portions will not typically include such domains. Where the second peptide portion comprises such a domain (e.g., in the case of a von Willebrand factor peptide portion), the VEGF peptide portion is preferably at least about 115 amino acids in length, more preferably between about 115-165 amino acids in length, and even more preferably about 120 amino acids in length (e.g., a VEGF<sub>120</sub> or VEGF<sub>121</sub> peptide portion).

**[0087]** Non-peptide factors such as glucocorticoids, adenosine diphosphate, and vitamins A, C, E, and K, can also aid in wound healing. Co-administration of such factors with the wound healing fusion protein (or polynucleotide encoding the wound healing fusion protein) can further facilitate wound healing. Preferably, the wound healing fusion protein will prevent or decrease scar formation, such as keloids and hypertrophic scars, as well as decreasing the extent of scar tissue formation either internally or externally, as applicable.

**[0088]** As indicated above, in some contexts a fusion protein consisting of a heparin-binding VEGF peptide portion is preferred over fusion proteins comprising a non-heparin-binding VEGF peptide portion. Accordingly, such fusion proteins also are provided by the invention. In general, the principles applicable to the non-heparin-binding VEGF peptide portion are also applicable to such heparin-binding VEGF peptide portions, except with respect to factors such as mobility (discussed with respect to non-heparin-binding VEGF

fusion proteins below), pH (as discussed above), and/or protein interactions (e.g., neurophilin interactions or VEGF receptor interactions), which typically will vary from those described above with respect to non-heparin-binding VEGF peptide portions (i.e., by exhibiting biological activity similar to heparin-binding VEGFs, such as VEGF<sub>189</sub> or VEGF<sub>165</sub>). The heparin-binding VEGF peptide portion can comprise any suitable heparin-binding VEGF (e.g., a VEGF<sub>189</sub> or homolog thereof). VEGF<sub>165</sub>, heparin-binding fragments thereof, and homologs thereof, are preferred wild-type and wild-type-derived heparin binding VEGF peptide portions components. Other advantageous heparin-binding VEGFs include VEGFs derived from VEGF<sub>121</sub>, which typically generated through addition of the heparin-binding domain of another VEGF, such as VEGF<sub>189</sub> or an artificial heparin-binding domain. Examples of such VEGFs include VEGF<sub>121.2</sub> (SEQ ID NO: 60) and VEGF<sub>121.3</sub> (SEQ ID NO: 61), which include a heparin binding domain derived from VEGF<sub>189</sub>, and VEGF<sub>121.5</sub> (SEQ ID NO: 62) and VEGF<sub>121.6</sub> (SEQ ID NO: 63), which include artificial heparin binding domains. Such VEGFs may exhibit higher heparin binding than VEGF<sub>165</sub> and, thus, can be advantageous in aspects where a heparin binding VEGF peptide portion is desirable. Similar modified heparin-binding VEGFs, which also can be suitable for incorporation in such fusion proteins, are described in International Patent Application WO 98/36075.

**[0089]** Preferably, for fusion proteins comprising a heparin-binding VEGF peptide portion, the second peptide portion is not an Angiopoietin-related factor, and more preferably not an angiopoietin. Moreover, the second peptide portion in such aspects desirably does not consist of a heparin-binding peptide which would interfere with the desired VEGF-heparin interaction. Thus, for example, the second peptide portion preferably is not a FGF peptide portion. Such fusion proteins can comprise any of the second peptide portions described herein, and often will consist of a wound healing or bone growth promoting second peptide portion (e.g., versus an angiogenic second peptide portion).

**[0090]** Heparin-binding VEGF fusion proteins can be administered to the host similar to the non-heparin-binding fusion proteins otherwise described herein. For example, such fusion proteins can be administered by preparing a vector, preferably an adenoviral vector such as those described elsewhere herein, comprising a polynucleotide encoding the heparin-binding VEGF fusion protein.

**[0091]** The VEGF peptide portion and second peptide portion can be associated in any suitable manner. Typically and preferably, the first and second peptide portions will be covalently associated (e.g., by means of a peptide or disulfide bond). The first and second peptide portions can be directly fused (e.g., the C-terminus of the VEGF peptide portion can be fused to the N-terminus of the second peptide portion through a peptide bond between

the two portions). The fusion protein can include any suitable number of modified bonds, e.g., isosteres, within or between the peptide portions. Alternatively, the fusion protein can include a peptide linker between the peptide portions that includes one or more amino acid sequences not forming part of the biologically active peptide portions. Any suitable peptide linker can be used. The linker can be any suitable size. Typically, the linker will be less than about 30 amino acid residues, preferably less than about 20 amino acid residues, and more preferably about 10 or less amino acid residues. Typically the linker will predominantly consist of neutral amino acid residues. Suitable linkers are generally described in, e.g., U.S. Patents 5,990,275 and 6,197,946, and European Patent Application 0 035 384.

**[0092]** In general, suitable linkers are formed from short sequences (e.g., about 5-30 amino acids) of primarily small, flexible, and neutral amino acids. Flexibility is an attribute of the size of the amino acid side chain. For example, glycine is the most flexible of the naturally occurring amino acids. As such, glycine rich amino acid sequences (e.g., sequences comprising at least about 50% glycine residues) usually are effective linkers. As such, a linker often can have a higher proportion of glycine residues. For example, linkers wherein glycine residues make up at least about 65%, at least about 70%, at least about 75%, at least about 80%, or more of the amino acid residues in the sequence are common. The flexibility of the linker sequence permits domains in the peptide portions to adopt active conformations. The linker sequence also will typically include at least one non-glycine residue, which, in combination with a series of glycine residues, can form a peptide motif (usually of 2-10 amino acids in length) that is repeated one or more times in the linker sequence. For example, linkers consisting of repeated motifs of glycine and serine residues can be suitable. Thus, the invention provides, for example, a fusion protein comprising a linker sequence according to the formula,  $(\text{Gly}_{1-5}\text{Ser}_{1-2})_Z$ , wherein Z represents 1, 2, 3, or 4. Other residues that commonly are employed in linker sequences include alanine and cysteine residues. Glutamine and glutamic acid, which regularly appear in naturally occurring, repeated peptide motifs (see, e.g., Katti et al., *Protein Science*, 9, 1203-1209 (2000), for discussion), also can be suitable additional residues, despite their relatively larger size (i.e., as compared to glycine). Such naturally occurring peptide repeats also may be suitable for introducing space between functional domains in the VEGF fusion protein. Examples of such naturally occurring repeated sequences are recorded in the Tandem Repeats in Protein Sequences (TRIPS) database, which can be accessed at <http://www.ncl-india.org/trips/>. Proline residues are remarkably nonflexible, and, as such, are normally not desirable. Similarly, aromatic residues are normally not desirable additional residues. Thus, for example, the invention provides VEGF fusion proteins comprising a linker comprising at least about 5 glycine residues that is free of Pro, Trp, and Tyr residues.

[0093] The length of the linker typically is selected to provide an effective distance between active peptide portions while maintaining sufficient stability and not excessively impairing synergies (e.g., increased half-life) obtained by the presence of the peptide portions in the fusion protein. Linkers also can provide additional advantages, such as the elimination of undesirable epitope sequences that might otherwise occur at the junction of the peptide portions (such matters are discussed elsewhere herein). A typical effective length for a linker in the fusion protein of the invention is about 5-30 amino acids. More commonly, the linker is about 8-20 amino acids in length. For example, a linker comprising about 10-15 residues can be advantageously incorporated between the VEGF and ARF peptide portions of select fusion proteins of the invention.

[0094] The linker sequence commonly will be primarily hydrophilic (e.g., the linker normally is composed of about 30% or less, about 20% or less, about 10% or less, or even about 5% or less hydrophobic amino acid residues). The linker sequence also generally can be characterized by having a Kyte & Doolittle hydropathy score (e.g., as determined by the GREASE program) of about -1.5 to about 0.5 (e.g., about -1 to about 0). The linker desirably comprises a sequence that is associated with a low energetic penalty (as measured by changes in stability) in the formation of secondary, tertiary, and quaternary structures as compared to a fusion protein lacking the linker.

[0095] Generally, the size and composition of the linker sequence is selected to ensure that desired biological properties of the VEGF and second peptide portions are substantially retained in the fusion protein. In other words, incorporation of the linker sequence allows the VEGF peptide portion and second peptide portion (or at least does not interfere with the ability of the peptide portions) to substantially retain biological activities they normally exhibit as individual polypeptides, such as promoting angiogenesis, bone growth, and/or wound healing and/or augmenting such biological desirable biological activities in the other peptide portion of the fusion protein (e.g., by increasing the overall *in vivo* half-life of the fusion protein). Thus, for example, where the absence of a linker might detract from the ability of the fusion protein to form dimers, particularly in the VEGF peptide portion, positioning of a suitable linker between the VEGF and second peptide portion can allow the VEGF peptide portion to form dimers. Desirably, the VEGF peptide portion forms dimers at least about 50%, at least about 60%, at least about 70%, at least about 80%, or even at least about 90% as frequently as the corresponding (or most closely related) native VEGF. Alternatively or additionally, where the absence of a linker might impair receptor binding, selection of a suitable linker and positioning thereof between the VEGF and second peptide portions can permit the peptide portions to retain much, if not all, of their affinity for their respective receptors. For example, the peptide portions in such a polypeptide can each exhibit at least about 50%, at least about 60%, at least about 70%, at least about 80%, at



least about 90% or more of the receptor affinity exhibited by corresponding (i.e., non-fusion protein) polypeptides. As a further illustration of this principle, positioning of a suitable linker between the VEGF peptide portion and second peptide portion in an VEGF<sub>121</sub>/ARF fusion protein of the invention may permit the VEGF peptide portion to dimerize and bind to VEGF target receptors with at least about 60%, preferably at least about 75%, and more preferably at least about 85% of the affinity exhibited by native VEGF<sub>121</sub>.

**[0096]** The linker can include one or more cleavage sites to promote separation of the peptide portions if desired under specific conditions (e.g., exposure to certain proteolytic enzymes). Examples of such cleavage sites include the Ile Glu Gly Arg linker sequence (SEQ ID NO: 64), which is cleaved by Factor X<sub>a</sub> protease. Other sites can include sequences which are cleaved by, for example, trypsin, enterokinase, collagenase, and thrombin. Alternatively, the cleavage site in the linker sequence can be a site capable of being cleaved upon exposure to a selected chemical or chemical state, e.g., cyanogen bromide, hydroxylamine, or low pH. Additional examples of suitable cleavable linkers are provided in U.S. Patent 4,719,326. Other suitable types of linkers are described in, e.g., U.S. Patent 6,010,883.

**[0097]** Cleavage, particularly when followed by degradation of one of the peptide portions, can offer a technique for providing a higher level of one of the two peptide portions, when desired. For example, a higher concentration of angiopoietin/ARF or HBNF-MK peptide portion can be desired after the induction of angiogenesis, to promote blood vessel maturation and/or reduce plasma leakage. In this regard, polynucleotides or vectors encoding for such cleavage factors that are expressed under different conditions than a polynucleotide encoding the fusion protein can be administered in association therewith so as to separate the peptide portions under desired conditions. Alternatively, such cleavage factors can be administered to or near an area of fusion protein administration or expression. Such cleavage sequences also can be introduced (or, if already present, exploited) in the VEGF peptide portion or second peptide portion. For example, a polynucleotide can encode a heparin-binding VEGF peptide portion (e.g., VEGF<sub>189</sub>), which can be cleaved in order to render the VEGF peptide portion a non-heparin-binding VEGF peptide portion (e.g., by using the proteolytic cleavage sites naturally occurring VEGF<sub>189</sub>). Typically and preferably, the first and second peptide portions will be directly fused, or separated by a non-cleavable linker of less than about 10 amino acid residues (e.g., 1-5 amino acid residues), so as to retain the improved/synergistic qualities of the fusion protein (e.g., greater mobility and/or larger *in vivo* half life) as desired herein.

**[0098]** Linkers which reduce the immunogenicity of the fusion protein in its intended recipient are preferred. Any linker which reduces the immune response of the intended recipient of the fusion protein is suitable in this respect. Typically, a flexible linker, which

does not interfere with the tertiary structure of the first peptide portion, the second peptide portion, or, most preferably, both peptide portions is used. By not interfering with the tertiary structure of the peptide portion(s), the flexible linker will not configure the fusion protein such that foreign epitopes are presented to the target's immune system.

Furthermore, the flexible linker is desirably immunological inert in the host system, and addition of it to the fusion protein desirably does not produce epitopes resulting in a strong immunological host response against the fusion protein, and desirably eliminates any sequences that might result in such immune response from the otherwise direct fusion of the first and second peptide portions. Any flexible linker can be used. Typically and preferably the flexible Gly<sub>4</sub>Ser<sub>3</sub> linker or derivative thereof (i.e., a linker comprising the sequence Gly Gly Gly Gly Ser Ser Ser (SEQ ID NO: 65) is used in such fusion proteins. The use of such flexible linkers is described in, e.g., McCafferty et al., *Nature*, 348, 552-554 (1990), Huston et al., *Proc. Natl. Acad. Sci. USA*, 85, 5879-5883 (1988), Glockshuber et al., *Biochemistry*, 29, 1362-1367 (1990), and Cheadle et al., *Molecular Immunol.*, 29, 21-30 (1992). Other glycine-rich flexible linkers also can be suitable, such as the Pro Ggly Ile Ser Gly Gly Gly Gly Gly Gly linker (SEQ ID NO: 66), described in Guan et al., *Anal. Biochem.*, 192(2), 262-67 (1991), the Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser linker (SEQ ID NO: 66), described in Huston et al., *Proc. Natl. Acad. Sci. USA*, 85, 5879-5883 (1988), and the Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Lys Glu Phe linker (SEQ ID NO: 67), described in Bird et al., *Science*, 242, 423-26 (1988). Other suitable flexible linkers include the immunoglobulin hinge linkers (as described in, e.g., U.S. Patents 5,672,683 and 6,165,476), and helical peptide linkers (as described in, e.g., U.S. Patent 6,132,992).

[0099] Alternatively, where the first and second peptide portions are directly fused, the fusion can be designed such that the intersection of the first and second peptide portions does not generate a sequence which results in a strong immune response against the fusion protein (e.g., as compared to the direct fusion of the wild-type peptide portions). Such determinations can be made by using algorithms which identify MHC class I and MHC class II epitope sequences (preferably through the use of bioinformatics software incorporating such algorithms or through the use of databases which provide listings of such epitopes identified with such algorithms). Any suitable algorithm, database, or program can be used. Examples of such algorithms, programs, and databases include the EPIMER/EPIMAX algorithm developed at the Brown University School of Medicine, the BONSAI algorithm developed at Stanford University, the TEPITOPE algorithm, the Zycos, Inc. "EPIQUEST" database, the SYFPEITHI program (which applies the algorithm of Rammensee et al.), the MAPPP program (available at <http://www.mpiib-berlin.mpg.de/MAPPP/addquery.html>), and the BIMAS program (available at [http://bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://bimas.dcrt.nih.gov/molbio/hla_bind/)), which are variously described in, e.g., Altuvia

et al., *Mol. Immunol.*, 31, 1-19 (1994), Brusic et al., *Nuc Acids Res.*, 22, 3663-3665 (1994), Hammer et al., *J. Exp. Med.*, 180, 2353-2358 (1994), Parker et al., *J. Immunol.*, 152, 163-175 (1994), Sturniolo et al. *Adv. Immunol.*, 66, 67-100 (1997), and Cunha-Neto, *Braz. J. Med. Biol. Res.*, 32(2), 199-205 (1999). The amino acid sequence which would result upon the production or expression of the fusion protein of interest, particularly the area where the first and second peptide portions are bonded (i.e., the "fusion point"), and surrounding region (typically about 15 or less, more typically about 10 amino acid residues or less, in both directions from the fusion point), can be inputted into such a program, referenced against such databases, or analyzed by similar technique, to determine whether the sequence would result in an undesired host immune response (e.g., formation of a complex with an MHC class I molecule, MHC class II molecule, or both). Thus, the invention provides a VEGF fusion protein wherein the first peptide portion, second peptide portion, or both portions, lack one or more amino acid residues corresponding to residues in their wild-type counterparts near the fusion point of the first and second peptide portions, typically within about 20 amino acids or less, more typically within about 10 amino acids or less of the fusion point. In such fusion proteins, the C-terminus of the first peptide portion, N-terminus of the second peptide portion (or visa versa depending upon the orientation of the first and second peptide portions in the fusion protein), or both termini in both portions, will thus lack one or more amino acid residues occurring in their wild-type counterparts, where the lack of such residues results in a lower level of host immune response against the fusion protein upon expression or administration (e.g., by reducing the immunogenicity of, or eliminating, sequences that result in a host cellular or humoral (typically cellular) immune response against the expressed or administered fusion protein). The residues that would result in the immunologically-undesirable amino acid sequence can be removed either through deletion or through non-immunologically equivalent substitutions (which typically will be non-homologous in nature). Typically and preferably about 15 or less, more typically about 5 or less of the residues at the fusion of the first and second peptide portions will require deletion or substitution. In some fusion proteins, even a single deletion or substitution will result in the desired reduction in the immunogenicity of the sequence formed by the fusion of the first peptide portion and second peptide portion. By "corresponding" in this context, it is meant that the deleted/substituted residue is homologous to, or more typically identical to, a sequence occurring in the wild-type peptide, and would align with the residue in the peptide portion's wild-type counterpart in an optimal alignment. Similar techniques can be applied to fusion proteins that contain a linker if necessary. Immunogenicity testing of the fusion protein or polynucleotides of the invention also can be assessed using any suitable immunogenicity model prior to administration to the target, particularly where the target of administration is a human, to

determine whether the area of fusion will exhibit an acceptable level of immunogenicity upon *in vivo* administration or expression.

**[00100]** Other techniques for reducing immunogenicity of the fusion protein, polynucleotide, or vector (including the vector composition and fusion protein composition) of the invention can be used in association with the administration of the fusion protein, polynucleotide, vector, or related compositions (e.g., the vector compositions of the invention). For example, the techniques provided in U.S. Patents 6,093,699 may reduce such an immune response to the fusion protein.

**[00101]** Where a linker is incorporated into the fusion protein, the presence of the linker preferably does not impede the biological activity of the first peptide portion or second peptide portion, and more preferably of either peptide portion, and more desirably enhances the biological activity of the separate peptide portions over a direct fusion of the peptide portions (e.g., the promotion of angiogenesis, bone growth, wound healing, VEGF receptor binding, Tie-2 receptor binding, multimerization, etc.). Examples of techniques used to assess the effect of linker sequences on the biological activities of fusion proteins are described in, e.g., Newton et al., *Biochemistry*, 35, 545-553 (1995), which can be modified as appropriate for the fusion proteins of the invention (e.g., using the biological assays described elsewhere herein). It will typically be advantageous for the linker to permit the first peptide portion, second peptide portion, or both portions, to exhibit a secondary and/or tertiary structure similar to that of their native peptide counterparts, which can be assessed using techniques provided herein or which are similar to such techniques.

**[00102]** The inclusion of a linker can be particularly advantageous where the second peptide portion corresponds to, or is highly homologous with, a factor that forms multimers more complicated than dimers (e.g., trimers) *in vivo*. As dimerization of the VEGF peptide portion typically is desired, the use of a second peptide portion that forms a dimer under normal physiological conditions is preferred. Monomeric factors also are regularly able to permit a VEGF peptide portion to undergo dimerization *in vivo* while retaining biological activity. Such VEGF peptide portion dimer/non-VEGF peptide portion dimer and VEGF peptide portion dimer/non-VEGF peptide portion monomer fusion proteins are advantageous aspects of the invention. In fusion proteins of the invention where the second peptide portion corresponds to, or is highly homologous to, a peptide that normally forms higher ordered multimers, one of skill in the art can use appropriate linker sequences to introduce space between the biologically active polypeptide portions. The activity of the respective peptide portions (e.g., receptor binding), conformational state (quaternary structure) of the peptide portions (e.g., dimer formation of the VEGF peptide portion), and/or primary, secondary, and tertiary structure of monomeric peptide portions of the fusion protein can readily be assessed by application of techniques described herein and/or

their known equivalents in the art to evaluate whether a particular linker sequence is suitable.

**[00103]** In addition to the VEGF peptide portion and second peptide portion, the fusion protein can include any suitable number of peptide portions in any suitable arrangement. For example, the fusion protein can include 3, 5, 10, or more peptide portions (e.g., including 2, 3, 4, or more angiogenic peptide portions, or angiogenic portions combined with SMC facilitating peptide portions). In such aspects, the peptide portions can include one or more repeated peptide portions or can be limited to several different peptide portions. Preferably, the fusion protein contains only non-heparin binding VEGF peptide portions. Thus, the fusion protein can be any size suitable to promote angiogenesis, bone growth, wound healing, or combination thereof. In this respect, the term "protein" as used herein is considered to be interchangeable with the terms "peptide" and "polypeptide" to refer to a molecule comprising a plurality of amino acid residues. Typically, the fusion protein will comprise about 200-1000 amino acid residues, more typically about 400-700 amino acid residues, and typically will weigh about 400-2000 kDa, more preferably about 50-100 kDa.

**[00104]** The first peptide portion can include any number of other elements or modifications, e.g., additional amino acid sequences or other peptide fragments, as long as the biological functions (e.g., bone growth promoting ability) of the fusion protein are not substantially diminished (i.e., not diminished by more than about 20%, preferably not more than about 10%, and even more preferably not at all) over a fusion protein lacking such additional elements. Examples of such elements include sequences encoding proteins for post-translational modification or for binding to a small molecule ligand.

**[00105]** Fusion proteins produced in recombinant host cells using the techniques described herein (or their equivalents in the art) are often subject to post-translational modifications (as a consequence of the selected host cell and/or as a desired modification (e.g., one that increases its therapeutic potential). Such post-translationally modified fusion proteins are contemplated. Examples of common post-translational modifications include carboxylation, glycosylation, hydroxylation, lipid or lipid derivative-attachment, methylation, myristylation, phosphorylation, and sulfation. Other post-translational modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formylation, GPI anchor formation, iodination, oxidation, proteolytic processing, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Similar modifications are described in, e.g., Creighton, *supra*, Seifter et al., *Meth. Enzymol.*, 182, 626-646 (1990), and Rattan et al., *Ann. N.Y. Acad.*

*Sci.*, 663, 48-62 (1992). Moreover, the fusion proteins of the invention include both methionine-containing and methionineless N-terminal variants of the fusion proteins described herein. The nature and extent of post-translational modifications is largely determined by the host cell's posttranslational modification capacity and the modification signals present in the polypeptide amino acid sequence. For instance, glycosylation often does not occur in bacterial hosts such as *E. coli*. Accordingly, when glycosylation is desired, a polypeptide should be expressed in a glycosylating host, generally a eukaryotic cell (e.g., a mammalian cell or an insect cell). Post-translational modifications can be verified by any suitable technique, including, e.g., x-ray diffraction, NMR imaging, mass spectrometry, and/or chromatography (e.g., reverse phase chromatography, affinity chromatography, or GLC). The fusion protein or portion thereof also or additionally can comprise one or more modified amino acids, non-naturally occurring amino acids (e.g.,  $\beta$  amino acids), or amino acid analogs, such as those listed in the *Manual of Patent Examining Procedure* § 2422 (7th Revision – 2000), which can be incorporated by protein synthesis, such as through solid phase protein synthesis (described in, e.g., Merrifield, *Adv. Enzymol.*, 32, 221-296 (1969)).

**[00106]** In view of the capacity for post-translational modifications and the desirability of fusion protein extracellular mobility, a common additional element present in the fusion protein is a signal sequence, which directs either organelle trafficking (e.g., an endoplasmic reticulum trafficking signal as described in, e.g., U.S. Patent 5,846,540) and/or cell secretion. Such sequences are typically present in the immature (i.e., not fully processed) form of the fusion protein, and are subsequently removed/degraded to arrive at the mature form of the protein. Both naturally occurring and heterologous signal sequences are suitable (e.g., a secretion sequence associated with the protein incorporated in the second peptide portion as discussed herein). For example, a heterologous signal sequence (e.g., a HBNF signal sequence, alkaline phosphatase signal sequence, fusion thereof, or homolog thereof) can be fused to the N-terminus of the VEGF peptide portion to facilitate the secretion of the fusion protein from recombinant host cells. Alternatively, the VEGF-A secretion signal sequence Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu Val Leu His His Ala Lys Trp Ser Gln Ala (SEQ ID NO: 68) (which is retained in all VEGF-As, e.g., VEGF<sub>121</sub>), or a portion thereof, can be used, preferably bound to the N-terminus of the VEGF peptide portion. Such sequences will necessarily vary with the host in which the fusion protein is expressed. Examples of heterologous secretion sequences include STII or Ipp for *E. coli*, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells. Further examples of signal sequences are described in, e.g., U.S. Patents 4,690,898, 5,284,768, 5,580,758, 5,652,139, and 5,932,445. Additional signal sequences can be identified using skill known in the art. For example, sequences identified by

screening a library can be analyzed using the SignalP program (see, e.g., Nielsen et al., *Protein Engineering*, 10, 1-6 (1997)), or similar sequence analysis software capable of identifying signal-sequence-like domains, or by otherwise analyzing the sequences for features associated with signal sequences, as described in, e.g., European Patent Application 0 621 337.

**[00107]** In view of the above, it should be clear that the fusion proteins of the invention include both mature (fully processed) and immature (nascent) peptide portions, particularly where such fusion proteins are produced through the expression of a polynucleotide of the invention. In this respect, a peptide portion of the fusion protein can comprise one or more "propeptide" regions, which are removed during processing. Accordingly, nucleotide sequences encoding such propeptide portions along with the "mature" amino acid sequence associated with the peptide portion are within the scope of the invention.

**[00108]** Other sequences that can be included in the fusion protein include binding regions, such as avidin or an epitope, which can be useful for purification and processing of the fusion protein. Examples of such sequences are described in, e.g., International Patent Application WO 00/15823. In addition, detectable markers can be attached to the fusion protein, so that the traffic of the fusion protein through a body or cell can be monitored conveniently. Such markers may include radionuclides, enzymes, fluorophores, small molecule ligands, and the like.

**[00109]** Recently, the production of fusion proteins comprising a prion-determining domain has been used to produce a protein vector capable of non-Mendelian transmission to progeny cells (see, e.g., Li et al., *J. Mol. Biol.*, 301(3), 567-73 (2000)). The inclusion of such prion-determining sequences in the fusion protein is contemplated, ideally to provide a heritable protein vector comprising the fusion protein that does not require a change in the host's genome.

**[00110]** The mature fusion protein also can include additional peptide portions which act to promote stability, purification, and/or detection of the fusion protein. For example, a reporter peptide portion (e.g., green fluorescent protein (GFP),  $\beta$ -galactosidase, or a detectable domain thereof) can be incorporated in the fusion protein. Purification facilitating peptide portions include those derived or obtained from maltose binding protein (MBP), glutathione-S-transferase (GST), or thioredoxin (TRX). The fusion protein also or alternatively can be tagged with an epitope which can be antibody purified (e.g., the Flag epitope, which is commercially available from Kodak (New Haven, Connecticut)), a hexahistidine peptide, such as the tag provided in a pQE vector available from QIAGEN, Inc. (Chatsworth, California), or an HA tag (as described in, e.g., Wilson et al., *Cell*, 37, 767 (1984)).

**[00111]** The fusion protein also can include a heterologous (i.e., non-VEGF and non-second peptide portion) multimerizing domain or multimerizing component (i.e., a domain of one of the peptide portions or a separate peptide portion which facilitates multimer formation), which permits the fusion protein to form multimers (including dimers). Examples of heterologous multimerization domains are the human immunoglobulin (IgG) multimerization domains (see, e.g., European Patent Application 0464533) and IgG-derived domains (e.g., the Fc domain as described in, e.g., Johanson et al., *J. Biol. Chem.*, 270, 9459-71 (1995)). Additional modified IgG multimerizing domains and other multimerizing domains are described in International Patent Application WO 00/37642 and the references cited therein.

**[00112]** Typically and preferably, the fusion protein, particularly with respect to angiogenic fusion proteins, will contain a multimerization domain, and thus form multimers (e.g., dimers), which can be either fusion protein homodimers or heterodimers formed with other proteins, preferably with other angiogenic, bone growth promoting, or wound healing promoting factors. It is sometimes desirable that the multimerization domain is obtained from an angiogenic, bone growth promoting, or wound healing promoting peptide (e.g., from the N-terminal portion of an angiopoietin, ARF, or a portion of a TGF- $\beta$  containing the TGF- $\beta$  dimerization domain), or a peptide associated with such biological activities (e.g., a vitronectin) versus other multimer-forming peptides, e.g., an IgG.

**[00113]** The fusion protein can include any suitable multimerization domain which results in the formation of any suitable multimer. The fusion protein multimer can be a heteromultimer (e.g., a heterodimer) or a homomultimer (e.g., a homodimer). Homomultimers or heteromultimers which involve association with proteins that exhibit significant levels (e.g., at least about 70%, preferably at least about 80%, and more preferably at least about 90%) sequence identity to the VEGF peptide portion or second peptide portion are preferred (e.g., a heteromultimer formed between the fusion protein and a VEGF<sub>121</sub> or Ang-1). Other heteromultimers also can be suitable, but testing of novel multimer combinations (e.g., using the techniques described herein or their equivalent) can be necessary to determine whether the multimer effectively induces angiogenesis, bone growth, wound healing, or other desired activity. Such analysis is commonly performed in the art (see, e.g., DiSalvo et al., *J. Biol. Chem.*, 270, 7717-23 (1995), Cao et al., *J. Biol. Chem.*, 271, 3154-62 (1996), and Olofsson et al., *Proc. Natl. Acad. Sci. USA*, 93, 2567-81 (1996)).

**[00114]** In some aspects, the fusion protein contains a multimerization domain which permits dimer formation without permitting formation of higher order multimers. For example, fusion proteins that include the dimerization domains of VEGF<sub>121</sub> or TGF- $\beta$  can limit multimerization to dimer formation.



**[00115]** The fusion protein can be further modified or derivatized in any suitable manner (e.g., by reaction with organic derivatizing agents). For example, the fusion protein can be linked to one or more nonproteinaceous polymers, typically a hydrophilic synthetic polymer, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylene, as described in, e.g., U.S. Patents 4,179,337, 4,301,144, 4,496,689, 4,640,835, 4,670,417, and 4,791,192, or a similar polymer such as polyvinylalcohol or polyvinylpyrrolidone (PVP). Mimetics of the fusion proteins are also contemplated. Suitable types of peptide mimetics are described in, e.g., U.S. Patent 5,668,110 and the references cited therein. Furthermore, the fusion protein can be modified by the addition of protecting groups to the side chains of one or more the amino acids of the fusion protein. Such protecting groups can facilitate transport of the fusion peptide through membranes, if desired, or through certain tissues, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide. Examples of suitable protecting groups include ester protecting groups, amine protecting groups, acyl protecting groups, and carboxylic acid protecting groups, which are known in the art (see, e.g., U.S. Patent 6,121,236). Synthetic fusion proteins of the invention can take any suitable form. For example, the fusion protein can be structurally modified from its naturally occurring configuration to form a cyclic peptide or other structurally modified peptide.

**[00116]** The second peptide portion is preferably derived from, based upon, or obtained from a soluble protein, comprises a soluble portion of an otherwise insoluble protein, or is rendered soluble upon, or shortly after, administration or expression (e.g., by partial enzymatic cleavage or controlled degradation), thereby promoting the extracellular matrix mobility of the fusion protein. The fusion protein preferably is capable of relatively high diffusion mobility in the extracellular matrix of a mammalian host. Desirably, for example, the fusion protein diffuses through the extracellular matrix in a mammalian host upon administration to a mammalian host from a point of administration, the cell in which a polynucleotide encoding the fusion protein is expressed, or both, farther than a protein consisting essentially of a naturally occurring heparin-binding form of a VEGF (e.g., farther than a VEGF<sub>189</sub> or VEGF<sub>206</sub> administered under substantially identical conditions, more preferably farther than a VEGF<sub>165</sub> administered under substantially identical conditions). Migration/diffusion of the fusion protein can be detected by any suitable technique (e.g., radioactive or fluorescent antibody binding and detection assays or direct fluorescent staining detection).

**[00117]** The fusion protein alternatively, or preferably additionally, will diffuse in the extracellular matrix in a mammalian host upon administration to a mammalian host from a point of administration, the cell in which a polynucleotide encoding is expressed, or both, farther than a protein consisting essentially of the second peptide portion. For example,

fusion proteins of the invention where the second peptide portion comprises a peptide that, in its native state, is associated with a high order of multimerization but are modified in the fusion protein to only form lower level multimers (e.g., tetramers, trimers, or dimers), for example, can exhibit significant improvements in mobility. The higher half-life associated with the fusion proteins of the invention (as further discussed herein) also permits longer range of diffusion, and, accordingly, reduces the number of doses of fusion protein (or vector containing a polynucleotide encoding the fusion protein) required for therapeutic administration.

**[00118]** As indicated above, the fusion proteins of the invention exhibit improved *in vivo* half-life over known angiogenic peptides and fusion proteins. For example, the fusion proteins of the invention typically will have a half life in a mammalian host at least twice as long (preferably at least three times as long, and more preferably at least five times as long) than the half life of a protein consisting essentially of an Ang-1. Typically, the fusion proteins will exhibit a half-life of at least three minutes, desirably at least about four minutes, more preferably at least five minutes, and even more preferably at least ten minutes (e.g., at least about 15, 20, 30, 60, 90, 180, 360, or 720 minutes) in a mammalian host upon administration (including direct administration as well as production upon expression of polynucleotides encoding the fusion proteins). The extended half-life is typically associated with the structure of the fusion protein, i.e., the combination of the VEGF peptide portion and second peptide portion where one or more domains of the second peptide portion (e.g., the Ang-1 coiled coil domain) or VEGF peptide portion which are associated with short *in vivo* half life are deleted or modified. Preferably, the fusion protein retains at least the eight cysteine residues conserved among the VEGFs, as previously mentioned, and more preferably, comprises even more cysteine residues in the second peptide portion, thereby rendering the fusion protein more resistant to extracellular degradation than other therapeutic factors (e.g., PDGFs). Wound healing fusion proteins including a CTGF second peptide portion are particularly preferred in this respect. Even longer half-life can be obtained, if desired, by fusion with a heterologous peptide portion which exhibits a longer *in vivo* half life (e.g., an IgG domain) (as described in, e.g., International Patent Application WO 00/24782), or by administering the fusion protein with a non-proteinaceous polymer, such as those described elsewhere herein.

**[00119]** The invention further provides polynucleotides including at least one nucleotide sequence which, when expressed in a cell permissive for expression of the nucleotide sequence, result in the production of the fusion protein. The polynucleotide sequence can be any suitable sequence (e.g., single stranded or double stranded RNA, DNA, or combinations thereof) and can include any suitable nucleotide base, base analog, and/or backbone (e.g., a backbone formed by, or including, a phosphothioate, rather than

phosphodiester, linkage). Examples of suitable modified nucleotides which can be incorporated in the polynucleotide sequence are provided in the *Manual of Patent Examining Procedure* § 2422 (7th Revision – 2000). The polynucleotide sequence can be any suitable length (e.g., about 100 nt, about 1000 nt, about 2500 nt, about 5000 nt, or even larger). The polynucleotide sequence can be any sequence that results in the fusion protein being produced upon expression, and, thus, is not limited to sequences which directly code for expression of the fusion protein. For example, the polynucleotide can comprise a sequence which results in the fusion protein through intein-like expression (as described in, e.g., Colson and Davis, *Mol. Microbiol.*, 12(3), 959-63 (1994), Duan et al., *Cell*, 89(4), 555-64 (1997), Perler, *Cell*, 92(1), 1-4 (1998), Evans et al., *Biopolymers* 51(5), 333-42 (1999), and de Grey, *Trends Biotechnol.*, 18(9), 394-99 (2000)), or a sequence which contains self-splicing introns which form the peptide portions and/or the fusion protein (as described in, e.g., U.S. Patent 6,010,884). The polynucleotides also can comprise sequences which result in splice modifications at the RNA level to produce an mRNA transcript encoding the fusion protein and/or at the DNA level by way of trans-splicing mechanisms prior to transcription (as described in, e.g., Chabot, *Trends Genet.*, 12(11), 472-78 (1996), Cooper, *Am. J. Hum. Genet.*, 61(2), 259-66 (1997), and Hertel et al., *Curr. Opin. Cell. Biol.*, 9(3), 350-57 (1997)). RNA based vectors may include removal of regions which promote degradation in the absence of hypoxia, e.g., by removal of the VEGF mRNA 3' and/or 5' UTRs (see Dibbens et al., *Mol. Biol. Cell.*, 10, 907-19 (1999)) or portion thereof, e.g., the AU rich hairpin structure region of the 3' UTR (see, e.g., Pages et al., *J. Biol. Chem.* (published on June 9, 2000 as manuscript M002104200 – American Society for Biochemistry and Molecular Biology, Inc.), and Levy, *J. Biol. Chem.*, 271, 25492-25497 and 2746-2753 (1996)), particularly where RNA vectors are administered in the absence of hypoxic conditions. The polynucleotide can comprise one or more sequences encoding fusion proteins wherein the fusion protein-encoding sequence is codon optimized for a particular species (e.g., humans) (using techniques such as those described in U.S. Patents 5,082,767, 5,786,464, and 6,114,148). For example, the second peptide portion can comprise a codon optimized mouse angiopoietin.

**[00120]** Preferably, in addition to the nucleic acid sequence which, when expressed, results in the fusion protein (the "fusion protein nucleic acid sequence"), the polynucleotide further includes one or more suitable "expression control sequences" operably linked to the sequence encoding the fusion protein. An expression control sequence is any nucleotide sequence that assists or modifies the expression (e.g., the transcription, translation, or both) of the nucleic acid encoding the angiogenic sequence. The expression control sequence can be naturally associated with the VEGF peptide portion or second peptide portion (e.g., a wild-type VEGF promoter), or can comprise a heterologous element with respect to the both

the VEGF and second peptide portion polynucleotides. For example, the fusion protein nucleic acid sequence can be operably linked to a constitutive promoter (e.g., the Rous sarcoma virus long terminal repeat (RSV LTR) promoter/enhancer or the cytomegalovirus major immediate early gene (CMV IE) promoter, which is particularly preferred), an inducible promoter, (e.g., a growth hormone promoter, metallothionein promoter, heat shock protein promoter, E1B promoter, hypoxia induced promoter, or MLP promoter and tripartite leader), an inducible-repressible promoter, a developmental stage-related promoter (e.g., a globin gene promoter), or a tissue specific promoter (e.g., a smooth muscle cell  $\alpha$ -actin promoter, VEGF receptor promoter, myosin light-chain 1A promoter, or vascular endothelial cadherin promoter). In some instances, host-native promoters can be preferred over non-native promoters (e.g., a human beta actin promoter or EF1 $\alpha$  promoter driving expression of the fusion protein nucleic acid sequence can be preferred in a human host), particularly where strict avoidance of gene expression silencing due to host immunological reactions is desirable. The polynucleotide can include expression control sequences wherein one or more regulatory elements have been deleted, modified, or inactivated. the polynucleotide also or alternatively can include a bi-directional promoter system (as described in e.g., U.S. Patent 5,017,478) linked to multiple genes of interest (e.g., multiple fusion protein encoding genes). The polynucleotide can further comprise site-specific recombination sites, which can be used to modulate transcription of the polynucleotide, as described in, e.g., U.S. Patents 5,801,030 and 6,063,627 and International Patent Application WO 97/09439.

**[00121]** The polynucleotide can include or consist of any suitable fusion protein nucleic acid sequence. Preferred fusion protein nucleic acid sequences include nucleotide sequences which, when expressed, result in the production of the above-described fusion proteins (e.g., a polynucleotide comprising a sequence encoding a VEGF121 fused to a polynucleotide encoding an Ang-1 peptide portion, an aFGF peptide portion, a HBNF peptide portion, an MK peptide portion, an alkaline phosphatase peptide portion, or a fragment thereof which promotes angiogenesis, bone growth, or wound healing, or associated with such a second peptide portion-encoding sequence through a polynucleotide encoding a linker sequence, a sequence which does not effect production of the fusion protein upon expression (e.g., a sequence coding for intein-like expression), or other transcriptionally inert sequence (e.g., an intron). The polynucleotide can contain any suitable number of copies of the fusion protein nucleic acid sequence.

**[00122]** Preferably, the polynucleotide comprises a second nucleotide sequence that, when expressed, produces a second protein which promotes angiogenesis, bone growth, wound healing, or any combination thereof. The second nucleotide sequence can thus encode, for example, a second fusion protein or one of the angiogenic, bone growth

promoting, or wound healing promoting factors described above (including their homologs and gene fragments thereof). The second nucleotide sequence also can encode a receptor for either the VEGF peptide portion or second peptide portion of the fusion protein, or for another encoded factor. In this respect, the polynucleotide can include any suitable number of protein-encoding sequences. Alternatively, the polynucleotide can encode for a ribozyme or for the production of an inhibitory (e.g., antisense) polynucleotide, which preferably facilitates one of the above-mentioned biological activities through inhibition of a biological activity inhibitor.

**[00123]** If the polynucleotide encodes multiple gene products, a combination of expression control sequences (e.g., promoters) can be used, preferably which correspond to a pre-planned pattern of activity with the desired pattern and level of expression of the encoded factors. Thus, nucleotide sequences in the polynucleotide can be under the control of separate promoters having different expression profiles, e.g., at least one nucleic acid sequence is operably linked to an RSV promoter and at least one other nucleic acid sequence is operably linked to a CMV promoter. Alternatively, a hybrid promoter can be constructed which combines the desirable aspects of multiple promoters. For example, a CMV-RSV hybrid promoter combining the CMV promoter's initial rush of activity with the RSV promoter's high maintenance level of activity is especially preferred for use in many embodiments of the inventive method. Thus, the invention provides polynucleotides where the fusion protein sequence is operably linked to a first promoter and a second nucleotide sequence is operably linked to a second promoter, such that the initiation of expression of the first nucleotide sequence and second nucleotide occurs at different times, in response to different factors, or both. Preferably, such promoter systems are designed to mimic expression patterns associated with normal biological activities, e.g., pathways or cascades. For example, a first promoter can drive the early expression (or separately inducible expression) of a first fusion protein which contains a VEGF peptide portion and an extracellular matrix degrading second peptide portion, and a second promoter can be later induced or otherwise later cause expression of a nucleic acid sequence encoding a factor that induces blood vessel remodeling, induces maturation, and/or reduces plasma leakage.

**[00124]** The polynucleotide can include multiple fusion protein genes and/or related genes to be serially and/or co-expressed. Thus, for example, the invention contemplates administration of polynucleotides which encode at least 3, at least 4, at least 5, or more, fusion protein genes or combinations of fusion protein and other angiogenic-bone growth promoting-, or wound healing promoting-factor encoding genes, which preferably mimic an expression pattern of a normal biological cascade. For example, a polynucleotide, which provides for sequential expression of (1) an MMP or TIMP (which provides matrix degradation), (2) an angiogenic VEGF fusion protein (which preferably attracts endothelial

cells and induces blood vessel formation), (3) a vascular maturation factor (e.g., an Ang-1, ARF, or related fusion protein), and (4) a stabilization and maintenance factor (e.g., an ephrin), can be administered to the host (preferably in an ischemic tissue) to mimic the normal cascade of factors associated with blood vessel development. Administration of polynucleotides that express both growth and wound healing promoting factors in such a cascade-like fashion also are provided. Alternatively, multiple polynucleotides (e.g., within multiple vectors) can be administered, wherein the polynucleotides encode one or multiple genes to provide such a cascade effect. However, the administration of a single polynucleotide under control of the above-described expression control sequence systems is preferred.

**[00125]** Production of the recombinant polynucleotide encoding the fusion protein can be accomplished by any suitable technique. Recombinant polynucleotide production is well understood, and methods of producing such molecules are provided in, e.g., Ibanez et al., *EMBO J.*, 10, 2105-10 (1991), Ibanez et al., *Cell*, 69, 329-41 (1992), and U.S. Patents 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648, and are more particularly described in Sambrook and Ausubel, *supra*.

**[00126]** The polynucleotide is preferably positioned in and/or administered in the form of a suitable delivery vehicle (i.e., a vector). The vector can be any suitable vector. For example, the nucleic acid can be administered as a naked DNA or RNA vector (including, for example, a linear expression element or a plasmid vector such as pBR322, pUC 19/18, or pUC 118/119) or as a precipitated nucleic acid vector construct (e.g., a  $\text{CaPO}_4$  precipitated construct). Methods of producing and using angiogenic naked DNA vectors are known in the art (see, e.g., U.S. Patent 6,228,844). The vector also can be a shuttle vector, able to replicate and/or be expressed (desirably both) in both eukaryotic and prokaryotic hosts (e.g., a vector comprising an origin of replication recognized in both eukaryotes and prokaryotes). The nucleic acid vectors of the invention can be associated with salts, carriers (e.g., PEG), formulations which aid in transfection (e.g., sodium phosphate salts, Dextran carriers, iron oxide carriers, or gold bead carriers), and/or other pharmaceutically acceptable carriers, some of which are described herein. Alternatively or additionally, the polynucleotide vector can be associated with one or more transfection-facilitating molecules such as a liposome (preferably a cationic liposome), a transfection facilitating peptide or protein-complex (e.g., a poly(ethylenimine), polylysine, or viral protein-nucleic acid complex), a virosome, a modified cell or cell-like structure (e.g., a fusion cell), or a viral vector.

**[00127]** More preferably, the polynucleotide is positioned in, and administered to the host via, a viral vector. The viral vector can be any suitable viral vector. A viral vector in

the context of the invention includes any combination of nucleotides and proteins which are derived from, obtained from, or based upon proteins and or nucleic acids that are present in a wild-type virus. The viral vector can be a vector which requires the presence of another vector or wild-type virus for replication and/or expression (i.e., a helper-dependent virus), such as an adenoviral vector amplicon. The viral vector preferably consists of an intact virus particle. Typically, such viral vectors consist essentially of a wild-type viral particle, or a viral particle modified in its protein and/or nucleic acid content to increase transgene capacity or aid in transfection and/or expression of the nucleic acid (examples of such vectors include the herpes virus/AAV amplicons). Such vectors are typically named for the type of virus they are obtained from, derived from, or based upon, as applicable. Examples of preferred viral vectors include herpes viral vectors, adeno-associated viral vectors, and adenoviral vectors.

[00128] The construction of recombinant viral vectors is well understood in the art. For example, adenoviral vectors can be constructed and/or purified using the methods set forth, for example, in U.S. Patents 5,965,358 and 6,168,941 and International Patent Applications WO 98/56937, WO 99/15686, WO 99/54441, and WO 00/32754. Adeno-associated viral vectors can be constructed and/or purified using the methods set forth, for example, in U.S. Patent 4,797,368 and Laughlin et al., *Gene*, 23, 65-73 (1983). Similar techniques are known in the art with respect to other viral vectors, particularly with respect to herpes viral vectors, lentiviral vectors, and other retroviral vectors.

[00129] Desirably, the viral vector is capable of expressing the polynucleotide for a sustained period (e.g., for a period of at least about 1 day, preferably about 1 week), without expressing the polynucleotide so long that undesired effects associated with prolonged expression, e.g., promiscuous angiogenesis, occurs (e.g., for a period of less than about 2 weeks). Thus, the viral vector preferably is capable of therapeutic, and transient, self-terminating expression of the polynucleotide (e.g., expression for a period of about 1 week or less). Preferably, the viral vector achieves gene transfer in both dividing and non-dividing, as well as terminally differentiated, cells, with high levels of expression in cardiovascular relevant sites such as the myocardium, vascular endothelium, and skeletal muscle. The viral vector desirably is safe for administration to the host. Advantageously, the viral vector operates in an episomal manner without insertion of genetic material to the host. Adenoviral vectors, which possess all of these aforementioned qualities, are particularly preferred delivery vectors for nucleic acid angiogenic mediators.

[00130] Any suitable adenoviral vector can be used as a delivery vehicle for the polynucleotide. For instance, an adenovirus can be of subgroup A (e.g., serotypes 12, 18, and 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, and 35), subgroup C (e.g., serotypes 1, 2, 5, and 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32,

33, 36-39, and 42-47), subgroup E (serotype 4), subgroup F (serotypes 40 and 41), or any other adenoviral serotype. Preferably, the adenoviral vector is based on, derived from, or consists of a serotype-2 or serotype-5 adenovirus.

[00131] Regions of the adenoviral genome (e.g., the E3 region) in the adenoviral vector can optionally and preferably be deleted in order to provide space for insertion of the polynucleotide or other nucleic acid sequences. In addition, regions of the adenoviral genome can be deleted or altered in order to interfere with viral replication. The adenoviral vector used in the inventive method is preferably deficient in at least one gene function required for viral replication, thereby resulting in a "replication-deficient" adenoviral vector. Preferably the adenoviral vector will be deficient in at least one essential gene function of the E1, E2, and/or E4 regions of the adenoviral genome. More preferably, the adenoviral vector is deficient in at least one essential gene function of the E1 region (e.g., deficient in at least part of the E1a region and/or at least part of the E1b region) of the adenoviral genome. Other portions of the genome also can be deleted, e.g., typically the E3 region, which is non-essential for viral replication. Thus, the adenoviral vector can be lacking multiple adenoviral gene functions, e.g., at least one essential gene function of the E1 region and at least one essential gene function of the E4 region, in addition to at least part of the E3 region. Examples of E1-deleted and other replication deficient adenoviral vectors are disclosed in, for example, U.S. Patents 5,851,806 and 5,994,106 and International Patent Applications WO 95/34671 and WO 97/21826. The adenoviral vector desirably retains at least one adenovirus inverted terminal repeat (ITR) (preferably the 5' and 3' ITRs). The adenoviral vector also desirably retains the adenovirus packaging sequence. Preferably, the recombinant adenovirus also comprises a mutation in the major late promoter (MLP), as discussed in International Patent Application WO 00/00628.

[00132] A particularly preferred adenoviral vector for use in the inventive method is deficient in the entire E1a region, at least part of the E1b region, and at least part of the E3 region of the adenoviral genome and contains a DNA encoding a VEGF<sub>121</sub>:Ang-1 fusion protein under the control of the CMV IE promoter in the E1 region of the adenoviral genome. Such a vector supports *in vivo* expression of the fusion protein that is maximized at one day following administration and is not detectable above baseline levels as little as one week after administration. This is ideal inasmuch as it is sufficient to provide substantial growth of new vasculature while minimizing adverse neovascularization at distal sites. In that regard, when this vector is locally administered to a target tissue, no detectable expression of the fusion protein can be detected in blood serum using standard ELISA monitoring assays. Advantageously, local administration to a target tissue of such adenoviral vectors including the polynucleotide encoding the fusion protein positioned in the E1 region of the adenoviral genome results in an at least 3-fold increase in blood flow in



the extremities of mammals (e.g., the hind limb of Sprague-Dawley rats) with iliac and femoral artery ligations.

[00133] The adenoviral vector can be subject to any number of additional or alternative modifications. For example, a particularly preferred vector comprises a replication deficient adenoviral vector which includes or expresses a modified adenoviral protein, non-adenoviral protein, or both, which increases the efficiency that the vector infects cells as compared to wild-type adenovirus, allows the vector to infect cells which are not normally infected by wild-type adenovirus, results in a reduced host immune response in a mammalian host as compared to wild-type adenovirus, or any combination thereof. Any suitable type of modification can be made to the vector, and several suitable modifications are known in the art. For example, the adenoviral vector coat protein can be modified. Examples of such modifications include modifying the adenoviral fiber, penton, pIX, pIIIa, or hexon proteins, and/or insertions of various native or non-native ligands into portions of such coat proteins. Manipulation of such coat proteins can broaden the range of cells infected by a viral vector or enable targeting of a viral vector to a specific cell type. One direct result of manipulation of the viral coat is that the adenovirus can bind to and enter a broader range of eukaryotic cells than a wild-type virus. Examples of adenoviruses including such modifications are described in International Patent Application WO 97/20051. Reduction of immune response against the adenoviral also or alternatively can be obtained through the methods described in U.S. Patent 6,093,699. In other embodiments, the viral coat is manipulated such that the virus is "targeted" to a particular cell type, e.g., those cells expressing unique receptors. Examples of such modified adenoviral vectors are described in U.S. Patents 5,559,099, 5,731,190, 5,712,136, 5,770,442, 5,846,782, 5,962,311, 5,965,541, and 6,057,155 and International Patent Applications WO 96/07734, WO 96/26281, WO 97/20051, WO 98/07865, WO 98/07877, WO 98/40509, WO 98/54346, and WO 00/15823. Other adenoviral vector protein modifications that decrease the potential for immunological recognition by the host and resultant coat-protein directed neutralizing antibody production, as described in, e.g., International Patent Applications WO 98/40509 and WO 00/34496. In non-viral vector systems, the use of targeting through targeted proteins (e.g., an asialoorosomucoid protein conjugate which promotes liver targeting (such as is described in Wu and Wu, *J. Biol. Chem.*, 263 (29), 14621-24 (1988)) or the targeted cationic lipid compositions of U.S. Patent 6,120,799).

[00134] The adenoviral vector also can include a *trans*-acting factor, *cis*-acting factor, or both, which preferably increases the persistence of transgene expression from the adenoviral vector's genome. Any suitable *trans*-acting factor can be used, such as HSV ICP0, which prolongs transgene expression (e.g., expression of the fusion protein sequence). Such

modifications are particularly preferred in E4-deleted adenoviral vectors. The use of *trans*-acting factors is further described in International Patent Application WO 00/34496.

Additionally or alternatively, the adenoviral vector comprises a nucleic acid sequence encoding a *cis*-acting factor. For example, a matrix attachment region (MAR) sequence (e.g., an immunoglobulin heavy chain  $\mu$  (as discussed in, e.g., Jenuwein et al., *Nature*, 385(16), 269 (1997)), locus control region (LCR) sequences, or apolipoprotein B sequence (as discussed in, e.g., Kalos et al., *Molec. Cell. Biol.*, 15(1) 198-207 (1995)) can be used to modify the persistence of expression from a transgene, such as a transgene inserted into an E4-deleted region of the adenoviral vector genome. LCR sequences are also believed to establish and/or maintain transcription of transgenes in a *cis* manner.

**[00135]** The polynucleotide can be positioned within any suitable location in the genome of the adenoviral vector. Typically, the polynucleotide will substitute for one or more of the aforementioned deleted regions of the adenoviral genome (e.g., the E1, E2, E3, and/or E4 region, most preferably replacing at least a portion of the E1 region). Alternatively, several polynucleotides encoding multiple fusion proteins, or fusion proteins and other proteins (e.g., a second angiogenic, bone growth promoting, or wound healing promoting peptide) can be inserted as expression cassettes into multiple deleted regions (e.g., a first angiogenic sequence can be inserted in a portion of the E1 region and the polynucleotide encoding the fusion protein can be inserted in the deleted E3 region, or vice versa).

**[00136]** Production of such deficient adenoviral vectors can be accomplished by use of a complementation cell line, which is capable of providing the deleted necessary adenoviral gene functions *in trans*. Several examples of suitable cells are known. Examples of suitable cells for producing such vectors include 293 cells (described in, e.g., Graham et al., *J. Gen. Virol.*, 36, 59-72 (1977)), PER.C6 cells (described in, e.g., U.S. Patent 5,994,128), 911 cells (as described in, e.g., Fallaux et al., *Human Gene Therapy*, 7, 215-222 (1996)), and 293-ORF6 cells (as described in, e.g., International Patent Application WO 95/34671 and Brough et al., *J. Virol.*, 71, 9206-13 (1997)). The cell line can provide either no homologous overlapping regions with the adenoviral vector, ideally resulting in no replication competent adenovirus (RCA), or, alternatively can partially overlap in one or more essential regions but lack homology in one or more essential regions (as exemplified by the cells in International Patent Application WO 95/34671). Desirably, the vector composition of the invention is formed from a purified stock of such vectors. A preferred method for purifying such vector stocks is provided in International Patent Application WO 99/54441. Methods for assessing the purity of such vector compositions are provided in International Patent Application WO 00/12765.

**[00137]** The polynucleotide encoding the fusion protein can be inserted in any of the above-described vectors in any suitable manner and in any suitable orientation. Whereas

the polynucleotide can be inserted in any suitable orientation, preferably the orientation of the nucleic acid is from right to left. By the polynucleotide having an orientation "from right to left," it is meant that the direction of transcription of the nucleic acid is opposite that of the region of the vector into which the polynucleotide is inserted.

**[00138]** The invention further provides methods of promoting angiogenesis, bone growth, wound healing, or any combination thereof in an individual (e.g., a mammalian host, such as a human) by administering to the individual the fusion protein, preferably in an amount effective to promote angiogenesis, bone growth, wound healing, or any combination thereof. Administration can be performed by any suitable method, and the fusion protein can be administered in any suitable form (including by way of the polynucleotide or vector described herein). Preferably, the fusion protein (or polynucleotide or vector encoding the fusion protein) is administered in a composition, with a carrier, preferably in a pharmaceutically acceptable composition, e.g. by combination with a pharmaceutically acceptable carrier.

**[00139]** The term "pharmaceutically acceptable" means that the composition is a non-toxic material that does not interfere with the effectiveness of the biological activity of the fusion protein or other effective ingredients. Any suitable carrier can be used, and several carriers for administration of therapeutic proteins are known in the art. The characteristics of the carrier will depend on the route of administration.

**[00140]** The pharmaceutical composition and/or pharmaceutically acceptable carrier also can include diluents, fillers, salts, buffers, stabilizers, solubilizers, and/or other materials suitable for inclusion in a pharmaceutically composition. The pharmaceutical composition of the invention also can contain preservatives, antioxidants, or other additives known to those of skill in the art. When the fusion protein (or polynucleotide or vector encoding is fusion protein) is administered with other agents or ingredients the combined amounts of the agents can be administered in combination, serially or simultaneously.

**[00141]** The pharmaceutical composition of the invention can be in the form of a liposome in which the fusion protein (or polynucleotide or vector encoding the fusion protein) is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is described in, e.g., U.S. Patents 4,837,028 and 4,737,323.

**[00142]** The pharmaceutical composition can be delivered to the individual by any suitable route of administration. Examples of suitable routes of administration include oral ingestion, inhalation, bucal application, rectal application, vaginal application, topical

application, insufflation, implantation, transmucosal administration, or cutaneous, subcutaneous, intraperitoneal, parenteral, myocardial, pericardial (e.g., intrapericardial), or injection (e.g., intravenous injection). Intravenous administration and injection are preferred.

**[00143]** If the pharmaceutical composition is administered orally, the composition preferably is administered in the form of a tablet, capsule, powder, solution, elixir, or troches. Oral compositions can include any suitable carriers or other agents. For example, tablets will typically contain a solid carrier, such as a gelatin. Generally, oral compositions also can include binders (e.g., microcrystalline cellulose, gum tragacanth or gelatin), excipients (e.g., starch or lactose), disintegrating agents (e.g., alginic acid, Primogel, or corn starch), lubricants (e.g., magnesium stearate or Sterotes), glidants (e.g., colloidal silicon dioxide), and/or sweetening/flavoring agents. Oral compositions preferably contain about 5-95%, preferably about 25-90%, fusion protein (or polynucleotide or vector encoding the fusion protein).

**[00144]** To administer the fusion protein (or polynucleotide or vector encoding the fusion protein) in a liquid form, such as in delivery by injection, a liquid carrier such as water, petroleum, physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ), phosphate buffered saline (PBS), or oils can be used as a carrier. Liquid pharmaceutical compositions can further contain physiological saline solution, dextrose or other saccharide solution, or glycols, such as ethylene glycol, propylene glycol, PEG, coating agents which promote proper fluidity, such as lecithin, isotonic agents, such as mannitol or sorbitol, and absorption-delaying agents, such as aluminum monostearate. When administered in liquid form, the pharmaceutical composition preferably contains about 0.5-90% by weight (wt.%) of fusion protein (or polynucleotide or vector encoding the fusion protein), more preferably about 1-50 wt.% fusion protein (or polynucleotide or vector encoding the fusion protein).

**[00145]** More particularly, when the pharmaceutical composition is administered by injection, the composition will preferably be in the form of a pyrogen-free, stable, parenterally acceptable aqueous solution. Preferably, the parenterally acceptable aqueous solution comprises an isotonic vehicle such as sodium chloride injection, Ringer's injection, dextrose injection, lactated Ringer's injection, or equivalent delivery vehicle (e.g., sodium chloride/dextrose injection).

**[00146]** In a particularly preferred aspect, the fusion protein (or polynucleotide or vector encoding the fusion protein) are administered in or near the heart. Administration in or near the heart can be to any suitable heart-associated region or tissue, using any suitable technique. Examples of suitable types of administration include direct (needle or biolistic) intracoronary injection (e.g., of a vector composition) and/or intracoronary administration

using implant devices (e.g., a fusion protein coated coronary stent). Pericardial, myocardial, and intracoronary administration are particularly preferred for angiogenic fusion proteins used to treat vascular occlusion in an individual's heart.

**[00147]** For compositions to be administered to bone, cartilage, tendon, or ligaments (e.g., for promoting bone growth or wound healing), the therapeutic method includes administering the composition, systematically or locally as an implant or device, desirably in a pyrogen-free, physiologically acceptable form. Further, the composition can desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage, or tissue damage. Bone and/or cartilage formations also or alternatively can include a matrix capable of delivering the fusion protein-containing composition to the bone and/or cartilage administration site, providing a structure for the developing bone and cartilage.

Advantageously, the matrix is capable of being resorbed into the body. Suitable materials for producing such matrixes include calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid, bone and/or dermal collagens, and polyanhydrides.

Additional suitable administration techniques and matrixes are discussed elsewhere herein.

**[00148]** Topical administration also can be suitable for wound healing and tissue repair. For example, a drug reservoir or monolithic matrix transdermal patch device can be used for such topical administration, as can creams, ointments, or salves.

**[00149]** Administration devices can be formed of any suitable material. Examples of suitable matrix materials for producing non-biodegradable administration devices include hydroxapatite, bioglass, aluminates, or other ceramics. In some applications, a sequestering agent, such as carboxymethylcellulose (CMC), methylcellulose, hydroxypropylmethylcellulose (HPMC), or autologous blood clot, can be used to prevent the fusion protein complex from disassociating from the device and/or matrix. Thus, such sequestering agents are preferably present in an amount which prevents desorption of the fusion protein from the matrix/device and/or provides better handling of the composition. Typically, such sequestering agents will make up about 0.5-20 wt.%, preferably 1-10 wt.%, of the composition, based on total formulation weight.

**[00150]** For administration by inhalation, the fusion protein (or polynucleotide or vector encoding the fusion protein) can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e. g., a gas such as carbon dioxide, or a nebulizer.

**[00151]** For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are preferably included in the composition. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be facilitated through the use of nasal sprays or suppositories.

**[00152]** The invention further provides sterile compositions, such as sterile powder compositions, that comprise the fusion protein (or polynucleotide or vector encoding the fusion protein), e.g., for the preparation of sterile injectable solutions. Such powder compositions can be prepared by, e.g., vacuum drying and freeze-drying, which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The compositions of the invention also or alternatively can be provided in unit dose containers and devices, including ampoules, disposable syringes, or multiple dose vials.

**[00153]** Additional pharmaceutically acceptable carriers are known in the art. Examples of additional suitable carriers are described in, e.g., Urquhart et al., *Lancet*, 16, 367 (1980), Lieberman et al., *Pharmaceutical Dosage Forms - Disperse Systems* (2nd ed., vol. 3, 1998), Ansel et al., *Pharmaceutical Dosage Forms & Drug Delivery Systems* (7th ed. 2000), Remington's *Pharmaceutical Sciences*, and U.S. Patents 5,708,025 and 5,994,106.

**[00154]** The specific amount of fusion protein (or polynucleotide or vector encoding the fusion protein) in a dosage of the composition administered to the individual will depend upon the biological effect desired in the individual, condition to be treated, and/or the specific characteristics of the fusion protein (or polynucleotide or vector encoding the fusion protein) and individual. Preferably, the pharmaceutical composition is administered in a therapeutically effective amount. A "therapeutically effective amount" means an amount sufficient to show a meaningful benefit in an individual, i.e., promoting at least one aspect of angiogenesis, bone growth, wound healing, or combination thereof, or treatment, healing, prevention, or amelioration of other relevant medical condition(s). Therapeutically effective amounts may vary depending on factors such as those described above. Thus, the attending physician (or other medical professional responsible for administering the composition) will typically decide the amount of fusion protein with which to treat each individual patient. Generalized guidance in making such determinations can be found, for example, in Platt, *Clin. Lab Med.*, 7, 289-99 (1987), and in "Drug Dosage," *J. Kans. Med. Soc.*, 70(1), 30-32 (1969).

**[00155]** Proper dosage can be determined by any suitable technique. In a simple dosage testing technique, low doses of the composition are administered to a test subject or system (e.g., an animal model, cell-free system, or whole cell assay system). Larger doses of the composition then can be administered until the desired therapeutic effect is obtained. For example, Doppler imaging can be used to detect blood flow and/or microscopy can be used to detect changes in blood vessel number or quality. Preferably, the dosage is within a range that includes the ED50, with low average toxicity. Such dosages are expected to typically contain about 0.01 mg-100 mg, preferably about 0.1-10 mg, more preferably about 0.1-1 mg, of fusion protein per kg body weight. Dosages with respect to vectors containing

polynucleotides encoding the fusion protein are described elsewhere herein; however, it should be understood that the discussion provided with respect to dosage and administration of the fusion protein and of such vectors are considered interchangeable unless explicitly stated otherwise or clearly contradicted by the text.

**[00156]** A more specific discussion of dosage with respect to wound healing fusion proteins is now provided as an example intended to further illustrate the invention, and in no way is intended to limit the invention.

**[00157]** In general, the effective dose of a wound healing-promoting fusion protein is expected to vary depending on the wound to be treated (e.g., size and type of wound), and the particular qualities of the fusion protein (particularly the second peptide portion). Typically, a dosage of about 1 ng/ml-500 µg/ml, preferably about 75 ng/ml-200 µg/ml, and more preferably about 30-100 ng/ml, will be effective (e.g., in a 5 ml topical application). Alternatively, the wound healing-promoting fusion protein can be administered in a dose of about 0.001 µg/kg-10 mg/kg of body weight. For VEGF/PDGF fusion proteins, a dose of about 75 ng/ml-7.5 µg/ml is preferred (e.g., 500 ng/ml). For VEGF/EGF fusion proteins, a dose of about 1000-5000 ng/ml is expected to be effective. VEGF/aFGF fusion proteins are preferably administered in dosages of at least 50 µg total fusion protein.

**[00158]** Dosage will vary with wound size. Deeper and severe wounds typically require higher doses of the fusion protein. Chronic wounds also may require higher dosages for effective treatment. With respect to wound size, dosage can be expressed, for example, as an amount of fusion protein per volume of wound tissue. For example, a dose of about 1-10 µg fusion protein in a 50 µl carrier composition can be administered per 2-5 cm wound (which corresponds to about 0.1-1 µg fusion protein/cm<sup>2</sup> of wound area). More particularly, for example, for a VEGF/IL-1 fusion protein, a dose of about 0.1-0.5 µg/cm<sup>2</sup> is preferred. Wound surface area is the area defined by the perimeter of the wound and can be estimated by multiplying the length and width of the wound. More accurate measurement of wound surface area can be obtained by use of a planimeter (Houston Instruments).

**[00159]** The dosage with respect to an angiogenic fusion protein desirably reduces or avoids the negative side effects associated with high dosages of VEGFs, such as macular degeneration, rheumatoid pannus formation, progression of atherosclerosis or plaque rupture, diabetic proliferative retinopathy, and increasing tumor growth. Thus, the dose of the angiogenic fusion protein or vector composition preferably will be such that the dose does not result in such effects. Similarly, dosages of bone growth promoting fusion protein and vector compositions preferably will be at a level below which abnormal levels of ossification occur. Vector compositions comprising targeted vectors, particularly targeted adenoviral vectors, are particularly preferred in these respects.

[00160] The invention further provides a method of producing the fusion protein by introducing a vector containing a polynucleotide, which, when expressed, results in the production of a fusion protein of the invention, into a suitable cell, such that the nucleotide sequence is expressed and the fusion protein is produced. The vector can be introduced into a suitable host cell for purpose of producing the fusion protein, which is then substantially isolated, preferably purified, which can be administered to an individual as described above. Any cell permissive for the uptake and maintenance of the vector and expression of the polynucleotide can be suitable. Examples of suitable cells include bacterial cells, such as *E. coli* and mammalian cloned cells, such as HeLa cells, CHO cells, and VERO cells. Preferred cells and vectors (i.e., cell-vector systems) are described elsewhere herein. Transformation of such cells can be accomplished using techniques described herein or in Sambrook and Ausubel, *supra*. The fusion protein produced in the host cell can be identified and substantially isolated (preferably completely isolated) using standard techniques, including genetic selection, cell surface display, phage and virus display, ribosome display, fluorescence-based cell sorting, and agar plate screening (preferably combined with automated colony picking). Where fewer candidates need to be screened, more sensitive and faster techniques such as HPLC, mass spectrometry, gas chromatography, or chromogenic techniques can be applied.

[00161] Alternatively, and preferably, such a vector is administered to an individual (e.g., a mammalian host, such as a human), resulting in the *in vivo* expression of the fusion protein. *In vivo* administration of the fusion protein by way of such vectors offers several advantages over direct protein administration, including, e.g., avoidance of the first pass effect and other metabolically-related processing problems, providing intracellular production and processing, and providing sustained administration over a period of time, thereby resulting in less need for repeated administration events. The vector containing the fusion protein-encoding polynucleotide will preferably be administered to an area of the individual's body such that it induces angiogenesis, bone growth, wound healing, or combination thereof.

[00162] In the case of vectors containing angiogenic fusion protein-encoding polynucleotides, the vector is desirably administered near one or more angiogenically functional locations (source locations) and at least one angiogenically dysfunctional location (target location). Desirably, the vector (or fusion protein) composition is administered in a gradient forming manner, as described in International Patent Application PCT/US00/030750. The source location can be any location in the individual (e.g., tissue or organ), which has physiologically normal levels of blood perfusion, such as an area near or imbued with existing blood vessels (e.g., a non-ischemic area). The target location preferably is an actual or potentially angiogenically dysfunctional location, e.g., a location



in the host that is either undergoing or is at risk of undergoing ischemia or any other condition wherein the growth of new, or extension of existing, blood vessels is desirable. Thus, the target location typically will be suffering from or be at risk of suffering from ischemic damage, which results when the tissue is deprived of an adequate supply of oxygenated blood. The interruption of the supply of oxygenated blood is often caused by a vascular occlusion. Such vascular occlusion can be caused by arteriosclerosis, trauma, surgical procedures, disease, and/or other indications. There are many ways to determine if a tissue is at risk of suffering ischemic damage from undesirable vascular occlusion including, e.g.,  $^{99m}\text{Tc}$ -sestamibi scanning, x-ray imaging, Doppler imaging, and MRI scanning. The target location also can comprise a tissue in which blood flow is attenuated by trauma, surgery, or other events. The alleviation of such attenuated blood supply, regardless of its origin, is contemplated by the invention. Thus, prevention or alleviation of damage from indications such as myocardial ischemia (particularly in patients suffering from insulin dependent diabetes), delayed wound healing, Buerger's disease, and stroke are contemplated.

**[00163]** Additionally, the planning of a surgical procedure can be predictive of the interruption of blood supply through a particular portion of a patient's vasculature. Prior treatment according to the method of the invention can substantially improve the desired outcome of these surgeries. In that case, treatment preferably occurs about one day to about six weeks before the surgery, and more preferably about two to about fourteen days prior to surgery. Other prophylactic uses of the vector also are contemplated.

**[00164]** The target and source locations can be in any suitable tissue susceptible to new blood vessel growth upon expression of a therapeutic amount of the angiogenic fusion protein. For example, the target and source locations can be located in a discrete organ such as the brain, heart, pancreas, limbs, or generalized areas of the body, such as a leg or a foot. Preferably, the target location and source location comprise portions of an organ system that includes at least two arteries (e.g., a heart which comprises at least three major arteries). In such aspects, the target location typically comprises at least a portion of an angiogenically dysfunctional artery in the system (e.g., an artery suffering from vascular occlusion), and some, if not all, of the angiogenically functional arteries in the system serve as source locations. In such aspects, the angiogenic mediator preferably is administered in a distribution between the target artery and the source arteries. Where the target location is an artery suffering from vascular occlusion, the method can comprise administration of the vector upstream, downstream, or to the occluded region of the artery (i.e., with respect to normal blood flow), or any combination thereof, as desired, preferably such that induced collateral blood vessel development bypasses the occluded region. "Tissue" in this sense is

thus meant to include interstitial spaces associated with solid tissue. The source and target locations also can comprise cavities or extracellular fluid next to a tissue.

**[00165]** The polynucleotide or vector can be administered in the form of a composition, e.g., with or in any suitable acceptable carrier, preferably a pharmaceutically acceptable carrier, such as those described elsewhere herein. Additional pharmaceutically acceptable carriers particularly suitable for administration of vectors are described in, for example, International Patent Application WO 98/32859.

**[00166]** The desired dosage (i.e., total dosage to the host) of the vector composition is such that the amount of fusion protein produced by expression of the polynucleotide in the vector results in a therapeutic and/or prophylactic effect in the area where the vector is administered. The dosage will depend on the type of fusion protein to be produced. Because a wide range of suitable fusion proteins are provided by the invention, dosage is described generally, augmented by examples relating to specific vector compositions. It will be understood that this type of description is meant to further illustrate the invention without limiting it to any particular vector composition.

**[00167]** Desirably, for vectors containing polynucleotides encoding angiogenic fusion proteins, the vector dosage is such that induction of angiogenesis in non-targeted tissue is minimized, and that the generation of disorganized vasculature beds, loss of function in the affected tissue, and promiscuous angiogenesis, which can be associated with over dosage, are avoided. Thus, the volume of vector composition is preferably set such that very little or no nucleic acid sequences encoding the angiogenic fusion protein are carried by the blood, lymphatic drainage, or physical mechanisms (e.g. gravitational flow or osmotic flow) to non-target locations.

**[00168]** Dosages of the vector composition will vary depending on the vector used to deliver the fusion protein-encoding polynucleotide and administration technique. For example, angiogenic fusion protein-encoding naked polynucleotide vectors will typically be administered in an amount containing about 500-6000  $\mu\text{g}$  of polynucleotide vector (e.g., plasmid or linear expression element) and more preferably about 1000-4000  $\mu\text{g}$  of polynucleotide vector. Because a large number of such vectors are available for administration, dosage is further described herein with respect to adenoviral vectors. It should be understood that the description of such dosages is intended to illustrate this aspect of the invention, and thereby enable the skilled artisan to determine proper dosage using other vectors. Accordingly, the focus on adenoviral vector dosage is not intended to limit the scope of the invention.

**[00169]** The dosage of an adenoviral vector containing a fusion protein-encoding polynucleotide will be at least about  $1 \times 10^6$  pfu (e.g.,  $1 \times 10^6$  -  $1 \times 10^{13}$  pfu) to an area near, at, or between the target and source locations. The dose preferably is at least about  $1 \times 10^7$  pfu

(e.g., about  $1 \times 10^7$  -  $1 \times 10^{13}$  pfu), more preferably at least about  $1 \times 10^8$  pfu (e.g., about  $1 \times 10^8$  -  $1 \times 10^{11}$  pfu), and most preferably at least about  $1 \times 10^9$  pfu (e.g., about  $1 \times 10^9$  -  $1 \times 10^{10}$  pfu). The dose typically is for a volume of targeted tissue of about  $0.5$ - $15 \text{ cm}^3$ , but can be for larger tissue volumes of up to  $100 \text{ cm}^3$  or even about  $150 \text{ cm}^3$ . The dose desirably is administered via multiple applications, and, as such, is divided among the multiple applications. Thus, if the dose is administered via 10 administrations, each administration involves about  $1 \times 10^5$  -  $1 \times 10^{12}$  pfu. Preferably, each application involves about  $1 \times 10^6$  -  $1 \times 10^{12}$  pfu, more preferably about  $1 \times 10^7$  -  $1 \times 10^{10}$  pfu, and most preferably about  $1 \times 10^8$  -  $1 \times 10^9$  pfu. For purposes of considering the dose in terms of particle units (pu), also referred to as viral particles, it can be assumed that there are 100 particles/pfu (e.g.,  $1 \times 10^{12}$  pfu is equivalent to  $1 \times 10^{14}$  pu). In a single round of vector administration, using, for example, an adenoviral vector deleted of the entire E1a region, part of the E1b region, and part of the E3 region of the adenoviral genome, wherein the vector comprises a nucleic acid encoding, e.g., a VEGF/KIAA0003-encoded peptide fusion protein under the control of a standard CMV immediate early promoter, about  $10^7$ - $10^{13}$  pfu, preferably about  $10^9$ - $10^{11}$  pfu, are administered to the host (e.g., to a discrete organ containing the source and/or target locations) with an estimated volume of about  $150 \text{ cm}^3$ . Under these conditions, a substantial level of VEGF/KIAA0003 fusion protein production is achieved in the tissue of interest without producing detectable levels of fusion protein production in distal tissues.

**[00170]** The vector composition can be administered to the individual by any suitable technique, including those techniques described herein with respect to fusion protein-containing compositions or polynucleotides and vectors. Preferably, the vector is injected into the individual. Injection can be performed in any suitable tissue or body part (e.g., intravenously, myocardially, parenterally, intrathecally, intradermally, subdermally, or into the interstitial space of a tissue/organ (e.g., of a muscle tissue)). By the term "injecting," it is meant that the vector containing solution is forcefully introduced into the target tissue. The vector composition can be microinjected, injected directly by a needle, or injected by biolistic injection. Injection can be performed using any suitable device, such as the device described in U.S. Patent 5,846,225. Alternatively, the vector containing composition can be delivered by means of percutaneous administration, typically by use of a device, such as a catheter (e.g., inserted into the femoral artery) or by a stent coated with a suitable vector containing composition (e.g., which is placed in a suitable artery, such as a coronary artery).

**[00171]** The vector alternatively or additionally can be administered to any suitable surface, either internal or external, at or near the source and/or target locations. For example, with respect to directly injecting a vector containing a polynucleotide encoding an angiogenic fusion protein into cardiac tissue, it is contemplated that such an injection can be

administered from any suitable surface of the heart (i.e., the angiogenic mediator can be administered endocardially, epicardially, and/or pericardially). Typically and preferably, cardiac administration will be to or in the left free ventricular wall of the heart which is easily accessible by minimally invasive thoracotomy. Alternatively, administration to other areas of the heart (e.g., the septum and/or right ventricle) can be accomplished by use of a catheter or other percutaneous delivery device. Such alternate techniques can be desired where the target location is positioned in the heart but away from the left free ventricular wall (e.g., where the target location is a vascular occlusion in the right coronary artery). For wounds at or near the skin surface, topical and/or transdermal administration of vectors containing polynucleotides encoding wound healing fusion proteins are often preferred routes of administration.

**[00172]** Vectors containing polynucleotides encoding bone growth-promoting fusion proteins can be administered in association with orthopedic implants, interfaces, and/or artificial joints, such as, surgical screws, pins, and the like. In preferred embodiments, the metal surface or surfaces of an implant or a portion thereof, such as a titanium surface, can be coated with a material that has an affinity for the vector composition, such as hydroxyl apatite in the case of polynucleotide vectors, and the coated metal is subsequently coated in the vector composition, prior to administration. For administration of vectors containing such polynucleotides, surgical pins or similar devices can be used to create a segmental defect (e.g., an about 0-10 mm, preferably about 0-5 mm defect) in the bone tissue wherein an implant material (preferably formed of a biodegradable matrix as discussed elsewhere herein or as described in U.S. Patents 4,526,909, 4,563,489, 4,596,574, and 5,270,300), coated with the vector composition, is then administered, followed by closure of the defect.

**[00173]** Alternatively, where a fracture exists, such compositions can be similarly administered to the fracture site. Preferably, the target of the vector composition for expression of the bone growth promoting fusion protein will include such a fracture site, an area of weak bone, such as an area of bone effected by osteoporosis, or a bone cavity site that one wishes to fill with new bone tissue (e.g., a dental or periodontal surgical related cavity, birth defect related cavity, or osteosarcoma removal related cavity). Such vector compositions also can be administered by use of collagen sponges, preferably surrounded with clotted blood placed in the cavity or osteomy gap, or collagen matrixes, such as those described in U.S. Patents 4,394,370, 4,526,909, 4,563,489, 4,596,574, 4,975,527, and 5,270,300, mineralized collagen compositions (as described in, e.g., U.S. Patent 5,231,169), or collagen compositions commercially available through Norian Corp. (Mountain View, California). For gaps or cavities (induced or natural) of about 2 mm or less, a fusion protein that increases the rate of bone growth can be suitable, whereas for a gap or cavity of about 5

mm or more administration of an osteotropic fusion protein associated with new bone growth is desired.

**[00174]** In the case of fractures or related injuries, devices which apply mechanical stress to the bone can assist in bone healing. In addition, electrical stimulation and distraction osteogenesis can be applied to assist in promoting bone growth. Related factors, such as other bone-growth related proteins, polynucleotides encoding such proteins, and/or combinations of fusion proteins provided by the invention, can be co-administered with the vector composition.

**[00175]** Dosage considerations for bone growth-related vector compositions will depend on the bone growth promoting fusion protein to be expressed in the host, delivery matrix or composition (if any), the amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the patient's or animal's age, sex, and diet, the severity of any infection, the time of administration and any further clinical factors that may affect bone growth, such as serum levels of various factors and hormones. The suitable dosage regimen, therefore, will be readily determinable by one of skill in the art in light of the present disclosure, bearing in mind the individual circumstances. In treating humans and animals, progress can be monitored by periodic assessment of bone growth and/or repair, e.g., using x-rays. Bone growth promoting vector compositions, particularly for larger gaps (e.g., about 5 mm), preferably permit expression of the fusion protein for at least about 1 week, more preferably at least about 4 weeks, and even more preferably at least about 8 weeks (e.g., 6-10 weeks). When expression is required for shorter periods of time (e.g., about 2 weeks or less), adenoviral vectors are preferred delivery vehicles for bone cells (as described in, e.g., Mehara et al., *J. Bone Miner. Res.*, 14(8), 1290-301 (1999) and Takayanagi et al., *J. Clin. Invest.*, 104(2), 137-46 (1999), Baltzer et al., *Knee Surg. Sports Traumatol. Arthrosc.*, 7(3), 197-202 (1999), Tanaka et al., *J. Bone Miner. Res.*, 13(11), 1714-20 (1998), and Riew et al., *Calcif. Tissue Int.*, 63(4), 357-60 (1998)), using, e.g., the pu/pfu dosages described above. However, for longer periods of expression, naked polynucleotide vectors can be preferred over adenoviral vectors for such methods. Retroviral vectors also can be suitable, particularly for expression of between 4-8 weeks (see, e.g., Mason et al., *Gene Ther.*, 5(8), 1098-104 (1998), for discussion). If acceptable, permanent cellular transformation, e.g., by microinjection of a polynucleotide associated with integration sequences, biolistic delivery of such a polynucleotide, or lentiviral transformation also can be used.

**[00176]** Compositions containing vectors comprising polynucleotides encoding wound growth-promoting fusion proteins also will vary with respect to dosage depending upon a number of factors. Typically, the vector composition will be able to express amounts of fusion proteins corresponding to the above-described amounts administered in protein form.

Preferably, for epidermal, intradermal, or subdermal wounds, administration through application of a topical composition, transdermal delivery (e.g., through a monolithic matrix transdermal patch), or biolistic delivery, is used, and preferably repeated after intervals varying between 1-7 days during a time period from about 1-120 days, depending on the healing process. Preferred formulations for wound healing vector compositions include HPMC and carboxymethyl cellulose preparations, PEG preparations, and matrixes, preferably which facilitate targeting of repair cells, delivery of the vector composition, and/or sustained administration of the vector composition. Examples of suitable matrixes include those described elsewhere herein and in U.S. Patent 5,270,300. Matrixes can take the form of sponges, implants, tubes, telfa pads, bandages, pads, lyophilized components, gels, patches, powders or nanoparticles. In addition, matrixes can be designed to allow for sustained release of the polynucleotide or vector composition over prolonged periods of time. In certain embodiments of the invented method, the wound healing vector composition is administered in conjunction with a wound dressing. Alternatively, administration can be accomplished through microspheres, particularly for skin-associated wounds. Examples of suitable microspheres are provided in U.S. Patents 5,264,207 and 6,086,863.

[00177] In other aspects, the wound healing-promoting vector composition can be administered with *in situ* tissue scaffolding to reduce scar healing and promote normal wound healing. Alternatively or additionally, the vector composition can be administered in association with an artificial skin, e.g., a skin manufactured from neonatal foreskin. Application of such compositions are particularly preferred in addressing burn wounds.

[00178] Adenoviral vectors can be used for short-term administration in wound healing, in dosages such as those described above. Where longer expression is desired, retroviral vectors (e.g., lentivirus vectors) or adeno-associated viral (AAV) vectors can be advantageously used (as described in, e.g., Buschacher et al., *Blood*, 5(8), 2499-504, Carter, *Contrib. Microbiol.*, 4, 85-86 (2000), Smith-Arica, *Curr. Cardiol. Rep.*, 3(1), 41-49 (2001), Taj, *J. Biomed. Sci.*, 7(4), 279-91 (2000), Vigna et al., *J. Gene Med.*, 2(5), 308-16 (2000), Klimatcheva et al., *Front. Biosci.*, 4, D481-96 (1999), Lever et al., *Biochem. Soc. Trans.*, 27(6), 841-47 (1999), Snyder, *J. Gene Med.*, 1(3), 166-75 (1999), Gerich et al., *Knee Surg. Sports Traumatol. Arthrosc.*, 5(2), 118-23 (1998), and During, *Adv. Drug Deliv. Review*, 27(1), 83-94 (1997), and U.S. Patents 4,797,368, 5,139,941, 5,173,414, 5,614,404, 5,658,785, 5,858,775, and 5,994,136). Alternatively, polynucleotide vectors can be used, or host integrative techniques can be employed. Preferably, for polynucleotide vectors, a collagen matrix-based delivery system of targeted DNA vectors is utilized (as described in, e.g., Chandler et al., *Mol. Ther.*, 2(2), 153-60 (2000)). Co-administration of the wound healing-promoting vector composition or fusion protein with related wound healing factors

is contemplated, such as the wound healing-promoting factors described herein, or non-protein factors involved in wound healing (e.g., vitamin-E or zinc).

**[00179]** The fusion protein, polynucleotide, or vector can be administered by or in association with *ex vivo* delivery of cells, tissues, or organs. Therefore, for example, a target tissue can be removed, contacted with the vector composition, and then re-implanted into the host (e.g., using techniques described in or similar to those provided in Crystal et al., *Cancer Chemother. Pharmacol.*, 43(Suppl.), S90-S99 (1999)). *Ex vivo* administration of an angiogenic fusion protein, or preferably angiogenic vector composition, to the target tissue also helps to minimize undesirable induction of angiogenesis in non-targeted tissue. A specific example of such a technique is the administration of an angiogenic vector composition to a tissue flap in surgical procedures involving replacement and/or transfer of tissue flaps (e.g., in breast reconstruction). "Tissue flaps" thus can comprise portions of removed tissue from a living tissue, a tissue of the recently deceased, a tissue from a different species (e.g., a pig tissue, preferably a tissue that is modified to exhibit a reduced immune response upon application to a human), or a synthetically generated tissue. Examples of suitable tissues are described in, e.g., U.S. Patent 6,140,039. Cultures of cells, particularly three dimensional cultures, which can be a suitable substitute, additive, or alternative to such tissues also can be administered in association with the fusion protein, polynucleotide, or vector of the invention. Examples of suitable cultures in this respect are provided in U.S. Patents 6,039,760, 6,022,743, 5,902,741, 5,863,531, 5,858,721, 5,849,588, 5,843,766, 5,830,708, 5,785,964, 5,624,840, 5,580,781, 5,578,485, 5,541,107, 5,518,915, 5,516,681, 5,516,680, 5,512,475, and 5,510,254. Related methods and compositions are provided in, e.g., U.S. Patents 6,121,042, 6,060,306, 6,027,306, 6,008,049, 5,928,945, 5,842,477, 5,780,295, 5,714,588, and 5,559,022. Cells that are genetically transformed with the polynucleotides or a host genome integrative vector also can be administered in an *ex vivo* manner to the host (e.g., using the techniques described in, or similar to those described in, U.S. Patent 5,399,346). For example, keratinocytes or fibroblasts can be cultured *in vitro*, transformed so as to express wound healing fusion protein at high levels, and subsequently administered to a wound site (typically re-administered), thereby effecting long term expression of the wound healing fusion protein, which is particularly preferred in skin regeneration (e.g., in treating severe burns).

**[00180]** As previously mentioned, the fusion protein, polynucleotide, vector, together or separately can be co-administered with any suitable factor, preferably a factor which promotes angiogenesis, wound healing, bone growth, related biological activity, or enhances the activity of the fusion protein, polynucleotide or vector. Thus, in some situations, combinations of fusion protein, polynucleotide, or vector and another factor (e.g., bone growth promoting, angiogenic, or wound healing promoting protein), or co-

administration of the vector and fusion protein can be desirable. Such co-administration can facilitate systemic treatment of diseases. For example, in the context of angiogenesis-related disorders, such as vascular ischemia, the administration of the fusion protein, fusion protein-encoding polynucleotide, or vector comprising such a polynucleotide can be associated with the administration of a smooth muscle tension modifier (e.g., a vasodilator, such as a direct vasodilator (e.g., hydralazine, minoxidil, reserpine, or combinations thereof), an atrial natriuretic peptide, a vasoactive intestinal peptide, a histamine, an epinephrine or modified epinephrine (e.g., a  $\beta$ -2 receptor targeted epinephrine homolog or a naturally occurring epinephrine administered in a  $\beta$ -2 receptor-targeting manner), a bradykinin, a paracrine which induces vasodilatation (e.g., adenosine, carbon dioxide, hydrogen ion, nitric oxide, or an endothelin), an ACE inhibitor (e.g., an ACE2 inhibitor), an adrenergic receptor blocker, a vascular-associated parasympathetic nervous system stimulator (e.g., acetylcholine), an angiotensin II-receptor blocker (ARB - e.g., tasosartan), and/or a calcium channel blocker). Other suitable non-vasodilator compounds which lower vascular resistance can be administered, and/or the application of mechanical techniques for lowering resistance (and, thus, increasing blood flow) can be applied, near or at tissues associated with the administration of the angiogenic fusion protein, fusion protein-encoding polynucleotide, or vector, and/or at one or more distal/peripheral tissues. Additionally, one or more biologically active catecholamines can be co-administered in association with the fusion protein, polynucleotide, or vector, particularly in association with the administration of an angiogenic fusion protein, polynucleotide, or vector to or near the heart. When an angiogenic fusion protein, polynucleotide, or vector is administered as a prophylactic (e.g., to a tissue at risk of ischemia due to an imminent vascular occlusion), co-administration of a factor which reduces the risk of occlusion, e.g., an anti-coagulant (such as a heparin, antithrombin III, a plasminogen, a prostacyclin (e.g. prostaglandin I or PGI<sub>2</sub>), Protein C, tissue plasminogen activator (t-PA), the anti-coagulants described in U.S. Patent 6,121,435, or homologs thereof), or an LDL cholesterol reducing factor (e.g., a bile acid sequestrant, such as cholestyramine, colestipol, and nicotinic acid (niacin), a statin (HMG CoA reductase inhibitor), such as, lovastatin, pravastatin, simvastatin, and atorvastatin (Lipitor), rosuvastatin calcium (Crestor), an endothelin agonist (e.g., tezosentan), a gemfibrozil, a probucol, or a clofibrate) also is contemplated. Administration of the fusion protein, polynucleotide, or vector can be in conjunction with a surgical method where an occlusion is removed, or where lipids (e.g., LDL cholesterol) are removed from cells which then are re-administered (i.e., an autotransplant).

**[00181]** In certain situations, it can be desirable to co-administer a factor which induces or promotes hematopoiesis with the fusion protein, polynucleotide, or vector of the invention. Any suitable hematopoietic factor can be co-administered in any suitable form.



The hematopoietic factor can be any suitable type of hematopoietic factor. Examples of such factors include red blood cell growth promoting factors (e.g., erythropoietin (EPO)), megakaryocyte growth promoting factors (e.g., granulocyte-macrophage colony stimulating factor (GM-CSF)), eosinophil growth promoting factors (e.g., GM-CSF), neutrophil growth promoting factors (e.g., granulocyte colony-stimulating factor (G-CSF)), and monocytes growth promoting factors (e.g., macrophage colony-stimulating factor (M-CSF)). Such factors can be administered in association with an administration of stem cells (or, more particularly hematopoietic precursor cells or angioblasts, such as bone marrow derived angioblasts (as described in, e.g., Kocher et al., *Nat. Med.*, 7(4), 430-36 (2001)), or alternatively, administration of developed cells, such as cardiac myocytes (using techniques described in or similar to those provided in Li et al., *J. Mol. Cell Cardiol.*, 31, 513-22 (1999)). Such cells can be obtained from a heterologous source or from a patient to which they are to be re-administered (e.g., through obtaining such cells from removed (and possibly cultured) bone marrow, blood, or fatty tissues of the individual). Similar co-administration of relevant cells can be performed for wound healing and bone growth promoting aspects of the invention (e.g., co-administration of keratinocytes in wound healing or of osteoblasts for promotion of bone growth). Co-administration of hematopoietic factors is particularly preferred in association with the administration of a wound healing fusion protein, polynucleotide, or vector of the invention.

**[00182]** Factors which block or enhance events in the angiogenic, wound healing, or bone growth promoting pathway also can be administered in association with the fusion protein, polynucleotide, or vector. For example, co-administration of PLC- $\gamma$ , Ras, Shc, Nck, PKC and/or PI3-kinase can be co-administered with the polynucleotide, vector, or fusion protein, to induce downstream signal pathways associated with VEGFR-2, as can factors which block such downstream interactions. Factors which induce VEGF expression, such as PDGF, keratinocyte growth factor, EGF, TNF- $\alpha$ , IGF-1, thyroid-stimulating hormone, IL-1 $\alpha$ , IL-4, IL-6, TGF- $\beta$ , IL-1 $\beta$ , prostaglandin E2 (PGE<sub>2</sub>), ACTH, v-Ha-ras, v-raf, and v-myc, also can be co-administered with the fusion protein, polynucleotide, or vector, as can chemical agents which upregulate VEGF expression, such as phorbol myristate acetate (as described in, e.g., Ilan et al., *J. Cell Sci.*, 111, 3621-31 (1998)) or other phorbol esters. The fusion protein, polynucleotide, or vector can be advantageously administered after or during administration of such a phorbol ester compound, which may induce vascular tube formation in collagenous tissues, as administration of an angiogenic fusion protein may sustain the integrity of the newly formed vascular tube and prevent endothelial cell apoptosis thereafter which might otherwise result from phorbol ester-induced angiogenesis. Factors which upregulate factors corresponding or related to the second peptide portion also or alternatively can be co-administered. For example, progesterone can be co-administered

with a fusion protein, polynucleotide, or vector to upregulate HBNF expression. Co-administration of factors that upregulate expression of a desired angiogenic factor, bone growth promoting factor, or wound healing promoting factor, where such a factor does not correspond or related to a peptide portion of the fusion protein also is within the scope of the invention (e.g., administration of a factor which upregulates Ang-1 expression in conjunction with the administration of a VEGF<sub>121</sub>/HBNF fusion protein).

**[00183]** Factors that inhibit inflammation also or alternatively can be administered with the fusion protein, polynucleotide, or vector of the invention. The inflammation inhibitor can be any suitable inflammation inhibitor. Examples of suitable inflammation inhibitors are provided in, e.g., U.S. Patent 5,830,880. In some circumstances, co-administration of a suitable factor which inhibit thrombosis can be desirable, such as the factors described in U.S. Patent 5,955,576.

**[00184]** Factors which are co-administered with the fusion protein, polynucleotide, or vector of the invention, can be co-administered in any suitable manner, and in any suitable order (i.e., concurrently or sequentially), such as administering a fusion protein, polynucleotide, or vector of the invention and separately administering a vector containing a polynucleotide encoding such a factor (or homolog thereof), or administering a vector containing a polynucleotide encoding such a factor which also encodes a fusion protein of the invention.

**[00185]** Factors which reduce naturally occurring anti-angiogenic factors (e.g., an endostatin (or fragment thereof, such as the collagen XVIII fragment), angiotensin (or fragment thereof, such as the plasminogen fragment), thrombospondins (e.g., thrombospondin-1), the 16kDa fragment of prolactin, and vasostatin (or calreticulin)), Cartilage-derived inhibitor (CDI), CD59 complement fragment, Gro-beta, Heparinases, Heparin hexasaccharide fragment, Human chorionic gonadotropin (hCG), IFNs, Interferon inducible protein (IP-10), IL-12, Kringle 5 (plasminogen fragment), 2-Methoxyestradiol, Placental ribonuclease inhibitor, Plasminogen activator inhibitor, Platelet factor-4 (PF4), Proliferin-related protein (PRP), Retinoids, Tetrahydrocortisol-S, other anti-angiogenic C-X-C chemokines, and/or vasculostatin also can be suitable for co-administration with the fusion protein, polynucleotide, or vector. For example, one or more factors which block one or more anti-angiogenic factors from binding with receptors required for activation, or which prevent cleavage or other conformational changes required for immature anti-angiogenic proteins to develop anti-angiogenic activity (e.g., blocking cleavage required for development of a mature, anti-angiogenic, endostatin, or preventing conversion of plasminogen to angiostatin), can be administered with the angiogenic fusion protein, polynucleotide, or vector. Such factors can be administered in any suitable form (e.g., as a polynucleotide inserted into a separate vector or the same vector with a fusion protein-

encoding polynucleotide). Alternatively, one or more antisense polynucleotides which prevent transcription and/or translation of an anti-angiogenic gene, or one or more monoclonal antibodies which deactivate the anti-angiogenic factor or block its activity.

**[00186]** Administration of anti-angiogenic factors or angiogenic factor antagonists in association with the administration of angiogenic fusion proteins, polynucleotides, and/or vectors can be desirable in some conditions. For example, administration of such factors can provide control over the level of blood vessel growth to be achieved by administration of the fusion protein, polynucleotide, or vector, and can provide a method of avoiding undesirable levels of blood vessel growth resulting from administration or expression of the angiogenic fusion protein.

**[00187]** The invention further provides a method comprising co-administration of different fusion proteins of the invention, polynucleotides encoding such various fusion proteins, or vectors containing such polynucleotides. For example, a VEGF<sub>121</sub>/angiopoietin fusion protein can be co-administered with a VEGF<sub>121</sub>/aFGF fusion protein, a VEGF<sub>121</sub>/HBNF fusion protein, or all three fusion proteins can be co-administered.

**[00188]** In addition to the other administration techniques described herein, the vector composition or fusion protein composition can be administered by direct surgical implantation. Alternatively or additionally, the fusion protein and/or vector composition can be co-administered with a group of therapeutic cells, e.g., stem cells, macrophages, or neurophils. For example, an angiogenic vector composition of the invention can be co-administered with stem cells to an ischemic location in the heart. The use of the vector composition and fusion protein of the invention also can be useful in organ generation and organ transfer.

**[00189]** The angiogenic fusion protein and vector compositions of the invention can be used to treat a wide variety of ailments including, e.g., coronary artery disease, peripheral vascular disease, congestive heart failure (e.g., left ventricular dysfunction and left ventricular hypertrophy), neuropathy (peripheral or otherwise), avascular necrosis (e.g., bone or dental necrosis), mesenteric ischemia, impotence (or erectile dysfunction), incontinence, arterio-venous fistula, veno-venous fistula, stroke, cerebrovascular ischemia, muscle wasting, pulmonary hypertension, gastrointestinal ulcers, vasculitis, non-healing ischemic ulcers, retinopathies, restenosis, cancer, orthosclerosis, radiation-induced tissue injury (such as that common with cancer treatment), and other hypoxia-associated or low blood perfusion-associated disorders. In addition, the angiogenic fusion protein and vector compositions also find utility in the study and/or aid of wound healing (e.g., healing of ischemic ulcers), plastic surgery procedures (e.g., healing or reattachment of skin and/or muscle flaps), prosthetic implant healing, vascular graft patency, and transplant longevity.

Thus, the invention provides methods of treating such ailments by administration of the fusion protein and/or vector compositions.

**[00190]** Compositions containing the bone growth-promoting fusion protein and, more preferably, the vector containing a polynucleotide encoding such fusion protein can be used to treat diseases like osteoporosis, improve poor bone healing (e.g., fibrous non-union), to promote implant integration and the function of artificial joints, to stimulate healing of other skeletal tissues such as Achilles tendon, or as an adjuvant to repair large defects. Such compositions also can be used to treat implant interface failures and allograft failures. Furthermore, the administration of such compositions provides a method of treating osteogenesis imperfecta (OI) and fractures, as well as facilitating bone reconstruction. The compositions also can be used for the treatment of periodontal tissues. Such compositions can also be used for treatment of rheumatoid and osteo arthritis. The methods and compositions of the invention also can be used for prophylactic purposes, e.g., in closed and open fracture reduction and the improved fixation of artificial joints.

**[00191]** The administration of the wound healing fusion protein and/or vector compositions of the invention can be used to treat ulcers (e.g., decubitus ulcers, venous stasis ulcers, arterial ulcers, diabetic ulcers and stasis ulcers), lesions, injuries, burns, trauma, periodontal conditions, lacerations, and other conditions, promote/enhance spinal chord healing, and promote/enhance tendon and/or ligament healing (either through direct healing or by promoting angiogenesis in such tissues). The fusion protein, polynucleotide, or vector can be used in the treatment of wounds to skin, muscle, neurologic tissue, soft tissue, internal organs, and any other suitable part of the body (e.g., those wounds described elsewhere herein). In addition, intraperitoneal wound tissue such as that resulting from invasive surgery can be treated with such compositions. For example, following the surgical removal of a colon section or other tissue, the surgical plane can be coated with the composition prior to closing the surgical site in order to accelerate internal capillary perfusion and healing. In addition, the rate of localized healing can be increased by the subdermal administration or injection of such compositions. Particular areas where application of the wound healing compositions offer therapeutic promise is in the treatment of the diabetic foot, pressure ulcers, and burns. The compositions also are useful in for treating acne, reducing scar tissue, and in recovery from general and plastic surgery. Moreover, the compositions can be used in treatment of dental tissue (e.g., the gums), for example, in conjunction with oral surgery.

**[00192]** The fusion protein, fusion protein-encoding polynucleotide, and vector of the invention are believed to be useful in several medically related contexts. For example, in surgical contexts, the fusion protein, polynucleotide, and/or vector can be used to treat orthopedic surgery-associated avascular necrosis, treat mesenteric ischemia, provide

prophylaxis against ischemia in association with ostomies, treat or provide prophylaxis for thoracic ischemia related spinal chord complications (aneurysm repairs), treat sexual dysfunction (e.g., urology-prostatectomy associated sexual dysfunction – for example in association with radical prostatectomy), provide smooth muscle tone in tissues (e.g., treat incontinence), prevent radiation-induced vascular necrosis (e.g., prevent tooth loss associated with radiation use in dentistry), promote gum and/or tooth regeneration, create and/or promote veno-venous or arterio-venous anastomosis, and enhance cartilage, tendon, and/or ligament repair replacement (either through direct healing or by promoting angiogenesis in such tissues or tissues associated therewith). The fusion protein, polynucleotide, or vector can be used to provide vascular protection in association, e.g., by inducing nitric oxide production and/or prostacyclin production, inducing antiapoptotic signaling pathways, and/or enhance the antithrombogenic and anti-inflammatory properties of mature endothelium.

**[00193]** The fusion protein, polynucleotide, and vector of the invention also can be useful in neurological applications, such as inducing angiogenesis in the treatment of cerebrovascular-associated vascular obstructive disease, acting as a neurotrophic agent (in association with peripheral neuropathies and/or degenerative disorders), treatment of sonic-related hearing loss, and enhancing CNS drug delivery by modifying the properties of the blood-brain barrier. The fusion protein, polynucleotide, and vector also can be useful in endocrine/metabolic contexts, such as the treatment of muscle wasting (sarcopenia) and the promotion/induction of hair growth (particularly in association with a hedgehog protein second peptide portion). Other cardiovascular-associated uses for the compositions of the invention include reducing oxidative stress, treatment of non-ischemia associated causes of heart failure, enhancing revascularization of vascular grafts (AV shunts, arterial conduits, and endovascular grafts), mobilizing progenitor cells to sites of interest, and improvement of organ transplant outcome. Pulmonary and gastrointestinal applications of the fusion protein, polynucleotide, and vector include administration in association with liver regeneration, treatment of pulmonary hypertension, and providing/increasing blood supply to a transplanted lung. Rheumatological/renal applications of the fusion protein, polynucleotide, and vector include the treatment of vasculitis, modulation of renal permeability and function, modulation of peritoneal permeability and function, and promotion of growth factors delivery to such tissues through such permeability modulation.

**[00194]** The methods of this invention are closely related in function. Thus, it is to be understood that the disclosure with respect to any aspect of the invention can be applied to any other suitable aspect. For example, forms of administration and delivery techniques for fusion protein compositions can be used for polynucleotide or, more particularly, vector compositions, and vice versa. Similarly, references to administration of the fusion protein,

polynucleotide, or vector of the invention encompasses the administration of pharmaceutically acceptable containing the fusion protein, polynucleotide, or vector, as applicable.

**[00195]** The invention also provides other related fusion proteins, comprising at least a first and second peptide portion, which exhibit similar biological activity (i.e., promotion of angiogenesis, wound healing, bone growth, or a combination thereof) as the VEGF fusion proteins of the invention. Such fusion proteins can comprise any combination of two or more of the second peptide portions described with respect to the VEGF fusion proteins of the invention that results in a fusion protein which promotes angiogenesis, bone growth, or wound healing. Preferred examples of such "second peptide portion fusion proteins" include fusion proteins that comprise a first HBNF peptide portion, an MK peptide portion, or a SEAP peptide portion, fused to any of the angiogenic, wound healing, or bone growth promoting second peptide portions described herein, including HBNF/SEAP fusion proteins, MK/SEAP fusion proteins, HBNF/CTGF fusion proteins, HBNF/scatter factor fusion proteins, MK/HGF fusion proteins, HBNF/BMP fusion proteins, MK/BMP fusion proteins, HBNF/FGF proteins, SEAP/BMP fusion proteins, SEAP/decorsin fusion proteins (or other second peptide portion fusion proteins wherein at least one of the peptide portions include a heterologous receptor binding domain, preferably an integrin binding domain), HBNF-MK/Ephrin fusion proteins, MK/FGF fusion proteins, HBNF/Ang-1 fusion proteins, MK/Ang-1 fusion proteins, other HBNF-MK/ARF fusion proteins (such as MK/NL5 fusion proteins), Ang-1/SEAP fusion proteins, and other ARF/SEAP fusion proteins (such as a NL1/SEAP fusion proteins). The second peptide portion fusion protein can be modified to reduce immunogenicity in a host as described above with respect to the VEGF fusion proteins of the invention, for example by incorporating a flexible linker between the peptide portions of the fusion protein that results in a lower immunogenicity than is exhibited against a direct fusion of the two peptide portions. Desirably, the second peptide portion fusion protein exhibits multiple biological functions (e.g., promotes at least two distinct aspects of angiogenesis, bone growth, or wound healing). Preferably, such fusion proteins exhibit higher levels of angiogenesis, bone growth, and/or wound healing than a protein consisting essentially of at least one of the fusion protein peptide portions, more preferably than both peptide portions, and most preferably than the co-administration of two proteins that separately consist essentially of the fusion protein's peptide portions. Routine methods for determining whether such combinations produce such desired effects are provided herein, and the second peptide portions described herein are expected, when combined to produce fusion proteins, to promote angiogenesis, bone growth, and/or wound healing when administered or expressed in a mammalian host. The invention further provides polynucleotides encoding such second peptide portion fusion proteins (e.g., a

polynucleotide encoding an HBNF/SEAP, HBNF/BMP, HBNF/CTGF, or HBNF/TGF- $\beta$  fusion protein), and vectors comprising such polynucleotides, which preferably are adenoviral vectors, and more preferably targeted adenoviral vectors, as described herein with respect to the VEGF fusion protein aspects of the invention. The polynucleotide can be any suitable polynucleotide, obtained by and/or modified by the techniques described with respect to VEGF fusion protein-encoding polynucleotides of the invention and the vector can be any of the vectors described herein (e.g., a modified adenoviral vector that results in a lower host immune response upon administration than a wild-type adenoviral vector through the presence of a trans acting factor such as HSV ICP0). The second peptide portion fusion proteins, polynucleotides, and vectors can be used in vector or fusion protein compositions similar to those described herein with respect to the VEGF fusion proteins and related polynucleotides of the invention. The second peptide portion fusion proteins can be co-administered with any of the factors described as potential co-administration partners for the VEGF fusion proteins of the invention (e.g., in association with an administration of angioblasts, stem cells, or other precursor cells, or in association with a vasodilator). The second peptide portion fusion proteins, polynucleotides, or vectors can be administered in the same manner as is described herein with respect to the VEGF fusion proteins of the invention, and can be used to treat any of the specific diseases provided herein with respect to such fusion proteins.

**[00196]** The invention further provides non-fusion protein proteins corresponding to the modified VEGF portions, modified second peptide portions, and second peptide fragments of the invention. Preferred examples of such proteins include the above-described HBNF homologs and fragments, MK homologs and fragments, SEAP homologs and fragments, proteins corresponding to any of the VEGFs or second peptide portions of the invention which comprise a heterologous receptor binding domain, and proteins containing RGD domains (e.g., a decorin-related protein). Polynucleotides encoding such factors can be obtained or produced using the techniques described herein. Such polynucleotides can be contained in any of the above-described vectors of the invention, preferably in one of the adenoviral vectors of the invention. The invention further provides a method of promoting angiogenesis, bone growth, and/or wound healing comprising administering such proteins, polynucleotides, or vectors. Such proteins can be co-administered with any of the factors described above that are suitable for co-administration with the VEGF fusion proteins of the invention. Such proteins, polynucleotides, and vectors can be administered to treat any of the diseases discussed herein with respect to the VEGF fusion proteins of the invention.

**[00197]** The invention also provides a modified VEGF, which has at least one domain that allows the modified VEGF to exhibit greater heparin binding than its wild type counterpart. Examples of such a VEGF include VEGF<sub>121.2</sub>, VEGF<sub>121.3</sub>, VEGF<sub>121.5</sub>, and

VEGF<sub>121.6</sub>, described above, which exhibit higher levels of heparin binding than VEGF<sub>121</sub>. Polynucleotides encoding such VEGFs can be obtained using the techniques described herein, and such polynucleotides can be inserted into any of the aforementioned vectors. Such VEGFs can be administered to promote angiogenesis, bone growth, or wound healing, using the methods described herein with respect to the VEGF fusion proteins, polynucleotides, and vectors of the invention. For example, such modified VEGFs can be administered in association with a vasodilator, or angioblasts, and such modified VEGFs can promote wound healing in association with a suitable wound healing factor, such as a SEAP, CTGF, HBNF, PDGF, or TGF- $\beta$ .

**[00198]** Any methods of administration described above with respect to the VEGF fusion proteins, polynucleotides, and vectors of the invention can be applied to a protein comprising or consisting of any of the above-described VEGFs, including the heparin-binding VEGFs, to promote angiogenesis, bone growth, and/or wound healing, or to treat or prevent any of the diseases discussed herein. For example, such VEGFs (e.g., VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>145</sub>, or VEGF<sub>189</sub>), or polynucleotides encoding such VEGFs, or related vectors, can be administered to treat ulcers, bone fracture, bone disease, hair loss, or erectile dysfunction, or to promote blood brain barrier permeability or vascular regularity after inducing angiogenesis with another angiogenic agent. Moreover, such VEGFs can be co-administered with any of the agents described above as potential co-administration partners with respect to the VEGF fusion proteins of the invention (e.g., a vasodilator or a culture of angioblasts).

## EXAMPLES

**[00199]** The following examples further illustrate the present invention but should not be construed as in any way limiting its scope.

### *Example 1*

**[00200]** This example describes the generation of a polynucleotide encoding a VEGF<sub>121</sub>/Ang-1 fusion protein and the production of a recombinant adenoviral vector comprising such a polynucleotide sequence.

**[00201]** The oligonucleotide primers CGCGGATCCACCATGAACTTTCTGCTGTCTTGG (SEQ ID NO: 69) (VEGF<sub>121</sub> primer 1) and CTAAATGGTTTCTCTTCCTCCCCGCCTCGGCTTGTCACA (SEQ ID NO: 70) are used to amplify an PCR product comprising the VEGF<sub>121</sub> gene sequence from plasmid pUCVEGF<sub>121</sub> or similar plasmid (e.g., one of the pMT-VEGF plasmids described in U.S. Patent 5,219,739), using standard PCR techniques. Primers TGTGACAAGCCTGAGGCGGGAGGAAGAGAAACCATTAG (SEQ ID NO: 71) and CGCGGATCCTCAAAAATCTAAAGGTCGA (SEQ ID NO: 72) (Ang-1 primer



1) are used to amplify a PCR product comprising a fragment of the human Ang-1 gene corresponding to the sequence encoding amino acid residues 275-498 of Ang-1 from plasmid pAd3511CMVAng-1. Aliquots of the amplified VEGF<sub>121</sub> and Ang-1 fragment PCR products are mixed. VEGF<sub>121</sub> primer 1 and Ang-1 primer 1 are used in another round of PCR using standard techniques utilizing the mixed aliquots as a template material, to form a resulting PCR product, comprising a polynucleotide sequence (SEQ ID NO: 73), encoding a VEGF<sub>121</sub>/Ang-1 fusion protein (SEQ ID NO: 74), which comprises the VEGF-A signal sequence.

**[00202]** The VEGF<sub>121</sub>/Ang-1-encoding PCR product is cut with *Bam* HI and cloned into a pAd3511CMV transfer vector, which comprises nucleotides 1-4511 of the adenoviral serotype 5 genome, except nucleotides 353-3511 (which encompass the adenoviral E1A and E1B coding regions), the CMV promoter, a multiple cloning site (including *Bam* HI), the SV40 poly A site, and a splice donor/acceptor site between Ad5 nucleotides 353 and 3511.

**[00203]** After insertion of the *Bam* HI fragment, the recombinant transfer vector is used to generate a transfection plasmid capable of producing an E1-deleted adenoviral vector containing the VEGF<sub>121</sub>/Ang-1 fusion protein-encoding sequence positioned in the E1 deletion upon transfection into a suitable host cell. The transfection plasmid can be generated by any suitable technique. Examples of such techniques include homologous recombination, or ligation to, one or more additional plasmids comprising the remainder of the adenoviral genome except the desired deleted regions (i.e., E1, E3, and optionally other regions, e.g., the E4 region). Any suitable homologous recombination technique can be used to generate the vector-producing plasmid. Examples of such techniques are provided in, e.g., Chinnadurai et al., *J. Virol.*, 32, 623-28 (1979), Berkner et al., *Biotechniques*, 6, 616-28 (1998), Chartier et al., *J. Virol.*, 70, 4805-10 (1996), and International Patent Application WO 96/25506. A preferred homologous recombination technique is described in International Patent Application WO 99/15686. Alternatively, any suitable ligation technique can be used, such as the techniques described in, e.g., Stow, *J. Virol.*, 37(1), 171-80 (1981), Stow, *Nucl. Acids Res.*, 10(17), 5105-19 (1982), and Berkner et al., *Nucl. Acids Res.*, 11(17), 6003-20 (1983).

**[00204]** After a suitable transfection plasmid containing the VEGF<sub>121</sub>/Ang-1 fusion protein-encoding sequence is generated, the transfection plasmid is transfected into a suitable E1 complementing cell line, such as a 293-ORF6 cell line (described in International Patent Application WO 95/34671), using standard techniques (e.g., calcium phosphate precipitated transfection), thereby resulting in the production of a stock of E1-deleted, replication-deficient, adenoviral vectors (AdVEGF<sub>121</sub>/Ang-1). Preferably, the vector-cell line system selected is such that replication competent adenovirus (RCA) levels in the stock are confirmed to be less than about  $1 \times 10^7$  plaque forming units (pfu),

preferably by using the techniques described in U.S. Patent 5,994,106. Levels of viral pfu can be determined using standard techniques (such as the techniques described in Chinnadurai et al., *supra* and Precious et al., "Purification and Titration of Adenoviruses" in *Virology: A Practical Approach*, 193-205 (Mahay et al., Eds., IRL Press 1985)). The use of such techniques results in the production of adenoviral vectors capable of expressing a VEGF<sub>121</sub>/Ang-1 fusion protein.

**[00205]** This example demonstrates a general strategy for the production of polynucleotides encoding VEGF fusion proteins of the invention and the incorporation of such polynucleotides into an adenoviral vector delivery vehicle. Similar techniques can be used to generate a large number of VEGF fusion protein-encoding polynucleotides using any suitable VEGF peptide portion-encoding and non-VEGF fusion partner-encoding sequences. Alternatively, standard polynucleotide synthesis techniques can be used to generate such VEGF/Ang-1-encoding sequences or other VEGF fusion protein-encoding sequences that also can be incorporated into such adenoviral gene transfer vectors.

#### *Example 2*

**[00206]** This example describes the generation of a polynucleotide encoding a VEGF<sub>121</sub>/HBNF fusion protein, the production of a vector containing such a polynucleotide, and the administration of such vectors to a mammalian host to induce angiogenesis.

**[00207]** VEGF<sub>121</sub> primer 1 and the oligonucleotide primer TTTGCACTCCGCGCCAAATTGCCGCCTCGGCTTGTCACA (SEQ ID NO: 75) are used to amplify a PCR product comprising the VEGF<sub>121</sub> gene (including the VEGF-A signal sequence) from plasmid pUCVEGF<sub>121</sub> using a standard PCR technique. Oligonucleotide primers TGTGACAAGCCGAGGCGGCAATTTGGCGCGGAGTGCAAA (SEQ ID NO: 76) and CGCGGATCCTTAATCCAGCATCTTCTCC (SEQ ID NO: 77) (HBNF primer 1) are used to amplify a PCR product comprising a fragment of the HBNF gene from plasmid pHHC12 (as described in Kretschmer et al., *supra*), which encodes residues 62-136 of human HBNF, using the standard PCR technique. Aliquots of the amplified VEGF<sub>121</sub> gene and HBNF gene amplified products are obtained and mixed. A PCR product comprising the VEGF<sub>121</sub>/HBNF fusion protein-encoding gene sequence (SEQ ID NO: 78) is obtained and amplified by performing PCR on the mixed amplified products using VEGF<sub>121</sub> primer 1 and HBNF primer 1. The PCR product is cut with *Bam* HI and cloned into pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells) to produce a replication-deficient adenoviral vector containing the VEGF<sub>121</sub>/HBNF fusion protein gene.

**[00208]** The AdVEGF<sub>121</sub>/HBNF vector is administered by needle injection in an appropriate carrier to at least one target location in a mammalian host. Resultant VEGF<sub>121</sub>/Ang-1 fusion protein (SEQ ID NO: 79) expression is confirmed by mRNA expression analysis, subsequent administration of an anti-VEGF antibody to the site of vector administration after sufficient time for fusion protein expression, and/or observation of the angiogenic effects of administering the vector, for example, by using the mouse ear or rat hind limb models for testing the angiogenesis-inducing capacity of a molecule, as described in more detail here.

**[00209]** In the mouse ear model,  $10^9$ - $10^{10}$  particles units (pu) of the vector is administered to Apo E<sup>-/-</sup> mice. All injections are delivered subcutaneously at the base of the ears of anesthetized mice (12 mg/kg xylazine and 60 mg/kg ketamine, IP). Gross morphological changes to the target tissue are observed at various days post-injection. Serial laser Doppler perfusion measurements are taken at various time points post-injection. Changes in blood vessel number are identified using an Olympus BX40F microscope at 400X to examine harvested ears that are perfusion fixed and embedded in paraffin. Control groups receiving other angiogenic proteins, vectors encoding angiogenic proteins (e.g., a heparin-binding VEGF), and null vectors (i.e., vectors containing a non-angiogenic gene or inert spacer in the deleted E1 region), similarly administered, are used for comparative testing.

**[00210]** It is expected that at about four days post-injection, administration of AdVEGF<sub>121</sub>/HBNF and resulting expression of the VEGF<sub>121</sub>/HBNF fusion protein will result in the formation of blood vessels in greater number and/or volume than vessels formed in animals receiving administration of a heparin-binding form of VEGF, HBNF, or vector encoding such factors and/or that the new blood vessels will exhibit a greater level of vessel maturation than vessels resulting from administration of VEGF<sub>121</sub> or a vector encoding VEGF<sub>121</sub>.

**[00211]** In the rat hind limb model, AdVEGF<sub>121</sub>/HBNF is administered to immature (e.g., six month old) CD rats. The right femoral artery of each rat is removed about seven days before administration of the nucleic acids. Each rat is administered  $10^9$ - $10^{10}$  pu of the vector via two injections to the thigh and one injection to the calf of the rat hind limb. Serial laser Doppler perfusion imaging is used to determine blood flow to foot skin. The rats are sacrificed about 28 days post-injection for angiography and histological analysis of skeletal muscle to determine capillary and arterial numbers. Control groups receiving other angiogenic proteins, vectors encoding angiogenic proteins (e.g., a VEGF), or null vectors, similarly administered, are used for comparative testing.

**[00212]** It is expected that at about 14-28 days post-injection, animals receiving AdVEGF<sub>121</sub>/HBNF in the hind limb model will exhibit tissue perfusion levels higher than in

control groups receiving administration of HBNF, a heparin-binding form of VEGF, or a vector encoding such factors.

### *Example 3*

**[00213]** This example describes the generation of a polynucleotide encoding a VEGF<sub>121</sub>/MK fusion protein, the production of a vector containing such a polynucleotide, and the administration of such vectors to a mammalian host to induce angiogenesis.

**[00214]** VEGF<sub>121</sub> primer 1 and oligonucleotide primer TGCAGTCGGCTCCAAA CTCCCGCCTCGGCTTGTCACA (SEQ ID NO: 80) are used to amplify a PCR product comprising the VEGF<sub>121</sub> gene PCR product from plasmid pUCVEGF<sub>121</sub> (including the VEGF-A signal sequence) using a standard PCR technique. Primers TGTGACAAGC CGAGGCGGGAGTTTGGAGCCGACTGCA (SEQ ID NO: 81) and CGCGGATCCC TAGTCCTTTCCCTTCCC (SEQ ID NO: 82) (MK primer 1) are used to similarly amplify a PCR product comprising a fragment of the MK gene from plasmid pMKHC4 (as described in Kretschmer et al., *supra*), which encodes human MK residues 59-123. Aliquots are taken from the VEGF<sub>121</sub> and MK PCR products and mixed. VEGF<sub>121</sub> primer 1 and MK primer 1 are used to obtain and amplify a PCR product comprising a polynucleotide encoding a VEGF<sub>121</sub>/MK fusion protein from the mixed amplified PCR products (SEQ ID NO: 83). The VEGF<sub>121</sub>/MK fusion protein-encoding PCR product is cut with *Bam* HI and cloned into pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells) to produce a vector containing the VEGF<sub>121</sub>/MK fusion protein-encoding polynucleotide. The adenoviral vector is then administered by direct injection into the mouse ear model or rat hind limb model, as described in Example 2, to assess the angiogenesis-inducing capacity of the expressed VEGF<sub>121</sub>/MK fusion protein (SEQ ID NO: 84).

### *Example 4*

**[00215]** This example describes generation of a polynucleotide encoding a VEGF<sub>121</sub>/NL1 fusion protein, the production of a vector containing such a polynucleotide, and the expression of the encoded VEGF<sub>121</sub>/NL1 fusion protein.

**[00216]** VEGF<sub>121</sub> primer 1 and primer CCATGGGCCCCGACGGCTTCCGCCTCGGCTT GTCACA (SEQ ID NO: 85) are used to amplify a PCR product comprising the VEGF<sub>121</sub> gene sequence (including the VEGF-A signal sequence) from plasmid pUCVEGF<sub>121</sub>. Oligonucleotide primers TGTGACAAGCCGAGGCGGAAGCCGTCGGGCCCCATGG

(SEQ ID NO: 86) and CGCGGATCCTTAGTGGAAGGTGTTGGGG (SEQ ID NO: 87) (NL1 primer 1) are used to amplify a PCR product comprising a fragment of the NL1 gene from plasmid pAd3511CMVNL1, which encodes residues 270-493 of human NL1. Aliquots are taken from the VEGF<sub>121</sub> and NL1 amplified PCR products and mixed. VEGF<sub>121</sub> primer 1 and NL1 primer 1 are used to obtain and amplify a PCR product comprising a polynucleotide sequence encoding a VEGF<sub>121</sub>/NL1 fusion protein (SEQ ID NO: 88) from the mixed PCR products. Preferably, the PCR reaction is performed or the fusion protein-encoding polynucleotide is synthesized (using standard techniques), such that a suitable linker sequence (e.g., a sequence encoding the linker Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser (i.e., GS<sub>(5)</sub>) (SEQ ID NO: 89), or a variant thereof) is positioned between the VEGF and NL1 peptide portions. The resulting fusion-protein encoding PCR product is cut with *Bam* HI and cloned into pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-CRF6 cells) to produce an adenoviral vector containing the VEGF<sub>121</sub>/NL1 or VEGF<sub>121</sub>/linker/NL1 fusion protein-encoding polynucleotide. The recombinant adenoviral vector is administered by direct injection into the mouse ear model or rat hind limb model, as described in Example 1, to determine the angiogenesis-inducing capacity of the expressed VEGF<sub>121</sub>/NL1 fusion protein (SEQ ID NO: 90) or, more preferably, the expressed VEGF<sub>121</sub>/linker/NL1 fusion protein.

#### *Example 5*

[00217] This example describes generation of a polynucleotide encoding a VEGF<sub>121</sub>/NL5 fusion protein, the production of a vector containing such a polynucleotide, and the expression of the encoded VEGF<sub>121</sub>/NL5 fusion protein.

[00218] VEGF<sub>121</sub> primer 1 and primer GAATGGTCCTTCATTGATCCGCCTCGGCTTGTCACA (SEQ ID NO: 91) are used to amplify a PCR product comprising the VEGF<sub>121</sub> gene sequence (including the VEGF-A signal sequence) from plasmid pUCVEGF<sub>121</sub>. Oligonucleotide primers TGTGACAAGCCGAGGCGGATCAATGAAGGACCATTC (SEQ ID NO: 92) and CGCGGATCCTCAGTCAATAGGCTTGATCA (SEQ ID NO: 93) (NL5 primer 1) are used to amplify a PCR product comprising a fragment of the NL5 gene from plasmid pAd3511CMVNL5, encoding NL5 residues 272-491. Aliquots are taken from the VEGF<sub>121</sub> and NL5 PCR products and mixed. VEGF<sub>121</sub> primer 1 and NL5 primer 1 are used to amplify a resulting PCR product comprising a polynucleotide sequence encoding a VEGF<sub>121</sub>/NL5 fusion protein (SEQ ID NO: 94) from the mixed PCR products. The resulting PCR product is cut with *Bam* HI and cloned into pAd3511CMV, which is

either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells) to produce a vector containing the VEGF<sub>121</sub>/NL5 fusion protein-encoding polynucleotide. The adenoviral vector is administered by direct injection into the mouse ear model or rat hind limb model, as described in Example 1, to assess the angiogenesis-inducing capacity of the expressed VEGF<sub>121</sub>/NL5 fusion protein (SEQ ID NO: 95). It is likely that, similar to other VEGF/ARF fusion proteins of the invention, the incorporation of a suitable linker between the VEGF and NL5 peptide portions of the fusion protein may improve the biological activity of both peptide portions.

#### *Example 6*

**[00219]** This example describes the generation of a novel Angiopoietin-2 homolog (Ang-2X), and the generation of a polynucleotide encoding a fusion protein that includes a VEGF<sub>121</sub> domain, the fibrinogen-like domain encoded by KIAA0003, and the coiled coil domain (CCD) from Ang-2X.

**[00220]** Ang-2X was derived from the results of a TNBLAST search of the high-throughput sequence database for the human genome project for sequences exhibiting significant levels of identity to Ang-1. Hits were identified on BAC clone RP11-16g12 (GenBank accession number AC018398). Nine contigs were identified and assembled by joining (complement 335846...336136), (complement 265610...265440), (complement 133812...133693), (complement 302082...302315), (complement 52191...52060), (complement 238562...238455), (complement 47913...47746), (complement 141153...141079), and (complement 18606...18544) to derive the following polynucleotide sequence:

```
ATGTGGCAGATTGTTTTCTTTACTCTGAGCTGTGATCTTGTCTTGGC
CGCAGCCTATAACAACTTTCGGAAGAGCATGGACAGCATAGGAAA
GAAGCAATATCAGGTCCAGCATGGGTCTTGCAGCTACACTTTCCTC
CTGCCAGAGATGGACAACTGCCGCTCTTCCTCCAGCCCCTACGTGT
CCAATGCTGTGCAGAGGGACGCGCCGCTCGAATACGATGACTCGG
TGCAGAGGCTGCAAGTGCTGGAGAACATCATGGAAAACAACACTC
AGTGGCTAATGAAGGTAGAGAATATATCCCAGGACAACATGAAGA
AAGAAATGGTAGAGATACAGCAGAATGCAGTACAGAACCCAGACGG
CTGTGATGATAGAAATAGGGACAAACCTGTTGAACCAAACAGCGG
AGCAAACGCGGAAGTTAACTGATGTGGAAGCCCAAGTATTAAATC
AGACCACGAGACTTGAACCTCAGCTCTTGGAACACTCCCTCTCGAC
AAACAAATTGGAAAAACAGATTTTGGACCAGACCAGTGAAATAAA
CAAATTGCAAGATAAGAACAGTTTCCTAGAAAAGAAGGTGCTAGC
TATGGAAGACAAGCACATCATCCAACCTACAGTCAATAAAAGAAGA
GAAAGATCAGCTACAGGTGTTAGTATCCAAGCAGAATTCCATCATT
```

GAAGAACTCGAAAAAAAAAATAGTGACTGCCACGGTGAATAATTCA  
 GTTCTTCAGAAGCAGCAACATGATCTCATGGAGACAGTTAATAACT  
 TACTGACTATGATGTCCACATCAAACGCAGCTAAGGACCCCACTGT  
 TGCTAAAGAAGAACAAATCAGCTTCAGAGACTGTGCTGAAGTATTC  
 AAATCAGGACACACCACGAATGGCATCTACACGTTAACATTCCCTA  
 ATTCTACAGAAGAGATCAAGGCCTACTGTGACATGGAAGCTGGAG  
 GAGGCGGGTGGACAATTATTCAGCGACGTGAGGATGGCAGCGTTG  
 CATTTCAGAGGACTTGGAAAGAATATAAAGTGGGATTTGGTAACCT  
 CTCAGAAAAATATTGGCTGGGAAATGAGTTTGTTCGCAACTGACT  
 AATCAGCAACGCTATGTGCTTAAAATACACCTTAAAGACTGGGAA  
 GGGAATGAGGCTTACTCATTGTATGAACATTTCTATCTCTCAAGTG  
 AAGAACTCAATTATAGGNNNNNNNNNNNNNNNNNNNNNGGCAATGA  
 TTTTAGCACAAAGGGATGGAGCCACCGNCANATGTATTTGCAAATGT  
 TCACAAATGCTAACAGNAGGTNNNNNNNNNNNNNNNNNNNNNNNN  
 NNNNNNTACTGGAAAGGCTCAGGCTATTCGCTCAAGGCCACAAC  
 CATGATGATCCGACCAGCAGATTTC

where N represents any polynucleotide (SEQ ID NO: 96). A polynucleotide having this sequence is generated using any standard polynucleotide synthesis.

[00221] The Ang-2X polynucleotide is predicted to encode a polypeptide having the following amino acid sequence:

Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala Ala Ala  
 Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys Gln Tyr Gln Val  
 Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro Glu Met Asp Asn Cys  
 Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala Val Gln Arg Asp Ala Pro Leu  
 Glu Tyr Asp Asp Ser Val Gln Arg Leu Gln Val Leu Glu Asn Ile Met Glu  
 Asn Asn Thr Gln Trp Leu Met Lys Leu Glu Asn Ile Ser Gln Asp Asn Met  
 Lys Lys Glu Met Val Glu Ile Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val  
 Met Ile Glu Ile Gly Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys  
 Leu Thr Asp Val Glu Ala Gln Val Ser Asn Ala Thr Thr Arg Leu Glu Leu  
 Gln Leu Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp  
 Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu Lys Lys  
 Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser Ile Lys Glu Glu  
 Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn Ser Ile Ile Glu Glu Leu  
 Glu Lys Lys Ile Val Thr Ala Thr Val Asn Asn Ser Val Leu Gln Lys Gln Gln  
 His Asp Leu Met Glu Thr Val Asn Asn Leu Leu Thr Met Met Ser Thr Ser  
 Asn Cys Lys Xaa Xaa Xaa Xaa Val Ala Lys Glu Glu Gln Ile Ser Phe Arg  
 Asp Cys Ala Glu Val Phe Lys Ser Gly His Thr Thr Asn Gly Ile Tyr Thr Leu  
 Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala Ala Ala  
 Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys Gln Tyr Gln Val  
 Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro Glu Met Asp Asn Cys  
 Arg Ser Ser Ser Ser Pro Tyr

(SEQ ID NO: 97), where Xaa represents any amino acid residue. Ang-2X is believed to have angiogenesis modulating activities similar to angiopoietins, particularly to Ang-2.

**[00222]** Appropriate primers to amplify a PCR product comprising a polynucleotide sequence encoding the VEGF<sub>121</sub> gene from plasmid pUCVEGF<sub>121</sub>, and (separately) amplifying a PCR product comprising a polynucleotide sequence encoding KIAA0003 from an appropriate plasmid (e.g., pAd3511CMVAng-1) are selected. Aliquots of the VEGF<sub>121</sub> and KIAA0003 PCR products are taken and mixed, and VEGF<sub>121</sub> primer 1 and an appropriate KIAA0003 primer (e.g., Ang-1 primer 1) then are used to obtain and amplify a polynucleotide encoding a KAP/VEGF<sub>121</sub> fusion protein (SEQ ID NO: 98) from the mixed PCR products. Preferably the KIAA0003 polynucleotide is modified to include a sequence encoding an appropriate linker (e.g., a GS<sub>(5)</sub> linker as described above), such that a polynucleotide encoding a KAP/linker/VEGF<sub>121</sub> polypeptide is obtained and amplified. Alternatively, a KIAA0003 polynucleotide can be synthetically produced, and ligated to a polynucleotide sequence encoding a suitable linker (e.g., a GS<sub>(5)</sub> linker) and a polynucleotide encoding VEGF<sub>121</sub> (e.g., the above-described VEGF<sub>121</sub> PCR product) to form a KAP/linker/VEGF<sub>121</sub> fusion protein-encoding polynucleotide.

**[00223]** Primers suitable for amplification of the polynucleotide sequence encoding the predicted coiled coil domain of Ang-2X (nucleotides 183-543 of the Ang-2X polynucleotide sequence (SEQ ID NO: 99) encoding predicted amino acid residues 61-181 of Ang-2X (SEQ ID NO: 100)) are selected and used to amplify an Ang-2X CCD-encoding sequence from the synthesized Ang-2X-encoding polynucleotide (alternatively the sequence is synthesized using standard techniques). Aliquots of the Ang-2X CCD PCR product and KIAA0003/linker/VEGF<sub>121</sub> PCR products (or ligation products) are mixed to form a template to which Ang-2 CCD and KIAA0003/linker/VEGF<sub>121</sub> primers are added to obtain and amplify a polynucleotide encoding an Ang-2X CCD/KIAA0003/linker/VEGF<sub>121</sub> fusion protein. Alternatively, the Ang-2X CCD-encoding polynucleotide is directly fused to the KIAA0003/linker/VEGF<sub>121</sub> PCR product or ligation product.

**[00224]** The fusion protein-encoding polynucleotide is placed in pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells), thereby producing an E1-deleted adenoviral vector encoding the Ang-2X CCD/KIAA0003/linker/VEGF<sub>121</sub> fusion protein (SEQ ID NO: 101). The recombinant adenoviral vector is then administered to a mammalian host, for example, using one of the models described in Example 1, to assess the angiogenesis-inducing capacity of the novel fusion protein.



*Example 7*

**[00225]** This example describes the generation of additional VEGF/Angiopoietin-related factor (ARF) fusion proteins. Suitable primers for obtaining and amplifying a polynucleotide encoding VEGF<sub>121</sub> (including the VEGF-A signal sequence) from plasmid pUCVEGF<sub>121</sub> are selected and used to produce a VEGF<sub>121</sub>-encoding polynucleotide PCR product. Primers for obtaining and amplifying a polynucleotide sequence encoding the fibrinogen-like domain (FLD) of NL1 (SEQ ID NO: 102) from plasmid pAd3511CMVNL1, or a polynucleotide sequence encoding the FLD of NL5 (SEQ ID NO: 103) from plasmid pAd3511CMVNL5, are selected and used to produce a NL1 FLD-encoding or NL5 FLD-encoding polynucleotide PCR product, as desired. Aliquots of the VEGF<sub>121</sub>-encoding polynucleotide PCR product and the NL1 FLD-encoding or NL5 FLD-encoding PCR products are obtained and mixed. Suitable primers are selected for obtaining and amplifying a polynucleotide encoding a VEGF<sub>121</sub>/NL1 FLD fusion protein or VEGF<sub>121</sub>/NL5 FLD fusion protein, as applicable. Preferably, the PCR reaction is modified, or the desired polynucleotide synthesized, such that a suitable linker (e.g., a GS<sub>(5)</sub> linker) is positioned between the VEGF and angiopoietin homolog peptide portions. The fusion protein-encoding polynucleotide is cut with a suitable restriction enzyme and cloned into plasmid pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells), thereby producing an E1-deleted adenoviral vector encoding the novel fusion protein. The vector is administered to a mammalian host, for example within the mouse ear or rat hind limb test models described in Example 1, resulting in the production of a VEGF<sub>121</sub>/linker/NL1 FLD fusion protein (SEQ ID NO: 104) or VEGF<sub>121</sub>/linker/NL5 FLD fusion protein (SEQ ID NO: 105).

*Example 8*

**[00226]** This example describes the generation of additional alternative VEGF<sub>121</sub>/Angiopoietin homolog fusion proteins. A polynucleotide encoding a KIAA0003/linker/VEGF<sub>121</sub> fusion protein is obtained as discussed in Example 6 and placed into pAd3511CMV. Suitable primers are selected for amplifying the KIAA0003/linker/VEGF<sub>121</sub> fusion protein-encoding polynucleotide from the plasmid. A second set of primers are selected for obtaining and amplifying a polynucleotide sequence encoding the coiled coil domain (CCD), predicted coiled coil domain, or structurally similar

domain (e.g., a domain comprising multiple alpha helices) of an angiopoietin-related factor (ARF).

**[00227]** Predicted coiled coil domain sequences may vary depending on the method used to predict the coiled coil domain. Accordingly, multiple CCD sequences can be provided for a single ARF. Combinations of such sequences or portions thereof also can be used in the context of the invention, and, more specifically, in the context of this Example.

**[00228]** Examples of suitable ARF CCD-encoding polynucleotide sequences include sequences encoding the Ang-1 predicted CCD (e.g., SEQ ID NO: 18 or SEQ ID NO: 106), an Ang-2 predicted CCD (e.g., SEQ ID NO: 107, SEQ ID NO: 108, or SEQ ID NO: 109), the Zap1 predicted CCD (SEQ ID NO: 110), a NL5 predicted CCD and/or the predicted CCD of the "Ang-3" of International Patent Application 00/11164 (SEQ ID NO: 111 or SEQ ID NO: 112), a NL1 predicted CCD (SEQ ID NO: 113 or SEQ ID NO: 114), an Ang-3 predicted CCD (SEQ ID NO: 115), an Ang-4 predicted CCD (SEQ ID NO: 116), or a polynucleotide corresponding to GenBank Accession number T11442 (SEQ ID NO: 117) or M62290 (SEQ ID NO: 118). Aliquots of the KIAA0003/VEGF<sub>121</sub> PCR product and the selected ARF coiled coil domain-encoding polynucleotide PCR product are obtained and mixed. Suitable primers are selected to obtain and amplify a polynucleotide sequence encoding the ARF CCD/KIAA0003/linker/VEGF<sub>121</sub> fusion protein. Alternatively, direct ligation or synthesis techniques can be used to generate polynucleotides encoding the desired fusion protein. The ARF CCD/KAP/linker/VEGF<sub>121</sub> fusion protein-encoding polynucleotide is placed into plasmid pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells), thereby producing an E1-deleted adenoviral vector encoding the novel fusion protein. The recombinant adenovirus vector is administered to a mammalian host, for example, using one or both of the experimental models described in Example 1, to assess the angiogenesis-inducing capacity of the fusion protein.

#### *Example 9*

**[00229]** This example describes the generation of a polynucleotide encoding another alternative VEGF<sub>121</sub>/Angiopoietin homolog fusion protein.

**[00230]** A polynucleotide corresponding to GenBank Accession No. W77823 (SEQ ID NO: 119) is obtained and cleaved by appropriate endonuclease (e.g., time limited *Bal* I digestion) or exonuclease, or subjected to PCR with appropriate primers, to obtain a polynucleotide having the sequence:

TATAAGCTGCGGCTGGGGCGATACCATGGCAATGCGGGTGACTCC  
 TTTACATGGCACAACGGCAAGCAGTTCACCACCCTGGACAGAGAT  
 CATGATGTCTACACAGGAACTGTGCCCACTACCAGAAGGGAGG  
 CTGGTGGTATAACGCCTGTGCCCACTCCAACCTCAACCG

(SEQ ID NO: 120), which corresponds to nucleotides 2-173 of W77823 (alternatively, such a sequence is synthesized using standard techniques). A polynucleotide sequence comprising this sequence fused to the sequence corresponding to GenBank Accession No. T11442 is obtained by additional PCR reactions, blunt ended ligation, or synthetic polynucleotide production. The resulting polynucleotide has the following sequence:

GCCCATGGAGAGACTGCCTGCAGGCCCTGGAGGATGGCCACGAC  
 ACCAGCTCCATCTACCTGGTGAAGCCGGAGAACACCAACCGCCTC  
 ATGCAGGTGTGGTGGCACCAGAGACACGACCCCGGGGGCTGGAC  
 CGTCATCCAGAGACGCCTGGATGGCTCTGTAACTTCTTCAGGAA  
 CTGGGAGACGTACAAGCAAGGGTTTGGGAACATTGACGGCGAAT  
 ACTGGCTGGGCCTGGAGAACATTTACTGGCTGACGAACCAAGGCA  
 ACTACAAACTCCTGGTGACCATGGAGGACTGGTCCGGCCGCAAAG  
 TCTTTGCAGAATACGCCAGTTTCCGCCTGGAACCTGAGAGCGAGT  
 ATTATAAGCTGCGGCTGGGGCGCTACCATGGCAATGCGGGTGACT  
 CCTTTACATGGCACAACGGCAAGCAGTTCACCACCCAGGACAGAG  
 ATCATGATGTCTACACAGTATAAGCTGCGGCTGGGGCGATACCAT  
 GGCAATGCGGGTGACTCCTTTACATGGCACAACGGCAAGCAGTTC  
 ACCACCCTGGACAGAGATCATGATGTCTACACAGGAACTGTGCC  
 CACTACCAGAAGGGAGGCTGGTGGTATAACGCCTGTGCCCACTCC  
 AACCTCAACCG

(SEQ ID NO: 121).

**[00231]** This polynucleotide is fused to a KIAA0003/VEGF<sub>121</sub>-encoding polynucleotide sequence described in Example 6, and the fused polynucleotide product inserted into plasmid pAd3511CMV, which is either ligated to, or recombined with, a second plasmid containing the additional desired portions of the adenoviral genome as described in Example 1 to form a transfection plasmid, which is subsequently transfected into cells capable of complementing the production of the encoded E1-deleted adenoviral vector (e.g., 293-ORF6 cells), to produce recombinant E1-deleted adenoviral vectors containing the polynucleotide encoding the W77823/T11442/KIAA0003/VEGF<sub>121</sub> fusion protein (SEQ ID NO: 122), which preferably is modified by incorporation of a sequence encoding a suitable linker (e.g., a GS<sub>(5)</sub> linker) positioned between the KIAA0003 sequence and VEGF<sub>121</sub> peptide portion-encoding sequence. The recombinant vector is administered to a mammalian host, for example, using one of the models described in Example 1, to assess the angiogenesis-inducing capacity of the novel fusion protein.

*Example 10*

[00232] This example describes the generation of a VEGF<sub>121</sub>/Angiopoietin homolog fusion protein, comprising a chimeric ARF peptide portion.

[00233] A polynucleotide encoding residues 1-280 of Ang2X (SEQ ID NO: 123) is synthesized using standard techniques and fused to a polynucleotide encoding residues 278-498 of Ang-1 (SEQ ID NO: 124), to obtain a polynucleotide (e.g., SEQ ID NO: 125), which encodes an Ang2X/Ang-1 (SEQ ID NO: 126). This polynucleotide is subsequently fused to a polynucleotide encoding VEGF<sub>121</sub> (including the VEGF-A signal sequence) and a flexible linker-encoding sequence (such as a sequence encoding a GS<sub>(5)</sub> linker) to produce a VEGF<sub>121</sub>/linker/Ang2X/Ang-1 chimera-encoding polynucleotide is inserted into an appropriate vector for administration to a mammalian host, preferably to an ischemic tissue, which is predicted to result in a VEGF<sub>121</sub>/linker/Ang2X/Ang-1 fusion protein (SEQ ID NO: 127), having angiogenesis-modulating properties.

*Example 11*

[00234] This example describes the stimulation of a VEGF receptor on a luciferase fusion protein reporter cell line by exemplary VEGF fusion proteins of the invention expressed from recombinant adenoviral vectors.

[00235] HeLa cells were engineered to express a luciferase fusion protein in response to VEGF protein stimulation of the flk-1/kdr VEGF-A receptor. Flk-1 activation phosphorylates MAPK, which in turn activates the Elk-1 transcription factor. HeLa cells stably transfected with a plasmid comprising an Elk-1/luciferase fusion protein-encoding polynucleotide sequence (Stratagene, Inc., La Jolla, CA) were co-transfected with a flk-1 plasmid. Cells expressing both flk-1 and the luciferase fusion protein were demonstrated to increase luciferase fusion protein expression following VEGF protein binding to flk-1.

[00236] A549 cells were transduced at 1000 MOI particle units (pu) with negative control vectors (AdNull and AdPEDF (adenoviral vectors expressing PEDF, a transgene not related to VEGF)), positive control vectors (AdVEGF<sub>121</sub>.10 (an E1-deficient VEGF<sub>121</sub>-expressing adenoviral vector) or AdVEGF<sub>121</sub>.11D (an E1-deficient, E4-deficient VEGF<sub>121</sub>-expressing adenoviral vector)), or adenoviral vectors expressing VEGF fusion proteins (chimeras) of the invention (specifically, VEGF<sub>121</sub>/Ang-1 as described in Example 1, VEGF<sub>121</sub>/MK as described in Example 3, and VEGF<sub>121</sub>/HBNF as described in Example 2). Supernatants from the A549 cells were applied to the flk-1/luciferase fusion protein reporter cells, and luciferase fusion protein levels were determined 24 hours later. Select populations of reporter cells were treated with VEGF protein as a positive control, phorbol 12-myristate 13-acetate (PMA) as a positive control, or A549 media (i.e., media from non-transduced cells) as a negative control, which identified a range corresponding to maximum

and minimum luciferase fusion protein levels. Light emission from the luciferase fusion protein was measured in Relative Light Units (RLU). Experiments were repeated three times, and the standard deviation for each set of experiments was determined. The results of these calculations are presented in Table 2 and graphically set out in Figure 1.

Table 2

<b>flk-1/luciferase fusion protein reporter cell treatment</b>	<b>RLU <math>\pm</math> SD</b>
<b>Negative Controls</b>	
A549 Media Control	1782 $\pm$ 260
AdNull	1784 $\pm$ 184
AdPEDF	1917 $\pm$ 193
<b>Positive Controls</b>	
VEGF <sub>121</sub> Protein Control (25ng/mL)	3962 $\pm$ 907
PMA Control	8217 $\pm$ 1778
AdVEGF <sub>121</sub> .10	6342 $\pm$ 536
AdVEGF <sub>121</sub> .11D	6434 $\pm$ 627
<b>VEGF Chimera-Expressing Adenovectors</b>	
AdVEGF <sub>121</sub> /Ang-1	2330 $\pm$ 121
AdVEGF <sub>121</sub> /MK	6236 $\pm$ 314
AdVEGF <sub>121</sub> /HBNF	8078 $\pm$ 404

[00237] These data indicate that observed increases in luciferase fusion protein expression were specific to VEGF or VEGF fusion protein expression. Supernatant from cells transfected with adenovector negative controls AdNull and AdPEDF resulted in luciferase fusion protein levels comparable to cells treated with A549 media control. Direct stimulation with VEGF<sub>121</sub> protein and A549 media infected from two different VEGF<sub>121</sub> adenovectors demonstrated 2 and 3 fold greater luciferase fusion protein levels than the negative controls.

[00238] Adenovectors expressing VEGF/MK and VEGF/HBNF chimeras of the invention exhibited significant stimulation of the VEGF flk-1 receptor. The VEGF<sub>121</sub>/Ang-1 chimera only had a modest increase in luciferase activity versus the negative controls. It is believed that the comparatively low level of flk-1 receptor activation with VEGF<sub>121</sub>/Ang-1 as compared to VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF is due to the lack of a linker sequence between the VEGF and Ang-1 active portions that may prevent the Ang-1 portion from

interfering with the VEGF portion's ability to interact with the flk-1 receptor and/or to dimerize. It is expected that repetition of the experiment with an adenovector expressing a suitable VEGF<sub>121</sub>/linker/Ang-1 fusion protein (e.g., a fusion protein comprising a suitable linker, such as a GS<sub>(3-7)</sub> linker, positioned between the Ang-1 and VEGF peptide portions) will result in increased levels of luciferase fusion protein expression as compared to the above-described negative controls.

[00239] This example demonstrates that fusion proteins comprising a VEGF peptide portion that binds to VEGF cellular receptors can be successfully generated using the techniques provided herein.

#### *Example 12*

[00240] This example describes changes in mouse ear morphology following intradermal injection of VEGF-fusion protein-expressing adenovectors of the invention.

[00241] Female C57BL/6 mice were randomly assigned to five groups of three animals each. Adenovectors expressing no transgene (AdNull) as a negative control, VEGF<sub>121</sub> as a positive control (AdVEGF<sub>121</sub>), or individual VEGF fusion proteins of the invention (AdVEGF<sub>121</sub>/Ang-1, AdVEGF<sub>121</sub>/MK, and AdVEGF<sub>121</sub>/HBNF) were injected into the intradermal space of the right ear to a dose of  $1 \times 10^{10}$  pu. The ears were observed daily for development of redness (erythema) in the area of injection resulting from neovascularization and/or increases in vascular permeability. The ear redness was scored on a subjective, open-ended scale. The means and standard deviations from these scores were calculated. The data obtained in the experiment are set forth in Table 3 and graphically summarized in Figure 2.

*Table 3*

<i>Adenovector</i>	<i>Days Post Adenovector Administration</i>						
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
AdNull	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
AdVEGF <sub>121</sub>	1.0 ± 0.0	2.7 ± 0.6	4.0 ± 1.0	6.3 ± 1.1	7.3 ± 1.5	9.0 ± 1.0	7.3 ± 2.1
AdVEGF <sub>121</sub> /Ang-1	1.3 ± 0.6	1.3 ± 0.6	1.7 ± 0.6	0.7 ± 0.6	1.0 ± 0.0	1.0 ± 0.0	1.0 ± 0.0
AdVEGF <sub>121</sub> /MK	1.0 ± 0.0	2.0 ± 0.0	3.0 ± 1.1	4.5 ± 0.7	5.5 ± 0.7	4.5 ± 0.7	5.0 ± 0.7
AdVEGF <sub>121</sub> /HBNF	1.7 ± 0.6	2.7 ± 0.6	4.0 ± 0.0	4.3 ± 0.6	4.3 ± 0.6	5.3 ± 1.5	5.0 ± 1.7

[00242] The results of this experiment, presented in Table 3 and Figure 2, indicate that VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF fusion proteins of the invention are angiogenic in a mammalian host, but do not produce a level of redness associated with VEGF<sub>121</sub> expression. The reduced redness observed with VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF expression as

compared to VEGF<sub>121</sub> results from the ability of these fusion proteins to protect against increased levels of vascular permeability observed with VEGF-induced angiogenesis (this observation was confirmed by additional experiments described below). The AdVEGF<sub>121</sub>/Ang-1 chimeric protein expressed by the adenovector used in this experiment lacked a linker between the VEGF and Ang-1 peptide portions and did not produce an angiogenic response, possibly due to this fusion protein's inability to interact with the VEGF receptors as discussed above in Example 11.

[00243] This example demonstrates that fusion proteins comprising a VEGF peptide portion are angiogenic *in vivo*. This example further demonstrates that the expression of a VEGF fusion protein comprising an appropriate fusion partners (e.g., an MK or HBNF fusion partner) reduces the level of vascular permeability in angiogenic tissue as compared to a wild-type VEGF polypeptide.

### Example 13

[00244] This example describes the changes in mouse ear blood vessel permeability following treatment with VEGF chimera protein-expressing adenovectors of the invention.

[00245] The Evans Blue vessel permeability assay measures extravasated Evans Blue in the interstitial space as a surrogate for vessel permeability. Briefly, the assay consists of an intrajugular injection of Evans Blue followed thirty minutes later with whole body perfusion of the vasculature by needle injection. After perfusion, the only Evans Blue remaining is the quantity extravasated out of the vessels. Some animals also are treated with a local injection into the ear with serotonin immediately following Evans Blue. Certain proteins, such as angiopoietin-1 (Ang-1), have been shown to protect against mustard oil induced vessel permeability in this model (see, e.g., Thurston, *Science*, 286, 2511-2514 (1999), and Thurston, *Nat. Med.*, 6, 460-463 (2000)). The inventors also have experimentally confirmed the ability of Ang-1 to protect against vessel leakage from inflammatory challenge.

[00246] As in Example 12, the intradermal murine ear model was utilized with C57BL/6 mice, three animals per treatment, for the Evans Blue assay. Seven days following administration of  $8 \times 10^9$  pu of either VEGF chimera-expressing or control adenovectors (AdNull and AdPEDF negative controls; AdVEGF<sub>121.10</sub> and AdVEGF<sub>121.11D</sub> positive controls), the animals were injected with Evans Blue, plus or minus serotonin treatment (challenge). After vascular perfusion, the ears were removed and placed in formamide at 55 °C to extract the dye from the tissues. Extracted Evans Blue was read spectrophotometrically at 620 nm using standard techniques and compared to a standard curve to determine the concentration of extravasated Evans Blue. The results of this experiment are presented in Figure 3.

**[00247]** As can be seen in Figure 3, treatment with AdVEGF<sub>121</sub>, AdVEGF<sub>121</sub> co-administered with AdMK, and the chimera vectors AdVEGF<sub>121</sub>/MK and AdVEGF<sub>121</sub>/HBNF resulted in increased Evans Blue extravasation in the absence of serotonin (basal permeability). The increase in Evans Blue extravasation results from greater vessel permeability, a greater number of blood vessels, or a combination thereof. In view of the results obtained in Example 11, the increase in basal permeability is likely due to a mixture of both phenomena.

**[00248]** The ability to protect against serotonin-induced vessel permeability using the Evans Blue assay is considered an indication of more mature angiogenic blood vessels. See, e.g., Suri et al., *Science*, 282, 468-471 (1998), Thurston et al. (1999), *supra*, and Thurston et al. (2000), *supra*).

**[00249]** Calculation of the ratio of serotonin-induced permeability to basal permeability removes the variable of vessel number and, as such, provides a way to distinguish between increased vascular permeability and increased number of blood vessels caused by expression of an angiogenic factor. When the ratio of Evans Blue concentration in the presence and absence of serotonin is calculated (see Figure 4), it can be seen that VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF protected against serotonin-induced extravasation more effectively than AdVEGF<sub>121</sub> alone and the naive and AdNull negative controls. Indeed, the AdVEGF<sub>121</sub>/MK and AdVEGF<sub>121</sub>/HBNF chimeras had better serotonin/basal ratios than were observed with the co-administration of AdVEGF<sub>121</sub> and AdAng-1. Co-administration control groups received twice the total vector, and adenovector alone is known to induce some vessel permeability (compare the naive to AdNull ratios). However, even if such a occurred due to the adenovector alone occurred when AdVEGF<sub>121</sub> and AdAng-1 were co-administered, the results of these experiments demonstrate that the MK and HBNF VEGF fusion proteins of the invention displayed strong anti-permeability activity *in vivo*.

**[00250]** The Evans Blue assay is able to test the functionality of the Ang-1 portion of a VEGF<sub>121</sub>/Ang-1 fusion protein. Co-administration of AdVEGF<sub>121</sub> plus AdAng-1 resulted in a slightly better serotonin-induced/basal permeability ratio than AdVEGF<sub>121</sub> alone, a result supported by the literature (see, e.g., Suri et al. (1998), Thurston et al. (1999), and Thurston et al. (2000), *supra*). However, treatment with AdVEGF<sub>121</sub>/Ang-1 did not suppress vessel permeability in the presence of serotonin. This result, along with the results from Examples 11 and 12, indicate neither the VEGF<sub>121</sub> nor the Ang-1 portion of this fusion protein is functional, a situation that is expected to be overcome by introduction of a suitable linker between the VEGF and Ang-1 peptide portions.

**[00251]** This example demonstrates that VEGF fusion proteins comprising multiple active peptide portions can be constructed in accordance with the principles described herein. Moreover, this example demonstrates that angiogenic fusion proteins of the



invention are as, if not more, effective than co-administration of VEGF and known anti-permeability factors (e.g., Ang-1, HBNF, or MK) in reducing vascular leakage associated with VEGF biological activity.

#### *Example 14*

[00252] This example describes the immunohistochemical evaluation of vessel density in a murine intradermal ear model following treatment with angiogenic fusion protein-expressing adenovectors of the invention.

[00253] C57BL/6 mice were treated with  $1 \times 10^{10}$  pu of either AdNull, AdVEGF<sub>121</sub>, AdVEGF<sub>121</sub>/MK, or AdVEGF<sub>121</sub>/HBNF in the intradermal ear model (three mice received such an administration of each type of vector). Seven days after treatment, the mice were euthanized, and the vector-treated ears were harvested. The tissues were embedded in paraffin using standard techniques and sectioned, and then the blood vessels were immunohistochemically stained using an anti-CD31 monoclonal antibody. CD31 is an endothelial cell marker and has been used widely to stain blood vessels. The stained vessels were counted microscopically utilizing a calibrated reticle. The blood vessels in ten to twenty randomly selected fields at 500x magnification were counted. Two sections per ear were evaluated, and the average vessel number/mm<sup>2</sup> tissue area for the entire treatment group was calculated. The mean values for each treatment group were calculated. The results of the experiment are summarized in Figure 5.

[00254] As can be seen in Figure 5, treatment with AdVEGF<sub>121</sub> and AdVEGF<sub>121</sub>/HBNF led to a detectable increase in vessel density. However only treatment with AdVEGF<sub>121</sub>/HBNF resulted in a significant increase over AdNull (t-test at  $\alpha=0.05$ ). The fact that the data did not show an increase in vessel density with AdVEGF<sub>121</sub>/MK treatment may be attributed to the small number of animals that were evaluated per treatment.

[00255] The results of this experiment demonstrate that the angiogenic VEGF fusion proteins of the invention are able to promote vascular formation *in vivo* by increasing blood vessel density in a target tissue.

#### *Example 15*

[00256] This example describes changes in murine ear morphology following treatment with the VEGF fusion protein-expressing adenovectors of the invention.

[00257] Using methods identical to those described in Example 14, as well as standard Hematoxylin and eosin staining, vector treated ear tissues were evaluated for vascular pathologies resulting from vector treatment. Anti-CD31 stained section images were obtained and evaluated for this purpose.

[00258] Treatment with AdNull resulted in no significant pathologies. Only some minor

perivascular infiltrates were observed. However, this observation is expected since adenovector is known to elicit an immune response.

[00259] Due to the powerful biological activities of VEGF, AdVEGF<sub>121</sub> treatment resulted in many pathological changes. Observed alterations included large areas of dispersed mononuclear infiltrates present throughout the tissues, thickening of capillary vessel walls, enlargement of blood vessels, and moderate areas of localized hemorrhaging.

[00260] Both AdVEGF<sub>121</sub>/MK and AdVEGF<sub>121</sub>/HBNF treated ears displayed less pathological changes than the AdVEGF<sub>121</sub> controls. In view of the results in Examples 11-14, it is believed that the expression of VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF led to the formation of more "mature," less leaky vessels, than those resulting from expression of VEGF<sub>121</sub>. AdVEGF<sub>121</sub>/MK treatment resulted in moderate perivascular mononuclear infiltration, minor to moderate hemorrhages, and some thickening of vessel walls with concomitant increases in vessel diameter.

[00261] Only moderate pathologies were observed following AdVEGF<sub>121</sub>/HBNF administration into the intradermal space of the ear. In this treatment group, there was only moderate perivascular mononuclear infiltration and some minor hemorrhages. The blood vessel morphology demonstrated thickening of vessel walls and increases in vessel size, more so than seen with AdVEGF<sub>121</sub>/MK.

[00262] This example demonstrates the ability of VEGF fusion proteins of the invention to generate growth of more mature blood vessels *in vivo* than vessels resulting from the expression of a wild-type VEGF polypeptide.

#### *Example 16*

[00263] This example describes a method for evaluating the quaternary structure of VEGF fusion proteins of the invention.

[00264] The biological activity of VEGF-A polypeptides is associated with dimerization of VEGF peptide monomers. MK exhibits increased biological potency in a dimerized form (see, e.g., Iwasaki et al., *EMBO J.*, 16, 6936-6946 (1997)). Dimerization of the VEGF peptide portion is believed to be important to VEGF-like biological activity. To test whether dimerization occurs in VEGF/MK fusion proteins of the invention, A549 cells are infected at 1000 MOI pu with control vectors or AdVEGF<sub>121</sub>/MK and maintained at 37 °C + 5% CO<sub>2</sub> for twenty-four hours. Following the incubation, the culture media containing the secreted transgene fusion proteins are collected. Cells transduced with AdVEGF<sub>121</sub> and AdNull serve as the positive and negative controls, respectively. VEGF<sub>121</sub> and VEGF<sub>121</sub>/MK fusion protein, semi-purified from the culture media by immunoprecipitation (e.g., with a VEGF monoclonal antibody), are analyzed by mass spectrometry. Mass spectrometry analysis of the VEGF<sub>121</sub>/MK precipitate is expected to reflect that the

immunoprecipitated polypeptide has a molecular weight twice that expected for the VEGF<sub>121</sub>/MK monomer, thereby indicating that the VEGF fusion protein has formed dimers. Such results can be confirmed by the use of electrophoresis techniques known in the art. Such VEGF fusion protein dimers are expected to exhibit *in vitro* and/or *in vivo* biological activity in both the VEGF and non-VEGF peptide portions similar to wild-type homologs of such peptide portions. As discussed above, the activity of peptide portions that form higher ordered polypeptides (e.g., trimers or complex multimers) can be maintained by use of a suitable linker separating the VEGF and non-VEGF peptide portions.

#### *Example 17*

**[00265]** This example describes a technique for further evaluating the anti-permeability effects of MK and HBNF, both individually and as part of VEGF fusion proteins of the invention. The experimental data described herein indicates that VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF possess both angiogenic and anti-permeability properties. To better assess the relative contributions of neovascularization and vessel permeability to the extravasation of Evans Blue from the interstitial space upon expression of such factors in a murine model, the following experiment is performed.

**[00266]** C57BL/6 mouse ears are treated with nothing, AdNull, AdVEGF<sub>121</sub>, AdAng-1, AdMK, AdHBNF, AdVEGF<sub>121</sub>/MK, or AdVEGF<sub>121</sub>/HBNF, as described with respect to the above-described Evans Blue assay experiments. One day following vector treatment, the Evans Blue permeability assay is performed in both the presence and absence of serotonin. Since the angiogenic neovascularization is only minimal at Day 1 (see Figure 2), the variable of angiogenic modification of vessel size and density is minimized. Furthermore since all these vectors incorporate the CMV promoter, the concentration of the transgene product is greater at Day 1 than at Day 7. The results of these experiments are expected to demonstrate that VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF are able to reduce vascular permeability and protect against serotonin challenge in a mouse ear model.

#### *Example 18*

**[00267]** This example describes the use of ricinus communis (ricin) lectin staining to evaluate the angiogenic properties of exemplary VEGF fusion proteins of the invention. The results of this experiment will indicate whether anti-permeability effects associated with select VEGF fusion proteins of the invention are dependent on preventing the formation of endothelial cell gaps.

**[00268]** Preventing the formation of endothelial gaps in blood vessels suppresses serotonin-induced permeability. Many plant lectins have been shown to specifically stain blood vessels (see, e.g., Thurston et al., *Am J. Physiol.*, 271, H2547-H2562 (1996)). Ricin

lectin also weakly stains blood vessel endothelial cells but preferentially binds the basement membrane of blood vessel. In vessels with endothelial gaps exposing the basement membrane, ricin lectin staining appears as focal patches in blood vessels. Thurston et al. (1999), *supra*, have, for example, used vascular perfusion with ricin lectin to demonstrate Ang-1 protection against mustard oil induced gap formation.

[00269] In the present experiment, recombinant or control adenovectors are administered in a murine intradermal ear model as described in Example 17. One day following vector treatment, serotonin is injected into the intradermal space in the base of the vector-treated ear. Thirty minutes later, the animals are perfusion fixed with formalin, followed by perfusion with biotinylated ricin lectin. Whole ear mounts are prepared, and the biotinylated is lectin visualized with horseradish peroxidase-labeled avidin and diaminobenzidine (or another suitable chromogen). Lectin staining is confirmed microscopically. In view of the protective properties of VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF, only a few, or no, focally stained patches will be observed. Such results will confirm the anti-permeability effects of such VEGF fusion proteins of the invention.

#### *Example 19*

[00270] This experiment compares the biological activities of MK and HBNF segments of VEGF/MK and VEGF/HBNF fusion proteins of the invention with native MK and HBNF polypeptides.

[00271] Both MK and HBNF possess heparin-binding sites and have demonstrated the ability to promote neurite outgrowth, increase plasminogen activator (PA) activity, and down-regulate plasminogen activator inhibitor-1 (PAI-1) activity (see, e.g., Inui et al., *J. Peptide Res.*, 55, 384-397 (2000)). A549 cells are infected with AdNull, AdVEGF<sub>121</sub>, AdMK, AdHBNF, AdVEGF<sub>121</sub>/MK, or AdVEGF<sub>121</sub>/HBNF, as described in Example 11. Culture media containing the adenovector-produced proteins is assayed for MK and HBNF activity by:

1. *Immobilized heparin binding.* Heparin immobilized on sepharose beads is incubated with the culture supernatant. Adenovector produced proteins bound to the heparin beads is scanned with FITC conjugated anti-VEGF, anti-MK, or anti-HBNF antibodies. After washing away unbound proteins, heparin-binding proteins captured on the sepharose beads are visualized by fluorescence microscopy. VEGF/MK and VEGF/HBNF can bind the heparin-coated beads and are subsequently visualized. Such a result is not obtained in the negative controls.

2. *PA/AI-1 activity.* Primary cultures of 18-day rat brain cells are exposed to A549 culture supernatants as in 1 above. PA and PAI-1 activity is determined by the methods of Inui et al. (2000), Supra. Treatment with culture media containing VEGF<sub>121</sub>/MK and VEGF<sub>121</sub>/HBNF results in decreased PAI-1 activity and increased PA activity reflecting retention of MK and HBNF activity, respectively, in such VEGF fusion proteins.
3.  *$\beta$ -Catenin dephosphorylation (VEGF<sub>121</sub>/HBNF only).* HBNF receptor binding results in  $\beta$ -catenin phosphorylation. Using techniques described herein and in Meng et al., *Proc. Natl. Acad. Sci. USA*, 97(6), 2603-2608 (2000), the ability of VEGF<sub>121</sub>/HBNF to increase  $\beta$ -catenin phosphorylation in a suitable cell system can be assayed. It is expected that the VEGF/HBNF fusion protein will result in a detectable increase in  $\beta$ -catenin phosphorylation, reflecting the activity of the HBNF peptide portion of the fusion protein.

The results of such experiments can demonstrate the retention of non-VEGF peptide portion biological activity in VEGF fusion proteins of the invention.

#### *Example 20*

**[00272]** This example demonstrates the increased stability of select VEGF fusion proteins of the invention as compared to wild-type VEGF polypeptides.

**[00273]** A549 cells (or cells of another appropriate cell line) are infected with AdNull, AdVEGF<sub>121</sub>, AdVEGF<sub>121</sub>/HBNF, and AdVEGF<sub>121</sub>/MK at a suitable concentration (e.g., 1000 MOI) in a serum free medium suitable for pulse labeling (e.g., using S<sup>35</sup>-methionine) by standard techniques (see, e.g., Bonifacino, *CURR. PROTOCOLS MOLEC. BIOL.*, 10.18.1-10.18.10 (John Wiley & Sons, Inc. 1998)). Additional control cultures receive no vector treatment. After a suitable period of time (e.g., about 1 hour), pulse labeling is paused, and the labeling medium replaced with a standard (non-Met-deficient) serum free medium. The cell cultures (including control plates) are subjected to immunoprecipitation using anti-VEGF antibodies at selected time points after medium replacement (e.g., 0 hours, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, and 2 days). The immunoprecipitate is subjected to SDS PAGE or other suitable protein electrophoresis and protein density assessed. Alternatively, the precipitated polypeptides can be counted using standard techniques. The maximum amount of protein is used to assess half-life of the VEGF fusion proteins and wild-type VEGF. The VEGF fusion proteins of the invention are expected to exhibit a longer half-life than wild-type VEGF<sub>121</sub>.

*Example 21*

**[00274]** This example demonstrates the improved biological properties associated with the use of a spacer sequence between VEGF and angiopoietin (or angiopoietin homolog) peptide portions in certain VEGF fusion proteins of the invention.

**[00275]** Polynucleotides encoding VEGF<sub>121</sub>/Ang-1 fusion proteins are prepared and inserted into adenoviral vectors as described in Example 1. A second set of vectors comprising a VEGF<sub>121</sub>/linker/Ang-1-encoding polynucleotide is prepared by standard techniques. Both sets of vectors are administered individually in a suitable concentration (e.g., MOI of about 1000) to flk-1/luciferase fusion protein reporter cells as described in Example 11 to assess VEGF receptor binding. VEGF<sub>121</sub>/GS<sub>(5)</sub>/Ang-1 polypeptides result in significantly higher levels of luciferase fusion protein than VEGF<sub>121</sub>/Ang-1 polypeptides lacking an intervening linker sequence, indicating that the presence of a linker permits the VEGF peptide portion of the fusion protein to interact with the VEGF receptor.

**[00276]** The VEGF<sub>121</sub>/Ang-1 and VEGF<sub>121</sub>/GS<sub>(5)</sub>/Ang-1 vectors also are administered to an appropriate animal model (e.g., an intradermal murine ear model as described above or the rabbit hindlimb model) to assess the angiogenic properties of the respective fusion proteins. The VEGF<sub>121</sub>/GS<sub>(5)</sub>/Ang-1 polypeptides are angiogenic and result in the production of more mature blood vessels than result from the administration and/or expression of native VEGF<sub>121</sub>.

**[00277]** All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

**[00278]** The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Terms such as “including,” “having,” “comprising,” “containing,” and the like are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise indicated, and as encompassing the phrases “consisting of” and “consisting essentially of.” Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the

invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

**[00279]** Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of the preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

## WHAT IS CLAIMED IS:

1. A fusion protein comprising a first non-heparin-binding VEGF peptide portion that binds to a VEGF receptor and is at least about 85% identical to VEGF<sub>121</sub> and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, or both angiogenesis and bone growth in a mammalian host.
2. The fusion protein of claim 1, wherein the first peptide portion comprises a wild-type VEGF-A amino acid sequence of about 150 amino acid residues or less that exhibits (1) a higher affinity for KDR receptors than the flt/flk receptors and (2) an about equal or less affinity for neuropilin-1, neuropilin-2, or both, as VEGF<sub>121</sub>.
3. The fusion protein of claim 1, wherein the first peptide portion comprises VEGF<sub>121</sub>.
4. The fusion protein of claim 1, wherein the fusion protein has a half-life in a mammalian host at least twice as long as the half-life of a protein consisting essentially of either the first peptide portion, the second peptide portion, or both.
5. The fusion protein of claim 1, wherein the second peptide portion comprises a peptide lacking its native multimerization domain or a peptide comprising a non-functional multimerization domain.
6. The fusion protein of claim 1, wherein the fusion protein is more angiogenic than a protein consisting essentially of either the first peptide portion, the second peptide portion, or both.
7. The fusion protein of claim 6, wherein blood vessels resulting from administration of the fusion protein to a mammalian host have less permeability than blood vessels resulting from administration of a protein consisting essentially of the first peptide portion.
8. The fusion protein of claim 7, wherein blood vessels resulting from administration of the fusion protein to a mammalian host exhibit greater maturity than blood vessels resulting from administration of a protein consisting essentially of the first peptide portion.



9. The fusion protein of claim 8, wherein blood vessels resulting from administration of the fusion protein to a mammalian host are associated with more smooth muscle cells, a greater concentration of smooth muscle cells, more endothelial cells, a greater concentration of endothelial cells, or any combination thereof, than blood vessels resulting from administration of a protein consisting essentially of the first peptide portion.

10. The fusion protein of claim 1, wherein the second peptide portion comprises a ligand that binds to a receptor on a native endothelial cell.

11. The fusion protein of claim 1, wherein the fusion protein diffuses through the extracellular matrix in a mammalian host upon administration to a mammalian host from a point of administration, the cell in which it is expressed, or both, farther than a protein consisting essentially of a naturally occurring heparin-binding form of a VEGF.

12. The fusion protein of claim 1, wherein administration of the fusion protein to an area in a mammalian host results in greater blood flow in the area of administration than the administration of a protein consisting essentially of the second peptide portion.

13. The fusion protein of claim 1, wherein the second peptide portion comprises a peptide which promotes blood vessel wall maturation, blood vessel wall dilatation, blood vessel remodeling, extracellular matrix degradation, decreases blood vessel permeability, or any combination thereof.

14. The fusion protein of claim 1, wherein the second peptide portion comprises an angiopoietin and a linker of about 5-20 amino acids positioned between the angiopoietin and VEGF peptide portions, a fibroblast growth factor, a member of the HBNF-MK family of growth factors, an alkaline phosphatase, or a fragment of any thereof which promotes angiogenesis, bone growth, wound healing, or any combination thereof.

15. The fusion protein of claim 14, wherein the second peptide portion comprises a peptide that is about 25% or more homologous to angiopoietin-1.

16. The fusion protein of claim 15, wherein the second peptide portion comprises a domain which exhibits about 35% or more homology to the fibrinogen-like domain of Ang-1.

17. The fusion protein of claim 16, wherein the second peptide portion comprises angiopoietin-1 or an angiogenically functional fragment thereof.
18. The fusion protein of claim 16, wherein the second peptide portion comprises an N-terminal truncated form of angiopoietin-1, and the truncated form comprises about 60% or less of the wild-type angiopoietin-1 amino acid sequence.
19. The fusion protein of claim 16, wherein the second peptide portion lacks the multimerization domain of angiopoietin-1.
20. The fusion protein of claim 16, wherein the second peptide portion comprises the peptide encoded by KIAA0003.
21. The fusion protein of claim 14, wherein the second peptide portion comprises an acidic fibroblast growth factor or a fragment thereof which promotes angiogenesis, bone growth, wound healing, or any combination thereof.
22. The fusion protein of claim 14, wherein the second peptide portion comprises a member of the HBNF-MK family of growth factors or a fragment thereof which promotes angiogenesis, bone growth, wound healing, or any combination thereof.
23. The fusion protein of claim 14, wherein the second peptide portion comprises a peptide that is at least about 50% identical to native HBNF, MK, or both.
24. The fusion protein of claim 22, wherein the second peptide portion comprises an N-terminal truncated form of HBNF or MK, and the truncated form comprises about 60% or less of the wild-type HBNF or MK amino acid sequence.
25. The fusion protein of claim 1, wherein:
  - (a) the amino acid sequence of the first peptide portion or second peptide portion, within about 15 amino acids of the fusion point of the fusion protein, lacks an amino acid residue corresponding to an amino acid residue in its wild-type counterpart, or
  - (b) the fusion protein further comprises a linker positioned between the first peptide portion and second peptide portion.

26. A polynucleotide comprising a nucleotide sequence which, when expressed in a cell permissive for expression of the nucleotide sequence, results in the production of a fusion protein according to claim 1.

27. A vector comprising the polynucleotide of claim 26.

28. The vector of claim 27, wherein the vector is a replication-deficient adenoviral vector.

29. The vector of claim 28, wherein the replication-deficient adenoviral vector comprises or expresses a modified adenoviral protein, non-adenoviral protein, or both, which increases the efficiency with which the vector infects cells as compared to wild-type adenovirus, allows the vector to infect cells which are not normally infected by wild-type adenovirus, results in a reduced host immune response in a mammalian host as compared to wild-type adenovirus, or any combination thereof.

30. The vector of claim 27, wherein the polynucleotide comprises a nucleotide sequence which upon expression results in a fusion protein comprising VEGF<sub>121</sub> fused to (a) angiopoietin-1, (b) an acidic fibroblast growth factor, (c) a HBNF, (d) a MK, (e) an alkaline phosphatase, or (f) a fragment of any of (a)-(e) which promotes angiogenesis, bone growth, or wound healing.

31. The vector of claim 27, wherein the polynucleotide comprises a second nucleotide sequence that, when expressed, produces a second protein which promotes angiogenesis, bone growth, wound healing, or any combination thereof, and

wherein the nucleotide sequence which results in the production of the fusion protein is operably linked to a first promoter and the second nucleotide sequence is operably linked to a second promoter, such that the initiation of expression of the first nucleotide sequence and the second nucleotide sequence occurs at different times, in response to different factors, or both.

32. A method of promoting angiogenesis, bone growth, wound healing, or any combination thereof in an individual comprising administering to the individual an amount of the fusion protein of claim 1 effective to promote angiogenesis, bone growth, wound healing, or any combination thereof.

33. A method of producing a fusion protein comprising introducing the vector of claim 27 into a cell such that the nucleotide sequence is expressed to produce a fusion protein.


34. A method of producing a fusion protein comprising introducing the vector of claim 28 into a cell such that the nucleotide sequence is expressed to produce a fusion protein.

35. A method of producing a fusion protein comprising introducing the vector of claim 31 into a cell and permitting or inducing expression of the first nucleotide sequence and the second nucleotide sequence in a manner which imitates a biological cascade associated with angiogenesis, bone growth, or wound healing.

36. A fusion protein that promotes angiogenesis, bone growth, wound healing, or a combination thereof in a mammalian host, the fusion protein comprising a first non-heparin-binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof, wherein the VEGF peptide portion is at least about 115 amino acids in length or the second peptide portion lacks a collagen binding domain.


37. The fusion protein of claim 36, wherein the fusion protein is free of functional collagen binding domains.

1 / 5




2 / 5

**FIG. 2**  
**Ear Redness versus Time**




3 / 5

FIG. 3




4 / 5

FIG. 4





5 / 5



## SEQUENCE LISTING

<110> GENVEC, INC.  
KOVESDI, IMRE  
KESSLER, PAUL D

<120> VEGF FUSION PROTEINS

<130> 216086

<150> US 09/832,355

<151> 2001-04-10

<160> 127

<170> PatentIn version 3.1

<210> 1

<211> 121

<212> PRT

<213> Homo sapiens

<400> 1

Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys  
1 5 10 15

Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu  
20 25 30

Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys  
35 40 45

Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu  
50 55 60

Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile  
65 70 75 80

Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe  
85 90 95

Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg  
100 105 110

Gln Glu Lys Cys Asp Lys Pro Arg Arg  
115 120

<210> 2

<211> 101

<212> PRT

<213> Homo sapiens

<400> 2

Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser  
1 5 10 15

Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro  
20 25 30

Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg  
35 40 45

Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu  
 50 55 60  
 Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly  
 65 70 75 80  
 Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys  
 85 90 95  
 Arg Pro Lys Lys Asp  
 100

<210> 3  
 <211> 44  
 <212> PRT  
 <213> Homo sapiens

<400> 3

Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe Val Gln Asp  
 1 5 10 15  
 Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser Arg Cys Lys  
 20 25 30  
 Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg  
 35 40

<210> 4  
 <211> 366  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 gcacccatgg cagaaggagg agggcagaat catcacgaag tggatgaagt catggatgtc 60  
 tatcagcgca gctactgcca tccaatcgag accctgggtg acatcttcca ggagtaccct 120  
 gatgagatcg agtacatctt caagccatcc tgtgtgcccc tgatgcatg cgggggctgc 180  
 tgcaatgacg agggcctgga gtgtgtgccc actgaggagt ccaacatcac catgcagatt 240  
 atgcggatca aacctcacca aggccagcac ataggagaga tgagcttcct acagcacaac 300  
 aaatgtgaat gcagaccaa gaaagataga gcaagacaag aaaaatgtga caagccgagg 360  
 cggtga 366

<210> 5  
 <211> 14  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> "Xaa" may be any amino acid.

<220>  
 <221> MISC\_FEATURE  
 <222> (5)..(7)

<223> "Xaa" may be any amino acid.

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> "Xaa" may be any amino acid.

<400> 5

Pro Xaa Cys Val Xaa Xaa Xaa Arg Cys Xaa Gly Cys Cys Asn  
1 5 10

<210> 6

<211> 25

<212> PRT

<213> Homo sapiens

<400> 6

Lys Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys  
1 5 10 15

Lys Ser Arg Tyr Lys Ser Trp Ser Val  
20 25

<210> 7

<211> 6

<212> PRT

<213> Homo sapiens

<400> 7

Ala Arg Gln Glu Lys Cys  
1 5

<210> 8

<211> 11

<212> PRT

<213> Homo sapiens

<400> 8

Ala Arg Gln Glu Lys Cys Asp Lys Pro Arg Arg  
1 5 10

<210> 9

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 9

Tyr Val Gly Ala Arg Cys Cys Leu  
1 5

<210> 10

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 10

Met Pro Trp Ser Leu Pro Gly Pro  
1 5

<210> 11

<211> 16

<212> PRT

<213> Homo sapiens

<400> 11

Tyr Val Gly Ala Arg Cys Cys Leu Met Pro Trp Ser Leu Pro Gly Pro  
1 5 10 15

<210> 12

<211> 23

<212> PRT

<213> Homo sapiens

<400> 12

Lys Ser Val Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys  
1 5 10 15

Ser Arg Tyr Lys Ser Trp Ser  
20

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> "Xaa" may be any amino acid

<220>

<221> MISC\_FEATURE

<222> (8)..(10)

<223> "Xaa" may be any amino acid

<400> 13

Cys Xaa Xaa Xaa Arg Asp Gly Xaa Xaa Xaa Cys  
1 5 10

<210> 14

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> "Xaa" may be between 6 and 12 of any amino acid

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> "Xaa" may be any amino acid

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> "Xaa" may be between 3 and 6 of any amino acid

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> "Xaa" may be between 3 and 6 of any amino acid

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> "Xaa" may be between 8 and 14 of any amino acid

<400> 14

Cys Xaa Cys Xaa Cys Xaa Cys Xaa Cys Xaa Cys  
1 5 10

<210> 15

<211> 498

<212> PRT

<213> Homo sapiens

<400> 15

Met Thr Val Phe Leu Ser Phe Ala Phe Leu Ala Ala Ile Leu Thr His  
1 5 10 15

Ile Gly Cys Ser Asn Gln Arg Arg Ser Pro Glu Asn Ser Gly Arg Arg  
20 25 30

Tyr Asn Arg Ile Gln His Gly Gln Cys Ala Tyr Thr Phe Ile Leu Pro  
35 40 45

Glu His Asp Gly Asn Cys Arg Glu Ser Thr Thr Asp Gln Tyr Asn Thr  
50 55 60

Asn Ala Leu Gln Arg Asp Ala Pro His Val Glu Pro Asp Phe Ser Ser  
65 70 75 80

Gln Lys Leu Gln His Leu Glu His Val Met Glu Asn Tyr Thr Gln Trp  
85 90 95

Leu Gln Lys Leu Glu Asn Tyr Ile Val Glu Asn Met Lys Ser Glu Met  
100 105 110

Ala Gln Ile Gln Gln Asn Ala Val Gln Asn His Thr Ala Thr Met Leu  
115 120 125

Glu Ile Gly Thr Ser Leu Leu Ser Gln Thr Ala Glu Gln Thr Arg Lys  
130 135 140

Leu Thr Asp Val Glu Thr Gln Val Leu Asn Gln Thr Ser Arg Leu Glu  
145 150 155 160

Ile Gln Leu Leu Glu Asn Ser Leu Ser Thr Tyr Lys Leu Glu Lys Gln  
 165 170 175  
 Leu Leu Gln Gln Thr Asn Glu Ile Leu Lys Ile His Glu Lys Asn Ser  
 180 185 190  
 Leu Leu Glu His Lys Ile Leu Glu Met Glu Gly Lys His Lys Glu Glu  
 195 200 205  
 Leu Asp Thr Leu Lys Glu Glu Lys Glu Asn Leu Gln Gly Leu Val Thr  
 210 215 220  
 Arg Gln Thr Tyr Ile Ile Gln Glu Leu Glu Lys Gln Leu Asn Arg Ala  
 225 230 235 240  
 Thr Thr Asn Asn Ser Val Leu Gln Lys Gln Gln Leu Glu Leu Met Asp  
 245 250 255  
 Thr Val His Asn Leu Val Asn Leu Cys Thr Lys Glu Gly Val Leu Leu  
 260 265 270  
 Lys Gly Gly Lys Arg Glu Glu Glu Lys Pro Phe Arg Asp Cys Ala Asp  
 275 280 285  
 Val Tyr Gln Ala Gly Phe Asn Lys Ser Gly Ile Tyr Thr Ile Tyr Ile  
 290 295 300  
 Asn Asn Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn  
 305 310 315 320  
 Gly Gly Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp  
 325 330 335  
 Phe Gln Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser  
 340 345 350  
 Gly Glu Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln  
 355 360 365  
 Arg Gln Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu Gly Asn Arg  
 370 375 380  
 Ala Tyr Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu Lys Gln Asn  
 385 390 395 400  
 Tyr Arg Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly Lys Gln Ser  
 405 410 415  
 Ser Leu Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp Asn  
 420 425 430  
 Asp Asn Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly Gly Trp Trp  
 435 440 445  
 Phe Asp Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr Ala  
 450 455 460  
 Gly Gln Asn His Gly Lys Leu Asn Gly Ile Lys Trp His Tyr Phe Lys  
 465 470 475 480  
 Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro Leu  
 485 490 495  
 Asp Phe

<210> 16  
 <211> 3041  
 <212> DNA  
 <213> Homo sapiens

<400> 16  
 gaaaaagaga ggaagagaaa ccatttagag actgtgcaga tgtatatcaa gctgggtttta 60  
 ataaaagtgg aatctacact atttatatta ataatatgcc agaaccctaaa aagggtgtttt 120  
 gcaatatgga tgtcaatggg ggaggttgga ctgtaataca acatcgtgaa gatggaagtc 180  
 tagatttcca aagaggctgg aaggaatata aaatgggttt tggaaatccc tccggtgaat 240  
 attggctggg gaatgagttt atttttgcca ttaccagtca gaggcagtac atgctaagaa 300  
 ttgagttaat ggactgggaa gggaaccgag cctattcaca gtatgacaga ttccacatag 360  
 gaaatgaaaa gcaaaactat aggttgtatt taaaaggtca cactgggaca gcaggaaaac 420  
 agagcagcct gatcttacac ggtgctgatt tcagcactaa agatgctgat aatgacaact 480  
 gtatgtgcaa atgtgccctc atgttaacag gaggatgggtg gtttgatgct tgtggcccct 540  
 ccaatctaaa tggaaatgtt tatactgctg gacaaaacca tggaaaactg aatgggataa 600  
 agtggcacta cttcaaaggg cccagttact ccttacgttc cacaactatg atgattcgac 660  
 ctttagattt ttgaaagcgc aatgtcagaa gcgattatga aagcaacaaa gaaatccgga 720  
 gaagctgcca ggtgagaaac tgtttgaaaa cttcagaagc aaacaatatt gtctcccttc 780  
 cagcaataag tggtagttat gtgaagtcac caaggttctt gaccgtgaat ctggagccgt 840  
 ttgagttcac aagagtctct acttgggggtg acagtgtctc cgtgggtcga ctatagaaaa 900  
 ctccactgac tgtcgggctt taaaaagggg agaaactgct gagcttgctg tgcttcaaac 960  
 tactactgga ccttattttg gaactatggt agccagatga taaatatggt taatttcattg 1020  
 taaaacagaa aaaaagagtg aaaaagagaa tatacatgaa gaatagaaac aagcctgcca 1080  
 taatcctttg gaaaagatgt attataccag tgaaaaggcg ttatatctat gcaaacctac 1140  
 taacaaatta tactgttgca caattttgat aaaaatttag aacagcattg tcctctgagt 1200  
 tggttaaatg ttaatggatt tcagaagcct aattccagta tcatacttac tagttgattt 1260  
 ctgcttacc atcttcaa at gaaaattcca tttttgtaag ccataatgaa ctgtagtaca 1320  
 tggacaataa gtgtgtggta gaaacaaact ccattactct gatttttgat acagttttca 1380  
 gaaaaagaaa tgaacataat caagtaagga tgtatgtggt gaaaacttac caccctcata 1440  
 ctatggtttt catttactct aaaaactgat tgaatgat ataaatatat ttatagcctg 1500  
 agtaaagtta aaagaatgta aaatatatca tcaagttctt aaaataatat acatgcattt 1560  
 aatatttcct ttgatattat acaggaaagc aatatttttg agtatgttaa gttgaagtaa 1620  
 aaccaagtac tctggagcag ttcattttac agtatctact tgcattgtga tacatacatg 1680  
 taacttcatt attttaaaaa tattttttaga actccaatac tcaccctggt atgtcttget 1740



```

aatttaaatt ttgctaatta actgaaacat gottaccaga ttcacactgt tccagtgtct 1800
ataaaaagaaa cactttgaag tctataaaaa ataaaataat tataaatatc attgtacata 1860
gcatgtttat atctgcaaaa aacctaatag ctaattaatc tggaatatgc aacattgtcc 1920
ttaattgatg caaataacac aaatgctcaa agaaatctac tatatccctt aatgaaatac 1980
atcattcttc atatatttct ccttcagtcc attcccttag gcaattttta atttttaaaa 2040
attattatca ggggagaaaa attggcaaaa ctattatatg taagggatat atatatacaa 2100
aaagaaaatt aatcatagtc acctgactaa gaaattctga ctgctagttg ccataaataa 2160
ctcaatggaa atattcctat gggataatgt attttaagtg aatttttggg gtgcttgaag 2220
ttactgcatt attttatcaa gaagtcttct ctgcctgtaa gtgtccaagg ttatgacagt 2280
aaacagtttt tattaataca tgagtcacta tgggatgaga aaattgaaat aaagctactg 2340
ggcctcctct cataaaagag acagttgttg gcaaggtagc aataccagtt tcaaacttgg 2400
tgacttgatc cactatgcct taatggtttc ctccatttga gaaaataaag ctattcacat 2460
tgттааgааа аааастттт аааgттtacc atcaagtctt ttttatattt atgtgtctgt 2520
attctacccc tttttgcctt acaagtгata tttgcaggta ttataccatt tttctattct 2580
tggtggcttc ttcatagcag gtaagcctct ccttctaaaa acttctcaac tgttttcatt 2640
taagggaaag aaaatgagta tttgtcctt ttgtgttcct acagacactt tcttaaacca 2700
gtttttggat aaagaatact atttccaaac tcatattaca aaaacaaaat aaaataataa 2760
aaaaagaaag catgatattt actgttttgt tgtctgggtt tgagaaatga aatattgttt 2820
ccaattattt ataataaatc agtataaaat gttttatgat tgttatgtgt attatgtaat 2880
acgtacatgt ttatggcaat ttaacatgtg tattcttttc atttaattgt ttcagaatag 2940
gataattagg tattcgaatt ttgtctttaa aattcatgtg gtttctatgc aaagttcttc 3000
atatcatcac aacattattt gatttaaata aaattgaaag t 3041

```

```

<210> 17
<211> 192
<212> PRT
<213> Homo sapiens

```

```

<400> 17

```

```

Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn Gly Gly
1           5           10           15
Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp Phe Gln
20           25           30
Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser Gly Glu
35           40           45
Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln Arg Gln
50           55           60

```

Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu Gly Asn Arg Ala Tyr  
 65 70 75 80  
 Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu Lys Gln Asn Tyr Arg  
 85 90 95  
 Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly Lys Gln Ser Ser Leu  
 100 105 110  
 Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp Asn Asp Asn  
 115 120 125  
 Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly Gly Trp Trp Phe Asp  
 130 135 140  
 Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr Ala Gly Gln  
 145 150 155 160  
 Asn His Gly Lys Leu Asn Gly Ile Lys Trp His Tyr Phe Lys Gly Pro  
 165 170 175  
 Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro Leu Asp Phe  
 180 185 190  
 <210> 18  
 <211> 235  
 <212> PRT  
 <213> Homo sapiens  
 <400> 18  
 His Asp Gly Asn Cys Arg Glu Ser Thr Thr Asp Gln Tyr Asn Thr Asn  
 1 5 10 15  
 Ala Leu Gln Arg Asp Ala Pro His Val Glu Pro Asp Phe Ser Ser Gln  
 20 25 30  
 Lys Leu Gln His Leu Glu His Val Met Glu Asn Tyr Thr Gln Trp Leu  
 35 40 45  
 Gln Lys Leu Glu Asn Tyr Ile Val Glu Asn Met Lys Ser Glu Met Ala  
 50 55 60  
 Gln Ile Gln Gln Asn Ala Val Gln Asn His Thr Ala Thr Met Leu Glu  
 65 70 75 80  
 Ile Gly Thr Ser Leu Leu Ser Gln Thr Ala Glu Gln Thr Arg Lys Leu  
 85 90 95  
 Thr Asp Val Glu Thr Gln Val Leu Asn Gln Thr Ser Arg Leu Glu Ile  
 100 105 110  
 Gln Leu Leu Glu Asn Ser Leu Ser Thr Tyr Lys Leu Glu Lys Gln Leu  
 115 120 125  
 Leu Gln Gln Thr Asn Glu Ile Leu Lys Ile His Glu Lys Asn Ser Leu  
 130 135 140  
 Leu Glu His Lys Ile Leu Glu Met Glu Gly Lys His Lys Glu Glu Leu  
 145 150 155 160  
 Asp Thr Leu Lys Glu Glu Lys Glu Asn Leu Gln Gly Leu Val Thr Arg  
 165 170 175

Gln Thr Tyr Ile Ile Gln Glu Leu Glu Lys Gln Leu Asn Arg Ala Thr  
 180 185 190  
 Thr Asn Asn Ser Val Leu Gln Lys Gln Gln Leu Glu Leu Met Asp Thr  
 195 200 205  
 Val His Asn Leu Val Asn Leu Cys Thr Lys Glu Gly Val Leu Leu Lys  
 210 215 220  
 Gly Gly Lys Arg Glu Glu Glu Lys Pro Phe Arg  
 225 230 235

<210> 19  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 19

Met Thr Val Phe Leu Ser Phe Ala Phe Leu Ala Ala Ile Leu Thr His  
 1 5 10 15  
 Ile Gly Cys Ser Asn Gln Arg Arg Ser Pro Glu Asn Ser Gly Arg Arg  
 20 25 30  
 Tyr Asn Arg Ile Gln His Gly Gln Cys Ala Tyr Thr Phe Ile Leu Pro  
 35 40 45  
 Glu Met Thr Val Phe Leu Ser Phe Ala Phe Leu Ala Ala Ile Leu Thr  
 50 55 60  
 His Ile Gly Cys Ser Asn Gln Arg Arg Ser Pro Glu Asn Ser Gly Arg  
 65 70 75 80  
 Arg Tyr Asn Arg Ile Gln His Gly Gln Cys Ala Tyr Thr Phe Ile Leu  
 85 90 95

Pro Glu

<210> 20  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<400> 20

His Arg Leu Pro Arg Asp Cys Gln Glu Leu Phe Gln Val Gly Glu Arg  
 1 5 10 15  
 Gln Ser Gly Leu Phe Glu Ile Gln Pro Gln Gly Ser Pro Pro Phe Leu  
 20 25 30  
 Val Asn Cys Lys Met Thr Ser Asp Gly Gly Trp Thr Val Ile Gln Arg  
 35 40 45  
 Arg His Asp Gly Ser Val Asp Phe Asn Arg Pro Trp Glu Ala Tyr Lys  
 50 55 60  
 Ala Gly Phe Gly Asp Pro His Gly Glu Phe Trp Leu Gly Leu Glu Lys  
 65 70 75 80  
 Val His Ser Ile Met Gly Asp Arg Asn Ser Arg Leu Ala Val Gln Leu  
 85 90 95

Arg Asp Trp Asp Gly Asn Ala Glu Leu Leu Gln Phe Ser Val His Leu  
 100 105 110  
 Gly Gly Glu Asp Thr Ala Tyr Ser Leu Gln Leu Thr Ala Pro Val Ala  
 115 120 125  
 Gly Gln Leu Gly Ala Thr Thr Val Pro Pro Ser Gly Leu Ser Val Pro  
 130 135 140  
 Phe Ser Thr Trp Asp Gln Asp His Asp Leu Arg Arg Asp Lys Asn Cys  
 145 150 155 160  
 Ala Lys Ser Leu Ser Gly Gly Trp Trp Phe Gly Thr Cys Ser His Ser  
 165 170 175  
 Asn Leu Asn Gly Gln Tyr Phe Arg  
 180

<210> 21  
 <211> 221  
 <212> PRT  
 <213> Homo sapiens

<400> 21

Glu Glu Gln Ile Ser Phe Arg Asp Cys Ala Glu Val Phe Lys Ser Gly  
 1 5 10 15  
 His Thr Thr Asn Gly Ile Tyr Thr Leu Thr Phe Pro Asn Ser Thr Glu  
 20 25 30  
 Glu Ile Lys Ala Tyr Cys Asp Met Glu Ala Gly Gly Gly Gly Trp Thr  
 35 40 45  
 Ile Ile Gln Arg Arg Glu Asp Gly Ser Val Asp Phe Gln Arg Thr Trp  
 50 55 60  
 Lys Glu Tyr Lys Val Gly Phe Gly Asn Pro Ser Gly Glu Tyr Trp Leu  
 65 70 75 80  
 Gly Asn Glu Phe Val Ser Gln Leu Thr Asn Gln Gln Arg Tyr Val Leu  
 85 90 95  
 Lys Ile His Leu Lys Asp Trp Glu Gly Asn Glu Ala Tyr Ser Leu Tyr  
 100 105 110  
 Glu His Phe Tyr Leu Ser Ser Glu Glu Leu Asn Tyr Arg Ile His Leu  
 115 120 125  
 Lys Gly Leu Thr Gly Thr Ala Gly Lys Ile Ser Ser Ile Ser Gln Pro  
 130 135 140  
 Gly Asn Asp Phe Ser Thr Lys Asp Gly Asp Asn Asp Lys Cys Ile Cys  
 145 150 155 160  
 Lys Cys Ser Gln Met Leu Thr Gly Gly Trp Trp Phe Asp Ala Cys Gly  
 165 170 175  
 Pro Ser Asn Leu Asn Gly Met Tyr Tyr Pro Gln Arg Gln Asn Thr Asn  
 180 185 190  
 Lys Phe Asn Gly Ile Lys Trp Tyr Tyr Trp Lys Gly Ser Gly Tyr Ser  
 195 200 205

Leu Lys Ala Thr Thr Met Met Ile Arg Pro Ala Asp Phe  
 210 215 220

<210> 22  
 <211> 219  
 <212> PRT  
 <213> Homo sapiens

<400> 22

Lys Met Gly Pro Lys Gly Glu Pro Gly Pro Arg Asn Cys Arg Glu Leu  
 1 5 10 15

Leu Ser Gln Gly Ala Thr Leu Ser Gly Trp Tyr His Leu Cys Leu Pro  
 20 25 30

Glu Gly Arg Ala Leu Pro Val Phe Cys Asp Met Asp Thr Glu Gly Gly  
 35 40 45

Gly Trp Leu Val Phe Gln Arg Arg Gln Asp Gly Ser Val Asp Phe Phe  
 50 55 60

Arg Ser Trp Ser Ser Tyr Arg Ala Gly Phe Gly Asn Gln Glu Ser Glu  
 65 70 75 80

Phe Trp Leu Gly Asn Glu Asn Leu His Gln Leu Thr Leu Gln Gly Asn  
 85 90 95

Trp Glu Leu Arg Val Glu Leu Glu Asp Phe Asn Gly Asn Arg Thr Phe  
 100 105 110

Ala His Tyr Ala Thr Phe Arg Leu Leu Gly Glu Val Asp His Tyr Gln  
 115 120 125

Leu Ala Leu Gly Lys Phe Ser Glu Gly Thr Ala Gly Asp Ser Leu Ser  
 130 135 140

Leu His Ser Gly Arg Pro Phe Thr Thr Tyr Asp Ala Asp His Asp Ser  
 145 150 155 160

Ser Asn Ser Asn Cys Ala Val Ile Val His Gly Ala Trp Trp Tyr Ala  
 165 170 175

Ser Cys Tyr Arg Ser Asn Leu Asn Gly Arg Tyr Ala Val Ser Glu Ala  
 180 185 190

Ala Ala His Lys Tyr Gly Ile Asp Trp Ala Ser Gly Arg Gly Val Gly  
 195 200 205

His Pro Tyr Arg Arg Val Arg Met Met Leu Arg  
 210 215

<210> 23  
 <211> 217  
 <212> PRT  
 <213> Homo sapiens

<400> 23

Asp Cys Ser Ser Leu Tyr Gln Lys Asn Tyr Arg Ile Ser Gly Val Tyr  
 1 5 10 15

Lys Leu Pro Pro Asp Asp Phe Leu Gly Ser Pro Glu Leu Glu Val Phe  
 20 25 30

Cys Asp Met Glu Thr Ser Gly Gly Gly Trp Thr Ile Ile Gln Arg Arg  
 35 40 45  
 Lys Ser Gly Leu Val Ser Phe Tyr Arg Asp Trp Lys Gln Tyr Lys Gln  
 50 55 60  
 Gly Phe Gly Ser Ile Arg Gly Asp Phe Trp Leu Gly Asn Glu His Ile  
 65 70 75 80  
 His Arg Leu Ser Arg Gln Pro Thr Arg Leu Arg Val Glu Met Glu Asp  
 85 90 95  
 Trp Glu Gly Asn Leu Arg Tyr Ala Glu Tyr Ser His Phe Val Leu Gly  
 100 105 110  
 Asn Glu Leu Asn Ser Tyr Arg Leu Phe Leu Gly Asn Tyr Thr Gly Asn  
 115 120 125  
 Val Gly Asn Asp Ala Leu Gln Tyr His Asn Asn Thr Ala Phe Ser Thr  
 130 135 140  
 Lys Asp Lys Asp Asn Asp Asn Cys Leu Asp Lys Cys Ala Gln Leu Arg  
 145 150 155 160  
 Lys Gly Gly Tyr Trp Tyr Asn Cys Cys Thr Asp Ser Asn Leu Asn Gly  
 165 170 175  
 Val Tyr Tyr Arg Leu Gly Glu His Asn Lys His Leu Asp Gly Ile Thr  
 180 185 190  
 Trp Tyr Gly Trp His Gly Ser Thr Tyr Ser Leu Lys Arg Val Glu Met  
 195 200 205  
 Lys Ile Arg Pro Glu Asp Phe Lys Pro  
 210 215

<210> 24  
 <211> 219  
 <212> PRT  
 <213> Homo sapiens

<400> 24

Lys Pro Val Gly Pro Trp Gln Asp Cys Ala Glu Ala Arg Gln Ala Gly  
 1 5 10 15  
 His Glu Gln Ser Gly Val Tyr Glu Leu Arg Val Gly Arg His Val Val  
 20 25 30  
 Ser Val Trp Cys Glu Gln Gln Leu Glu Gly Gly Gly Trp Thr Val Ile  
 35 40 45  
 Gln Arg Arg Gln Asp Gly Ser Val Asn Phe Phe Thr Thr Trp Gln His  
 50 55 60  
 Tyr Lys Ala Gly Phe Gly Arg Pro Asp Gly Glu Tyr Trp Leu Gly Leu  
 65 70 75 80  
 Glu Pro Val Tyr Gln Leu Thr Ser Arg Gly Asp His Glu Leu Leu Val  
 85 90 95  
 Leu Leu Glu Asp Trp Gly Gly Arg Gly Ala Arg Ala His Tyr Asp Gly  
 100 105 110

Phe Ser Leu Glu Pro Glu Ser Asp His Tyr Arg Leu Arg Leu Gly Gln  
           115                                  120                                  125  
 Tyr His Gly Asp Ala Gly Asp Ser Leu Ser Trp His Asn Asp Lys Pro  
           130                                  135                                  140  
 Phe Ser Thr Val Asp Arg Asp Arg Asp Ser Tyr Ser Gly Asn Cys Ala  
   145                                  150                                  155                                  160  
 Leu Tyr Gln Arg Gly Gly Trp Trp Tyr His Ala Cys Ala His Ser Asn  
                                   165                                  170                                  175  
 Leu Asn Gly Val Trp His His Gly Gly His Tyr Arg Ser Arg Tyr Gln  
                                   180                                  185                                  190  
 Asp Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly Ala Tyr Ser Leu Arg  
                                   195                                  200                                  205  
 Lys Ala Ala Met Leu Ile Arg Pro Leu Lys Leu  
           210                                  215  
 <210> 25  
 <211> 215  
 <212> PRT  
 <213> Homo sapiens  
 <400> 25  
 Leu Pro Arg Asp Cys Gln Glu Leu Phe Gln Val Gly Glu Arg Gln Ser  
   1                                  5                                  10                                  15  
 Gly Leu Phe Glu Ile Gln Pro Gln Gly Ser Pro Pro Phe Leu Val Asn  
                                   20                                  25                                  30  
 Cys Lys Met Thr Ser Asp Gly Gly Trp Thr Val Ile Gln Arg Arg His  
                                   35                                  40                                  45  
 Asp Gly Ser Val Asp Phe Asn Arg Pro Trp Glu Ala Tyr Lys Ala Gly  
           50                                  55                                  60  
 Phe Gly Asp Pro His Gly Glu Phe Trp Leu Gly Leu Glu Lys Val His  
   65                                  70                                  75                                  80  
 Ser Ile Thr Gly Asp Arg Asn Ser Arg Leu Ala Val Gln Leu Arg Asp  
                                   85                                  90                                  95  
 Trp Asp Gly Asn Ala Glu Leu Leu Gln Phe Ser Val His Leu Gly Gly  
                                   100                                  105                                  110  
 Glu Asp Thr Ala Tyr Ser Leu Gln Leu Thr Ala Pro Val Ala Gly Gln  
                                   115                                  120                                  125  
 Leu Gly Ala Thr Thr Val Pro Pro Ser Gly Leu Ser Val Pro Phe Ser  
           130                                  135                                  140  
 Thr Trp Asp Gln Asp His Asp Leu Arg Arg Asp Lys Asn Cys Ala Lys  
   145                                  150                                  155                                  160  
 Ser Leu Ser Gly Gly Trp Trp Phe Gly Thr Cys Ser His Ser Asn Leu  
                                   165                                  170                                  175  
 Asn Gly Gln Tyr Phe Arg Ser Ile Pro Gln Gln Arg Gln Lys Leu Lys  
                                   180                                  185                                  190

Lys Gly Ile Phe Trp Lys Thr Trp Arg Gly Arg Tyr Tyr Pro Leu Gln  
 195 200 205

Ala Thr Thr Met Leu Ile Gln  
 210 215

<210> 26  
 <211> 222  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 26

Pro Arg Asp Cys Gln Glu Leu Phe Gln Val Gly Glu Arg Gln Ser Gly  
 1 5 10 15

Leu Phe Glu Ile Gln Pro Gln Gly Ser Pro Pro Phe Leu Val Asn Cys  
 20 25 30

Lys Met Thr Ser Asp Gly Gly Trp Thr Val Ile Gln Arg Arg His Asp  
 35 40 45

Gly Ser Val Asp Phe Asn Arg Pro Trp Glu Ala Tyr Lys Ala Gly Phe  
 50 55 60

Gly Asp Pro His Gly Glu Phe Trp Leu Gly Leu Glu Lys Val His Ser  
 65 70 75 80

Ile Thr Gly Asp Arg Asn Ser Arg Leu Ala Val Gln Leu Arg Asp Trp  
 85 90 95

Asp Gly Asn Ala Glu Leu Leu Gln Phe Ser Val His Leu Gly Gly Glu  
 100 105 110

Asp Thr Ala Tyr Ser Leu Gln Leu Thr Ala Pro Val Ala Gly Gln Leu  
 115 120 125

Gly Ala Thr Thr Val Pro Pro Ser Gly Leu Ser Val Pro Phe Ser Thr  
 130 135 140

Trp Asp Gln Asp His Asp Leu Arg Arg Asp Lys Asn Cys Ala Lys Ser  
 145 150 155 160

Leu Ser Gly Gly Trp Trp Phe Gly Thr Cys Ser His Ser Asn Leu Asn  
 165 170 175

Gly Gln Tyr Phe Arg Ser Ile Pro Gln Gln Arg Gln Lys Leu Lys Lys  
 180 185 190

Gly Ile Phe Trp Lys Thr Trp Arg Gly Arg Tyr Tyr Pro Leu Gln Ala  
 195 200 205

Thr Thr Met Leu Ile Gln Pro Met Ala Ala Glu Ala Ala Ser  
 210 215 220

<210> 27  
 <211> 222  
 <212> PRT  
 <213> Artificial Sequence



&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 27

```

His Asp Gly Ile Pro Ala Glu Cys Thr Thr Ile Tyr Asn Arg Gly Glu
1          5          10          15
His Thr Ser Gly Met Tyr Ala Ile Arg Pro Ser Asn Ser Gln Val Phe
          20          25          30
His Val Tyr Cys Asp Val Ile Ser Gly Ser Pro Trp Thr Leu Ile Gln
          35          40          45
His Arg Ile Asp Gly Ser Gln Asn Phe Asn Glu Thr Trp Glu Asn Tyr
          50          55          60
Lys Tyr Gly Phe Gly Arg Leu Asp Gly Glu Phe Trp Leu Gly Leu Glu
65          70          75          80
Lys Ile Tyr Ser Ile Val Lys Gln Ser Asn Tyr Val Leu Arg Ile Glu
          85          90          95
Leu Glu Asp Trp Lys Asp Asn Lys His Tyr Ile Glu Tyr Ser Phe Tyr
          100          105          110
Leu Gly Asn His Glu Thr Asn Tyr Thr Leu His Leu Val Ala Ile Thr
          115          120          125
Gly Asn Val Pro Asn Ala Ile Pro Glu Asn Lys Asp Leu Val Phe Ser
          130          135          140
Thr Trp Asp His Lys Ala Lys Gly His Phe Asn Cys Pro Glu Gly Tyr
145          150          155          160
Ser Gly Gly Trp Trp Trp His Asp Glu Cys Gly Glu Asn Asn Leu Asn
          165          170          175
Gly Lys Tyr Asn Lys Pro Arg Ala Lys Ser Lys Pro Glu Arg Arg Arg
          180          185          190
Gly Leu Ser Trp Lys Ser Gln Asn Gly Arg Leu Tyr Ser Ile Lys Ser
          195          200          205
Thr Lys Met Leu Ile His Pro Thr Asp Ser Glu Ser Phe Glu
          210          215          220

```

&lt;210&gt; 28

&lt;211&gt; 214

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 28

```

Arg Asp Cys Gln Glu Leu Phe Gln Glu Gly Glu Arg His Ser Gly Leu
1          5          10          15
Phe Gln Ile Gln Pro Leu Gly Ser Pro Pro Phe Leu Val Asn Cys Glu
          20          25          30
Met Thr Ser Asp Gly Gly Trp Thr Val Ile Gln Arg Arg Leu Asn Gly
          35          40          45

```

Ser Val Asp Phe Asn Gln Ser Trp Glu Ala Tyr Lys Asp Gly Phe Gly  
 50 55 60  
 Asp Pro Gln Gly Glu Phe Trp Leu Gly Leu Glu Lys Met His Ser Ile  
 65 70 75 80  
 Thr Gly Asn Arg Gly Ser Gln Leu Ala Val Gln Leu Gln Asp Trp Asp  
 85 90 95  
 Gly Asn Ala Lys Leu Leu Gln Phe Pro Ile His Leu Gly Gly Glu Asp  
 100 105 110  
 Thr Ala Tyr Ser Leu Gln Leu Thr Glu Pro Thr Ala Asn Glu Leu Gly  
 115 120 125  
 Ala Thr Asn Val Ser Pro Asn Gly Leu Ser Leu Pro Phe Ser Thr Trp  
 130 135 140  
 Asp Gln Asp His Asp Leu Arg Gly Asp Leu Asn Cys Ala Lys Ser Leu  
 145 150 155 160  
 Ser Gly Gly Trp Trp Phe Gly Thr Cys Ser His Ser Asn Leu Asn Gly  
 165 170 175  
 Gln Tyr Phe His Ser Ile Pro Arg Gln Arg Gln Glu Arg Lys Lys Gly  
 180 185 190  
 Ile Phe Trp Lys Thr Trp Lys Gly Arg Tyr Tyr Pro Leu Gln Ala Thr  
 195 200 205  
 Thr Leu Leu Ile Gln Pro  
 210

<210> 29  
 <211> 216  
 <212> PRT  
 <213> Homo sapiens

<400> 29

Phe Gln Asp Cys Ala Glu Ile Lys Arg Ser Gly Val Asn Thr Ser Gly  
 1 5 10 15  
 Val Tyr Thr Ile Tyr Glu Thr Asn Met Thr Lys Pro Leu Lys Val Phe  
 20 25 30  
 Cys Asp Met Glu Thr Asp Gly Gly Gly Trp Thr Leu Ile Gln His Arg  
 35 40 45  
 Glu Asp Gly Ser Val Asn Phe Gln Arg Thr Trp Glu Glu Tyr Lys Glu  
 50 55 60  
 Gly Phe Gly Asn Val Ala Arg Glu His Trp Leu Gly Asn Glu Ala Val  
 65 70 75 80  
 His Arg Leu Thr Ser Arg Thr Ala Tyr Leu Leu Arg Val Glu Leu His  
 85 90 95  
 Asp Trp Glu Gly Arg Gln Thr Ser Ile Gln Tyr Glu Asn Phe Gln Leu  
 100 105 110  
 Gly Ser Glu Arg Gln Arg Tyr Ser Leu Ser Val Asn Asp Ser Ser Ser  
 115 120 125

Ser Ala Gly Arg Lys Asn Ser Leu Ala Pro Gln Gly Thr Lys Phe Ser  
 130 135 140

Thr Lys Asp Met Asp Asn Asp Asn Cys Met Cys Lys Cys Ala Gln Met  
 145 150 155 160

Leu Ser Gly Gly Trp Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn  
 165 170 175

Gly Ile Tyr Tyr Ser Val His Gln His Leu His Lys Ile Asn Gly Ile  
 180 185 190

Arg Trp His Tyr Phe Arg Gly Pro Ser Tyr Ser Leu His Gly Thr Arg  
 195 200 205

Met Met Leu Arg Pro Met Gly Ala  
 210 215

<210> 30  
 <211> 216  
 <212> PRT  
 <213> Homo sapiens

<400> 30

Phe Gln Asp Cys Ala Glu Ile Gln Arg Ser Gly Ala Ser Ala Ser Gly  
 1 5 10 15

Val Tyr Thr Ile Gln Val Ser Asn Ala Thr Lys Pro Arg Lys Val Phe  
 20 25 30

Cys Asp Leu Gln Ser Ser Gly Gly Arg Trp Thr Leu Ile Gln Arg Arg  
 35 40 45

Glu Asn Gly Thr Val Asn Phe Gln Arg Asn Trp Lys Asp Tyr Lys Gln  
 50 55 60

Gly Phe Gly Asp Pro Ala Gly Glu His Trp Leu Gly Asn Glu Val Val  
 65 70 75 80

His Gln Leu Thr Arg Arg Ala Ala Tyr Ser Leu Arg Val Glu Leu Gln  
 85 90 95

Asp Trp Glu Gly His Glu Ala Tyr Ala Gln Tyr Glu His Phe His Leu  
 100 105 110

Gly Ser Glu Asn Gln Leu Tyr Arg Leu Ser Val Val Gly Tyr Ser Gly  
 115 120 125

Ser Ala Gly Arg Gln Ser Ser Leu Val Leu Gln Asn Thr Ser Phe Ser  
 130 135 140

Thr Leu Asp Ser Asp Asn Asp His Cys Leu Cys Lys Cys Ala Gln Val  
 145 150 155 160

Met Ser Gly Gly Trp Trp Phe Asp Ala Cys Gly Leu Ser Asn Leu Asn  
 165 170 175

Gly Val Tyr Tyr His Ala Pro Asp Asn Lys Tyr Lys Met Asp Gly Ile  
 180 185 190

Arg Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ala Ser Arg  
 195 200 205

Met Met Ile Arg Pro Leu Asp Ile  
210 215

<210> 31  
<211> 224  
<212> PRT  
<213> Homo sapiens

<400> 31

Lys Pro Ser Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu Glu Asp Gly  
1 5 10 15  
His Asp Thr Ser Ser Ile Tyr Leu Val Lys Pro Glu Asn Thr Asn Arg  
20 25 30  
Leu Met Gln Val Trp Cys Asp Gln Arg His Asp Pro Gly Gly Trp Thr  
35 40 45  
Val Ile Gln Arg Arg Leu Asp Gly Ser Val Asn Phe Phe Arg Asn Trp  
50 55 60  
Glu Thr Tyr Lys Gln Gly Phe Gly Asn Ile Asp Gly Glu Tyr Trp Leu  
65 70 75 80  
Gly Leu Glu Asn Ile Tyr Trp Leu Thr Asn Gln Gly Asn Tyr Lys Leu  
85 90 95  
Leu Val Thr Met Glu Asp Trp Ser Gly Arg Lys Val Phe Ala Glu Tyr  
100 105 110  
Ala Ser Phe Arg Leu Glu Pro Glu Ser Glu Tyr Tyr Lys Leu Arg Leu  
115 120 125  
Gly Arg Tyr His Gly Asn Ala Gly Asp Ser Phe Thr Trp His Asn Gly  
130 135 140  
Lys Gln Phe Thr Thr Leu Asp Arg Asp His Asp Val Tyr Thr Gly Asn  
145 150 155 160  
Cys Ala His Tyr Gln Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His  
165 170 175  
Ser Asn Leu Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg  
180 185 190  
Tyr Gln Asp Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser  
195 200 205  
Leu Lys Lys Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His  
210 215 220

<210> 32  
<211> 220  
<212> PRT  
<213> Homo sapiens

<400> 32

Ile Asn Glu Gly Pro Phe Lys Asp Cys Gln Gln Ala Lys Glu Ala Gly  
1 5 10 15  
His Ser Val Ser Gly Ile Tyr Met Ile Lys Pro Glu Asn Ser Asn Gly  
20 25 30

```
<210>      33
<211>      136
<212>      PRT
<213>      Homo sapiens

<400>      33
```

Gly 1	Lys	Lys	Glu 5	Lys	Pro	Glu	Lys	Lys	Val 10	Lys	Lys	Ser	Asp	Cys 15	Gly
Glu	Trp	Gln 20	Trp	Ser	Val	Cys	Val 25	Pro	Thr	Ser	Gly	Asp	Cys 30	Gly	Leu
Gly	Thr 35	Arg	Glu	Gly	Thr	Arg	Thr 40	Gly	Ala	Glu	Cys	Lys 45	Gln	Thr	Met
Lys 50	Thr	Gln	Arg	Cys	Lys	Ile 55	Pro	Cys	Asn	Trp	Lys 60	Lys	Gln	Phe	Gly
Ala 65	Glu	Cys	Lys	Tyr 70	Gln	Phe	Gln	Ala	Trp 75	Gly	Glu	Cys	Asp	Leu 80	Asn
Thr	Ala	Leu	Lys	Thr 85	Arg	Thr	Gly	Ser	Leu 90	Lys	Arg	Ala	Leu	His 95	Asn
Ala	Glu	Cys	Gln 100	Lys	Thr	Val	Thr 105	Ile	Ser	Lys	Pro	Cys	Gly 110	Lys	Leu

Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys Lys Lys Lys Lys Glu Gly  
 115 120 125

Lys Lys Gln Glu Lys Met Leu Asp  
 130 135

<210> 34  
 <211> 121  
 <212> PRT  
 <213> Homo sapiens

<400> 34

Lys Lys Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu Cys Ala  
 1 5 10 15

Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser Ser Lys Asp Cys Gly Val  
 20 25 30

Gly Phe Arg Glu Gly Thr Cys Gly Ala Gln Thr Gln Arg Ile Arg Cys  
 35 40 45

Arg Val Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys Tyr  
 50 55 60

Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr Lys Val  
 65 70 75 80

Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gln Cys Gln Glu  
 85 90 95

Thr Ile Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala Lys Ala  
 100 105 110

Lys Ala Lys Lys Gly Lys Gly Lys Asp  
 115 120

<210> 35  
 <211> 43  
 <212> PRT  
 <213> Homo sapiens

<400> 35

Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn Thr Ala  
 1 5 10 15

Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn Ala Glu  
 20 25 30

Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys  
 35 40

<210> 36  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<400> 36

Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn  
 1 5 10 15

Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn  
20 25 30

Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu  
35 40 45

Thr Lys Pro Lys Pro Gln  
50

<210> 37

<211> 72

<212> PRT

<213> Homo sapiens

<400> 37

Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn  
1 5 10 15

Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn  
20 25 30

Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu  
35 40 45

Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys Lys Lys Lys Lys Glu Gly  
50 55 60

Lys Lys Gln Glu Lys Met Leu Asp  
65 70

<210> 38

<211> 80

<212> PRT

<213> Homo sapiens

<400> 38

Cys Gly Glu Trp Thr Trp Gly Pro Cys Ile Pro Asn Ser Lys Asp Cys  
1 5 10 15

Gly Leu Gly Thr Arg Glu Gly Thr Cys Lys Gln Glu Thr Arg Lys Leu  
20 25 30

Lys Cys Lys Ile Pro Cys Asn Trp Lys Lys Gln Phe Gly Ala Asp Cys  
35 40 45

Lys Tyr Lys Phe Glu Ser Trp Gly Glu Cys Asp Ala Asn Thr Gly Leu  
50 55 60

Lys Thr Arg Ser Gly Thr Leu Lys Lys Ala Leu Tyr Asn Ala Asp Cys  
65 70 75 80

<210> 39

<211> 21

<212> PRT

<213> Homo sapiens

<400> 39

Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly  
1 5 10 15

Glu Trp Gln Trp Ser

20

<210> 40  
 <211> 16  
 <212> PRT  
 <213> Homo sapiens

<400> 40

Ser Lys Lys Lys Lys Lys Glu Gly Lys Lys Gln Glu Lys Met Leu Asp  
 1 5 10 15

<210> 41  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<400> 41

Asp Cys Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr  
 1 5 10 15

Gly Thr Lys Val Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala  
 20 25 30

Gln Cys Gln Glu Thr Ile Arg Val Thr Lys Pro Cys Thr Pro Lys Thr  
 35 40 45

Lys Ala Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp  
 50 55 60

<210> 42  
 <211> 42  
 <212> PRT  
 <213> Homo sapiens

<400> 42

Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr  
 1 5 10 15

Lys Val Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gln Cys  
 20 25 30

Gln Glu Thr Ile Arg Val Thr Lys Pro Cys  
 35 40

<210> 43  
 <211> 32  
 <212> PRT  
 <213> Homo sapiens

<400> 43

Met Gln Ala Gln Gln Tyr Gln Gln Gln Arg Arg Lys Phe Ala Ala Ala  
 1 5 10 15

Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala  
 20 25 30

<210> 44  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens



&lt;400&gt; 44

Met Gln His Arg Gly Phe Leu Leu Leu Thr Leu Leu Ala Leu Leu Ala  
 1 5 10 15

Leu Thr Ser Ala  
 20

&lt;210&gt; 45

&lt;211&gt; 139

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

Phe Asn Leu Pro Pro Gly Asn Tyr Lys Lys Pro Lys Leu Leu Tyr Cys  
 1 5 10 15

Ser Asn Gly Gly His Phe Leu Arg Ile Leu Pro Asp Gly Thr Val Asp  
 20 25 30

Gly Thr Arg Asp Arg Ser Asp Gln His Ile Gln Leu Gln Leu Ser Ala  
 35 40 45

Glu Ser Val Gly Glu Val Tyr Ile Lys Ser Thr Glu Thr Gly Gln Tyr  
 50 55 60

Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln Thr Pro Asn  
 65 70 75 80

Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Asn His Tyr Asn Thr  
 85 90 95

Tyr Ile Ser Lys Lys His Ala Glu Lys Asn Trp Phe Val Gly Leu Lys  
 100 105 110

Lys Asn Gly Ser Cys Lys Arg Gly Pro Arg Thr His Tyr Gly Gln Lys  
 115 120 125

Ala Ile Leu Phe Leu Pro Leu Pro Val Ser Ser  
 130 135

&lt;210&gt; 46

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

Met Ala Glu Gly Glu Ile Thr Thr Phe Thr Ala Leu Thr Glu Lys  
 1 5 10 15

&lt;210&gt; 47

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

Lys Lys Asn Gly Ser Cys Lys Arg  
 1 5

&lt;210&gt; 48

<211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (5)..(5)  
 <223> "Xaa" may be between 5 and 7 of any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> "Xaa" may be up to 3 of any amino acid

<400> 48

Arg Leu Tyr Cys Xaa Leu Xaa Pro Asp Gly Arg  
 1 5 10

<210> 49  
 <211> 4  
 <212> PRT  
 <213> Homo sapiens

<400> 49

Ile Ser Lys Lys  
 1

<210> 50  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 50

Lys Lys Pro Lys Leu  
 1 5

<210> 51  
 <211> 535  
 <212> PRT  
 <213> Homo sapiens

<400> 51

Met Leu Gly Pro Cys Met Leu Leu Leu Leu Leu Leu Gly Leu Arg  
 1 5 10 15

Leu Gln Leu Ser Leu Gly Ile Ile Pro Val Glu Glu Glu Asn Pro Asp  
 20 25 30

Phe Trp Asn Arg Glu Ala Ala Glu Ala Leu Gly Ala Ala Lys Lys Leu  
 35 40 45

Gln Pro Ala Gln Thr Ala Ala Lys Asn Leu Ile Ile Phe Leu Gly Asp  
 50 55 60

Gly Met Gly Val Ser Thr Val Thr Ala Ala Arg Ile Leu Lys Gly Gln  
 65 70 75 80

Lys Lys Asp Lys Leu Gly Pro Glu Ile Pro Leu Ala Met Asp Arg Phe  
 85 90 95  
 Pro Tyr Val Ala Leu Ser Lys Thr Tyr Asn Val Asp Lys His Val Pro  
 100 105 110  
 Asp Ser Gly Ala Thr Ala Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn  
 115 120 125  
 Phe Gln Thr Ile Gly Leu Ser Ala Ala Ala Arg Phe Asn Gln Cys Asn  
 130 135 140  
 Thr Thr Arg Gly Asn Glu Val Ile Ser Val Met Asn Arg Ala Lys Lys  
 145 150 155 160  
 Ala Gly Lys Ser Val Gly Val Val Thr Thr Thr Arg Val Gln His Ala  
 165 170 175  
 Ser Pro Ala Gly Thr Tyr Ala His Thr Val Asn Arg Asn Trp Tyr Ser  
 180 185 190  
 Asp Ala Asp Val Pro Ala Ser Ala Arg Gln Glu Gly Cys Gln Asp Ile  
 195 200 205  
 Ala Thr Gln Leu Ile Ser Asn Met Asp Ile Asp Val Ile Leu Gly Gly  
 210 215 220  
 Gly Arg Lys Tyr Met Phe Arg Met Gly Thr Pro Asp Pro Glu Tyr Pro  
 225 230 235 240  
 Asp Asp Tyr Ser Gln Gly Gly Thr Arg Leu Asp Gly Lys Asn Leu Val  
 245 250 255  
 Gln Glu Trp Leu Ala Lys Arg Gln Gly Ala Arg Tyr Val Trp Asn Arg  
 260 265 270  
 Thr Glu Leu Met Gln Ala Ser Leu Asp Pro Ser Val Thr His Leu Met  
 275 280 285  
 Gly Leu Phe Glu Pro Gly Asp Met Lys Tyr Glu Ile His Arg Asp Ser  
 290 295 300  
 Thr Leu Asp Pro Ser Leu Met Glu Met Thr Glu Ala Ala Leu Arg Leu  
 305 310 315 320  
 Leu Ser Arg Asn Pro Arg Gly Phe Phe Leu Phe Val Glu Gly Gly Arg  
 325 330 335  
 Ile Asp His Gly His His Glu Ser Arg Ala Tyr Arg Ala Leu Thr Glu  
 340 345 350  
 Thr Ile Met Phe Asp Asp Ala Ile Glu Arg Ala Gly Gln Leu Thr Ser  
 355 360 365  
 Glu Glu Asp Thr Leu Ser Leu Val Thr Ala Asp His Ser His Val Phe  
 370 375 380  
 Ser Phe Gly Gly Tyr Pro Leu Arg Gly Ser Ser Ile Phe Gly Leu Ala  
 385 390 395 400  
 Pro Gly Lys Ala Arg Asp Arg Lys Ala Tyr Thr Val Leu Leu Tyr Gly  
 405 410 415  
 Asn Gly Pro Gly Tyr Val Leu Lys Asp Gly Ala Arg Pro Asp Val Thr

420                      425                      430  
 Glu Ser Glu Ser Gly Ser Pro Glu Tyr Arg Gln Gln Ser Ala Val Pro  
                          435                      440                      445  
 Leu Asp Glu Glu Thr His Ala Gly Glu Asp Val Ala Val Phe Ala Arg  
                          450                      455                      460  
 Gly Pro Gln Ala His Leu Val His Gly Val Gln Glu Gln Thr Phe Ile  
                          465                      470                      475                      480  
 Ala His Val Met Ala Phe Ala Ala Cys Leu Glu Pro Tyr Thr Ala Cys  
                          485                      490                      495  
 Asp Leu Ala Pro Pro Ala Gly Thr Thr Asp Ala Ala His Pro Gly Arg  
                          500                      505                      510  
 Ser Val Val Pro Ala Leu Leu Pro Leu Leu Ala Gly Thr Leu Leu Leu  
                          515                      520                      525  
 Leu Glu Thr Ala Thr Ala Pro  
                          530                      535

<210> 52  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 52

Met Leu Gly Pro Cys Met Leu Leu Leu Leu Leu Leu Leu Gly Leu Arg  
 1                      5                      10                      15

Leu Gln Leu Ser Leu Gly  
                          20

<210> 53  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 53

Ala Ala His Pro Gly Arg Ser Val Val Pro Ala Leu Leu Pro Leu Leu  
 1                      5                      10                      15

Ala Gly Thr Leu Leu Leu Leu Glu Thr Ala Thr Ala Pro  
                          20                      25

<210> 54  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<400> 54

Gly Met Gly Val Ser Thr Val Thr Ala Ala Arg Ile Leu Lys Gly Gln  
 1                      5                      10                      15

Lys Lys Asp Lys Leu Gly Pro Glu Ile Pro Leu Ala Met Asp Arg Phe  
                          20                      25                      30

Pro Tyr Val Ala Leu Ser Lys Thr Tyr Asn Val Asp Lys His Val Pro  
                          35                      40                      45

Asp Ser Gly Ala Thr Ala Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn  
 50 55 60

Phe Gln Thr Ile Gly Leu Ser Ala Ala Ala Arg Phe Asn Gln Cys Asn  
 65 70 75 80

Thr Thr Arg Gly Asn Glu Val Ile Ser Val Met Asn Arg Ala Lys Lys  
 85 90 95

Ala Gly Lys Ser Val Gly Val Val Thr Thr Thr Arg  
 100 105

<210> 55  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<220>  
 <221> MISC\_FEATURE  
 <222> (8)..(8)  
 <223> "Xaa" may be any amino acid

<400> 55

Ala Gln Val Pro Asp Ser Ala Xaa Thr Ala Thr Ala Tyr Leu Cys Gly  
 1 5 10 15

Val Lys Ala Asn  
 20

<210> 56  
 <211> 86  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (30)..(30)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (33)..(34)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (36)..(36)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE

<222> (39)..(39)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (41)..(41)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (44)..(44)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (47)..(47)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (56)..(57)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (65)..(65)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (78)..(79)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (81)..(81)  
 <223> "Xaa" may be any amino acid

<220>  
 <221> MISC\_FEATURE  
 <222> (83)..(83)  
 <223> "Xaa" may be any amino acid

<400> 56

Thr Asn Val Ala Lys Asn Xaa Ile Met Phe Leu Gly Asp Gly Met Gly  
 1 5 10 15

Val Ser Thr Val Thr Ala Ala Arg Ile Leu Lys Gly Gln Xaa His His  
 20 25 30

Xaa Xaa Gly Xaa Glu Thr Xaa Leu Xaa Met Asp Xaa Phe Pro Xaa Val  
 35 40 45

Ala Leu Ser Lys Thr Tyr Asn Xaa Xaa Ala Gln Val Pro Asp Ser Ala  
 50 55 60

Xaa Thr Ala Thr Ala Tyr Leu Cys Gly Val Lys Ala Asn Xaa Xaa Thr  
 65 70 75 80

Xaa Gly Xaa Ser Ala Ala  
 85

<210> 57

<211> 53  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> "Xaa" may be any amno acid  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (16)..(16)  
 <223> "Xaa" may be any amno acid  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (22)..(22)  
 <223> "Xaa" may be any amno acid  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (34)..(35)  
 <223> "Xaa" may be any amno acid  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (41)..(42)  
 <223> "Xaa" may be any amno acid  
  
 <400> 57

Glu	Asp	Thr	Leu	Thr	Xaa	Val	Thr	Ala	Asp	His	Ser	His	Val	Phe	Xaa
1				5					10					15	
Phe	Gly	Gly	Tyr	Thr	Xaa	Arg	Gly	Asn	Ser	Ile	Phe	Gly	Leu	Ala	Pro
		20					25						30		
Met	Xaa	Xaa	Asp	Thr	Asp	Lys	Lys	Xaa	Xaa	Thr	Ala	Ile	Leu	Tyr	Gly
		35				40						45			
Asn	Gly	Pro	Gly	Tyr											
		50													

<210> 58  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 58

Val	Val	Pro	Ala	Leu	Leu	Pro	Leu	Leu	Ala	Gly	Thr	Leu	Leu	Leu	Leu
1				5					10					15	
Glu	Thr	Ala	Thr	Ala	Pro										
			20												

<210> 59  
 <211> 154  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 59

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
1           5           10           15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
           20           25           30
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
           35           40           45
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
           50           55           60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
           65           70           75           80
Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
           85           90           95
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
           100          105          110
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
           115          120          125
Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val
           130          135          140
Arg Gly Lys Gly Cys Asp Lys Pro Arg Arg
145          150

```

&lt;210&gt; 60

&lt;211&gt; 162

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 60

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
1           5           10           15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
           20           25           30
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
           35           40           45
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
           50           55           60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
           65           70           75           80
Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
           85           90           95
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
           100          105          110
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys

```



115                                      120                                      125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val  
     130                                      135                                      140  
 Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Cys Asp Lys Pro  
     145                                      150                                      155                                      160  
 Arg Arg  
 <210> 61  
 <211> 150  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 61  
 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
     1                                      5                                      10                                      15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
                     20                                      25                                      30  
 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
                     35                                      40                                      45  
 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
                     50                                      55                                      60  
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
     65                                      70                                      75                                      80  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
                     85                                      90                                      95  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
                     100                                      105                                      110  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
                     115                                      120                                      125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Lys Lys  
                     130                                      135                                      140  
 Cys Asp Lys Pro Arg Arg  
     145                                      150  
 <210> 62  
 <211> 154  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 62  
 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
     1                                      5                                      10                                      15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly

20							25					30				
Gly	Gly	Gln	Asn	His	His	Glu	Val	Val	Lys	Phe	Met	Asp	Val	Tyr	Gln	
		35					40					45				
Arg	Ser	Tyr	Cys	His	Pro	Ile	Glu	Thr	Leu	Val	Asp	Ile	Phe	Gln	Glu	
	50					55					60					
Tyr	Pro	Asp	Glu	Ile	Glu	Tyr	Ile	Phe	Lys	Pro	Ser	Cys	Val	Pro	Leu	
65					70				75						80	
Met	Arg	Cys	Gly	Gly	Cys	Cys	Asn	Asp	Glu	Gly	Leu	Glu	Cys	Val	Pro	
				85					90					95		
Thr	Glu	Glu	Ser	Asn	Ile	Thr	Met	Gln	Ile	Met	Arg	Ile	Lys	Pro	His	
			100					105				110				
Gln	Gly	Gln	His	Ile	Gly	Glu	Met	Ser	Phe	Leu	Gln	His	Asn	Lys	Cys	
		115					120					125				
Glu	Cys	Arg	Pro	Lys	Lys	Asp	Arg	Ala	Arg	Gln	Glu	Lys	Lys	Lys	Lys	
	130					135					140					
Lys	Lys	Lys	Lys	Cys	Asp	Lys	Pro	Arg	Arg							
145					150											

```
<210> 63
<211> 7
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Synthetic

<400> 63

Gly Gly Gly Gly Ser Ser Ser  
1 5

```
<210> 64
<211> 4
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Synthetic

<400> 64

Ile Glu Gly Arg  
1

```
<210> 65
<211> 9
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Synthetic

<400> 65

Pro Gly Ile Ser Gly Gly Gly Gly Gly  
1 5

<210> 66  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 66

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
 1 5 10 15

<210> 67  
 <211> 13  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 67

Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Lys Glu Phe  
 1 5 10

<210> 68  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens

<400> 68

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15

Val Leu His His Ala Lys Trp Ser Gln Ala  
 20 25

<210> 69  
 <211> 33  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 69

Cys Gly Cys Gly Gly Ala Thr Cys Cys Ala Cys Cys Ala Thr Gly Ala  
 1 5 10 15

Ala Cys Thr Thr Thr Cys Thr Gly Cys Thr Gly Thr Cys Thr Thr Gly  
 20 25 30

Gly

<210> 70  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Synthetic

<400> 70

ctaaatggtt tctcttcttc cccgcctcgg cttgtcaca

39

<210> 71

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 71

tgtgacaagc ctgaggcggg aggaagagaa accatttag

39

<210> 72

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 72

cgcggtatcct caaaaatcta aaggtcga

28

<210> 73

<211> 1107

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 73

gctgcaccca tggcagaagg aggagggcag aatcatcacg aagtggtgaa gttcatggat	60
gtctatcagc gcagctactg ccatccaatc gagaccctgg tggacatctt ccaggagtac	120
cctgatgaga tcgagtacat cttcaagcca atgaactttc tgctgtcttg ggtgcattgg	180
agccttgccct tgctgctcta cctccaccat gccaaagtgg cccagtcctg tgtgcccctg	240
atgcgatgcg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc	300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg	360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa	420
aaatgtgaca agccgaggcg ggaggaagag aaaccattta gagactgtgc agatgtatat	480
caagctgggtt ttaataaaag tggaatctac actatttata ttaataatat gccagaaccc	540
aaaaaggtgt tttgcaatat ggatgtcaat gggggagggt ggactgtaat acaacatcgt	600
gaagatggaa gtctagattt ccaaagaggc tggaaggaa ataaaatggg ttttggaat	660
ccctccggtg aatattggct ggggaatgag tttatTTTTT ccattaccag tcagaggcag	720
tacatgctaa gaattgagtt aatggactgg gaagggaacc gagcctattc acagtatgac	780
agattccaca taggaaatga aaagcaaac tataggttgt atttaaaagg tcacactggg	840

acagcaggaa aacagagcag cctgatctta cacggtgctg atttcagcac taaagatgct 900  
 gataatgaca actgtatgtg caaatgtgcc ctcatgttaa caggaggatg gtggtttgat 960  
 gcttgtggcc cctccaatct aaatggaatg ttctatactg cgggacaaaa ccatggaaaa 1020  
 ctgaatggga taaagtggca ctacttcaaa gggcccagtt actccttacg ttccacaact 1080  
 atgatgattc gacctttaga tttttga 1107

<210> 74  
 <211> 368  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 74

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
 20 25 30  
 Gly Gly Gln Asn His His Glu Val Lys Phe Met Asp Val Tyr Gln  
 35 40 45  
 Arg Ser Tyr Cys His Pro ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
 50 55 60  
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys  
 130 135 140  
 Pro Arg Arg Glu Glu Glu Lys Pro Phe Arg Asp Cys Ala Asp Val Tyr  
 145 150 155 160  
 Gln Ala Gly Phe Asn Lys Ser Gly Ile Tyr Thr Ile Tyr Ile Asn Asn  
 165 170 175  
 Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn Gly Gly  
 180 185 190  
 Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp Phe Gln  
 195 200 205  
 Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser Gly Glu  
 210 215 220  
 Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln Arg Gln  
 225 230 235 240

**<220>**

&lt;223&gt; Synthetic

&lt;400&gt; 78

```

atgaactttc tgctgtcttg ggtgcattgg agccttgccct tgctgctcta cctccaccat      60
gccaaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg      120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac      180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgccctg      240
atgcatgacg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc      300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg      360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa      420
aaatgtgaca agccgaggcg gcaatttggc gcggagtgc aataccagtt ccaggcctgg      480
ggagaatgtg acctgaacac agccctgaag accagaactg gaagtctgaa gcgagccctg      540
cacaatgccg aatgccagaa gactgtcacc atctccaagc cctgtggcaa actgaccaag      600
cccaaacctc aagcagaatc taagaagaag aaaaaggaag gcaagaaaca ggagaagatg      660
ctggattaa                                     669

```

&lt;210&gt; 79

&lt;211&gt; 222

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 79

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
1              5              10              15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
                20              25              30
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
                35              40              45
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
                50              55              60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
65              70              75              80
Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
                85              90              95
Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
                100             105             110
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
                115             120             125
Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys
130             135             140

```

Pro Arg Arg Gln Phe Gly Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp  
 145 150 155 160

Gly Glu Cys Asp Leu Asn Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu  
 165 170 175

Lys Arg Ala Leu His Asn Ala Glu Cys Gln Lys Thr Val Thr Ile Ser  
 180 185 190

Lys Pro Cys Gly Lys Leu Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys  
 195 200 205

Lys Lys Lys Lys Glu Gly Lys Lys Gln Glu Lys Met Leu Asp  
 210 215 220

<210> 80

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 80

tgcagtcggc tccaaactcc cgcctcggct tgtcaca

37

<210> 81

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 81

tgtgacaagc cgaggcggga gtttgagacc gactgca

37

<210> 82

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 82

cgcggatccc tagtcctttc ccttccc

27

<210> 83

<211> 639

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 83

atgaactttc tgetgtcttg ggtgcattgg agccttgctt tgetgtcteta cctccaccat

60

gccaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg

120

gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctgggtggac

180

atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg

240



```

atgcgatgcg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc      300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg      360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa      420
aaatgtgaca agccgaggcg ggagtttgga gccgactgca agtacaagtt tgagaactgg      480
ggtgcggtg atggggggcac aggcaccaaa gtccgccaaag gcaccctgaa gaaggcgcg      540
tacaatgctc agtgccagga gaccatccgc gtcaccaagc cctgcacccc caagaccaaa      600
gcaaaggcca aagccaagaa agggaaggga aaggactag                                639

```

```

<210> 84
<211> 212
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Synthetic peptide

```

```

<400> 84

```

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
1           5           10           15

Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
          20           25           30

Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
          35           40           45

Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
          50           55           60

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
65           70           75           80

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
          85           90           95

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
          100          105          110

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
          115          120          125

Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys
          130          135          140

Pro Arg Arg Glu Phe Gly Ala Asp Cys Lys Tyr Lys Phe Glu Asn Trp
145          150          155          160

Gly Ala Cys Asp Gly Gly Thr Gly Thr Lys Val Arg Gln Gly Thr Leu
          165          170          175

Lys Lys Ala Arg Tyr Asn Ala Gln Cys Gln Glu Thr Ile Arg Val Thr
          180          185          190

Lys Pro Cys Thr Pro Lys Thr Lys Ala Lys Ala Lys Ala Lys Lys Gly
          195          200          205

```

Lys Gly Lys Asp  
210

<210> 85  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 85  
ccatgggccc gacggcttcc gcctcggctt gtcaca 36

<210> 86  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 86  
tgtgacaagc cgaggcggaa gccgtcgggc ccatgg 36

<210> 87  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 87  
cgcggatcct tagtggaagg tggtgggg 28

<210> 88  
<211> 1116  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 88  
atgaactttc tgctgtcttg ggtgcattgg agccttgctt tgctgtctta cctccaccat 60  
gccaagtggg cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg 120  
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac 180  
atcttcagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg 240  
atgcatgacg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc 300  
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg 360  
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa 420  
aaatgtgaca agccgaggcg gaagccgtcg ggcccatgga gagactgcct gcaggccctg 480  
gaggatggcc acgacaccag ctccatctac ctggtgaagc cggagaacac caaccgcctc 540  
atgcaggtgt ggtgcgacca gagacacgac cccgggggct ggaccgtcat ccagagacgc 600

ctggatggct ctgttaactt cttcaggaac tgggagacgt acaagcaagg gtttgggaaac 660  
 attgatggcg aatactggct gggcctggag aacatttact ggctgacgaa ccaaggcaac 720  
 tacaaactcc tggtgaccat ggaggactgg tccggccgca aagtctttgc agaatacgcc 780  
 agtttccgcc tggaaacctga gagcgagtat tataagctgc ggctggggcg ctaccatggc 840  
 aatgcggggtg actcctttac atggcacaac ggcaagcagt tcaccaccct ggacagagat 900  
 catgatgtct acacaggaaa ctgtgccac taccagaagg gaggctggtg gtataacgcc 960  
 tgtgccact ccaacctcaa cggggtctgg taccgcgggg gccattaccg gagccgctac 1020  
 caggacggag tctactgggc tgagttccga ggaggtctt actcactcaa gaaagtgggtg 1080  
 atgatgatcc gaccgaaccc caacaccttc cactaa 1116

<210> 89  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 89

Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser  
 1 5 10

<210> 90  
 <211> 371  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 90

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15

Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
 20 25 30

Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
 35 40 45

Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
 50 55 60

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys

115	120	125
Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys 130 135 140		
Pro Arg Arg Lys Pro Ser Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu 145 150 155 160		
Glu Asp Gly His Asp Thr Ser Ser Ile Tyr Leu Val Lys Pro Glu Asn 165 170 175		
Thr Asn Arg Leu Met Gln Val Trp Cys Asp Gln Arg His Asp Pro Gly 180 185 190		
Gly Trp Thr Val Ile Gln Arg Arg Leu Asp Gly Ser Val Asn Phe Phe 195 200 205		
Arg Asn Trp Glu Thr Tyr Lys Gln Gly Phe Gly Asn Ile Asp Gly Glu 210 215 220		
Tyr Trp Leu Gly Leu Glu Asn Ile Tyr Trp Leu Thr Asn Gln Gly Asn 225 230 235 240		
Tyr Lys Leu Leu Val Thr Met Glu Asp Trp Ser Gly Arg Lys Val Phe 245 250 255		
Ala Glu Tyr Ala Ser Phe Arg Leu Glu Pro Glu Ser Glu Tyr Tyr Lys 260 265 270		
Leu Arg Leu Gly Arg Tyr His Gly Asn Ala Gly Asp Ser Phe Thr Trp 275 280 285		
His Asn Gly Lys Gln Phe Thr Thr Leu Asp Arg Asp His Asp Val Tyr 290 295 300		
Thr Gly Asn Cys Ala His Tyr Gln Lys Gly Gly Trp Trp Tyr Asn Ala 305 310 315 320		
Cys Ala His Ser Asn Leu Asn Gly Val Trp Tyr Arg Gly Gly His Tyr 325 330 335		
Arg Ser Arg Tyr Gln Asp Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly 340 345 350		
Ser Tyr Ser Leu Lys Lys Val Val Met Met Ile Arg Pro Asn Pro Asn 355 360 365		
Thr Phe His 370		

<210> 91  
 <211> 36  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <400> 91  
 gaatggtcct tcattgatcc gcctcggctt gtcaca

36

<210> 92  
 <211> 36  
 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 92

tgtgacaagc cgaggcggat caatgaagga ccattc

36

<210> 93

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 93

cgcggtatcct cagtcaatag gcttgatca

29

<210> 94

<211> 1104

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 94

atgaactttc tgctgtcttg ggtgcattgg agccttgccct tgctgctcta cctccaccat	60
gccaagtggc cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg	120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctgggtggac	180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg	240
atgcatgctg ggggctgctg caatgacgag ggccctggagt gtgtgcccac tgaggagtcc	300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg	360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa	420
aaatgtgaca agccgaggcg gatcaatgaa ggaccattca aagactgtca gcaagcaaaa	480
gaagctgggc attcggtcag tgggatttat atgattaaac ctgaaaacag caatggacca	540
atgcagttat ggtgtgaaaa cagtttggac cctggggggt ggactgttat tcagaaaaga	600
acagacggct ctgtcaactt cttcagaaat tgggaaaatt ataagaaagg gtttggaaac	660
attgacggag aatactggct tggactggaa aatatctata tgcttagcaa tcaagataat	720
tacaagttat tgattgaatt agaagactgg agtgataaaa aagtctatgc agaatacagc	780
agctttcgtc tggaacctga aagtgaattc tatagactgc gcctgggaac ttaccaggga	840
aatgcagggg attctatgat gtggcataat ggtaaacaaat tcaccacact ggacagagat	900
aaagatatgt atgcaggaaa ctgcgcccac tttcataaag gaggctgggt gtacaatgcc	960
tgtgcacatt ctaacctaaa tggagtatgg tacagaggag gccattacag aagcaagcac	1020
caagatggaa ttttctgggc cgaatacaga ggcgggtcat actccttaag agcagttcag	1080

atgatgatca agcctattga ctga

1104

&lt;210&gt; 95

&lt;211&gt; 367

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 95

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
1           5           10           15

Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
           20           25           30

Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
           35           40           45

Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
           50           55           60

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
           65           70           75           80

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
           85           90           95

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
           100          105          110

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
           115          120          125

Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys
           130          135          140

Pro Arg Arg Ile Asn Glu Gly Pro Phe Lys Asp Cys Gln Gln Ala Lys
           145          150          155          160

Glu Ala Gly His Ser Val Ser Gly Ile Tyr Met Ile Lys Pro Glu Asn
           165          170          175

Ser Asn Gly Pro Met Gln Leu Trp Cys Glu Asn Ser Leu Asp Pro Gly
           180          185          190

Gly Trp Thr Val Ile Gln Lys Arg Thr Asp Gly Ser Val Asn Phe Phe
           195          200          205

Arg Asn Trp Glu Asn Tyr Lys Lys Gly Phe Gly Asn Ile Asp Gly Glu
           210          215          220

Tyr Trp Leu Gly Leu Glu Asn Ile Tyr Met Leu Ser Asn Gln Asp Asn
           225          230          235          240

Tyr Lys Leu Leu Ile Glu Leu Glu Asp Trp Ser Asp Lys Lys Val Tyr
           245          250          255

Ala Glu Tyr Ser Ser Phe Arg Leu Glu Pro Glu Ser Glu Phe Tyr Arg
           260          265          270

Leu Arg Leu Gly Thr Tyr Gln Gly Asn Ala Gly Asp Ser Met Met Trp

```

275	280	285
His Asn Gly Lys Gln Phe Thr Thr Leu Asp Arg Asp Lys Asp Met Tyr		
290	295	300
Ala Gly Asn Cys Ala His Phe His Lys Gly Gly Trp Trp Tyr Asn Ala		
305	310	315
Cys Ala His Ser Asn Leu Asn Gly Val Trp Tyr Arg Gly Gly His Tyr		
325	330	335
Arg Ser Lys His Gln Asp Gly Ile Phe Trp Ala Glu Tyr Arg Gly Gly		
340	345	350
Ser Tyr Ser Leu Arg Ala Val Gln Met Met Ile Lys Pro Ile Asp		
355	360	365

<210> 96  
 <211> 1387  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Synthetic  
  
 <220>  
 <221> misc\_feature  
 <222> (1201)..(1219)  
 <223> "n" may be any nucleotide  
  
 <220>  
 <221> misc\_feature  
 <222> (1254)..(1254)  
 <223> "n" may be any nucleotide  
  
 <220>  
 <221> misc\_feature  
 <222> (1257)..(1257)  
 <223> "n" may be any nucleotide  
  
 <220>  
 <221> misc\_feature  
 <222> (1290)..(1290)  
 <223> "n" may be any nucleotide  
  
 <220>  
 <221> misc\_feature  
 <222> (1295)..(1324)  
 <223> "n" may be any nucleotide

<400> 96	
atgtggcaga ttgttttctt tactctgagc tgtgatcttg tcttgccgc agcctataac	60
aactttcggga agagcatgga cagcatagga aagaagcaat atcaggtcca gcatgggtcc	120
tgcagctaca ctttcctcct gccagagatg gacaactgcc gctcttcctc cagcccctac	180
gtgtccaatg ctgtgcagag ggacgcgccg ctggaatacg atgactcggt gcagaggctg	240
caagtgctgg agaacatcat ggaaaacaac actcagtggc taatgaaggt agagaatata	300
tcccaggaca acatgaagaa agaaatggta gagatacagc agaatgcagt acagaaccag	360
acggctgtga tgatagaaat agggacaaac ctgttgaacc aaacagcgga gcaaacgcgg	420

```

aagttaactg atgtggaagc ccaagtatta aatcagacca cgagacttga acttcagctc      480
ttggaacact ccctctcgac aaacaaattg gaaaaacaga ttttggacca gaccagtgaa      540
ataaacaaat tgcaagataa gaacagtttc ctagaaaaga aggtgctagc tatggaagac      600
aagcacatca tccaactaca gtcaataaaa gaagagaaaag atcagctaca ggtgttagta      660
tccaagcaga attccatcat tgaagaactc gaaaaaaaaa tagtgactgc cacgggtgaat      720
aattcagttc ttcagaagca gcaacatgat ctcatggaga cagttaataa cttactgact      780
atgatgtcca catcaaagc agctaaggac cccactggtg ctaaagaaga acaaatacagc      840
ttcagagact gtgctgaagt attcaaatca ggacacacca cgaatggcat ctacacgtta      900
acattcccta attctacaga agagatcaag gcctactgtg acatggaagc tggaggaggc      960
gggtggacaa ttattcagcg acgtgaggat ggcagcgttg catttcagag gacttggaaa     1020
gaatataaag tgggatttgg taacctctca gaaaaatatt ggctgggaaa tgagtttgtt     1080
tcgcaactga ctaatcagca acgctatgtg cttaaatac accttaaaga ctgggaaggg     1140
aatgaggctt actcattgta tgaacatttc tatctctcaa gtgaagaact caattatagg     1200
nnnnnnnnnn nnnnnnnnng gcaatgattt tagcacaagg gatggagcca ccgncanatg     1260
tatttgcaaa tggtcacaaa tgctaacagn aggtnnnnnn nnnnnnnnnn nnnnnnnnnn     1320
nnnntactgg aaaggctcag gctattcgct caaggccaca accatgatga tccgaccagc     1380
agatttc                                             1387

```

<210> 97  
 <211> 360  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<220>  
 <221> MISC\_FEATURE  
 <222> (269)..(272)  
 <223> "Xaa" may be any nucleotide

<400> 97

```

Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala
1              5              10              15
Ala Ala Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys
20              25              30
Gln Tyr Gln Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro
35              40              45
Glu Met Asp Asn Cys Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala
50              55              60
Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu
65              70              75              80

```



Gln Val Leu Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys  
                                     85                                    90                                    95  
 Leu Glu Asn Ile Ser Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile  
                                     100                                    105                                    110  
 Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly  
                                     115                                    120                                    125  
 Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp  
                                     130                                    135                                    140  
 Val Glu Ala Gln Val Ser Asn Ala Thr Thr Arg Leu Glu Leu Gln Leu  
                                     145                                    150                                    155                                    160  
 Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp  
                                     165                                    170                                    175  
 Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu  
                                     180                                    185                                    190  
 Lys Lys Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser  
                                     195                                    200                                    205  
 Ile Lys Glu Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn  
                                     210                                    215                                    220  
 Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn  
                                     225                                    230                                    235                                    240  
 Asn Ser Val Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn  
                                     245                                    250                                    255  
 Asn Leu Leu Thr Met Met Ser Thr Ser Asn Cys Lys Xaa Xaa Xaa Xaa  
                                     260                                    265                                    270  
 Val Ala Lys Glu Glu Gln Ile Ser Phe Arg Asp Cys Ala Glu Val Phe  
                                     275                                    280                                    285  
 Lys Ser Gly His Thr Thr Asn Gly Ile Tyr Thr Leu Met Trp Gln Ile  
                                     290                                    295                                    300  
 Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala Ala Ala Tyr Asn  
                                     305                                    310                                    315                                    320  
 Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys Gln Tyr Gln Val  
                                     325                                    330                                    335  
 Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro Glu Met Asp Asn  
                                     340                                    345                                    350  
 Cys Arg Ser Ser Ser Ser Pro Tyr  
                                     355                                    360

<210> 98  
 <211> 339  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 98

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
 20 25 30  
 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
 35 40 45  
 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
 50 55 60  
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys  
 130 135 140  
 Pro Arg Arg Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val  
 145 150 155 160  
 Asn Gly Gly Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu  
 165 170 175  
 Asp Phe Gln Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro  
 180 185 190  
 Ser Gly Glu Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser  
 195 200 205  
 Gln Arg Gln Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu Gly Asn  
 210 215 220  
 Arg Ala Tyr Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu Lys Gln  
 225 230 235 240  
 Asn Tyr Arg Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly Lys Gln  
 245 250 255  
 Ser Ser Leu Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp  
 260 265 270  
 Asn Asp Asn Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly Gly Trp  
 275 280 285  
 Trp Phe Asp Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr  
 290 295 300  
 Ala Gly Gln Asn His Gly Lys Leu Asn Gly Ile Lys Trp His Tyr Phe  
 305 310 315 320  
 Lys Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro  
 325 330 335

Leu Asp Phe

<210> 99  
 <211> 361  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 99  
 gtccaatgct gtgcagaggg acgcgccgct cgaatacgat gactcgggtgc agaggctgca 60  
 agtgctggag aacatcatgg aaaacaacac tcagtggcta atgaaggtag agaatatatc 120  
 ccaggacaac atgaagaaag aaatggtaga gatacagcag aatgcagtac agaaccagac 180  
 ggctgtgatg atagaaatag ggacaaacct gttgaaccaa acagcggagc aaacgcggaa 240  
 gttaactgat gtggaagccc aagtattaaa tcagaccacg agacttgaac ttcagctctt 300  
 ggaacactcc ctctcgacaa acaaattgga aaaacagatt ttggaccaga ccagtgaat 360  
 a 361

<210> 100  
 <211> 123  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 100

Val	Ser	Asn	Ala	Val	Gln	Arg	Asp	Ala	Pro	Leu	Glu	Tyr	Asp	Asp	Ser
1				5					10					15	
Val	Gln	Arg	Leu	Gln	Val	Leu	Glu	Asn	Ile	Met	Glu	Asn	Asn	Thr	Gln
			20					25					30		
Trp	Leu	Met	Lys	Leu	Glu	Asn	Ile	Ser	Gln	Asp	Asn	Met	Lys	Lys	Glu
		35				40						45			
Met	Val	Glu	Ile	Gln	Gln	Asn	Ala	Val	Gln	Asn	Gln	Thr	Ala	Val	Met
	50					55					60				
Ile	Glu	Ile	Gly	Thr	Asn	Leu	Leu	Asn	Gln	Thr	Ala	Glu	Gln	Thr	Arg
65				70					75					80	
Lys	Leu	Thr	Asp	Val	Glu	Ala	Gln	Val	Ser	Asn	Ala	Thr	Thr	Arg	Leu
				85					90					95	
Glu	Leu	Gln	Leu	Leu	Glu	His	Ser	Leu	Ser	Thr	Asn	Lys	Leu	Glu	Lys
		100						105					110		
Gln	Ile	Leu	Asp	Gln	Thr	Ser	Glu	Ile	Asn	Lys					
		115					120								

<210> 101  
 <211> 472  
 <212> PRT  
 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 101

Val Ser Asn Ala Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp Asp Ser  
 1 5 10 15  
 Val Gln Arg Leu Gln Val Leu Glu Asn Ile Met Glu Asn Asn Thr Gln  
 20 25 30  
 Trp Leu Met Lys Leu Glu Asn Ile Ser Gln Asp Asn Met Lys Lys Glu  
 35 40 45  
 Met Val Glu Ile Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val Met  
 50 55 60  
 Ile Glu Ile Gly Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg  
 65 70 75 80  
 Lys Leu Thr Asp Val Glu Ala Gln Val Ser Asn Ala Thr Thr Arg Leu  
 85 90 95  
 Glu Leu Gln Leu Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys  
 100 105 110  
 Gln Ile Leu Asp Gln Thr Ser Glu Ile Asn Lys Met Asn Phe Leu Leu  
 115 120 125  
 Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu Tyr Leu His His Ala  
 130 135 140  
 Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His  
 145 150 155 160  
 His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His  
 165 170 175  
 Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile  
 180 185 190  
 Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly  
 195 200 205  
 Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn  
 210 215 220  
 Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile  
 225 230 235 240  
 Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys  
 245 250 255  
 Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys Pro Arg Arg Gly Ser  
 260 265 270  
 Gly Ser Gly Ser Gly Ser Gly Ser Met Pro Glu Pro Lys Lys Val Phe  
 275 280 285  
 Cys Asn Met Asp Val Asn Gly Gly Gly Trp Thr Val Ile Gln His Arg  
 290 295 300  
 Glu Asp Gly Ser Leu Asp Phe Gln Arg Gly Trp Lys Glu Tyr Lys Met  
 305 310 315 320

Gly Phe Gly Asn Pro Ser Gly Glu Tyr Trp Leu Gly Asn Glu Phe Ile  
 325 330 335  
 Phe Ala Ile Thr Ser Gln Arg Gln Tyr Met Leu Arg Ile Glu Leu Met  
 340 345 350  
 Asp Trp Glu Gly Asn Arg Ala Tyr Ser Gln Tyr Asp Arg Phe His Ile  
 355 360 365  
 Gly Asn Glu Lys Gln Asn Tyr Arg Leu Tyr Leu Lys Gly His Thr Gly  
 370 375 380  
 Thr Ala Gly Lys Gln Ser Ser Leu Ile Leu His Gly Ala Asp Phe Ser  
 385 390 395 400  
 Thr Lys Asp Ala Asp Asn Asp Asn Cys Met Cys Lys Cys Ala Leu Met  
 405 410 415  
 Leu Thr Gly Gly Trp Trp Phe Asp Ala Cys Gly Pro Ser Asn Leu Asn  
 420 425 430  
 Gly Met Phe Tyr Thr Ala Gly Gln Asn His Gly Lys Leu Asn Gly Ile  
 435 440 445  
 Lys Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr  
 450 455 460  
 Met Met Ile Arg Pro Leu Asp Phe  
 465 470  
 <210> 102  
 <211> 224  
 <212> PRT  
 <213> Homo sapiens  
 <400> 102  
 Lys Pro Ser Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu Glu Asp Gly  
 1 5 10 15  
 His Asp Thr Ser Ser Ile Tyr Leu Val Lys Pro Glu Asn Thr Asn Arg  
 20 25 30  
 Leu Met Gln Val Trp Cys Asp Gln Arg His Asp Pro Gly Gly Trp Thr  
 35 40 45  
 Val Ile Gln Arg Arg Leu Asp Gly Ser Val Asn Phe Phe Arg Asn Trp  
 50 55 60  
 Glu Thr Tyr Lys Gln Gly Phe Gly Asn Ile Asp Gly Glu Tyr Trp Leu  
 65 70 75 80  
 Gly Leu Glu Asn Ile Tyr Trp Leu Thr Asn Gln Gly Asn Tyr Lys Leu  
 85 90 95  
 Leu Val Thr Met Glu Asp Trp Ser Gly Arg Lys Val Phe Ala Glu Tyr  
 100 105 110  
 Ala Ser Phe Arg Leu Glu Pro Glu Ser Glu Tyr Tyr Lys Leu Arg Leu  
 115 120 125  
 Gly Arg Tyr His Gly Asn Ala Gly Asp Ser Phe Thr Trp His Asn Gly  
 130 135 140

Lys Gln Phe Thr Thr Leu Asp Arg Asp His Asp Val Tyr Thr Gly Asn  
 145 150 155 160  
 Cys Ala His Tyr Gln Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His  
 165 170 175  
 Ser Asn Leu Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg  
 180 185 190  
 Tyr Gln Asp Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser  
 195 200 205  
 Leu Lys Lys Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His  
 210 215 220  
 <210> 103  
 <211> 220  
 <212> PRT  
 <213> Homo sapiens  
 <400> 103  
 Ile Asn Glu Gly Pro Phe Lys Asp Cys Gln Gln Ala Lys Glu Ala Gly  
 1 5 10 15  
 His Ser Val Ser Gly Ile Tyr Met Ile Lys Pro Glu Asn Ser Asn Gly  
 20 25 30  
 Pro Met Gln Leu Trp Cys Glu Asn Ser Leu Asp Pro Gly Gly Trp Thr  
 35 40 45  
 Val Ile Gln Lys Arg Thr Asp Gly Ser Val Asn Phe Phe Arg Asn Trp  
 50 55 60  
 Glu Asn Tyr Lys Lys Gly Phe Gly Asn Ile Asp Gly Glu Tyr Trp Leu  
 65 70 75 80  
 Gly Leu Glu Asn Ile Tyr Met Leu Ser Asn Gln Asp Asn Tyr Lys Leu  
 85 90 95  
 Leu Ile Glu Leu Glu Asp Trp Ser Asp Lys Lys Val Tyr Ala Glu Tyr  
 100 105 110  
 Ser Ser Phe Arg Leu Glu Pro Glu Ser Glu Phe Tyr Arg Leu Arg Leu  
 115 120 125  
 Gly Thr Tyr Gln Gly Asn Ala Gly Asp Ser Met Met Trp His Asn Gly  
 130 135 140  
 Lys Gln Phe Thr Thr Leu Asp Arg Asp Lys Asp Met Tyr Ala Gly Asn  
 145 150 155 160  
 Cys Ala His Phe His Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His  
 165 170 175  
 Ser Asn Leu Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Lys  
 180 185 190  
 His Gln Asp Gly Ile Phe Trp Ala Glu Tyr Arg Gly Gly Ser Tyr Ser  
 195 200 205  
 Leu Arg Ala Val Gln Met Met Ile Lys Pro Ile Asp  
 210 215 220

<210> 104  
 <211> 381  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 104

Met	Asn	Phe	Leu	Leu	Ser	Trp	Val	His	Trp	Ser	Leu	Ala	Leu	Leu	Leu	1	5	10	15
Tyr	Leu	His	His	Ala	Lys	Trp	Ser	Gln	Ala	Ala	Pro	Met	Ala	Glu	Gly	20	25	30	
Gly	Gly	Gln	Asn	His	His	Glu	Val	Val	Lys	Phe	Met	Asp	Val	Tyr	Gln	35	40	45	
Arg	Ser	Tyr	Cys	His	Pro	Ile	Glu	Thr	Leu	Val	Asp	Ile	Phe	Gln	Glu	50	55	60	
Tyr	Pro	Asp	Glu	Ile	Glu	Tyr	Ile	Phe	Lys	Pro	Ser	Cys	Val	Pro	Leu	65	70	75	80
Met	Arg	Cys	Gly	Gly	Cys	Cys	Asn	Asp	Glu	Gly	Leu	Glu	Cys	Val	Pro	85	90	95	
Thr	Glu	Glu	Ser	Asn	Ile	Thr	Met	Gln	Ile	Met	Arg	Ile	Lys	Pro	His	100	105	110	
Gln	Gly	Gln	His	Ile	Gly	Glu	Met	Ser	Phe	Leu	Gln	His	Asn	Lys	Cys	115	120	125	
Glu	Cys	Arg	Pro	Lys	Lys	Asp	Arg	Ala	Arg	Gln	Glu	Lys	Cys	Asp	Lys	130	135	140	
Pro	Arg	Arg	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Gly	Ser	Lys	Pro	Ser	145	150	155	160
Gly	Pro	Trp	Arg	Asp	Cys	Leu	Gln	Ala	Leu	Glu	Asp	Gly	His	Asp	Thr	165	170	175	
Ser	Ser	Ile	Tyr	Leu	Val	Lys	Pro	Glu	Asn	Thr	Asn	Arg	Leu	Met	Gln	180	185	190	
Val	Trp	Cys	Asp	Gln	Arg	His	Asp	Pro	Gly	Gly	Trp	Thr	Val	Ile	Gln	195	200	205	
Arg	Arg	Leu	Asp	Gly	Ser	Val	Asn	Phe	Phe	Arg	Asn	Trp	Glu	Thr	Tyr	210	215	220	
Lys	Gln	Gly	Phe	Gly	Asn	Ile	Asp	Gly	Glu	Tyr	Trp	Leu	Gly	Leu	Glu	225	230	235	240
Asn	Ile	Tyr	Trp	Leu	Thr	Asn	Gln	Gly	Asn	Tyr	Lys	Leu	Leu	Val	Thr	245	250	255	
Met	Glu	Asp	Trp	Ser	Gly	Arg	Lys	Val	Phe	Ala	Glu	Tyr	Ala	Ser	Phe	260	265	270	
Arg	Leu	Glu	Pro	Glu	Ser	Glu	Tyr	Tyr	Lys	Leu	Arg	Leu	Gly	Arg	Tyr	275	280	285	

His Gly Asn Ala Gly Asp Ser Phe Thr Trp His Asn Gly Lys Gln Phe  
 290 295 300  
 Thr Thr Leu Asp Arg Asp His Asp Val Tyr Thr Gly Asn Cys Ala His  
 305 310 315 320  
 Tyr Gln Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His Ser Asn Leu  
 325 330 335  
 Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg Tyr Gln Asp  
 340 345 350  
 Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser Leu Lys Lys  
 355 360 365  
 Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His  
 370 375 380

<210> 105  
 <211> 377  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 105

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
 20 25 30  
 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
 35 40 45  
 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
 50 55 60  
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys  
 130 135 140  
 Pro Arg Arg Gly Ser Gly Ser Gly Ser Gly Ser Ile Asn Glu  
 145 150 155 160  
 Gly Pro Phe Lys Asp Cys Gln Gln Ala Lys Glu Ala Gly His Ser Val  
 165 170 175  
 Ser Gly Ile Tyr Met Ile Lys Pro Glu Asn Ser Asn Gly Pro Met Gln  
 180 185 190



Leu Trp Cys Glu Asn Ser Leu Asp Pro Gly Gly Trp Thr Val Ile Gln  
 195 200 205  
 Lys Arg Thr Asp Gly Ser Val Asn Phe Phe Arg Asn Trp Glu Asn Tyr  
 210 215 220  
 Lys Lys Gly Phe Gly Asn Ile Asp Gly Glu Tyr Trp Leu Gly Leu Glu  
 225 230 235 240  
 Asn Ile Tyr Met Leu Ser Asn Gln Asp Asn Tyr Lys Leu Leu Ile Glu  
 245 250 255  
 Leu Glu Asp Trp Ser Asp Lys Lys Val Tyr Ala Glu Tyr Ser Ser Phe  
 260 265 270  
 Arg Leu Glu Pro Glu Ser Glu Phe Tyr Arg Leu Arg Leu Gly Thr Tyr  
 275 280 285  
 Gln Gly Asn Ala Gly Asp Ser Met Met Trp His Asn Gly Lys Gln Phe  
 290 295 300  
 Thr Thr Leu Asp Arg Asp Lys Asp Met Tyr Ala Gly Asn Cys Ala His  
 305 310 315 320  
 Phe His Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His Ser Asn Leu  
 325 330 335  
 Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Lys His Gln Asp  
 340 345 350  
 Gly Ile Phe Trp Ala Glu Tyr Arg Gly Gly Ser Tyr Ser Leu Arg Ala  
 355 360 365  
 Val Gln Met Met Ile Lys Pro Ile Asp  
 370 375

<210> 106  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens

<400> 106

Arg Glu Ser Thr Thr Asp Gln Tyr Asn Thr Asn Ala Leu Gln Arg Asp  
 1 5 10 15  
 Ala Pro His Val Glu Pro Asp Phe Ser Ser Gln Lys Leu Gln His Leu  
 20 25 30  
 Glu His Val Met Glu Asn Tyr Thr Gln Trp Leu Gln Lys Leu Glu Asn  
 35 40 45  
 Tyr Ile Val Glu Asn Met Lys Ser Glu Met Ala Gln Ile Gln Gln Asn  
 50 55 60  
 Ala Val Gln Asn His Thr Ala Thr Met Leu Glu Ile Gly Thr Ser Leu  
 65 70 75 80  
 Leu Ser Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp Val Glu Thr  
 85 90 95  
 Gln Val Leu Asn Gln Thr Ser Arg Leu Glu Ile Gln Leu Leu Glu Asn  
 100 105 110

Ser Leu Ser Thr Tyr Lys Leu Glu Lys Gln Leu Leu Gln Gln Thr Asn  
 115 120 125  
 Glu Ile Leu Lys Ile His Glu Lys Asn Ser Leu Leu Glu His Lys Ile  
 130 135 140  
 Leu Glu Met Glu Gly Lys His Lys Glu Glu Leu Asp Thr Leu Lys Glu  
 145 150 155 160  
 Glu Lys Glu Asn Leu Gln Gly Leu Val Thr Arg Gln Thr Tyr Ile Ile  
 165 170 175  
 Gln Gln Leu Glu Lys Gln Leu Asn Arg Ala Thr Thr Asn Asn Ser Val  
 180 185 190  
 Leu Gln Lys Gln Gln Leu Glu Leu Met Asp Thr Val His Asn  
 195 200 205

<210> 107  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens

<400> 107

Cys Asp Leu Val Leu Ala Ala Ala Tyr Asn Asn Phe Arg Lys Ser Met  
 1 5 10 15  
 Asp Ser Ile Gly Lys Lys Gln Tyr Gln Val Gln His Gly Ser Cys Ser  
 20 25 30  
 Tyr Thr Phe Leu Leu Pro Glu Met Asp Asn Cys Arg Ser Ser Ser  
 35 40 45  
 Pro Tyr Val Ser Asn Ala Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp  
 50 55 60  
 Asp Ser Val Gln Arg Leu Gln Val Leu Glu Asn Ile Met Glu Asn Asn  
 65 70 75 80  
 Thr Gln Trp Leu Met Lys Leu Glu Asn Tyr Ile Gln Asp Asn Met Lys  
 85 90 95  
 Lys Glu Met Val Glu Ile Gln Gln Asn Ala Val Gln Asn Gln Thr Ala  
 100 105 110  
 Val Met Ile Glu Ile Gly Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln  
 115 120 125

<210> 108  
 <211> 127  
 <212> PRT  
 <213> Homo sapiens

<400> 108

Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp  
 1 5 10 15  
 Val Glu Ala Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu  
 20 25 30  
 Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp

35 40 45  
 Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu  
 50 55 60  
 Lys Lys Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser  
 65 70 75 80  
 Ile Lys Glu Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn  
 85 90 95  
 Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn  
 100 105 110  
 Asn Ser Val Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val  
 115 120 125  
 <210> 109  
 <211> 196  
 <212> PRT  
 <213> Homo sapiens  
 <400> 109  
 Pro Tyr Val Ser Asn Ala Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp  
 1 5 10 15  
 Asp Ser Val Gln Arg Leu Gln Val Leu Glu Asn Ile Met Glu Asn Asn  
 20 25 30  
 Thr Gln Trp Leu Met Lys Leu Glu Asn Tyr Ile Gln Asp Asn Met Lys  
 35 40 45  
 Lys Glu Met Val Glu Ile Gln Gln Asn Ala Val Gln Asn Gln Thr Ala  
 50 55 60  
 Val Met Ile Glu Ile Gly Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln  
 65 70 75 80  
 Thr Arg Lys Leu Thr Asp Val Glu Ala Gln Val Leu Asn Gln Thr Thr  
 85 90 95  
 Arg Leu Glu Leu Gln Leu Leu Glu His Ser Leu Ser Thr Asn Lys Leu  
 100 105 110  
 Glu Lys Gln Ile Leu Asp Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp  
 115 120 125  
 Lys Asn Ser Phe Leu Glu Lys Lys Val Leu Ala Met Glu Asp Lys His  
 130 135 140  
 Ile Ile Gln Leu Gln Ser Ile Lys Glu Glu Lys Asp Gln Leu Gln Val  
 145 150 155 160  
 Leu Val Ser Lys Gln Asn Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile  
 165 170 175  
 Val Thr Ala Thr Val Asn Asn Ser Val Leu Gln Lys Gln Gln His Asp  
 180 185 190  
 Leu Met Glu Thr  
 195  
 <210> 110

<211> 105  
 <212> PRT  
 <213> Homo sapiens

<400> 110

```

His Gly Leu Leu Gln Leu Gly Gln Gly Leu Arg Glu His Ala Glu Arg
1          5          10          15
Thr Arg Ser Gln Leu Ser Ala Leu Glu Arg Arg Leu Ser Ala Cys Gly
          20          25          30
Ser Ala Cys Gln Gly Thr Glu Gly Ser Thr Asp Leu Pro Leu Ala Pro
          35          40          45
Glu Ser Arg Val Asp Pro Glu Val Leu His Ser Leu Gln Thr Gln Leu
          50          55          60
Lys Ala Gln Asn Ser Arg Ile Gln Gln Leu Phe His Lys Val Ala Gln
65          70          75          80
Gln Gln Arg His Leu Glu Lys Gln His Leu Arg Ile Gln His Leu Gln
          85          90          95
Ser Gln Phe Gly Leu Leu Asp His Lys
          100          105

```

<210> 111  
 <211> 192  
 <212> PRT  
 <213> Homo sapiens

<400> 111

```

Gly Pro Ile Cys Val Asn Thr Lys Gly Gln Asp Ala Ser Thr Ile Lys
1          5          10          15
Asp Met Ile Thr Arg Met Asp Leu Glu Asn Leu Lys Asp Val Leu Ser
          20          25          30
Arg Gln Lys Arg Glu Ile Asp Val Leu Gln Leu Val Val Asp Val Asp
          35          40          45
Gly Asn Ile Val Asn Glu Val Lys Leu Leu Arg Lys Glu Ser Arg Asn
          50          55          60
Met Asn Ser Arg Val Thr Gln Leu Tyr Met Gln Leu Leu His Glu Ile
65          70          75          80
Ile Arg Lys Arg Asp Asn Ser Leu Glu Leu Ser Gln Leu Glu Asn Lys
          85          90          95
Ile Leu Asn Val Thr Thr Glu Met Leu Lys Met Ala Thr Arg Tyr Arg
          100          105          110
Glu Leu Glu Val Lys Tyr Ala Ser Leu Thr Asp Leu Val Asn Asn Gln
          115          120          125
Ser Val Met Ile Thr Leu Leu Glu Glu Gln Cys Leu Arg Ile Phe Ser
          130          135          140
Arg Gln Asp Thr His Val Ser Pro Pro Leu Val Gln Val Val Pro Gln
145          150          155          160

```

His Ile Pro Asn Ser Gln Gln Tyr Thr Pro Gly Leu Leu Gly Gly Asn  
 165 170 175

Glu Ile Gln Arg Asp Pro Gly Tyr Pro Arg Asp Leu Met Pro Pro Pro  
 180 185 190

<210> 112  
 <211> 135  
 <212> PRT  
 <213> Homo sapiens

<400> 112

Asp Ala Ser Thr Ile Lys Asp Met Ile Thr Arg Met Asp Leu Glu Asn  
 1 5 10 15

Leu Lys Asp Val Leu Ser Arg Gln Lys Arg Glu Ile Asp Val Leu Gln  
 20 25 30

Leu Val Val Asp Val Asp Gly Asn Ile Val Asn Glu Val Lys Leu Leu  
 35 40 45

Arg Lys Glu Ser Arg Asn Met Asn Ser Arg Val Thr Gln Leu Tyr Met  
 50 55 60

Gln Leu Leu His Glu Ile Ile Arg Lys Arg Asp Asn Ser Leu Glu Leu  
 65 70 75 80

Ser Gln Leu Glu Asn Lys Ile Leu Asn Val Thr Thr Glu Met Leu Lys  
 85 90 95

Met Ala Thr Arg Tyr Arg Glu Leu Glu Val Lys Tyr Ala Ser Leu Thr  
 100 105 110

Asp Leu Val Asn Asn Gln Ser Val Met Ile Thr Leu Leu Glu Glu Gln  
 115 120 125

Cys Leu Arg Ile Phe Ser Arg  
 130 135

<210> 113  
 <211> 101  
 <212> PRT  
 <213> Homo sapiens

<400> 113

Glu Leu Glu Leu Leu Asn Asn Glu Leu Leu Lys Gln Lys Arg Gln Ile  
 1 5 10 15

Glu Thr Leu Gln Gln Leu Val Glu Val Asp Gly Gly Ile Val Ser Glu  
 20 25 30

Val Lys Leu Leu Arg Lys Glu Ser Arg Asn Met Asn Ser Arg Val Thr  
 35 40 45

Gln Leu Tyr Met Gln Leu Leu His Glu Ile Ile Arg Lys Arg Asp Asn  
 50 55 60

Ala Leu Glu Leu Ser Gln Leu Glu Asn Arg Ile Leu Asn Gln Thr Ala  
 65 70 75 80

Asp Met Leu Gln Leu Ala Ser Lys Tyr Lys Asp Leu Glu His Lys Tyr  
 85 90 95

Gln His Leu Ala Thr  
100

<210> 114  
<211> 493  
<212> PRT  
<213> Homo sapiens

<400> 114

Met Arg Pro Leu Cys Val Thr Cys Trp Trp Leu Gly Leu Leu Ala Ala  
1 5 10 15

Met Gly Ala Val Ala Gly Gln Glu Asp Gly Phe Glu Gly Thr Glu Glu  
20 25 30

Gly Ser Pro Arg Glu Phe Ile Tyr Leu Asn Arg Tyr Lys Arg Ala Gly  
35 40 45

Glu Ser Gln Asp Lys Cys Thr Tyr Thr Phe Ile Val Pro Gln Gln Arg  
50 55 60

Val Thr Gly Ala Ile Cys Val Asn Ser Lys Glu Pro Glu Val Leu Leu  
65 70 75 80

Glu Asn Arg Val His Lys Gln Glu Leu Glu Leu Leu Asn Asn Glu Leu  
85 90 95

Leu Lys Gln Lys Arg Gln Ile Glu Thr Leu Gln Gln Leu Val Glu Val  
100 105 110

Asp Gly Gly Ile Val Ser Glu Val Lys Leu Leu Arg Lys Glu Ser Arg  
115 120 125

Asn Met Asn Ser Arg Val Thr Gln Leu Tyr Met Gln Leu Leu His Glu  
130 135 140

Ile Ile Arg Lys Arg Asp Asn Ala Leu Glu Leu Ser Gln Leu Glu Asn  
145 150 155 160

Arg Ile Leu Asn Gln Thr Ala Asp Met Leu Gln Leu Ala Ser Lys Tyr  
165 170 175

Lys Asp Leu Glu His Lys Tyr Gln His Leu Ala Thr Leu Ala His Asn  
180 185 190

Gln Ser Glu Ile Ile Ala Gln Leu Glu Glu His Cys Gln Arg Val Pro  
195 200 205

Ser Ala Arg Pro Val Pro Gln Pro Pro Pro Ala Ala Pro Pro Arg Val  
210 215 220

Tyr Gln Pro Pro Thr Tyr Asn Arg Ile Ile Asn Gln Ile Ser Thr Asn  
225 230 235 240

Glu Ile Gln Ser Asp Gln Asn Leu Lys Val Leu Pro Pro Pro Leu Pro  
245 250 255

Thr Met Pro Thr Leu Thr Ser Leu Pro Ser Ser Thr Asp Lys Pro Ser  
260 265 270

Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu Glu Asp Gly His Asp Thr  
275 280 285

Ser Ser Ile Tyr Leu Val Lys Pro Glu Asn Thr Asn Arg Leu Met Gln  
 290 295 300  
 Val Trp Cys Asp Gln Arg His Asp Pro Gly Gly Trp Thr Val Ile Gln  
 305 310 315 320  
 Arg Arg Leu Asp Gly Ser Val Asn Phe Phe Arg Asn Trp Glu Thr Tyr  
 325 330 335  
 Lys Gln Gly Phe Gly Asn Ile Asp Gly Glu Tyr Trp Leu Gly Leu Glu  
 340 345 350  
 Asn Ile Tyr Trp Leu Thr Asn Gln Gly Asn Tyr Lys Leu Leu Val Thr  
 355 360 365  
 Met Glu Asp Trp Ser Gly Arg Lys Val Phe Ala Glu Tyr Ala Ser Phe  
 370 375 380  
 Arg Leu Glu Pro Glu Ser Glu Tyr Tyr Lys Leu Arg Leu Gly Arg Tyr  
 385 390 395 400  
 His Gly Asn Ala Gly Asp Ser Phe Thr Trp His Asn Gly Lys Gln Phe  
 405 410 415  
 Thr Thr Leu Asp Arg Asp His Asp Val Tyr Thr Gly Asn Cys Ala His  
 420 425 430  
 Tyr Gln Lys Gly Gly Trp Trp Tyr Asn Ala Cys Ala His Ser Asn Leu  
 435 440 445  
 Asn Gly Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg Tyr Gln Asp  
 450 455 460  
 Gly Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser Leu Lys Lys  
 465 470 475 480  
 Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His  
 485 490

<210> 115  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<400> 115

Thr Asn Lys Leu Glu Arg Gln Met Leu Met Gln Ser Arg Glu Leu Gln  
 1 5 10 15  
 Arg Leu Gln Gly Arg Asn Arg Ala Leu Glu Thr Arg Leu Gln Ala Leu  
 20 25 30  
 Glu Ala Gln His Gln Ala Gln Leu Asn Ser Leu Gln Glu Lys Arg Glu  
 35 40 45  
 Gln Leu His Ser Leu Leu  
 50

<210> 116  
 <211> 145  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 116

Thr Gln Gln Val Lys Gln Leu Glu Gln Ala Leu Gln Asn Asn Thr Gln  
1 5 10 15

Trp Leu Lys Lys Leu Glu Arg Ala Ile Lys Thr Ile Leu Arg Ser Lys  
20 25 30

Leu Glu Gln Val Gln Gln Gln Met Ala Gln Asn Gln Thr Ala Pro Met  
35 40 45

Leu Glu Leu Gly Thr Ser Leu Leu Asn Gln Thr Thr Ala Gln Ile Arg  
50 55 60

Lys Leu Thr Asp Met Glu Ala Gln Leu Leu Asn Gln Thr Ser Arg Met  
65 70 75 80

Asp Ala Gln Met Pro Glu Thr Phe Leu Ser Thr Asn Lys Leu Glu Asn  
85 90 95

Gln Leu Leu Leu Gln Arg Gln Lys Leu Gln Gln Leu Gln Gly Gln Asn  
100 105 110

Ser Ala Leu Glu Lys Arg Leu Gln Ala Leu Glu Thr Lys Gln Gln Glu  
115 120 125

Glu Leu Ala Ser Ile Leu Ser Lys Lys Ala Lys Leu Leu Asn Thr Leu  
130 135 140

Ser  
145

&lt;210&gt; 117

&lt;211&gt; 465

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

gccccatggag agactgcctg caggccctgg aggatggcca cgacaccagc tccatctacc 60

tggtgaagcc ggagaacacc aaccgcctca tgcaggtgtg gtgcgaccag agacacgacc 120

ccgggggctg gaccgtcatc cagagacgcc tggatggctc tggttaacttc ttcaggaact 180

gggagacgta caagcaaggg ttgggaaca ttgacggcga atactggctg ggcctggaga 240

acatttactg gctgacgaac caaggcaact acaaactcct ggtgaccatg gaggactggt 300

ccggccgcaa agtctttgca gaatacgcca gtttccgcct ggaacctgag agcgagtatt 360

ataagctgcg gctggggcgc taccatggca atgcgggtga ctctttaca tggcacaacg 420

gcaagcagtt caccacccag gacagagatc atgatgtcta cacag 465

&lt;210&gt; 118

&lt;211&gt; 305

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

ggattgccag gagctgttcc aggttgggga gaggcagagt ggactatttg aaatccagcc 60

tcaggggtct ccgccatttt tggtgaactg caagatgacc tcagatggag gctggacagt 120



```

aattcagagg cgccacgatg gctcagtgga cttcaaccgg ccctkggtag cctacaaggc      180
ggtgggttttg ggggatcccc acggcgagtt ctggcttggg tcttggagaa aggkgcatag      240
catcacgggg ggaccggaac agccgmctgg ccgtgcaamc tgcgggggact gggatgggca      300
aacgc                                              305

```

```

<210> 119
<211> 458
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (224)..(224)
<223> "n" may be any nucleotide

```

```

<220>
<221> misc_feature
<222> (347)..(347)
<223> "n" may be any nucleotide

```

```

<220>
<221> misc_feature
<222> (353)..(353)
<223> "n" may be any nucleotide

```

```

<220>
<221> misc_feature
<222> (384)..(384)
<223> "n" may be any nucleotide

```

```

<220>
<221> misc_feature
<222> (400)..(400)
<223> "n" may be any nucleotide

```

```

<220>
<221> misc_feature
<222> (446)..(446)
<223> "n" may be any nucleotide

```

```

<400> 119
attataagct gcggctgggg cgataccatg gcaatgcggg tgactccttt acatggcaca      60
acggcaagca gttcaccacc ctggacagag atcatgatgt ctacacagga aactgtgccc      120
actaccagaa gggaggctgg tggataaacg cctgtgccca ctccaacctc aaccgggggtc      180
tgggtaccgc ggggccatta ccggagccgc taccaggacg gagngtactg ggctgagttc      240
cgaggaggct cttactcact caaggaaacg tggatgatgat gatccgaccg aaccccaaca      300
ccttccacta agccagctcc ccctcctgac ctctccgtgg ccattgncag gangcccacc      360
ctggtcacgc tggccacagc acanagaaca actcctcacn agttcatcct gaggctggga      420
ggaccgggat gctggattct gttttncga agtcactg                                              458

```

```

<210> 120
<211> 173
<212> DNA
<213> Artificial Sequence

```

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 120

tataagctgc ggctggggcg ataccatggc aatgcgggtg actcctttac atggcacaac	60
ggcaagcagt tcaccaccct ggacagagat catgatgtct acacaggaaa ctgtgcccac	120
taccagaagg gaggctggtg gtataacgcc tgtgcccact ccaacctcaa ccg	173

&lt;210&gt; 121

&lt;211&gt; 638

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 121

gccccatggag agactgcctg caggccctgg aggatggcca cgacaccagc tccatctacc	60
tggtgaagcc ggagaacacc aaccgcctca tgcaggtgtg gtgcgaccag agacacgacc	120
ccgggggctg gaccgtcatc cagagacgcc tggatggctc tgttaacttc ttcaggaact	180
gggagacgta caagcaagg tttgggaaca ttgacggcga atactggctg ggcctggaga	240
acatttactg gctgacgaac caaggcaact acaaactcct ggtgaccatg gaggactggt	300
ccggccgcaa agtctttgca gaatacgcca gtttccgcct ggaacctgag agcgagtatt	360
ataagctgcg gctggggcgc taccatggca atgcgggtga ctctttaca tggcacaacg	420
gcaagcagtt caccaccag gacagagatc atgatgtcta cacagtataa gctgcggctg	480
gggcgatacc atggcaatgc gggtgactcc tttacatggc acaacggcaa gcagttcacc	540
accctggaca gagatcatga tgtctacaca ggaaactgtg cccactacca gaagggaggc	600
tggtggtata acgcctgtgc ccaactccaac ctcaaccg	638

&lt;210&gt; 122

&lt;211&gt; 4045

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 122

gccccatggag agactgcctg caggccctgg aggatggcca cgacaccagc tccatctacc	60
tggtgaagcc ggagaacacc aaccgcctca tgcaggtgtg gtgcgaccag agacacgacc	120
ccgggggctg gaccgtcatc cagagacgcc tggatggctc tgttaacttc ttcaggaact	180
gggagacgta caagcaagg tttgggaaca ttgacggcga atactggctg ggcctggaga	240
acatttactg gctgacgaac caaggcaact acaaactcct ggtgaccatg gaggactggt	300
ccggccgcaa agtctttgca gaatacgcca gtttccgcct ggaacctgag agcgagtatt	360
ataagctgcg gctggggcgc taccatggca atgcgggtga ctctttaca tggcacaacg	420

gcaagcagtt caccacccag gacagagatc atgatgtcta cacagtataa gctgcggtg	480
gggcgatacc atggcaatgc gggtgactcc ttacatggc acaacggcaa gcagttcacc	540
accctggaca gagatcatga tgtctacaca ggaaactgtg cccactacca gaagggaggc	600
tgggtggtata acgcctgtgc ccactccaac ctcaaccgga aaaagagagg aagagaaacc	660
atntagagac tgtgcagatg tatatcaagc tgggttttaaat aaaagtggaa tctacactat	720
ttatatattaat aatatgccag aacccaaaaa ggtgttttgc aatatggatg tcaatggggg	780
aggttggact gtaatacaac atcgtgaaga tggaagtcta gatttccaaa gaggctggaa	840
ggaatataaa atgggttttg gaaatccctc cgggtgaatat tggctgggga atgagtttat	900
ttttgccatt accagtcaga ggcagtacat gctaagaatt gagttaatgg actgggaagg	960
gaaccgagcc tattcacagt atgacagatt ccacatagga aatgaaaagc aaaactatag	1020
gttgtattta aaaggtcaca ctgggacagc aggaaaacag agcagcctga tcttacacgg	1080
tgctgatttc agcactaaag atgctgataa tgacaactgt atgtgcaaat gtgccctcat	1140
gttaacagga ggatggtggt ttgatgcttg tggcccctcc aatctaaatg gaatgttcta	1200
tactgcggga caaaaccatg gaaaactgaa tgggataaag tggcactact tcaaagggcc	1260
cagttactcc ttacgttcca caactatgat gattcgacct ttagatTTTT gaaagcgcaa	1320
tgtcagaagc gattatgaaa gcaacaaaga aatccggaga agctgccagg tgagaaactg	1380
tttgaaaact tcagaagcaa acaatattgt ctcccttcca gcaataagtg gtagttatgt	1440
gaagtcacca aggttcttga cagtgaatct ggagccgttt gagttcaca gagtctctac	1500
ttggggtgac agtgctcacg tggctcgact atagaaaact ccactgactg tgggcttta	1560
aaaaggggaag aaactgctga gcttgctgtg cttcaaacta ctactggacc ttattttgga	1620
actatggtag ccagatgata aatatggtta atttcatgta aaacagaaaa aaagagtga	1680
aaagagaata tacatgaaga atagaaacaa gcctgccata atcctttgga aaagatgtat	1740
tataccagtg aaaaggcggt atatctatgc aaacctacta acaaattata ctgttgacaca	1800
attttgataa aaatttagaa cagcattgtc ctctgagttg gttaaattgt aatggatttc	1860
agaagcctaa ttccagtatc atacttacta gttgatttct gcttaccat cttcaaata	1920
aaattccatt tttgtaagcc ataatgaact gtagtacatg gacaataagt gtgtggtaga	1980
aacaaactcc attactctga tttttgatac agttttcaga aaaagaaatg aacataatca	2040
agtaaggatg tatgtggtga aaacttacca ccccatact atgggtttca ttactctaa	2100
aaactgattg aatgatatat aaatatattt atagcctgag taaagttaaa agaattgtaa	2160
atatatcatc aagttcttaa aataatatac atgcatttaa tatttccttt gatattatac	2220
aggaaagcaa tattttggag tatgttaagt tgaagtaaaa ccaagtactc tggagcagtt	2280
cattttacag tatctacttg catgtgtata catacatgta acttcattat tttaaaaata	2340

```

tttttagaac tccaatactc accctgttat gtcttgctaa tttaaatttt gctaattaac 2400
tgaaacatgc ttaccagatt cacactgttc cagtgtctat aaaagaaaca ctttgaagtc 2460
tataaaaaat aaaataatta taaatatcat tgtacatagc atgtttatat ctgcaaaaaa 2520
cctaatagct aattaatctg gaatatgcaa cattgtcctt aattgatgca aataacacaa 2580
atgctcaaag aaatctacta tatcccttaa tgaaatacat cattcttcat atatttctcc 2640
ttcagtccat tcccttaggc aatttttaat ttttaaaaat tattatcagg ggagaaaaat 2700
tggcaaaaact atttatatgta agggatatat atatacaaaa agaaaattaa tcatagtcac 2760
ctgactaaga aattctgact gctagttgcc ataaataact caatggaaat attcctatgg 2820
gataatgtat ttttaagtga tttttggggt gcttgaagtt actgcattat tttatcaaga 2880
agtccttctc gcctgtaagt gtccaagggt atgacagtaa acagttttta ttaaacaatg 2940
agtcactatg ggatgagaaa attgaaataa agctactggg cctcctctca taaaagagac 3000
agttgttggc aaggtagcaa taccagtttc aaacttgggt acttgatcca ctatgcctta 3060
atgggttctc ccatttgaga aaataaagct attcacattg ttaagaaaaa tactttttaa 3120
agtttaccat caagtctttt ttatatattat gtgtctgtat tctaccctt tttgccttac 3180
aagtgatatt tgcaggtatt ataccatttt tctattcttg gtggcttctt catagcaggt 3240
aagcctctcc ttctaaaaac ttctcaactg ttttcattta agggaaagaa aatgagtatt 3300
ttgtcctttt gtgttcctac agacactttc ttaaaccagt ttttgataa agaatactat 3360
ttccaaactc atattacaaa aacaaaataa aataataaaa aaagaaagca tgatatttac 3420
tgttttgttg tctgggtttg agaaatgaaa tattgtttcc aattatttat aataaatcag 3480
tataaaatgt tttatgattg ttatgtgtat tatgtaatac gtacatgttt atggcaattt 3540
aacatgtgta ttcttttcat ttaattgttt cagaatagga taattaggta ttcgaaattt 3600
gtcttttaaa ttcatgtggt ttctatgcaa agttcttcat atcatcaca cattatttga 3660
tttaataaaa attgaaagtg caccatggc agaaggagga gggcagaatc atcacgaagt 3720
ggtgaagttc atggatgtct atcagcgcag ctactgccat ccaatcgaga ccctgggtgga 3780
catcttccag gagtaccctg atgagatcga gtacatcttc aagccatcct gtgtgcccct 3840
gatgcgatgc gggggctgct gcaatgacga gggcctggag tgtgtgcca ctgaggagtc 3900
caacatcacc atgcagatta tgcggatcaa acctaccaa ggccagcaca taggagagat 3960
gagcttcta cagcacaaca aatgtgaatg cagaccaaag aaagatagag caagacaaga 4020
aaaatgtgac aagccgaggc ggtga 4045

```

&lt;210&gt; 123

&lt;211&gt; 280

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 123

Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala  
 1 5 10 15

Ala Ala Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys  
 20 25 30

Gln Tyr Gln Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro  
 35 40 45

Glu Met Asp Asn Cys Arg Ser Ser Ser Pro Tyr Val Ser Asn Ala  
 50 55 60

Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu  
 65 70 75 80

Gln Val Leu Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys  
 85 90 95

Val Glu Asn Ile Ser Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile  
 100 105 110

Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly  
 115 120 125

Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp  
 130 135 140

Val Glu Ala Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu  
 145 150 155 160

Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp  
 165 170 175

Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu  
 180 185 190

Lys Lys Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser  
 195 200 205

Ile Lys Glu Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn  
 210 215 220

Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn  
 225 230 235 240

Asn Ser Val Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn  
 245 250 255

Asn Leu Leu Thr Met Met Ser Thr Ser Asn Ala Ala Lys Asp Pro Thr  
 260 265 270

Val Ala Lys Glu Glu Gln Ile Ser  
 275 280

&lt;210&gt; 124

&lt;211&gt; 221

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

&lt;400&gt; 124

Glu Glu Glu Lys Pro Phe Arg Asp Cys Ala Asp Val Tyr Gln Ala Gly  
1 5 10 15

Phe Asn Lys Ser Gly Ile Tyr Thr Ile Tyr Ile Asn Asn Met Pro Glu  
20 25 30

Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn Gly Gly Gly Trp Thr  
35 40 45

Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp Phe Gln Arg Gly Trp  
50 55 60

Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser Gly Glu Tyr Trp Leu  
65 70 75 80

Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln Arg Gln Tyr Met Leu  
85 90 95

Arg Ile Glu Leu Met Asp Trp Glu Gly Asn Arg Ala Tyr Ser Gln Tyr  
100 105 110

Asp Arg Phe His Ile Gly Asn Glu Lys Gln Asn Tyr Arg Leu Tyr Leu  
115 120 125

Lys Gly His Thr Gly Thr Ala Gly Lys Gln Ser Ser Leu Ile Leu His  
130 135 140

Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp Asn Asp Asn Cys Met Cys  
145 150 155 160

Lys Cys Ala Leu Met Leu Thr Gly Gly Trp Trp Phe Asp Ala Cys Gly  
165 170 175

Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr Ala Gly Gln Asn His Gly  
180 185 190

Lys Leu Asn Gly Ile Lys Trp His Tyr Phe Lys Gly Pro Ser Tyr Ser  
195 200 205

Leu Arg Ser Thr Thr Met Met Ile Arg Pro Leu Asp Phe  
210 215 220

&lt;210&gt; 125

&lt;211&gt; 1506

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 125

atgtggcaga ttgttttctt tactctgagc tgtgatcttg tcttggccgc agcctataac 60

aactttcgga agagcatgga cagcatagga aagaagcaat atcaggtcca gcatgggtcc 120

tgcagctaca ctttctcct gccagagatg gacaactgcc gctcttcctc cagccccctac 180

gtgtccaatg ctgtgcagag ggacgcgccg ctcgaatacg atgactcggt gcagaggctg 240

caagtgctgg agaacatcat ggaaaacaac actcagtggc taatgaaggt agagaatata 300  
 tcccaggaca acatgaagaa agaaatggta gagatacagc agaatgcagt acagaaccag 360  
 acggctgtga tgatagaaat agggacaaac ctgttgaacc aaacagcggg gcaaacgcgg 420  
 aagttaactg atgtggaagc ccaagtatta aatcagacca cgagacttga acttcagctc 480  
 ttggaacact ccctctcgac aaacaaattg gaaaaacaga ttttggacca gaccagtga 540  
 ataaacaaat tgcaagataa gaacagtttc ctagaaaaga aggtgctagc tatggaagac 600  
 aagcacatca tccaactaca gtcaataaaa gaagagaaag atcagctaca ggtgttagta 660  
 tccaagcaga attccatcat tgaagaactc gaaaaaaaa tagtgactgc cacggtgaat 720  
 aattcagttc ttcagaagca gcaacatgat ctcatggaga cagttaataa cttactgact 780  
 atgatgtcca catcaaagc agctaaggac cccactgttg ctaaagaaga acaaatcagc 840  
 gaggaagaga aaccatttag agactgtgca gatgtatata aagctggttt taataaaagt 900  
 ggaatctaca ctatttatat taataatatg ccagaacca aaaaggtgtt ttgcaatatg 960  
 gatgtcaatg ggggaggttg gactgtaata caacatcgtg aagatggaag tctagatttc 1020  
 caaagaggct ggaaggaata taaaatgggt tttggaaatc cctccggtga atattggctg 1080  
 gggaatgagt ttatttttgc cattaccagt cagaggcagt acatgctaag aattgagtta 1140  
 atggactggg aagggaaccg agcctattca cagtatgaca gattccacat aggaaatgaa 1200  
 aagcaaaact ataggttgta tttaaaaggt cacactggga cagcaggaaa acagagcagc 1260  
 ctgatcttac acggtgctga tttcagcact aaagatgctg ataatgacaa ctgtatgtgc 1320  
 aaatgtgcc tcatgttaac aggaggatgg tggtttgatg cttgtggccc ctccaatcta 1380  
 aatggaatgt tctatactgc gggacaaaac catggaaaac tgaatgggat aaagtggcac 1440  
 tacttcaaag ggcccagtta ctcttacgt tccacaacta tgatgattcg accttagat 1500  
 ttttga 1506

<210> 126

<211> 501

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 126

Met Trp Gln Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala  
 1 5 10 15

Ala Ala Tyr Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys  
 20 25 30

Gln Tyr Gln Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro  
 35 40 45

Glu Met Asp Asn Cys Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala

50	55	60
Val Gln Arg Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu		
65	70	75
Gln Val Leu Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys		
	85	90
Val Glu Asn Ile Ser Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile		
	100	105
Gln Gln Asn Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly		
	115	120
Thr Asn Leu Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp		
	130	135
Val Glu Ala Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu		
	145	150
Leu Glu His Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp		
	165	170
Gln Thr Ser Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu		
	180	185
Lys Lys Val Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser		
	195	200
Ile Lys Glu Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn		
	210	215
Ser Ile Ile Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn		
	225	230
Asn Ser Val Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn		
	245	250
Asn Leu Leu Thr Met Met Ser Thr Ser Asn Ala Ala Lys Asp Pro Thr		
	260	265
Val Ala Lys Glu Glu Gln Ile Ser Glu Glu Glu Lys Pro Phe Arg Asp		
	275	280
Cys Ala Asp Val Tyr Gln Ala Gly Phe Asn Lys Ser Gly Ile Tyr Thr		
	290	295
Ile Tyr Ile Asn Asn Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met		
	305	310
Asp Val Asn Gly Gly Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly		
	325	330
Ser Leu Asp Phe Gln Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly		
	340	345
Asn Pro Ser Gly Glu Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile		
	355	360
Thr Ser Gln Arg Gln Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu		
	370	375
Gly Asn Arg Ala Tyr Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu		
	385	390
		395
		400



Lys Gln Asn Tyr Arg Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly  
 405 410 415  
 Lys Gln Ser Ser Leu Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp  
 420 425 430  
 Ala Asp Asn Asp Asn Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly  
 435 440 445  
 Gly Trp Trp Phe Asp Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe  
 450 455 460  
 Tyr Thr Ala Gly Gln Asn His Gly Lys Leu Asn Gly Ile Lys Trp His  
 465 470 475 480  
 Tyr Phe Lys Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile  
 485 490 495  
 Arg Pro Leu Asp Phe  
 500

<210> 127  
 <211> 658  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Synthetic peptide

<400> 127

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu  
 1 5 10 15  
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly  
 20 25 30  
 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln  
 35 40 45  
 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu  
 50 55 60  
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu  
 65 70 75 80  
 Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro  
 85 90 95  
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His  
 100 105 110  
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys  
 115 120 125  
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Cys Asp Lys  
 130 135 140  
 Pro Arg Arg Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Met Trp Gln  
 145 150 155 160  
 Ile Val Phe Phe Thr Leu Ser Cys Asp Leu Val Leu Ala Ala Ala Tyr  
 165 170 175

Asn Asn Phe Arg Lys Ser Met Asp Ser Ile Gly Lys Lys Gln Tyr Gln  
 180 185 190  
 Val Gln His Gly Ser Cys Ser Tyr Thr Phe Leu Leu Pro Glu Met Asp  
 195 200 205  
 Asn Cys Arg Ser Ser Ser Ser Pro Tyr Val Ser Asn Ala Val Gln Arg  
 210 215 220  
 Asp Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg Leu Gln Val Leu  
 225 230 235 240  
 Glu Asn Ile Met Glu Asn Asn Thr Gln Trp Leu Met Lys Val Glu Asn  
 245 250 255  
 Ile Ser Gln Asp Asn Met Lys Lys Glu Met Val Glu Ile Gln Gln Asn  
 260 265 270  
 Ala Val Gln Asn Gln Thr Ala Val Met Ile Glu Ile Gly Thr Asn Leu  
 275 280 285  
 Leu Asn Gln Thr Ala Glu Gln Thr Arg Lys Leu Thr Asp Val Glu Ala  
 290 295 300  
 Gln Val Leu Asn Gln Thr Thr Arg Leu Glu Leu Gln Leu Leu Glu His  
 305 310 315 320  
 Ser Leu Ser Thr Asn Lys Leu Glu Lys Gln Ile Leu Asp Gln Thr Ser  
 325 330 335  
 Glu Ile Asn Lys Leu Gln Asp Lys Asn Ser Phe Leu Glu Lys Lys Val  
 340 345 350  
 Leu Ala Met Glu Asp Lys His Ile Ile Gln Leu Gln Ser Ile Lys Glu  
 355 360 365  
 Glu Lys Asp Gln Leu Gln Val Leu Val Ser Lys Gln Asn Ser Ile Ile  
 370 375 380  
 Glu Glu Leu Glu Lys Lys Ile Val Thr Ala Thr Val Asn Asn Ser Val  
 385 390 395 400  
 Leu Gln Lys Gln Gln His Asp Leu Met Glu Thr Val Asn Asn Leu Leu  
 405 410 415  
 Thr Met Met Ser Thr Ser Asn Ala Ala Lys Asp Pro Thr Val Ala Lys  
 420 425 430  
 Glu Glu Gln Ile Ser Glu Glu Glu Lys Pro Phe Arg Asp Cys Ala Asp  
 435 440 445  
 Val Tyr Gln Ala Gly Phe Asn Lys Ser Gly Ile Tyr Thr Ile Tyr Ile  
 450 455 460  
 Asn Asn Met Pro Glu Pro Lys Lys Val Phe Cys Asn Met Asp Val Asn  
 465 470 475 480  
 Gly Gly Gly Trp Thr Val Ile Gln His Arg Glu Asp Gly Ser Leu Asp  
 485 490 495  
 Phe Gln Arg Gly Trp Lys Glu Tyr Lys Met Gly Phe Gly Asn Pro Ser  
 500 505 510

Gly Glu Tyr Trp Leu Gly Asn Glu Phe Ile Phe Ala Ile Thr Ser Gln  
515 520 525

Arg Gln Tyr Met Leu Arg Ile Glu Leu Met Asp Trp Glu Gly Asn Arg  
530 535 540

Ala Tyr Ser Gln Tyr Asp Arg Phe His Ile Gly Asn Glu Lys Gln Asn  
545 550 555 560

Tyr Arg Leu Tyr Leu Lys Gly His Thr Gly Thr Ala Gly Lys Gln Ser  
565 570 575

Ser Leu Ile Leu His Gly Ala Asp Phe Ser Thr Lys Asp Ala Asp Asn  
580 585 590

Asp Asn Cys Met Cys Lys Cys Ala Leu Met Leu Thr Gly Gly Trp Trp  
595 600 605

Phe Asp Ala Cys Gly Pro Ser Asn Leu Asn Gly Met Phe Tyr Thr Ala  
610 615 620

Gly Gln Asn His Gly Lys Leu Asn Gly Ile Lys Trp His Tyr Phe Lys  
625 630 635 640

Gly Pro Ser Tyr Ser Leu Arg Ser Thr Thr Met Met Ile Arg Pro Leu  
645 650 655

Asp Phe

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number  
**WO 02/083851 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/475**,  
14/515, A61K 39/00

(21) International Application Number: PCT/US02/11406

(22) International Filing Date: 10 April 2002 (10.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/832,355 10 April 2001 (10.04.2001) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/832,355 (CIP)  
Filed on 10 April 2001 (10.04.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): GEN-VEC, INC. [US/US]; 65 West Watkins Mill Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KOVESDI, Imre [US/US]; 7713 Warbler Lane, Rockville, MD 20855 (US). KESSLER, Paul, D. [US/US]; 1716 Algonquin Road, Frederick, MD 21701 (US).

(74) Agents: SMITH, Len, S. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
24 December 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: VEGF FUSION PROTEINS

(57) Abstract: The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides, encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

WO 02/083851 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/11406

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C07K 14/475, 14/515; A61K 39/00  
US CL : 435/69.7; 530/399; 424/192.1, 198.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7; 530/399; 424/192.1, 198.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/37642 A1 (REGENERON PHARMACEUTICALS, INC.) 29 June 2000 (29.06.2000), entire document, esp. pages 9, 26, 27 and Figs. 1A and 1B. Note that desc. has inadequate description of KIAA003- claim 20 is presumed to be equivalent to claim 19.	1-4, 6-20, 25-27, 33, 36, 37
Y	US 5,409,897 A (THOMAS et al.) 25 April 1995 (25.04.1995), entire document.	21-24, 28-31 21
Y	US 5,401,832 A (LINEMEYER et al.) 28 March 1995 (28.03.1995), entire document.	21
Y	US 5,227,302 A (HELDIN et al.) 13 July 1993 (13.07.1993), entire document, especially col. 13.	21
Y	US 5,461,029 A (BACKER et al.) 24 October 1995 (24.10.1995), entire document.	22-24
Y	US 6,140,087 A (GRAHAM et al.) 31 October 2000 (31.10.2000), entire document.	28-31, 34, 35
Y	US 5,194,596 A (TISCHER et al.) 16 March 1993 (16.03.1993), entire document.	1-37

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 September 2003 (12.09.2003)

Date of mailing of the international search report

28 OCT 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Lorraine Spector, Ph.D.

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/11406

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☒

The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains claims directed to more than onespecies of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows: Angiopoietin 1, HBNF, MK, acidic fibroblast growth factor, alkaline phosphatase.

The claims are deemed to correspond to the species listed above in the following manner:

- a) Angiopoietin 1 (claims 14-20, 30)
- b) HBNF (claims 14, 22, 23, 24, 30)
- c) MK (claims 14, 22-24, 30)
- d) acidic fibroblast growth factor (claims 14, 21, 30)
- e) alkaline phosphatase (claims 14, 30).

The following claims are generic: 1-13, 25-29, 31-37.

And it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of the five species comprises a distinct physical and chemical structure, and requires a separate search of the prior art. Therefore, unity of invention is lacking.

**Continuation of B. FIELDS SEARCHED Item 3:**

EAST, MEDLINE

search term; vegf, hbgr-1, ecgf, acidic fgf, hbnf, mk, midkine, cytokine fusion